PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9820176-10	1998	In contrast, induction seemed to determine resistance in EHR2 cells in vitro exposed to daunorubicin 10(-8) M. The revertant EHR2/0.8/R was treated in vivo with daunorubicin for 24 h. After treatment, P-glycoprotein increased in EHR2/0.8/R (sevenfold) and the cell line developed resistance to daunorubicin (12-fold), suggesting that in EHR2/0.8/R the mdr1 gene was activated by induction.	Daunorubicin	161-173	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	352-356
9820176-10	1998	In contrast, induction seemed to determine resistance in EHR2 cells in vitro exposed to daunorubicin 10(-8) M. The revertant EHR2/0.8/R was treated in vivo with daunorubicin for 24 h. After treatment, P-glycoprotein increased in EHR2/0.8/R (sevenfold) and the cell line developed resistance to daunorubicin (12-fold), suggesting that in EHR2/0.8/R the mdr1 gene was activated by induction.	Daunorubicin	161-173	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	352-356
9827923-0	1998	Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.	Daunorubicin	27-39	PSC	Homo sapiens	13-23
18967370-0	1998	Electrochemical detection of lectin using a galactosamine labeled with daunomycin.	Daunorubicin	71-81	LOW QUALITY PROTEIN: lectin	Glycine max	29-35
18967370-2	1998	Because the lectin has binding sites to galactosamine, galactosamine labeled with daunomycin having electroactivity was prepared.	Daunorubicin	82-92	LOW QUALITY PROTEIN: lectin	Glycine max	12-18
18967370-3	1998	When labeled galactosamine (LG) combines with lectin, the part of daunomycin is taken in the binding sites of the lectin and becomes electroinactive.	Daunorubicin	66-76	LOW QUALITY PROTEIN: lectin	Glycine max	46-52
18967370-3	1998	When labeled galactosamine (LG) combines with lectin, the part of daunomycin is taken in the binding sites of the lectin and becomes electroinactive.	Daunorubicin	66-76	LOW QUALITY PROTEIN: lectin	Glycine max	114-120
9849860-1	1998	Glomerular distribution of rat plasma fibronectin was examined during the course of puromycin (PAN)- and daunomycin (DM)-induced nephrosis.	Daunorubicin	105-115	fibronectin 1	Rattus norvegicus	38-49
9753037-1	1998	To address a possible impairment of multidrug resistance mechanisms in acquired aplastic anaemia (AA), the functions of P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) were respectively assessed by rhodamine 123 (Rh123) and daunorubicin (DNR) efflux in peripheral blood lymphocytes from AA patients.	Daunorubicin	248-260	ATP binding cassette subfamily B member 1	Homo sapiens	120-134
9753037-1	1998	To address a possible impairment of multidrug resistance mechanisms in acquired aplastic anaemia (AA), the functions of P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) were respectively assessed by rhodamine 123 (Rh123) and daunorubicin (DNR) efflux in peripheral blood lymphocytes from AA patients.	Daunorubicin	248-260	ATP binding cassette subfamily B member 1	Homo sapiens	136-140
9753037-1	1998	To address a possible impairment of multidrug resistance mechanisms in acquired aplastic anaemia (AA), the functions of P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) were respectively assessed by rhodamine 123 (Rh123) and daunorubicin (DNR) efflux in peripheral blood lymphocytes from AA patients.	Daunorubicin	248-260	ATP binding cassette subfamily C member 3	Homo sapiens	146-185
9753037-1	1998	To address a possible impairment of multidrug resistance mechanisms in acquired aplastic anaemia (AA), the functions of P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) were respectively assessed by rhodamine 123 (Rh123) and daunorubicin (DNR) efflux in peripheral blood lymphocytes from AA patients.	Daunorubicin	248-260	ATP binding cassette subfamily C member 3	Homo sapiens	187-190
9744556-7	1998	At pH 7.2, 50% of the P-glycoprotein-mediated efflux of daunorubicin and idarubicin was inhibited by about 40 +/- 10 microM vinblastine and that of pirarubicin by 10 +/- 2 microM vinblastine.	Daunorubicin	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	22-36
9570100-2	1998	The cytostatic agent daunorubicin was labeled with carbon-11 to probe P-gp with PET.	Daunorubicin	21-33	ATP binding cassette subfamily B member 1	Homo sapiens	70-74
9647783-0	1998	Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump.	Daunorubicin	17-29	ATP binding cassette subfamily C member 1	Homo sapiens	141-144
9647783-0	1998	Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump.	Daunorubicin	17-29	ATP binding cassette subfamily C member 1	Homo sapiens	145-149
9647783-1	1998	Overexpression of the multidrug resistance-associated protein (MRP1) gene encoding a human GS-X pump in cultured cells resulted in increased cellular resistance to antitumor agents, including doxorubicin (Dox) and daunomycin (Dau), as well as certain heavy metals.	Daunorubicin	214-224	ATP binding cassette subfamily C member 1	Homo sapiens	22-67
9647783-1	1998	Overexpression of the multidrug resistance-associated protein (MRP1) gene encoding a human GS-X pump in cultured cells resulted in increased cellular resistance to antitumor agents, including doxorubicin (Dox) and daunomycin (Dau), as well as certain heavy metals.	Daunorubicin	214-224	ATP binding cassette subfamily C member 1	Homo sapiens	91-95
9647783-1	1998	Overexpression of the multidrug resistance-associated protein (MRP1) gene encoding a human GS-X pump in cultured cells resulted in increased cellular resistance to antitumor agents, including doxorubicin (Dox) and daunomycin (Dau), as well as certain heavy metals.	Daunorubicin	226-229	ATP binding cassette subfamily C member 1	Homo sapiens	22-67
9647783-1	1998	Overexpression of the multidrug resistance-associated protein (MRP1) gene encoding a human GS-X pump in cultured cells resulted in increased cellular resistance to antitumor agents, including doxorubicin (Dox) and daunomycin (Dau), as well as certain heavy metals.	Daunorubicin	226-229	ATP binding cassette subfamily C member 1	Homo sapiens	91-95
9647783-2	1998	However, studies with membrane vesicles prepared from the resistant cells revealed that Dox and Dau are poor substrates for the transport mediated by MRP/GS-X pump, suggesting that metabolic modifications of these drugs might be required for the transport.	Daunorubicin	96-99	ATP binding cassette subfamily C member 1	Homo sapiens	150-153
9647783-2	1998	However, studies with membrane vesicles prepared from the resistant cells revealed that Dox and Dau are poor substrates for the transport mediated by MRP/GS-X pump, suggesting that metabolic modifications of these drugs might be required for the transport.	Daunorubicin	96-99	ATP binding cassette subfamily C member 1	Homo sapiens	154-158
9624121-0	1998	Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin.	Daunorubicin	80-92	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	10-13
9624121-0	1998	Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin.	Daunorubicin	80-92	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	40-45
9624121-4	1998	Here, we report that the expression of the rat mdr1b can be induced by anticancer drug daunorubicin.	Daunorubicin	87-99	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	47-52
9624121-5	1998	Further analysis identified a bona fide p53-binding site spanning from base pairs -199 to -180 (5"-GAACATGTAGAGACATGTCT-3") in the rat mdr1b promoter that is essential for basal and daunorubicin-inducible promoter activities.	Daunorubicin	182-194	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	40-43
9624121-5	1998	Further analysis identified a bona fide p53-binding site spanning from base pairs -199 to -180 (5"-GAACATGTAGAGACATGTCT-3") in the rat mdr1b promoter that is essential for basal and daunorubicin-inducible promoter activities.	Daunorubicin	182-194	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	135-140
9558371-7	1998	Chemosensitivity to daunorubicin increased in MDR1-AS-treated blast cells up to 5.9-fold in the K562/ADM cells and 3.0- to 6.4-fold in the AML blast cells.	Daunorubicin	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
9605426-3	1998	The effective concentration for 50% helicase blockade (EC50) values ranged from 0.34 microM for daunorubicin to 40.8 microM for 3"-deaminodaunorubicin.	Daunorubicin	96-108	helicase for meiosis 1	Homo sapiens	36-44
9592977-2	1998	The aim of this study was to evaluate the frequency and the role of a PGP and an LRP overexpression in affecting the intracellular daunorubicin accumulation (IDA) and in predicting the therapy outcome on a subset of overt secondary acute non lymphocytic leukemias (ANLL).	Daunorubicin	131-143	ATP binding cassette subfamily B member 1	Homo sapiens	70-73
9592977-2	1998	The aim of this study was to evaluate the frequency and the role of a PGP and an LRP overexpression in affecting the intracellular daunorubicin accumulation (IDA) and in predicting the therapy outcome on a subset of overt secondary acute non lymphocytic leukemias (ANLL).	Daunorubicin	131-143	major vault protein	Homo sapiens	81-84
9587947-0	1998	Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy.	Daunorubicin	26-38	low density lipoprotein receptor	Homo sapiens	108-120
9620540-5	1998	Significant increase of malondialdehyde content, and DT-diaphorase and glutathione-S-transferase activities were found in myocardial tissue from daunomycin-treated rats.	Daunorubicin	145-155	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	53-66
9620540-5	1998	Significant increase of malondialdehyde content, and DT-diaphorase and glutathione-S-transferase activities were found in myocardial tissue from daunomycin-treated rats.	Daunorubicin	145-155	hematopoietic prostaglandin D synthase	Rattus norvegicus	71-96
9528861-0	1998	Nuclear factor - kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug.	Daunorubicin	79-89	tumor protein p53	Homo sapiens	48-51
9528861-2	1998	In the HCT116 colon carcinoma cell line, which retains a wild-type inducible p53 gene, we show that the anthracycline daunomycin is a potent inducer of p53 and NF-kappaB transcription factors.	Daunorubicin	118-128	tumor protein p53	Homo sapiens	77-80
9528861-2	1998	In the HCT116 colon carcinoma cell line, which retains a wild-type inducible p53 gene, we show that the anthracycline daunomycin is a potent inducer of p53 and NF-kappaB transcription factors.	Daunorubicin	118-128	tumor protein p53	Homo sapiens	152-155
9528861-2	1998	In the HCT116 colon carcinoma cell line, which retains a wild-type inducible p53 gene, we show that the anthracycline daunomycin is a potent inducer of p53 and NF-kappaB transcription factors.	Daunorubicin	118-128	nuclear factor kappa B subunit 1	Homo sapiens	160-169
9528861-4	1998	In addition, daunomycin induced the p53 promoter through the binding of p50/p65 NF-kappaB heterodimers to the kappaB site in the p53 promoter.	Daunorubicin	13-23	tumor protein p53	Homo sapiens	36-39
9528861-4	1998	In addition, daunomycin induced the p53 promoter through the binding of p50/p65 NF-kappaB heterodimers to the kappaB site in the p53 promoter.	Daunorubicin	13-23	nuclear factor kappa B subunit 1	Homo sapiens	72-75
9528861-4	1998	In addition, daunomycin induced the p53 promoter through the binding of p50/p65 NF-kappaB heterodimers to the kappaB site in the p53 promoter.	Daunorubicin	13-23	RELA proto-oncogene, NF-kB subunit	Homo sapiens	76-79
9528861-4	1998	In addition, daunomycin induced the p53 promoter through the binding of p50/p65 NF-kappaB heterodimers to the kappaB site in the p53 promoter.	Daunorubicin	13-23	nuclear factor kappa B subunit 1	Homo sapiens	80-89
9528861-4	1998	In addition, daunomycin induced the p53 promoter through the binding of p50/p65 NF-kappaB heterodimers to the kappaB site in the p53 promoter.	Daunorubicin	13-23	tumor protein p53	Homo sapiens	129-132
9528861-6	1998	Overexpression of a stable unresponsive IkappaBalpha mutant in HCT116 cells resulted in a complete inhibition of the NF-kappaB activation but only a partial impairment of the p53 protein accumulation induced by daunomycin.	Daunorubicin	211-221	NFKB inhibitor alpha	Homo sapiens	40-52
9528861-6	1998	Overexpression of a stable unresponsive IkappaBalpha mutant in HCT116 cells resulted in a complete inhibition of the NF-kappaB activation but only a partial impairment of the p53 protein accumulation induced by daunomycin.	Daunorubicin	211-221	tumor protein p53	Homo sapiens	175-178
9528861-7	1998	We conclude that the p53-activating signal generated by daunomycin is partially regulated by NF-kappaB.	Daunorubicin	56-66	tumor protein p53	Homo sapiens	21-24
9528861-7	1998	We conclude that the p53-activating signal generated by daunomycin is partially regulated by NF-kappaB.	Daunorubicin	56-66	nuclear factor kappa B subunit 1	Homo sapiens	93-102
9504636-3	1998	Drug resistance towards Dau, Dox and Etop was correlated to the MDR1 expression of the AML cells (P<0.05) with high MDR1 expression being associated with high drug resistance towards these drugs.	Daunorubicin	24-27	ATP binding cassette subfamily B member 1	Homo sapiens	64-68
9504636-3	1998	Drug resistance towards Dau, Dox and Etop was correlated to the MDR1 expression of the AML cells (P<0.05) with high MDR1 expression being associated with high drug resistance towards these drugs.	Daunorubicin	24-27	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
9523982-4	1998	The transport of daunomycin (DNM), a P-gp substrate, was used to study age-related functional differences in P-gp.	Daunorubicin	17-27	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	37-41
9523982-4	1998	The transport of daunomycin (DNM), a P-gp substrate, was used to study age-related functional differences in P-gp.	Daunorubicin	29-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	37-41
9523982-5	1998	DNM uptake in the presence of ATP was greater than uptake in the absence of ATP in both young and adult cLPM vesicles, showing that P-gp is functional in both groups.	Daunorubicin	0-3	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	132-136
9485038-5	1998	In particular, IGF-II-deficient betaTCs are more sensitive to apoptotic stimuli, such as serum deprivation and staurosporine, and to chemotherapeutic agents, such as daunomycin, etoposide, or vincristine.	Daunorubicin	166-176	insulin-like growth factor 2	Mus musculus	15-21
9458355-4	1998	In addition, KG1a cells were demonstrated to display resistance to anticancer drug substrates for P-gp such as vincristine and daunorubicin and to poorly accumulate vincristine.	Daunorubicin	127-139	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
9685063-8	1998	Daunorubicin applied in combination with G-CSF at 5 ng/ml or with IL-3 at 0.5 ng/ml exerted a significantly higher degree of cytotoxicity on normal hematopoietic progenitor cells, resulting in 21% and 30% surviving colonies as compared with the 38% recorded for daunorubicin alone (P < 0.05).	Daunorubicin	262-274	interleukin 3	Homo sapiens	66-70
9685063-11	1998	We conclude that G-CSF and IL-3 augment the effect of daunorubicin on normal hematopoietic progenitor cells.	Daunorubicin	54-66	colony stimulating factor 3	Homo sapiens	17-22
9685063-11	1998	We conclude that G-CSF and IL-3 augment the effect of daunorubicin on normal hematopoietic progenitor cells.	Daunorubicin	54-66	interleukin 3	Homo sapiens	27-31
9430558-2	1998	In this study the authors examined whether daunomycin could induce multidrug resistance (MDR), mediated by the mdr-1 gene product P-glycoprotein, in the cells responsible for reproliferation in vivo and in human retinal pigment epithelial (RPE) cells in vitro.	Daunorubicin	43-53	ATP binding cassette subfamily B member 1	Homo sapiens	111-116
9430558-2	1998	In this study the authors examined whether daunomycin could induce multidrug resistance (MDR), mediated by the mdr-1 gene product P-glycoprotein, in the cells responsible for reproliferation in vivo and in human retinal pigment epithelial (RPE) cells in vitro.	Daunorubicin	43-53	ATP binding cassette subfamily B member 1	Homo sapiens	130-144
9430558-7	1998	RESULTS: P-glycoprotein expression was detected in 10 of 10 patients pre-exposed to intravitreal daunomycin.	Daunorubicin	97-107	ATP binding cassette subfamily B member 1	Homo sapiens	9-23
9430558-9	1998	P-glycoprotein expression was strong within 8 months after daunomycin treatment and faded thereafter.	Daunorubicin	59-69	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
9430558-12	1998	Induction of the MDR phenotype in RPE cells by daunomycin was associated with a minor increase in the mdr-1 mRNA level but a prominent increase in P-glycoprotein expression, thus suggesting a primarily translational mechanism of MDR development in human RPE cells.	Daunorubicin	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	102-107
9430558-12	1998	Induction of the MDR phenotype in RPE cells by daunomycin was associated with a minor increase in the mdr-1 mRNA level but a prominent increase in P-glycoprotein expression, thus suggesting a primarily translational mechanism of MDR development in human RPE cells.	Daunorubicin	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	147-161
9430558-13	1998	CONCLUSIONS: Intravitreal daunomycin induced P-glycoprotein expression in PVR.	Daunorubicin	26-36	ATP binding cassette subfamily B member 1	Homo sapiens	45-59
9443942-1	1998	The multidrug resistance protein (MRP) has been shown to mediate ATP-dependent efflux of anticancer agents of diverse structure, such as daunorubicin (DNR), vincristine and etoposide.	Daunorubicin	137-149	ATP binding cassette subfamily C member 1	Homo sapiens	4-32
9443942-1	1998	The multidrug resistance protein (MRP) has been shown to mediate ATP-dependent efflux of anticancer agents of diverse structure, such as daunorubicin (DNR), vincristine and etoposide.	Daunorubicin	137-149	ATP binding cassette subfamily C member 1	Homo sapiens	34-37
9443942-1	1998	The multidrug resistance protein (MRP) has been shown to mediate ATP-dependent efflux of anticancer agents of diverse structure, such as daunorubicin (DNR), vincristine and etoposide.	Daunorubicin	151-154	ATP binding cassette subfamily C member 1	Homo sapiens	4-32
9443942-1	1998	The multidrug resistance protein (MRP) has been shown to mediate ATP-dependent efflux of anticancer agents of diverse structure, such as daunorubicin (DNR), vincristine and etoposide.	Daunorubicin	151-154	ATP binding cassette subfamily C member 1	Homo sapiens	34-37
9393672-6	1997	At high levels of ADR resistance, the cells expressed the mdr3 gene concomitant with the appearance of vincristine resistance and energy-dependent daunomycin and vincristine efflux.	Daunorubicin	147-157	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	58-62
9481450-3	1997	More recently, workers have focused on induction of apoptosis and have shown that daunorubicin stimulates production of the apoptotic mediator, ceramide and that the activity of doxorubicin can be blocked by inhibitors of CD95 (fas).	Daunorubicin	82-94	Fas cell surface death receptor	Homo sapiens	222-226
9353133-1	1997	The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM).	Daunorubicin	160-172	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
9353133-1	1997	The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM).	Daunorubicin	160-172	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
9353133-1	1997	The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM).	Daunorubicin	174-177	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
9353133-1	1997	The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM).	Daunorubicin	174-177	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
9353133-2	1997	Phorbol ester (PMA), added to stimulate phosphorylation of P-gp by protein kinase C (PKC), caused a decrease in the cellular accumulation of DNR and VP-16, both in multidrug-resistant (MDR) P-gp-overexpressing cells and in wild-type cells.	Daunorubicin	141-144	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
9353133-2	1997	Phorbol ester (PMA), added to stimulate phosphorylation of P-gp by protein kinase C (PKC), caused a decrease in the cellular accumulation of DNR and VP-16, both in multidrug-resistant (MDR) P-gp-overexpressing cells and in wild-type cells.	Daunorubicin	141-144	ATP binding cassette subfamily B member 1	Homo sapiens	190-194
9334814-9	1997	Moreover, a significant correlation between MRP expression and chemoresistance against daunomycin (DM), doxorubicin (DOX), etoposide (VP-16) and vinblastine (VBL), but not cisplatin (CDDP) and bleomycin (Bleo) (MTT-based survival assay), was detected.	Daunorubicin	87-97	ATP binding cassette subfamily C member 3	Homo sapiens	44-47
9281595-6	1997	Consistent with these findings, accumulation of [3H]vincristine and [3H]VP-16 was decreased, and efflux of [3H]vincristine was increased in both murine and human MRP-transfected cell populations, whereas only human MRP-transfected cells displayed decreased accumulation and increased efflux of [3H]daunorubicin.	Daunorubicin	298-310	ATP binding cassette subfamily C member 1	Homo sapiens	162-165
9300796-1	1997	We have characterized the ATPase activity of a sensitive and five progressively daunorubicin resistant Ehrlich ascites tumor cell lines passaged in mice.	Daunorubicin	80-92	dynein, axonemal, heavy chain 8	Mus musculus	26-32
9252419-2	1997	This study reports on the localization of the binding site of P-glycoprotein for iodomycin, the Bolton-Hunter derivative of the anthracycline daunomycin.	Daunorubicin	142-152	ATP binding cassette subfamily B member 1	Homo sapiens	62-76
9639738-5	1997	RESULT: Ovarian carcinoma cells with positive MDR1 gene expression showed cross drug-resistance to ADM, daunorubicin (DNR), vincristine (VCR) and etoposide (VP-16), the value of inhibiting concentration (IC50) is 4.1-15.5 times of that of the cells with negative MDR1 gene expression.	Daunorubicin	104-116	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
9245703-4	1997	Our data have shown that out of several chemotherapeutic agents tested ethidium bromide, actinomycin C1, daunorubicin and nogalamycin were inhibitors of DNA unwinding activity of human DNA helicase II with ID50 values of 8.44 microM, 11.68 microM, 6.23 microM and 0.42 microM respectively.	Daunorubicin	105-117	X-ray repair cross complementing 5	Homo sapiens	185-200
9240970-0	1997	Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin.	Daunorubicin	118-130	coagulation factor II, thrombin	Homo sapiens	0-15
9240970-2	1997	Treatment of U937 and HL-60 cells with 0.5-1 microM of the chemotherapeutic drug daunorubicin induced a greater than 30% activation of neutral sphingomyelinase activity within 4-10 min with concomitant sphingomyelin hydrolysis and ceramide generation.	Daunorubicin	81-93	sphingomyelin phosphodiesterase 2	Homo sapiens	135-159
9240970-3	1997	DNA fragmentation and the classical morphological features of apoptosis were observed within 4-6 h. Pretreatment of cells with the serine protease inhibitors N-tosyl-L-phenylalanyl chloromethyl ketone (20 microM) or dichloroisocoumarin (20 microM) for 30 min inhibited daunorubicin-induced neutral sphingomyelinase activation, sphingomyelin hydrolysis, ceramide generation, and apoptosis.	Daunorubicin	269-281	coagulation factor II, thrombin	Homo sapiens	131-146
9199297-11	1997	Furthermore, since recent data indicate that NF-kappaB protects cells from tumor necrosis factor alpha-, ionizing radiation-, and chemotherapeutic agent daunorubicin-mediated apoptosis, our results provide an explanation for chemotherapeutic resistance in ER-negative breast cancers.	Daunorubicin	153-165	nuclear factor kappa B subunit 1	Homo sapiens	45-54
9199297-11	1997	Furthermore, since recent data indicate that NF-kappaB protects cells from tumor necrosis factor alpha-, ionizing radiation-, and chemotherapeutic agent daunorubicin-mediated apoptosis, our results provide an explanation for chemotherapeutic resistance in ER-negative breast cancers.	Daunorubicin	153-165	tumor necrosis factor	Homo sapiens	75-102
9626758-8	1997	The photoaffinity labeling as well as CyA transport by canalicular membrane vesicles were inhibited by CyA and the p-glycoprotein substrates daunomycin and PSC-833, but not by taurocholate, indicating that CyA is excreted by p-glycoprotein.	Daunorubicin	141-151	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	115-129
9626758-8	1997	The photoaffinity labeling as well as CyA transport by canalicular membrane vesicles were inhibited by CyA and the p-glycoprotein substrates daunomycin and PSC-833, but not by taurocholate, indicating that CyA is excreted by p-glycoprotein.	Daunorubicin	141-151	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	225-239
9169462-4	1997	Like paclitaxel, vinblastine, vincristine, daunomycin, and doxorubicin each caused activation of NF-kappaB.	Daunorubicin	43-53	nuclear factor kappa B subunit 1	Homo sapiens	97-106
9187258-1	1997	The expression of a P-glycoprotein (Pgp1) cDNA encoding two amino acid substitutions in the sixth transmembrane domain of the protein (G338A339 to A338P339) confers a unique cross-resistance profile that displays preferential resistance to actinomycin D and diminished resistance to colchicine and daunorubicin.	Daunorubicin	298-310	CD44 molecule (Indian blood group)	Homo sapiens	36-40
9188796-11	1997	A substrate binding site on MRP is proposed that comprises a pocket in which both DNR and GS-DNP or GSSG bind in random order to different, only partly overlapping sites.	Daunorubicin	82-85	ATP binding cassette subfamily C member 1	Homo sapiens	28-31
9148901-0	1997	Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells.	Daunorubicin	0-12	nuclear factor kappa B subunit 1	Homo sapiens	23-31
9148901-3	1997	Since the generation of ceramide has been directly linked with the activation of the transcription factor, NFkappaB, this was investigated as a novel target for the action of daunorubicin.	Daunorubicin	175-187	nuclear factor kappa B subunit 1	Homo sapiens	107-115
9148901-4	1997	Here we describe how treatment of HL-60 promyelocytes and Jurkat T lymphoma cells with daunorubicin results in the activation of the transcription factor NFkappaB.	Daunorubicin	87-99	nuclear factor kappa B subunit 1	Homo sapiens	154-162
9148901-7	1997	Daunorubicin also induced IkappaB degradation and increased the expression of an NFkappaB-linked reporter gene.	Daunorubicin	0-12	nuclear factor kappa B subunit 1	Homo sapiens	81-89
9148901-13	1997	These data therefore suggest that the effect of daunorubicin on NFkappaB is unlikely to involve ceramide, but may involve reactive oxygen species generated as a result of endogenous cellular processes rather than reductive metabolism of the drug.	Daunorubicin	48-60	nuclear factor kappa B subunit 1	Homo sapiens	64-72
9180292-1	1997	In the present study it was investigated whether and by which mechanisms the co-administration of interleukin-3 (IL-3) and the P-glycoprotein blocker PSC 833 can augment mitoxantrone (MX) and daunorubicin (DAU) cytotoxicity in two human growth factor dependent P-glycoprotein (P-gp) positive myeloid leukemic cell lines, Mo-7 and GF-D8.	Daunorubicin	192-204	interleukin 3	Homo sapiens	98-111
9180292-1	1997	In the present study it was investigated whether and by which mechanisms the co-administration of interleukin-3 (IL-3) and the P-glycoprotein blocker PSC 833 can augment mitoxantrone (MX) and daunorubicin (DAU) cytotoxicity in two human growth factor dependent P-glycoprotein (P-gp) positive myeloid leukemic cell lines, Mo-7 and GF-D8.	Daunorubicin	192-204	interleukin 3	Homo sapiens	113-117
9180292-1	1997	In the present study it was investigated whether and by which mechanisms the co-administration of interleukin-3 (IL-3) and the P-glycoprotein blocker PSC 833 can augment mitoxantrone (MX) and daunorubicin (DAU) cytotoxicity in two human growth factor dependent P-glycoprotein (P-gp) positive myeloid leukemic cell lines, Mo-7 and GF-D8.	Daunorubicin	192-204	ATP binding cassette subfamily B member 1	Homo sapiens	127-141
9180292-3	1997	Increased cytotoxicity occurred in Mo-7 cells preincubated with 24h IL-3 followed by 1 h MX (cell survival: 85% +/- 6 vs 68% +/- 2, at 0.05 microM MX, P < 0.005) or DAU (79% +/- 8 vs 62% +/- 9 at 0.8 microg/ml DAU, P < 0.05).	Daunorubicin	168-171	interleukin 3	Homo sapiens	68-72
9180292-3	1997	Increased cytotoxicity occurred in Mo-7 cells preincubated with 24h IL-3 followed by 1 h MX (cell survival: 85% +/- 6 vs 68% +/- 2, at 0.05 microM MX, P < 0.005) or DAU (79% +/- 8 vs 62% +/- 9 at 0.8 microg/ml DAU, P < 0.05).	Daunorubicin	213-216	interleukin 3	Homo sapiens	68-72
9180292-8	1997	The administration of IL-3 plus PSC 833 in the Mo-7 cell line resulted in an additive effect on DAU cytotoxicity.	Daunorubicin	96-99	interleukin 3	Homo sapiens	22-26
9180292-9	1997	At 0.8 microg/ml DAU and 2 microg/ml PSC 833, the percentage surviving cells decreased from 62% +/- 9 in the absence of IL-3 to 37% +/- 3 in the presence of IL-3 (P < 0.01).	Daunorubicin	17-20	interleukin 3	Homo sapiens	120-124
9180292-9	1997	At 0.8 microg/ml DAU and 2 microg/ml PSC 833, the percentage surviving cells decreased from 62% +/- 9 in the absence of IL-3 to 37% +/- 3 in the presence of IL-3 (P < 0.01).	Daunorubicin	17-20	interleukin 3	Homo sapiens	157-161
9180292-12	1997	In summary, the results demonstrate that the combined administration of IL-3 and PSC 833 can enhance the cytotoxic effects of DAU but not MX in these P-gp positive cell lines whereas the effects of MX could be modulated by factors which influence topo II activity.	Daunorubicin	126-129	interleukin 3	Homo sapiens	72-76
9180292-12	1997	In summary, the results demonstrate that the combined administration of IL-3 and PSC 833 can enhance the cytotoxic effects of DAU but not MX in these P-gp positive cell lines whereas the effects of MX could be modulated by factors which influence topo II activity.	Daunorubicin	126-129	ATP binding cassette subfamily B member 1	Homo sapiens	150-154
9163728-0	1997	Isolation and characterization of daunorubicin-resistant AML-2 sublines.	Daunorubicin	34-46	RUNX family transcription factor 3	Homo sapiens	57-62
9163728-1	1997	An attempt was made to isolate resistant sublines of acute myelogenous leukemia (OCI/ AML-2) cells by chronic exposure to gradually increasing concentrations of daunorubicin in order to determine the mechanism of its resistance to this drug.	Daunorubicin	161-173	RUNX family transcription factor 3	Homo sapiens	86-91
9163728-4	1997	The daunorubicin-resistant AML-2 sublines also showed cross resistance to various anticancer drugs including another anthracycline doxorubicin, a Vinca alkaloid vincristine, and an epipodophyllotoxin etoposide.	Daunorubicin	4-16	RUNX family transcription factor 3	Homo sapiens	27-32
9163728-10	1997	These daunorubicin-resistant AML-2 sublines could provide a useful model for the study of multidrug resistance mediated by PGP.	Daunorubicin	6-18	RUNX family transcription factor 3	Homo sapiens	29-34
9163728-10	1997	These daunorubicin-resistant AML-2 sublines could provide a useful model for the study of multidrug resistance mediated by PGP.	Daunorubicin	6-18	ATP binding cassette subfamily B member 1	Homo sapiens	123-126
9150390-0	1997	Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells.	Daunorubicin	61-73	BCL2 apoptosis regulator	Homo sapiens	13-18
9815696-4	1997	Functional Pgp in these tumor cells was shown by the modulatory effect of PSC833 on daunorubicin accumulation.	Daunorubicin	84-96	ATP binding cassette subfamily B member 1	Homo sapiens	11-14
9150713-2	1997	By the addition of MS-209, the intracellular daunorubicin (DNR) contents which had been found to be low in P-gp-positive AML blasts and in K562/ADM were significantly enhanced to the level of P-gp-negative blasts and that of sensitive K562.	Daunorubicin	45-57	phosphoglycolate phosphatase	Homo sapiens	107-111
9150713-2	1997	By the addition of MS-209, the intracellular daunorubicin (DNR) contents which had been found to be low in P-gp-positive AML blasts and in K562/ADM were significantly enhanced to the level of P-gp-negative blasts and that of sensitive K562.	Daunorubicin	45-57	phosphoglycolate phosphatase	Homo sapiens	192-196
9063374-8	1997	All patients had been pretreated with drugs inducing P-gp-related resistance including daunorubicin and/or doxorubicin or vindesine (CML patients).	Daunorubicin	87-99	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
9029025-6	1997	All the PGP+/LRP+/MRP- cases had a defect in IDA (mean daunorubicin (DNR) accumulation 192 +/- 44; P < 0.001).	Daunorubicin	55-67	ATP binding cassette subfamily B member 1	Homo sapiens	8-11
9029025-6	1997	All the PGP+/LRP+/MRP- cases had a defect in IDA (mean daunorubicin (DNR) accumulation 192 +/- 44; P < 0.001).	Daunorubicin	55-67	major vault protein	Homo sapiens	13-16
9029025-6	1997	All the PGP+/LRP+/MRP- cases had a defect in IDA (mean daunorubicin (DNR) accumulation 192 +/- 44; P < 0.001).	Daunorubicin	55-67	ATP binding cassette subfamily C member 3	Homo sapiens	18-21
8960067-3	1997	However, we found that exposure to 200 microM genistein elicited an elevation in intracellular accumulation of rhodamine 123 (R123) and daunorubicin (DNR) in Pgp-expressing cell lines.	Daunorubicin	136-148	ATP binding cassette subfamily B member 1	Homo sapiens	158-161
9381969-10	1997	Future work will concentrate on substituting transferrin based agents with daunorubicin or doxorubicin attached to the surface of the transferrin, and gallium or indium bound to the iron binding site, to increase efficacy of the second component of the sequential combination chemotherapy.	Daunorubicin	75-87	transferrin	Homo sapiens	134-145
9376262-6	1997	We found, in a P-gp+ leiomyosarcoma, an RF of 16 for SYTO16 and 2.7 for daunorubicin.	Daunorubicin	72-84	ATP binding cassette subfamily B member 1	Homo sapiens	15-19
9376262-7	1997	This means that complete inhibition of P-gp function in these sarcoma cells would lead to an increase of daunorubicin accumulation with 170% compared with 30% in the CD34+ cells.	Daunorubicin	105-117	ATP binding cassette subfamily B member 1	Homo sapiens	39-43
9376262-10	1997	Because the RF for SYTO16 is much higher than for daunorubicin, it can be applied for the determination of P-gp function in relatively small numbers of low-P-gp-expressing tumour cells by laser scanning microscopy.	Daunorubicin	50-62	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
9001418-1	1997	Using cyclosporin A (CsA) to inhibit P-glycoprotein (P-gp) function we showed previously that there was a discordance between the ability of acute myeloid leukemic (AML) blast cells to accumulate daunorubicin and P-gp antigen expression (Xie et al, Leukemia 1995; 9:1882-1887).	Daunorubicin	196-208	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
9001418-5	1997	Also the observed cyanide effect did not correlate with the expression of mRNA for multidrug resistance-associated protein (MRP), the only other member of the ABC family of membrane transporters that is known to be capable of effluxing daunorubicin.	Daunorubicin	236-248	ATP binding cassette subfamily C member 3	Homo sapiens	83-122
8937472-11	1996	These studies demonstrate that murine MRP, overexpressed and found predominantly in the plasma membrane of vincristine-selected PC-V40 cells, is associated with an energy-dependent increased efflux of vincristine, but not with efflux or altered distribution of daunorubicin.	Daunorubicin	261-273	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	38-41
8909298-9	1996	The P-glycoprotein-modulating agents cyclosporin A, PSC833, and verapamil, which have modest reversing effects on MRP-overexpressing cell lines, were weak competitive inhibitors of daunorubicin transport, with Ki values of 35, 84, and 95 microM, respectively.	Daunorubicin	181-193	ATP binding cassette subfamily C member 1	Homo sapiens	114-117
8944692-6	1996	Daunorubicin, vinblastine, etoposide, cyclosporin, and PSC-833, substrates/modulators of P-glycoprotein, were also potent inhibitors of E217G transport, and E217G competitively inhibited the ATP-dependent transport of daunorubicin.	Daunorubicin	0-12	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	89-103
8944692-6	1996	Daunorubicin, vinblastine, etoposide, cyclosporin, and PSC-833, substrates/modulators of P-glycoprotein, were also potent inhibitors of E217G transport, and E217G competitively inhibited the ATP-dependent transport of daunorubicin.	Daunorubicin	218-230	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	89-103
8944692-7	1996	C219, a monoclonal antibody against P-glycoprotein, inhibited ATP-dependent transport of E217G and daunorubicin but not of taurocholate or S-(2,4-dinitrophenyl)glutathione.	Daunorubicin	99-111	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	36-50
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Daunorubicin	81-91	nuclear factor kappa B subunit 1	Homo sapiens	121-130
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Daunorubicin	81-91	nuclear factor kappa B subunit 1	Homo sapiens	132-137
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Daunorubicin	81-91	RELA proto-oncogene, NF-kB subunit	Homo sapiens	138-142
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Daunorubicin	81-91	acyl-CoA thioesterase 1	Homo sapiens	153-158
8932379-7	1996	In ACH-2 cells latently infected by HIV-1, camptothecin, daunomycin and etoposide are able to enhance virus production.	Daunorubicin	57-67	acyl-CoA thioesterase 1	Homo sapiens	3-8
8864119-2	1996	The activation of the transcription factor nuclear factor-kappa B (NF-kappaB) by tumor necrosis factor (TNF), ionizing radiation, or daunorubicin (a cancer chemotherapeutic compound), was found to protect from cell killing.	Daunorubicin	133-145	nuclear factor kappa B subunit 1	Homo sapiens	43-65
8864119-2	1996	The activation of the transcription factor nuclear factor-kappa B (NF-kappaB) by tumor necrosis factor (TNF), ionizing radiation, or daunorubicin (a cancer chemotherapeutic compound), was found to protect from cell killing.	Daunorubicin	133-145	nuclear factor kappa B subunit 1	Homo sapiens	67-76
8885844-5	1996	Drug uptake assays performed with membrane vesicles prepared from NIH3T3 cells transfected with a murine MRP expression vector revealed ATP-dependent transport for the natural product cytotoxic drugs daunorubicin and vincristine, as well as for the glutathione S-conjugates leukotriene C4 and azidophenacyl-S-glutathione.	Daunorubicin	200-212	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	105-108
8906433-0	1996	Changes in cholinesterase activities after daunorubicin administration to rabbits.	Daunorubicin	43-55	cholinesterase	Oryctolagus cuniculus	11-25
8906433-2	1996	Acetyl- and butyrylcholinesterase (AChE, BuChE) activities were studied in rabbits with experimentally induced daunorubicin cardiomyopathy.	Daunorubicin	111-123	cholinesterase	Oryctolagus cuniculus	0-33
8790221-0	1996	Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET.	Daunorubicin	18-30	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	57-71
8877882-0	1996	Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles.	Daunorubicin	38-48	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-28
8877882-2	1996	Recent studies using isolated rat canalicular liver plasma membrane (cLPM) vesicles indicate that daunomycin (DNM) is a substrate for the ATP-dependent P-gp efflux system in the rat liver.	Daunorubicin	98-108	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	152-156
8877882-2	1996	Recent studies using isolated rat canalicular liver plasma membrane (cLPM) vesicles indicate that daunomycin (DNM) is a substrate for the ATP-dependent P-gp efflux system in the rat liver.	Daunorubicin	110-113	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	152-156
8877882-4	1996	The objective of this study was to examine the inhibitory effects of various organic compounds, most of which have been studied previously in MDR cancer cells, on P-gp-mediated [3H]DNM uptake into cLPM.	Daunorubicin	181-184	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	163-167
8877882-10	1996	Phosphatidylcholine, a substrate for the gene product of the class III P-gp gene, produced significant inhibition of [3H]DNM transport (30.6% at a 10-fold-higher substrate concentration), suggesting that transport may be mediated, at least in part, by this P-gp gene product.	Daunorubicin	121-124	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	71-75
8877882-10	1996	Phosphatidylcholine, a substrate for the gene product of the class III P-gp gene, produced significant inhibition of [3H]DNM transport (30.6% at a 10-fold-higher substrate concentration), suggesting that transport may be mediated, at least in part, by this P-gp gene product.	Daunorubicin	121-124	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	257-261
8687500-4	1996	Four new daunorubicin glucuronides were synthesized by coupling a glucuronide group to daunorubicin via an aliphatic (GA1 and GB1) or an aromatic (GA3, GB6) carbamate spacer, to be released by electron shift (A-type) or by ring closure (B-type).	Daunorubicin	9-21	gamma-aminobutyric acid type B receptor subunit 1	Homo sapiens	126-129
8687500-4	1996	Four new daunorubicin glucuronides were synthesized by coupling a glucuronide group to daunorubicin via an aliphatic (GA1 and GB1) or an aromatic (GA3, GB6) carbamate spacer, to be released by electron shift (A-type) or by ring closure (B-type).	Daunorubicin	9-21	succinyl-CoA:glutarate-CoA transferase	Homo sapiens	147-150
8687500-10	1996	Complete activation was confirmed in OVCAR-3 cells pretreated with a specific antibody-human beta-glucuronidase conjugate, where GA3 had similar antiproliferative effects to those of daunorubicin.	Daunorubicin	183-195	glucuronidase beta	Homo sapiens	93-111
8913437-1	1996	The effects of nine reversers of P-glycoprotein on the uptake of daunomycin into MDR1-transfected P388 cells were quantitatively determined in undiluted human or mouse plasma and compared with their effects when measurements are made in a conventional cell culture medium (RPMI 1640) containing only 10% serum.	Daunorubicin	65-75	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	81-85
8913319-2	1996	The P-glycoprotein-expressing CCRF-CEM/VLB100 subline and the MRP-expressing CCRF-CEM/E1000 subline are both 50-fold resistant to daunorubicin.	Daunorubicin	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	4-18
8913319-2	1996	The P-glycoprotein-expressing CCRF-CEM/VLB100 subline and the MRP-expressing CCRF-CEM/E1000 subline are both 50-fold resistant to daunorubicin.	Daunorubicin	130-142	ATP binding cassette subfamily C member 1	Homo sapiens	62-65
8913319-3	1996	However, accumulation of daunorubicin and rhodamine 123 was > 85% reduced in the P-glycoprotein-expressing subline compared to 40-50% in the MRP-expressing subline.	Daunorubicin	25-37	ATP binding cassette subfamily B member 1	Homo sapiens	84-98
8913319-3	1996	However, accumulation of daunorubicin and rhodamine 123 was > 85% reduced in the P-glycoprotein-expressing subline compared to 40-50% in the MRP-expressing subline.	Daunorubicin	25-37	ATP binding cassette subfamily C member 1	Homo sapiens	144-147
8692921-11	1996	The broad substrate specificity of MRP was confirmed by the observation that daunorubicin transport was competitively inhibited by reduced and oxidized glutathione, the glutathione conjugates S-(p-azidophenacyl)-glutathione (APA-SG) and S-(2,4-dinitrophenyl)glutathione (DNP-SG), arsenate, and the LTD4 antagonist MK571.	Daunorubicin	77-89	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	35-38
8688320-5	1996	Furthermore, the expression of P-glycoprotein (P-gp) and multidrug resistance-related protein (MRP), which both can contribute to resistance to daunorubicin and doxorubicin, were immunohistochemically investigated.	Daunorubicin	144-156	ATP binding cassette subfamily B member 1	Homo sapiens	31-45
8688320-5	1996	Furthermore, the expression of P-glycoprotein (P-gp) and multidrug resistance-related protein (MRP), which both can contribute to resistance to daunorubicin and doxorubicin, were immunohistochemically investigated.	Daunorubicin	144-156	ATP binding cassette subfamily B member 1	Homo sapiens	47-51
8688320-5	1996	Furthermore, the expression of P-glycoprotein (P-gp) and multidrug resistance-related protein (MRP), which both can contribute to resistance to daunorubicin and doxorubicin, were immunohistochemically investigated.	Daunorubicin	144-156	chromosome 19 open reading frame 48	Homo sapiens	95-98
8774266-11	1996	Intracellular daunorubicin accumulation increased greatly in the K562/Adm cells after they were treated with oligomers for 48 h and P-glycoprotein synthesis was strikingly reduced.	Daunorubicin	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	132-146
8875677-2	1996	Furthermore, both DT-diaphorase and glutathione (GSH) have been regarded as protective cellular compounds against daunorubicin cardiotoxicity, but their role in daunorubicin nephrotoxicity remains unclear.	Daunorubicin	114-126	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	18-31
8875677-5	1996	A significant increase of MDA concentration (2.41 vs. 1.64 p < 0.001) and DT-diaphorase activity (0.2 vs. 0.12, p < 0.001) was found in the renal tissue of daunorubicin injected rats.	Daunorubicin	162-174	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	77-90
8875677-7	1996	The results of this study give evidence that a high dosage of daunorubicin induces lipid peroxidation in renal tissue of rats stimulating the activation of DT-diaphorase and the detoxificative depletion of GSH.	Daunorubicin	62-74	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	156-169
8650203-4	1996	Expression of mouse Mdr1 in the mutant confers cross-resistance to daunomycin, quinidine, chloroquine, rhodamine 6G, and puromycin.	Daunorubicin	67-77	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	20-24
8676093-1	1996	Multidrug resistance (MDR), which is due, in part, to the overexpression of P-glycoprotein, confers resistance to a variety of natural product chemotherapeutic agents such as daunorubicin, vincristine, and colchicine.	Daunorubicin	175-187	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
8648264-4	1996	The milder GdA- variety of G6PD deficiency restricted the biotransformation of daunorubicin at therapeutic levels, in hemolysates and intact erythrocytes, within 15 minutes, for at least 24 hours.	Daunorubicin	79-91	guanine deaminase	Homo sapiens	11-14
8743082-3	1996	We show here that doxorubicin (Dox), a well-known anticancer drug and its derivative, daunomycin, inhibit the ability of Tat to activate the HIV-1 LTR.	Daunorubicin	86-96	Tat	Human immunodeficiency virus 1	121-124
9081366-13	1996	Our data point to similar, if not identical, mechanisms of drug transport by PGP and inhibition of drug transport by chemosensitisers at least for the substrates rhodamine-123, vincristine and daunomycin.	Daunorubicin	193-203	ATP binding cassette subfamily B member 1	Homo sapiens	77-80
8621644-9	1996	Consistent with the presence of overlapping but non-identical sites, studies using chemotherapeutic drugs to inhibit MRP-mediated E(2)17 beta G transport indicated that daunorubicin had the highest relative potency of the drugs tested, whereas it was the least potent inhibitor of LTC4 transport.	Daunorubicin	169-181	ATP binding cassette subfamily C member 1	Homo sapiens	117-120
9816222-6	1996	P-gp function was measured in an assay of [3H]daunomycin accumulation.	Daunorubicin	46-56	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
8616077-0	1996	Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation.	Daunorubicin	158-170	ATP binding cassette subfamily B member 1	Homo sapiens	10-14
8616077-0	1996	Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation.	Daunorubicin	158-170	ATP binding cassette subfamily C member 1	Homo sapiens	19-22
8636432-5	1996	In accordance with this localization, MRP caused increased transport of the glutathione S-conjugate S-(2, 4-dinitrophenyl)-glutathione and of the anticancer drug daunorubicin to the basal side of the epithelial cell layer.	Daunorubicin	162-174	ATP binding cassette subfamily C member 1	Homo sapiens	38-41
8643093-0	1996	Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.	Daunorubicin	125-137	ATP binding cassette subfamily B member 1	Homo sapiens	78-92
8643093-7	1996	The apparent Km values for P-glycoprotein-mediated transport, the intracellular free cytosolic drug concentrations at half-maximal velocity for the cell lines used, were approximately 2.2 microM for daunorubicin and and approximately 1 microM for idarubicin and 8-(S)-fluoroidarubicin.	Daunorubicin	199-211	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
8620441-6	1996	The effect of two classes of anthracycline (daunomycin and aclacinomycin A) and different types of intercalators (daunomycin and actinomycin D) had additive effects on induction of NPM-translocation.	Daunorubicin	44-54	nucleophosmin 1	Homo sapiens	181-184
8620441-6	1996	The effect of two classes of anthracycline (daunomycin and aclacinomycin A) and different types of intercalators (daunomycin and actinomycin D) had additive effects on induction of NPM-translocation.	Daunorubicin	114-124	nucleophosmin 1	Homo sapiens	181-184
9816184-4	1996	The fluorescent Pgp substrates daunorubicin (DNR) and rhodamine 123 (R123) were used as probes for Pgp function.	Daunorubicin	31-43	ATP binding cassette subfamily B member 1	Homo sapiens	16-19
9816184-4	1996	The fluorescent Pgp substrates daunorubicin (DNR) and rhodamine 123 (R123) were used as probes for Pgp function.	Daunorubicin	31-43	ATP binding cassette subfamily B member 1	Homo sapiens	99-102
8742366-4	1996	Whereas IFN-alpha failed to decrease significantly the ED90 of cytarabine in the three human myeloid leukemia cell lines, it significantly decreased the ED90 of carboplatin and to a lesser extent daunorubicin in both liquid suspension and agar clonogenic cultures.	Daunorubicin	196-208	interferon alpha 1	Homo sapiens	8-17
8822043-10	1996	Further, our in vitro studies demonstrated that daunorubicin interacted with calmodulin as measured by N-phenyl-1-napthylamine (NPN) fluorescence.	Daunorubicin	48-60	calmodulin 1	Rattus norvegicus	77-87
8822043-13	1996	Our results further indicate that daunorubicin interacts with calmodulin and enhances nitric oxide synthase activity which is dependent on calmodulin.	Daunorubicin	34-46	calmodulin 1	Rattus norvegicus	62-72
8822043-13	1996	Our results further indicate that daunorubicin interacts with calmodulin and enhances nitric oxide synthase activity which is dependent on calmodulin.	Daunorubicin	34-46	calmodulin 1	Rattus norvegicus	139-149
8575863-5	1996	We could also show that the combination of suboptimal doses of these blockers can restore the uptake of the Pgp substrate rhodamine 123 into L1210MDR, 3T3MDR and KB-VI cells and can reduce the survival rate of these cells when treated in combination with daunorubicin.	Daunorubicin	255-267	phosphoglycolate phosphatase	Mus musculus	108-111
8862011-1	1996	We investigated the expression of P-glycoprotein (P-gp) in 50 adults with de novo acute myeloid leukemia (AML) at the initial diagnosis in order to further define the relationship between the presence of P-gp on leukemic cells and the efficacy of two different anthracycline drugs, Daunorubicin (DNR) and Idarubicin (IRR), in terms of remission, induction and survival.	Daunorubicin	282-294	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
8599980-9	1996	G-CSF significantly enhanced the cytotoxic effect of daunorubicin, mitoxantrone, etoposide and Ara-C by 20-40%, which GM-CSF and IL-3 showed a significantly increased toxicity for Ara-C only.	Daunorubicin	53-65	colony stimulating factor 3	Homo sapiens	0-5
8599980-9	1996	G-CSF significantly enhanced the cytotoxic effect of daunorubicin, mitoxantrone, etoposide and Ara-C by 20-40%, which GM-CSF and IL-3 showed a significantly increased toxicity for Ara-C only.	Daunorubicin	53-65	interleukin 3	Homo sapiens	129-133
8558937-10	1996	The blast cells with MRP mRNA expression higher than HL-60/W had a lower median accumulation of daunorubicin compared to those whose MRP expression was less than HL-60/W, suggesting a functional defect in drug transport in the cells with higher MRP expression; a similar trend toward lower daunorubicin accumulation was also noted in the one-third of samples that displayed the highest expression of MDR1 mRNA (also determined by RT-PCR).	Daunorubicin	96-108	ATP binding cassette subfamily C member 3	Homo sapiens	21-24
8558937-10	1996	The blast cells with MRP mRNA expression higher than HL-60/W had a lower median accumulation of daunorubicin compared to those whose MRP expression was less than HL-60/W, suggesting a functional defect in drug transport in the cells with higher MRP expression; a similar trend toward lower daunorubicin accumulation was also noted in the one-third of samples that displayed the highest expression of MDR1 mRNA (also determined by RT-PCR).	Daunorubicin	96-108	ATP binding cassette subfamily B member 1	Homo sapiens	400-404
8558937-10	1996	The blast cells with MRP mRNA expression higher than HL-60/W had a lower median accumulation of daunorubicin compared to those whose MRP expression was less than HL-60/W, suggesting a functional defect in drug transport in the cells with higher MRP expression; a similar trend toward lower daunorubicin accumulation was also noted in the one-third of samples that displayed the highest expression of MDR1 mRNA (also determined by RT-PCR).	Daunorubicin	290-302	ATP binding cassette subfamily C member 3	Homo sapiens	21-24
8558937-12	1996	The identification of MRP overexpression in MDR AML cell lines and in some AML patient blast cells with low intracellular daunorubicin accumulation warrants further study of MRP as a component of clinical drug resistance in AML.	Daunorubicin	122-134	ATP binding cassette subfamily C member 3	Homo sapiens	22-25
8895200-2	1996	The PKC activator 12-O-tetradecanoylphorbol-13-acetate (TPA) reduced daunomycin accumulation in both drug-sensitive KB-3-1 and MDR KB-C1 cells in a time-dependent manner.	Daunorubicin	69-79	proline rich transmembrane protein 2	Homo sapiens	4-7
8895200-8	1996	We therefore propose that the TPA-induced reduction in daunomycin accumulation in KB cells is due to a PKC-mediated process, which is maintained after depletion of certain PKC subspecies or is due to activation of downregulation insensitive PKC subspecies.	Daunorubicin	55-65	proline rich transmembrane protein 2	Homo sapiens	103-106
21594339-0	1996	Melanoma-specific cytotoxicity of a human MGSA/GRO alpha C-terminal peptide conjugated to daunorubicin.	Daunorubicin	90-102	C-X-C motif chemokine ligand 1	Homo sapiens	42-46
8847145-0	1995	On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP).	Daunorubicin	66-78	ATP binding cassette subfamily C member 3	Homo sapiens	145-184
8847145-0	1995	On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP).	Daunorubicin	66-78	ATP binding cassette subfamily C member 3	Homo sapiens	186-189
8521976-1	1995	A conjugate of the antineoplastic drug daunomycin (DNM) with maleylated bovine serum albumin (MBSA-DNM) was taken up with high efficiency by a multidrug resistant variant, JD100, of the murine-macrophage tumour cell line, J774A.1, through the scavenger receptors resulting in cessation of DNA synthesis.	Daunorubicin	39-49	albumin	Mus musculus	79-92
8521976-1	1995	A conjugate of the antineoplastic drug daunomycin (DNM) with maleylated bovine serum albumin (MBSA-DNM) was taken up with high efficiency by a multidrug resistant variant, JD100, of the murine-macrophage tumour cell line, J774A.1, through the scavenger receptors resulting in cessation of DNA synthesis.	Daunorubicin	51-54	albumin	Mus musculus	79-92
7499263-6	1995	A substrate for the P-glycoprotein-mediated drug pump, vincristine or daunomycin, did not prevent swelling-induced activation of the Cl- current.	Daunorubicin	70-80	ATP binding cassette subfamily B member 1	Homo sapiens	20-34
7585598-4	1995	MRP transfectants displayed increased resistance to several lipophilic drugs, including doxorubicin, daunorubicin, etoposide, actinomycin D, vincristine, and vinblastine.	Daunorubicin	101-113	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	0-3
7585598-8	1995	Analysis of drug kinetics using radiolabeled daunorubicin revealed decreased accumulation and increased efflux in MRP transfectants.	Daunorubicin	45-57	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	114-117
7585598-9	1995	Confocal microscopic analysis of intracellular daunorubicin in MRP transfectants was consistent with reduced intracellular drug concentrations, and also revealed an altered pattern of intracellular drug distribution characterized by the initial accumulation of drug in a perinuclear location, followed by the development of a punctate pattern of drug scattered throughout the cytoplasm.	Daunorubicin	47-59	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	63-66
8586906-0	1995	Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia.	Daunorubicin	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	57-71
8586906-1	1995	Intracellular accumulation of free or thermosensitive liposome-encapsulated daunorubicin (TLED) at 37 or 43 degrees C, was evaluated using flow cytometry in chemosensitive and P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells.	Daunorubicin	76-88	ATP binding cassette subfamily B member 1	Homo sapiens	176-190
7475279-2	1995	Transport function was assessed by measuring the modulating effect of the Pgp inhibitor cyclosporin A (CsA) on the cellular accumulation of daunorubicin, and Pgp antigen expression by surface immunofluorescence using the MRK-16 antibody.	Daunorubicin	140-152	ATP binding cassette subfamily B member 1	Homo sapiens	74-77
7475279-6	1995	Despite the additional refinements of neuraminidase treatment and antigen quantification, the correlation between Pgp antigen expression and daunorubicin accumulation remained extremely weak (r = 0.11; P = 0.63).	Daunorubicin	141-153	ATP binding cassette subfamily B member 1	Homo sapiens	114-117
7553643-0	1995	Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.	Daunorubicin	19-31	carbonyl reductase 1	Homo sapiens	77-95
7553643-1	1995	Carbonyl reductase (CBR) catalyzes the reduction of daunorubicin (DN) to its corresponding alcohol, daunorubicinol (DNOL), and changes the pharmacological properties of this cancer chemotherapeutic drug.	Daunorubicin	52-64	carbonyl reductase 1	Homo sapiens	0-18
7553643-1	1995	Carbonyl reductase (CBR) catalyzes the reduction of daunorubicin (DN) to its corresponding alcohol, daunorubicinol (DNOL), and changes the pharmacological properties of this cancer chemotherapeutic drug.	Daunorubicin	52-64	carbonyl reductase 1	Homo sapiens	20-23
7553643-1	1995	Carbonyl reductase (CBR) catalyzes the reduction of daunorubicin (DN) to its corresponding alcohol, daunorubicinol (DNOL), and changes the pharmacological properties of this cancer chemotherapeutic drug.	Daunorubicin	66-68	carbonyl reductase 1	Homo sapiens	0-18
7553643-1	1995	Carbonyl reductase (CBR) catalyzes the reduction of daunorubicin (DN) to its corresponding alcohol, daunorubicinol (DNOL), and changes the pharmacological properties of this cancer chemotherapeutic drug.	Daunorubicin	66-68	carbonyl reductase 1	Homo sapiens	20-23
7553643-2	1995	The DN reductase associated with CBR reduces the C13 methyl ketone group and does not metabolize the quinone ring of DN.	Daunorubicin	4-6	carbonyl reductase 1	Homo sapiens	33-36
7553643-6	1995	CBR activity increased 83-fold in the K562-transfected cells and was associated with a 2-3-fold reduction in DN toxicity.	Daunorubicin	109-111	carbonyl reductase 1	Homo sapiens	0-3
8673023-2	1995	Conjugates of alpha-fetoprotein with doxorubicin, daunomycin, calichemicin, carboxyphosphamide, bleomycetin, chlorbutin, cis-platinum, methotrexate were synthesized.	Daunorubicin	50-60	alpha fetoprotein	Homo sapiens	14-31
7575653-0	1995	Behavior of N-acylated daunorubicins in MDR1 gene transfected and parental cells.	Daunorubicin	23-36	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
7575653-1	1995	The substrate specificity of the P-glycoprotein (P-170), a multidrug transporter, was studied using N-acylated daunorubicin derivatives and four MDR1 cDNA transfected cell lines.	Daunorubicin	111-123	ATP binding cassette subfamily B member 1	Homo sapiens	33-47
7644478-4	1995	Glutathione depletion resulted in a decreased efflux of daunorubicin from MRP-transfected cells, but not from MDR1-transfected cells, suggesting that glutathione is specifically required for the export of drugs from cells by MRP.	Daunorubicin	56-68	ATP binding cassette subfamily C member 3	Homo sapiens	74-77
7644478-4	1995	Glutathione depletion resulted in a decreased efflux of daunorubicin from MRP-transfected cells, but not from MDR1-transfected cells, suggesting that glutathione is specifically required for the export of drugs from cells by MRP.	Daunorubicin	56-68	ATP binding cassette subfamily C member 3	Homo sapiens	225-228
7579561-3	1995	The intracellular concentrations of epirubicin (EPIR), daunomycin (DM), adriamycin (ADM) and THP-adriamycin (THP) were increased by the addition of CsA or FK506 in VJ-300, but not in KB cells.	Daunorubicin	55-65	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	148-151
7579561-3	1995	The intracellular concentrations of epirubicin (EPIR), daunomycin (DM), adriamycin (ADM) and THP-adriamycin (THP) were increased by the addition of CsA or FK506 in VJ-300, but not in KB cells.	Daunorubicin	67-69	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	148-151
7587719-0	1995	Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.	Daunorubicin	122-134	ATP binding cassette subfamily B member 1	Homo sapiens	138-152
7628644-3	1995	Intracellular glutathione (GSH) depletion which occurred when cells were exposed to buthionine sulfoximine had no effect on the efflux of calcein, whereas it reversed the daunorubicin accumulation deficit in MRP overexpressing tumor cells.	Daunorubicin	171-183	ATP binding cassette subfamily C member 1	Homo sapiens	208-211
7628644-4	1995	In conclusion, ATP-dependent transport of calcein and possibly other organic anions by MRP is not inhibited by a large decrease of the intracellular GSH concentration, that inhibits daunorubicin efflux by MRP.	Daunorubicin	182-194	ATP binding cassette subfamily C member 1	Homo sapiens	205-208
7632166-4	1995	The other drugs--haloperidol, metyrapone, loxoprofen, daunorubicin and acetohexamide--were highly reduced by carbonyl reductase and/or aldehyde reductase.	Daunorubicin	54-66	aldo-keto reductase family 1 member A1	Homo sapiens	135-153
7599070-6	1995	The effects of BSO on daunorubicin accumulation in the COR-L23/R and GLC4/ADR cells were associated with cellular GSH depletion.	Daunorubicin	22-34	aldo-keto reductase family 1 member B	Homo sapiens	74-77
8523640-4	1995	All those who were receiving hydroxyurea did not fare well but one who was put on DAT (daunorubicin, cyftosine arabinocide, 6 thioguanine)regimen went into remission with complete disappearance of lesions.	Daunorubicin	87-99	solute carrier family 6 member 3	Homo sapiens	82-85
7637207-4	1995	3) Daunomycin-induced nephrotic rats showed increases in the content of apo B-48 and C-III, and a decrease in that of apo E in chylomicron.	Daunorubicin	3-13	apolipoprotein E	Rattus norvegicus	118-123
7637207-5	1995	The apoprotein composition of VLDL in daunomycin-induced nephrotic rats showed increased apo B and decreased apo E.	Daunorubicin	38-48	apolipoprotein E	Rattus norvegicus	109-114
7582860-0	1995	Daunomycin inhibits insulin-like growth factor I-dependent protein tyrosine phosphorylation.	Daunorubicin	0-10	insulin-like growth factor 1	Rattus norvegicus	20-48
7582860-1	1995	The effect of the antitumor antibiotic daunomycin (DN) was studied on insulin-like growth factor I (IGF-I)-dependent protein tyrosine phosphorylation.	Daunorubicin	39-49	insulin-like growth factor 1	Rattus norvegicus	70-98
7582860-1	1995	The effect of the antitumor antibiotic daunomycin (DN) was studied on insulin-like growth factor I (IGF-I)-dependent protein tyrosine phosphorylation.	Daunorubicin	39-49	insulin-like growth factor 1	Rattus norvegicus	100-105
7582860-1	1995	The effect of the antitumor antibiotic daunomycin (DN) was studied on insulin-like growth factor I (IGF-I)-dependent protein tyrosine phosphorylation.	Daunorubicin	51-53	insulin-like growth factor 1	Rattus norvegicus	70-98
7582860-1	1995	The effect of the antitumor antibiotic daunomycin (DN) was studied on insulin-like growth factor I (IGF-I)-dependent protein tyrosine phosphorylation.	Daunorubicin	51-53	insulin-like growth factor 1	Rattus norvegicus	100-105
7582860-2	1995	DN was found to inhibit IGF-I-dependent phosphorylation of the artificial substrate poly(Glu:Tyr)4:1 by intrinsic IGF-I receptor kinase either from mouse cerebellum or from rat spinal cord.	Daunorubicin	0-2	insulin-like growth factor 1	Mus musculus	24-29
7582860-2	1995	DN was found to inhibit IGF-I-dependent phosphorylation of the artificial substrate poly(Glu:Tyr)4:1 by intrinsic IGF-I receptor kinase either from mouse cerebellum or from rat spinal cord.	Daunorubicin	0-2	insulin-like growth factor I receptor	Mus musculus	114-128
7582860-5	1995	The IGF-I-dependent protein tyrosine phosphorylation of endogenous proteins of the rat spinal cord was also inhibited by 50 microM DN.	Daunorubicin	131-133	insulin-like growth factor 1	Rattus norvegicus	4-9
7670142-3	1995	The P-glycoprotein expressing, multidrug resistant sublines developed to daunorubicin (K/DNR), doxorubicin (K/DOX) and epirubicin (K/EPR) were cross-resistant to the other anthracyclines and to vinblastine, taxol, colchicine and actinomycin D, but were not resistant to idarubicin or etoposide.	Daunorubicin	73-85	ATP binding cassette subfamily B member 1	Homo sapiens	4-18
7794760-5	1995	We report a comparison of the effects of PSC 833 and CSA on daunorubicin (DAU) transport kinetics and chemosensitivity in these cell lines.	Daunorubicin	60-72	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	53-56
7794760-5	1995	We report a comparison of the effects of PSC 833 and CSA on daunorubicin (DAU) transport kinetics and chemosensitivity in these cell lines.	Daunorubicin	74-77	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	53-56
7794760-6	1995	Both CEM/VBL100 and K562 cl.6 DAU-resistant cells displayed high levels of P-glycoprotein (PGP), decreased DAU accumulation and increased DAU efflux when compared to their parental cells.	Daunorubicin	30-33	ATP binding cassette subfamily B member 1	Homo sapiens	75-89
7794760-6	1995	Both CEM/VBL100 and K562 cl.6 DAU-resistant cells displayed high levels of P-glycoprotein (PGP), decreased DAU accumulation and increased DAU efflux when compared to their parental cells.	Daunorubicin	30-33	ATP binding cassette subfamily B member 1	Homo sapiens	91-94
7794760-7	1995	PSC 833 was 1.6-, 3.4-, 4.9- and 4.6-fold more effective than CSA in reversing DAU resistance in higher resistance CEM/VLB100, K/DAU400, K/DAU500 and K/DAU600 cells respectively.	Daunorubicin	79-82	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	62-65
7794760-8	1995	DAU transport kinetics showed that PSC 833 was more effective than CSA in increasing cellular DAU accumulation and decreasing DAU efflux in higher resistant leukaemia subclones.	Daunorubicin	94-97	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	67-70
7794760-8	1995	DAU transport kinetics showed that PSC 833 was more effective than CSA in increasing cellular DAU accumulation and decreasing DAU efflux in higher resistant leukaemia subclones.	Daunorubicin	94-97	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	67-70
7734315-2	1995	The induction of mdr1 RNA expression by three anthracyclines, (doxorubicin, daunorubicin, epirubicin), VP-16 and two vinca alkaloids (vincristine, vinblastine) was semiquantitatively assessed by scanning Northern blots on a phosphorimager.	Daunorubicin	76-88	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
7734315-4	1995	A significant increase (P < 0.02) in expression of mdr1 was noted within 4 hrs of exposure to 1.5 micrograms ml-1 daunorubicin or epirubicin.	Daunorubicin	117-129	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
7734315-6	1995	With increasing concentrations of daunorubicin or epirubicin in a fixed 24 h time period, mdr1 expression increased, although a biphasic response was seen.	Daunorubicin	34-46	ATP binding cassette subfamily B member 1	Homo sapiens	90-94
7734315-7	1995	Based on MRK 16 binding, an increase in P-gp levels was seen in the CEM/A7R line after a 24 h exposure to 1 microgram ml-1 daunorubicin or epirubicin.	Daunorubicin	123-135	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
7734315-8	1995	The rapid increase in mdr1 expression after a short period of exposure to doxorubicin, daunorubicin or epirubicin suggests that induction of mdr1 expression may have an important role in the development of drug-resistant tumours.	Daunorubicin	87-99	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
7734315-8	1995	The rapid increase in mdr1 expression after a short period of exposure to doxorubicin, daunorubicin or epirubicin suggests that induction of mdr1 expression may have an important role in the development of drug-resistant tumours.	Daunorubicin	87-99	ATP binding cassette subfamily B member 1	Homo sapiens	141-145
7769842-7	1995	Daunorubicin (DNR) accumulation studies showed that inhibitors of P-gp increased DNR accumulation only in the immature AML cells whereas they had no impact on the mature AML cell lines.	Daunorubicin	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
7769842-7	1995	Daunorubicin (DNR) accumulation studies showed that inhibitors of P-gp increased DNR accumulation only in the immature AML cells whereas they had no impact on the mature AML cell lines.	Daunorubicin	14-17	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
7656812-7	1995	However, the resistances of K562/Dox cells to epirubicin and daunorubicin still remained for about 5.6 and > 6.6 folds, respectively, even at verapamil concentration of 6 mumol/L, suggesting at least a relatively big fraction of drug resistance was not directly related to the altered cellular pharmacokinetics associated with overexpression of P-glycoprotein.	Daunorubicin	61-73	ATP binding cassette subfamily B member 1	Homo sapiens	348-362
7840607-4	1995	Stimulation of ATPase activity of purified, reconstituted P-glycoprotein by vinblastine, colchicine, and daunomycin was seen with sheep brain and bovine liver lipids, but not with E. coli lipids.	Daunorubicin	105-115	multidrug resistance protein 1	Ovis aries	58-72
7840607-6	1995	Azidopine labeling of the drug binding sites in purified, reconstituted P-glycoprotein was carried out; vinblastine, colchicine, and daunomycin competed for labeling in all three lipids.	Daunorubicin	133-143	multidrug resistance protein 1	Ovis aries	72-86
7819048-5	1995	Experiments with the P-95 positive MCF-7 multidrug-resistant subline demonstrated decreased daunorubicin accumulation and retention relative to the sensitive parent line.	Daunorubicin	92-104	nibrin	Homo sapiens	21-25
7819048-6	1995	AML blast cells positive for P-95 also demonstrated greater overall in vitro survival in the presence of daunorubicin relative to the P-95-negative samples.	Daunorubicin	105-117	nibrin	Homo sapiens	29-33
9106395-2	1995	However, it is determined in this study that murine L929 fibrosarcoma cells, when pretreated with bovine testicular hyaluronidase for 12-24 h, became resistant to the cytotoxic effect of TNF-alpha in the presence of DNA intercalators, such as ActD, doxorubicin, and daunorubicin.	Daunorubicin	266-278	tumor necrosis factor	Bos taurus	187-196
7659186-1	1995	A set of multidrug resistant (MDR) murine leukemia P388 sublines processing 30-50-fold mdr1 gene amplification was obtained as a result of experimental chemotherapy with rubomycin, ruboxyl, vinblastine, vincristine, or combination of rubomycin and vincristine.	Daunorubicin	170-179	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-33
7659186-1	1995	A set of multidrug resistant (MDR) murine leukemia P388 sublines processing 30-50-fold mdr1 gene amplification was obtained as a result of experimental chemotherapy with rubomycin, ruboxyl, vinblastine, vincristine, or combination of rubomycin and vincristine.	Daunorubicin	234-243	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	30-33
8835287-3	1995	Dihydrocytochalasin B and cytochalasin E consistently sensitized P-glycoprotein-overexpressing human breast carcinoma cells (MCF-7/ADR) to daunomycin, vinblastine, and actinomycin D without affecting the cytotoxicity of cisplatin.	Daunorubicin	139-149	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
7773504-18	1995	This indicates that in resistant cells intracellular DAU at least in part may be inaccessible for P-Gp and that vesicular drug transport appears to contribute to DAU resistance by removing intracellular DAU via exocytosis.	Daunorubicin	53-56	phosphoglycolate phosphatase	Homo sapiens	98-102
7816612-4	1994	Daunomycin did indeed alter the binding of actinomycin to the DNA, such that the antibiotic was displaced from its primary GpC sites onto secondary sites in the DNA, though not to AT regions especially.	Daunorubicin	0-10	glycophorin C (Gerbich blood group)	Homo sapiens	123-126
7977168-2	1994	The increased uptake of liposomes by colon adenocarcinoma cell lines may enable DaunoXome to circumvent the p-glycoprotein-mediated anthracycline resistance of colon cancer cells.	Daunorubicin	80-89	ATP binding cassette subfamily B member 1	Homo sapiens	108-122
7727866-6	1994	The detection of functional GP170 can be identified by rhodamine or daunorubicin intracellular accumulation with flux cytometry or by scintigraphically imaging GP170 expression in vivo with Tc-Sestamibi.	Daunorubicin	68-80	ATP binding cassette subfamily B member 1	Homo sapiens	28-33
21559714-1	1994	Pluronic P-85 (poly(55)(oxypropylene)dipoly(s)(oxyethylene)) was used to form daunorubicin containing micelles.	Daunorubicin	78-90	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	9-13
7807996-13	1994	OCI/AML-2 cells treated with HC before drug accumulated fewer cells with nicked DNA after daunorubicin (DNR).	Daunorubicin	90-102	RUNX family transcription factor 3	Homo sapiens	4-9
7986198-12	1994	In conclusion, the greater intracellular drug tolerance that MDR cells show for DAU compared to IDA makes IDA more effective than DAU in MDR cells overexpressing P-glycoprotein (P-gp).	Daunorubicin	80-83	ATP binding cassette subfamily B member 1	Homo sapiens	162-176
7986198-12	1994	In conclusion, the greater intracellular drug tolerance that MDR cells show for DAU compared to IDA makes IDA more effective than DAU in MDR cells overexpressing P-glycoprotein (P-gp).	Daunorubicin	80-83	ATP binding cassette subfamily B member 1	Homo sapiens	178-182
7986198-12	1994	In conclusion, the greater intracellular drug tolerance that MDR cells show for DAU compared to IDA makes IDA more effective than DAU in MDR cells overexpressing P-glycoprotein (P-gp).	Daunorubicin	130-133	ATP binding cassette subfamily B member 1	Homo sapiens	162-176
7986198-12	1994	In conclusion, the greater intracellular drug tolerance that MDR cells show for DAU compared to IDA makes IDA more effective than DAU in MDR cells overexpressing P-glycoprotein (P-gp).	Daunorubicin	130-133	ATP binding cassette subfamily B member 1	Homo sapiens	178-182
7948045-4	1994	Externally added catalase and desferrioxamine mesylate protected against the additional cytotoxicity of daunomycin in differentiated cells, pointing to hydrogen peroxide and iron ions as mediators of the toxic effect.	Daunorubicin	104-114	catalase	Homo sapiens	17-25
7927929-0	1994	Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells.	Daunorubicin	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	60-74
7934168-5	1994	When the frequency of additive and synergistic interactions were calculated according to the multiplicative concept for drug interactions, the highest frequencies were observed for CdA+AraC and CdA+Dnr.	Daunorubicin	198-201	cytidine deaminase	Homo sapiens	181-184
7934168-5	1994	When the frequency of additive and synergistic interactions were calculated according to the multiplicative concept for drug interactions, the highest frequencies were observed for CdA+AraC and CdA+Dnr.	Daunorubicin	198-201	cytidine deaminase	Homo sapiens	194-197
7808368-9	1994	In leukemias we administered vincristine (1.5 mg/m2), and daunomycin (40 mg/m2), in solid tumors VP16 (150 mg/m2) and adriamycin (60 mg/m2).	Daunorubicin	58-68	host cell factor C1	Homo sapiens	97-101
7945406-0	1994	Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.	Daunorubicin	58-70	ATP binding cassette subfamily C member 1	Homo sapiens	91-94
7945406-2	1994	We have recently reported that daunorubicin (DNR) accumulation was decreased in the multidrug resistance-associated protein overexpressing GLC4/ADR non-Pgp MDR small cell lung cancer cell line due to an enhanced energy-dependent efflux which could be inhibited by the isoflavonoid genistein.	Daunorubicin	31-43	ATP binding cassette subfamily C member 3	Homo sapiens	84-123
7945406-2	1994	We have recently reported that daunorubicin (DNR) accumulation was decreased in the multidrug resistance-associated protein overexpressing GLC4/ADR non-Pgp MDR small cell lung cancer cell line due to an enhanced energy-dependent efflux which could be inhibited by the isoflavonoid genistein.	Daunorubicin	31-43	aldo-keto reductase family 1 member B	Homo sapiens	144-147
7945406-2	1994	We have recently reported that daunorubicin (DNR) accumulation was decreased in the multidrug resistance-associated protein overexpressing GLC4/ADR non-Pgp MDR small cell lung cancer cell line due to an enhanced energy-dependent efflux which could be inhibited by the isoflavonoid genistein.	Daunorubicin	31-43	phosphoglycolate phosphatase	Homo sapiens	152-155
7945406-2	1994	We have recently reported that daunorubicin (DNR) accumulation was decreased in the multidrug resistance-associated protein overexpressing GLC4/ADR non-Pgp MDR small cell lung cancer cell line due to an enhanced energy-dependent efflux which could be inhibited by the isoflavonoid genistein.	Daunorubicin	45-48	ATP binding cassette subfamily C member 3	Homo sapiens	84-123
7945406-2	1994	We have recently reported that daunorubicin (DNR) accumulation was decreased in the multidrug resistance-associated protein overexpressing GLC4/ADR non-Pgp MDR small cell lung cancer cell line due to an enhanced energy-dependent efflux which could be inhibited by the isoflavonoid genistein.	Daunorubicin	45-48	aldo-keto reductase family 1 member B	Homo sapiens	144-147
7945406-2	1994	We have recently reported that daunorubicin (DNR) accumulation was decreased in the multidrug resistance-associated protein overexpressing GLC4/ADR non-Pgp MDR small cell lung cancer cell line due to an enhanced energy-dependent efflux which could be inhibited by the isoflavonoid genistein.	Daunorubicin	45-48	phosphoglycolate phosphatase	Homo sapiens	152-155
7916458-3	1994	MRP-overexpressing SW-1573 cells are resistant to doxorubicin, daunorubicin, vincristine, VP-16, colchicine, and rhodamine 123, but not to 4"-(9-acridinylamino)methanesulfon-m-anisidide or taxol.	Daunorubicin	63-75	ATP binding cassette subfamily C member 1	Homo sapiens	0-3
7916458-5	1994	The decreased accumulation of daunorubicin is abolished by permeabilization of the plasma membrane with digitonin, showing that MRP can lower the intracellular daunorubicin level against a concentration gradient.	Daunorubicin	30-42	ATP binding cassette subfamily C member 1	Homo sapiens	128-131
7916458-5	1994	The decreased accumulation of daunorubicin is abolished by permeabilization of the plasma membrane with digitonin, showing that MRP can lower the intracellular daunorubicin level against a concentration gradient.	Daunorubicin	160-172	ATP binding cassette subfamily C member 1	Homo sapiens	128-131
7849073-3	1994	GOx was covalently derivatized using 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide and N-hydroxysulfosuccinimide to form amide bonds between the aliphatic primary amine groups on daunomycin and dopamine and carboxylate side chains of aspartate and glutamate residues.	Daunorubicin	181-191	hydroxyacid oxidase 1	Homo sapiens	0-3
7849073-4	1994	Derivatives with 2.5 +/- 0.1 daunomycin groups and 4 +/- 1 dopamine groups were obtained, with activities of 50% and 75%, respectively, relative to native GOx in a dye-peroxidase assay.	Daunorubicin	29-39	hydroxyacid oxidase 1	Homo sapiens	155-158
8001461-8	1994	However, in a subset of patients, a striking correlation (r = .97, P = .001) was noted between the presence of gp180 as determined by the D value and the functional activity of the P-glycoprotein as expressed by increased daunorubicin accumulation in the presence of verapamil.	Daunorubicin	222-234	protein tyrosine phosphatase receptor type C	Homo sapiens	111-116
7914421-6	1994	The expressed ribozyme decreased the level of mdr1 mRNA expression, inhibited the formation of P-glycoprotein and reduced the cell"s resistance to daunorubicin dramatically; this means that the resistant cells were 1,600-fold more resistant than the parental cell line (EPP85-181P), whereas those cell clones that showed ribozyme expression were only 5.3-fold more resistant than the parental cell line.	Daunorubicin	147-159	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
7914421-6	1994	The expressed ribozyme decreased the level of mdr1 mRNA expression, inhibited the formation of P-glycoprotein and reduced the cell"s resistance to daunorubicin dramatically; this means that the resistant cells were 1,600-fold more resistant than the parental cell line (EPP85-181P), whereas those cell clones that showed ribozyme expression were only 5.3-fold more resistant than the parental cell line.	Daunorubicin	147-159	ATP binding cassette subfamily B member 1	Homo sapiens	95-109
7914424-0	1994	Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.	Daunorubicin	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	55-69
7914424-1	1994	The aim of this study was to examine the relationship between the pharmacokinetics of daunorubicin (DNR), overexpression of P-glycoprotein (Pgp) and treatment response in acute leukaemia.	Daunorubicin	86-98	ATP binding cassette subfamily B member 1	Homo sapiens	124-138
7914424-1	1994	The aim of this study was to examine the relationship between the pharmacokinetics of daunorubicin (DNR), overexpression of P-glycoprotein (Pgp) and treatment response in acute leukaemia.	Daunorubicin	86-98	ATP binding cassette subfamily B member 1	Homo sapiens	140-143
7912556-6	1994	In the 15 P-glycoprotein-positive samples, a significant increase in daunorubicin fluorescence, by at least one reversing agent, was seen in 10 cases, among which S9788 reversing activity was higher than that of the two other agents in seven cases.	Daunorubicin	69-81	ATP binding cassette subfamily B member 1	Homo sapiens	10-24
7913494-6	1994	Qualitatively similar results were observed with daunomycin, a well established substrate for P-glycoprotein.	Daunorubicin	49-59	ATP binding cassette subfamily B member 1	Homo sapiens	94-108
7913318-0	1994	Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.	Daunorubicin	12-24	phosphoglycolate phosphatase	Mus musculus	95-109
7912204-0	1994	Cooperative P-glycoprotein mediated daunorubicin transport into DNA-loaded plasma membrane vesicles.	Daunorubicin	36-48	ATP binding cassette subfamily B member 1	Homo sapiens	12-26
7909523-5	1994	ATP-dependent transport of the permanently charged amphiphilic cations was inhibited by the P-glycoprotein inhibitors and substrates quinidine, verapamil, and daunorubicin.	Daunorubicin	159-171	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	92-106
7909435-4	1994	We found that colchicine, vinblastine, daunomycin and verapamil (50 microM) caused block of a 40 pS outwardly-rectifying chloride channel in cells expressing P-glycoprotein.	Daunorubicin	39-49	ATP binding cassette subfamily B member 1	Homo sapiens	158-172
7914109-1	1994	The low daunomycin (DAU) retention in P388 cells displaying P-glycoprotein (Pgp)-mediated multidrug resistance (MDR) can be increased by the presence of various resistance-modifying agents (RMAs).	Daunorubicin	8-18	phosphoglycolate phosphatase	Mus musculus	60-74
7914109-1	1994	The low daunomycin (DAU) retention in P388 cells displaying P-glycoprotein (Pgp)-mediated multidrug resistance (MDR) can be increased by the presence of various resistance-modifying agents (RMAs).	Daunorubicin	8-18	phosphoglycolate phosphatase	Mus musculus	76-79
7914109-1	1994	The low daunomycin (DAU) retention in P388 cells displaying P-glycoprotein (Pgp)-mediated multidrug resistance (MDR) can be increased by the presence of various resistance-modifying agents (RMAs).	Daunorubicin	20-23	phosphoglycolate phosphatase	Mus musculus	60-74
7914109-1	1994	The low daunomycin (DAU) retention in P388 cells displaying P-glycoprotein (Pgp)-mediated multidrug resistance (MDR) can be increased by the presence of various resistance-modifying agents (RMAs).	Daunorubicin	20-23	phosphoglycolate phosphatase	Mus musculus	76-79
7909520-0	1994	The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate.	Daunorubicin	104-116	ATP binding cassette subfamily B member 1	Homo sapiens	69-83
7909520-11	1994	These and other observations are in agreement with a model in which daunorubicin and verapamil are non-competing substrates for P-glycoprotein.	Daunorubicin	68-80	ATP binding cassette subfamily B member 1	Homo sapiens	128-142
7909520-12	1994	In conclusion, we obtained evidence that verapamil is actively transported by the MDR-related P-glycoprotein and that verapamil and daunorubicin are non-competing substrates for P-glycoprotein.	Daunorubicin	132-144	ATP binding cassette subfamily B member 1	Homo sapiens	94-108
7909520-12	1994	In conclusion, we obtained evidence that verapamil is actively transported by the MDR-related P-glycoprotein and that verapamil and daunorubicin are non-competing substrates for P-glycoprotein.	Daunorubicin	132-144	ATP binding cassette subfamily B member 1	Homo sapiens	178-192
21566991-2	1994	demonstration of molecular and biochemical heterogeneity of PKC, we examined the effect of 12-deoxyphorbol 13-phenylacetate (dPP) on intracellular accumulation and drug sensitivity of daunorubicin (DNR) in drug sensitive P388 murine leukemia cell line.	Daunorubicin	184-196	decapentaplegic	Drosophila melanogaster	125-128
8043436-6	1994	Addition of CSA to the resistant cells led to a dose-dependent increase in cellular DAU retention, while no such effect was observed in the sensitive cells by the introduction of CSA.	Daunorubicin	84-87	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	12-15
8127142-1	1994	The long-term results of a therapeutic regimen for adult acute lymphoblastic leukemia (ALL) have been analysed with the main purpose to evaluate the impact of Daunorubicin (DNM) dosage given during the induction.	Daunorubicin	159-171	dynamin 1	Homo sapiens	173-176
7914749-11	1994	Additionally, one daunorubicin-cytarabine-pretreated refractory AML patient was treated with the oral form of the P-gp modulator drug dexniguldipine and achieved complete remission for a duration of 7 months.	Daunorubicin	18-30	ATP binding cassette subfamily B member 1	Homo sapiens	114-118
7906263-0	1994	5"-Deoxy-5-fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related with P-gp 170 expression.	Daunorubicin	35-47	phosphoglycolate phosphatase	Homo sapiens	117-121
7905300-5	1993	Exposure of the MDR-CEM cells to Pgp-directed RMAs, during their loading with DAU (DAU-loading phase), hardly restored DAU retention: SDZ 280-446 being as poorly active as SDZ PSC 833, and about only 3- and 4-fold more active than CsA and verapamil.	Daunorubicin	78-81	ATP binding cassette subfamily B member 1	Homo sapiens	33-36
7905300-5	1993	Exposure of the MDR-CEM cells to Pgp-directed RMAs, during their loading with DAU (DAU-loading phase), hardly restored DAU retention: SDZ 280-446 being as poorly active as SDZ PSC 833, and about only 3- and 4-fold more active than CsA and verapamil.	Daunorubicin	83-86	ATP binding cassette subfamily B member 1	Homo sapiens	33-36
7905300-5	1993	Exposure of the MDR-CEM cells to Pgp-directed RMAs, during their loading with DAU (DAU-loading phase), hardly restored DAU retention: SDZ 280-446 being as poorly active as SDZ PSC 833, and about only 3- and 4-fold more active than CsA and verapamil.	Daunorubicin	83-86	ATP binding cassette subfamily B member 1	Homo sapiens	33-36
7905300-9	1993	Therefore, although the MDR-CEM cells expressed easily detectable membranous Pgp molecules and probably used them for DAU efflux, they displayed an additional efflux mechanism that was not sensitive to the Pgp inhibitors.	Daunorubicin	118-121	ATP binding cassette subfamily B member 1	Homo sapiens	77-80
8279755-14	1993	Other transferrin complexes and conjugates of gallium, indium, and daunorubicin have also shown growth inhibition in tissue culture and animals.	Daunorubicin	67-79	transferrin	Homo sapiens	6-17
7693039-11	1993	In these 12 AML samples, the presence of functional resistance as defined by reduced daunorubicin accumulation was evaluated in CD34+ and CD34- AML cells.	Daunorubicin	85-97	CD34 molecule	Homo sapiens	128-132
7693039-11	1993	In these 12 AML samples, the presence of functional resistance as defined by reduced daunorubicin accumulation was evaluated in CD34+ and CD34- AML cells.	Daunorubicin	85-97	CD34 molecule	Homo sapiens	138-142
7693039-12	1993	In 8 of 8 P-170+ patients, intracellular daunorubicin accumulation in CD34+ AML blast cells was lower than in CD34- cells, and it increased after cyclosporin addition.	Daunorubicin	41-53	CD34 molecule	Homo sapiens	70-74
8373443-2	1993	A conjugate of the antineoplastic drug daunomycin (DNM) with maleylated bovine serum albumin (MBSA) bound to the transformed cells of a macrophage lineage with high affinity and saturation kinetics through scavenger receptors present on the surface of macrophages.	Daunorubicin	39-49	albumin	Mus musculus	79-92
8373443-2	1993	A conjugate of the antineoplastic drug daunomycin (DNM) with maleylated bovine serum albumin (MBSA) bound to the transformed cells of a macrophage lineage with high affinity and saturation kinetics through scavenger receptors present on the surface of macrophages.	Daunorubicin	51-54	albumin	Mus musculus	79-92
8103798-8	1993	Agents that bind to P-glycoprotein, such as vinblastine, daunorubicin and reserpine, markedly inhibited the secretion of digoxin.	Daunorubicin	57-69	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	20-34
7687521-1	1993	Idarubicin (Ida), an analogue of daunomycin, was linked to a mouse monoclonal antibody against the B cell differentiation antigen CD19.	Daunorubicin	33-43	CD19 molecule	Homo sapiens	130-134
8350628-7	1993	MEG-01/nu was evaluated for sensitivity to cytosine arabinoside, vincristine, and daunorubicin in vitro and in vivo.	Daunorubicin	82-94	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	0-3
8350628-8	1993	Daunorubicin exhibited significant anti-tumor activity against MEG-01/nu in vivo, while cytosine arabinoside did so in vitro.	Daunorubicin	0-12	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	63-66
8099135-0	1993	Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression.	Daunorubicin	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
8487584-0	1993	Effect of verapamil on daunorubicin accumulation in human leukemic cells with different levels of MDR1 gene expression.	Daunorubicin	23-35	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
8501853-6	1993	3) LCAT activity in serum was increased in daunomycin-induced nephrotic rats.	Daunorubicin	43-53	lecithin cholesterol acyltransferase	Rattus norvegicus	3-7
8501853-7	1993	4) Apolipoproteins composition of HDL in daunomycin-induced nephrotic rats showed the increased apoA-I and the decreased apo E. These results show that the increased cholesterol esters in liver tissue are due to hepatocytes in daunomycin-induced nephrotic rats.	Daunorubicin	41-51	apolipoprotein A1	Rattus norvegicus	96-102
8501853-8	1993	The increased HDL cholesterol content may contribute to the increase of LCAT activity in daunomycin-induced nephrotic rats.	Daunorubicin	89-99	lecithin cholesterol acyltransferase	Rattus norvegicus	72-76
8501853-9	1993	The increase of LCAT activity in serum results in the increased apo A-I content in daunomycin-induced nephrotic rats.	Daunorubicin	83-93	lecithin cholesterol acyltransferase	Rattus norvegicus	16-20
8435667-2	1993	He was treated with vasopressin (DDAVP) with a good response and concurrently induced with daunorubicin and conventional doses of cytosine arabinoside.	Daunorubicin	91-103	arginine vasopressin	Homo sapiens	20-31
8094292-4	1993	Further we show that the steroid hormones cortisol, testosterone, and progesterone cause an immediate, dose-dependent increase of daunorubicin accumulation in Pgp overexpressing cells.	Daunorubicin	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	159-162
8431519-3	1993	The RNA synthesis-inhibiting drugs daunorubicin, cyclophosphamide, ifosfamide, and cis-diamine-dichloroplatinum produced a dose-dependent decrease of the production of erythropoietin.	Daunorubicin	35-47	erythropoietin	Homo sapiens	168-182
8398342-3	1993	The resistant cells show only a small sensitisation to vincristine and daunorubicin on treatment with cyclosporin A and its more potent analogue, PSC-833 despite an increase in drug accumulation.	Daunorubicin	71-83	PSC	Homo sapiens	146-149
1360981-2	1992	P-gp has been localized to the apical plasma membrane of the bile canaliculus where it has been shown to transport [3H]daunomycin.	Daunorubicin	119-129	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-4
1360981-3	1992	In this study, we investigated whether alterations in membrane lipid fluidity of canalicular membrane vesicles (CMV) could modulate the P-gp-mediated accumulation of [3H]daunomycin and [3H]vinblastine.	Daunorubicin	170-180	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	136-140
1360981-11	1992	Verapamil competitively inhibited P-gp-mediated accumulation of [3H]daunomycin but failed to alter the fluidity of CMV.	Daunorubicin	68-78	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	34-38
1296812-0	1992	In vivo cytotoxicity and antineoplastic activity of a transferrin-daunorubicin conjugate.	Daunorubicin	66-78	transferrin	Homo sapiens	54-65
1296812-3	1992	We would like to take advantage of this physiologic phenomenon using an active transferrin-daunorubicin conjugate to target cancer cells.	Daunorubicin	91-103	transferrin	Homo sapiens	79-90
1296812-4	1992	We have compared the in vitro and the in vivo activity of free daunorubicin and of daunorubicin transferrin conjugate on cancer cells.	Daunorubicin	83-95	transferrin	Homo sapiens	96-107
1356264-8	1992	Several other drugs that are known to be transported by P-glycoprotein enhanced the ATPase activity in a dose-dependent manner with relative potencies as follows: doxorubicin = vinblastine greater than daunomycin greater than actinomycin D greater than verapamil greater than colchicine.	Daunorubicin	202-212	ATP binding cassette subfamily B member 1	Homo sapiens	56-70
20732145-0	1992	Effects of adriamycin and daunomycin on ornithine decarboxylase activity and DNA synthesis in mouse epidermal cells.	Daunorubicin	26-36	ornithine decarboxylase, structural 1	Mus musculus	40-63
20732145-2	1992	The magnitude and duration of ODC induction by 5 mum-daunomycin (DAU) are much smaller.	Daunorubicin	52-63	ornithine decarboxylase, structural 1	Mus musculus	30-33
1391803-0	1992	Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.	Daunorubicin	75-87	interleukin 3	Homo sapiens	41-45
1353020-0	1992	Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells.	Daunorubicin	12-24	ATP binding cassette subfamily B member 1	Homo sapiens	38-52
1353020-15	1992	The apparent Km values for P-glycoprotein-mediated transport, the intracellular free cytosolic daunorubicin concentrations at half-maximal velocity for the cell lines used, were approximately 1.5 microM.	Daunorubicin	95-107	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
1353020-17	1992	In cell lines with relatively low levels of P-glycoprotein, passive daunorubicin efflux was even the main route of daunorubicin transport from the cells, determining the intracellular steady-state concentrations of daunorubicin.	Daunorubicin	68-80	ATP binding cassette subfamily B member 1	Homo sapiens	44-58
1353020-17	1992	In cell lines with relatively low levels of P-glycoprotein, passive daunorubicin efflux was even the main route of daunorubicin transport from the cells, determining the intracellular steady-state concentrations of daunorubicin.	Daunorubicin	115-127	ATP binding cassette subfamily B member 1	Homo sapiens	44-58
1353020-17	1992	In cell lines with relatively low levels of P-glycoprotein, passive daunorubicin efflux was even the main route of daunorubicin transport from the cells, determining the intracellular steady-state concentrations of daunorubicin.	Daunorubicin	115-127	ATP binding cassette subfamily B member 1	Homo sapiens	44-58
1319280-0	1992	Generation of cytotoxic monoclonals against AK-5 histiocytoma: conjugation with daunomycin and use in chemotherapy.	Daunorubicin	80-90	adenylate kinase isoenzyme 5	Rattus norvegicus	44-48
1319280-5	1992	Total regression of AK-5 histiocytoma was obtained after injection of daunomycin-MAb conjugate into tumor bearing animals suggesting the specific targeting of the antineoplastic drug to the tumor.	Daunorubicin	70-80	adenylate kinase isoenzyme 5	Rattus norvegicus	20-24
1350280-8	1992	Cytoplasts from P-glycoprotein containing multidrug-resistant K562 cells demonstrated a verapamil-reversible, decreased daunorubicin accumulation that was observed in resistant whole cells.	Daunorubicin	120-132	ATP binding cassette subfamily B member 1	Homo sapiens	16-30
1350280-11	1992	Parental K562 cells and cytoplasts exhibit an energy-dependent accumulation of daunorubicin into cytoplasmic organelles that is also present in resistant cells and cytoplasts when P-glycoprotein mediated efflux is inhibited.	Daunorubicin	79-91	ATP binding cassette subfamily B member 1	Homo sapiens	180-194
1571541-9	1992	Our results suggest caution in the use of GM-CSF to sensitize myeloid leukemia cells to daunorubicin + ara-C chemotherapy.	Daunorubicin	88-100	colony stimulating factor 2	Homo sapiens	42-48
1353726-0	1992	Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.	Daunorubicin	42-54	ATP binding cassette subfamily B member 1	Homo sapiens	15-19
1348448-11	1992	It should be stressed, however, that these effects were substantially smaller than the effects of Pgp overexpression on the accumulation and cytotoxicity of the anthracycline daunorubicin and the epipodophyllotoxin etoposide in the same cell lines.	Daunorubicin	175-187	ATP binding cassette subfamily B member 1	Homo sapiens	98-101
1348241-2	1992	The action of Pgp in tumor cells can be detected by measuring the increase of daunorubicin accumulation upon blocking Pgp with drugs such as verapamil.	Daunorubicin	78-90	ATP binding cassette subfamily B member 1	Homo sapiens	14-17
1348241-2	1992	The action of Pgp in tumor cells can be detected by measuring the increase of daunorubicin accumulation upon blocking Pgp with drugs such as verapamil.	Daunorubicin	78-90	ATP binding cassette subfamily B member 1	Homo sapiens	118-121
1348241-9	1992	This method provides a tool allowing the detection of cellular mechanisms (including Pgp) which are related to active outward transport of daunorubicin.	Daunorubicin	139-151	ATP binding cassette subfamily B member 1	Homo sapiens	85-88
1347031-3	1992	Jejunal and ileal brush border membrane vesicles, but not basolateral membrane vesicles, manifested adenosine triphosphate (ATP)-dependent transport of daunomycin, a substrate for Gp170, and contained a approximately 170-kilodalton protein that reacts with anti-Gp170 monoclonal antibody.	Daunorubicin	152-162	ATP binding cassette subfamily B member 1	Homo sapiens	180-185
1347031-5	1992	ATP-dependent daunomycin transport by brush border vesicles was unidirectional (inside to outside) and temperature dependent and was blocked by Gp170 inhibitors but not by taurocholate or bromsulphalein glutathione.	Daunorubicin	14-24	ATP binding cassette subfamily B member 1	Homo sapiens	144-149
1311584-1	1992	The anthraquinone-based antitumour agents mitoxantrone, daunorubicin and ametantrone were found to be substrates for NAD(P)H (quinone acceptor) oxidoreductase (DT-diaphorase) [QAO] isolated from rat liver.	Daunorubicin	56-68	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	160-173
1346496-5	1992	Finally, we show that a photoaffinity analog of daunorubicin, [3H]azidobenzoyl-daunorubicin ([3H]AB-DNR), is a good affinity labeling reagent for Pgp.	Daunorubicin	48-60	ATP binding cassette subfamily B member 1	Homo sapiens	146-149
1309222-4	1992	The reduced accumulation of daunorubicin in the SW-1573/2R120 and GLC4/ADR cells was accompanied by a lower initial (2 min) uptake rate of this drug.	Daunorubicin	28-40	aldo-keto reductase family 1 member B	Homo sapiens	71-74
1309222-6	1992	However, daunorubicin was extruded 5-fold faster from GLC4/ADR cells than from the parental cells.	Daunorubicin	9-21	aldo-keto reductase family 1 member B	Homo sapiens	59-62
1309222-7	1992	In the presence of the energy metabolism inhibitors sodium azide and deoxyglucose, the reduced daunorubicin accumulations in the SW-1573/2R120 and GLC4/ADR MDR cells were (almost) completely reversed.	Daunorubicin	95-107	aldo-keto reductase family 1 member B	Homo sapiens	152-155
1309222-9	1992	Also, the enhanced efflux of daunorubicin from GLC4/ADR cells was inhibited.	Daunorubicin	29-41	aldo-keto reductase family 1 member B	Homo sapiens	52-55
1299375-0	1992	Enhanced antitumor activity of daunomycin conjugated with antigastric cancer monoclonal antibody MGb2.	Daunorubicin	31-41	secretoglobin family 2A member 1	Homo sapiens	97-101
1299375-1	1992	In the present study, an antigastric cancer monoclonal antibody, MGb2, was chosen to prepare an antibody-daunomycin conjugate.	Daunorubicin	105-115	secretoglobin family 2A member 1	Homo sapiens	65-69
1299375-4	1992	A tetrazolium dye colorimetric assay indicated that the MGb2-daunomycin conjugate exhibited selective cytotoxicity against human gastric cancer cells SGC-7901 in vitro.	Daunorubicin	61-71	secretoglobin family 2A member 1	Homo sapiens	56-60
1299375-6	1992	MGb2-daunomycin conjugate could significantly suppress the growth of human gastric carcinoma GAII inoculated under the renal capsules of BALB/c nude mice.	Daunorubicin	5-15	secretoglobin family 2A member 1	Homo sapiens	0-4
1299375-7	1992	Intraperitoneal injection of MGb2-daunomycin conjugate twice a week for 3 weeks at a dose of 1 mg/kg of drug gave a tumor inhibition rate of 91.58%, far more effective than free daunomycin or an irrelevant conjugate.	Daunorubicin	34-44	secretoglobin family 2A member 1	Homo sapiens	29-33
1299375-7	1992	Intraperitoneal injection of MGb2-daunomycin conjugate twice a week for 3 weeks at a dose of 1 mg/kg of drug gave a tumor inhibition rate of 91.58%, far more effective than free daunomycin or an irrelevant conjugate.	Daunorubicin	178-188	secretoglobin family 2A member 1	Homo sapiens	29-33
1663723-0	1991	Cytotoxicity of transferrin-daunorubicin conjugates on small cell carcinoma of the lung (SCCL) cell line NCI-H69.	Daunorubicin	28-40	transferrin	Homo sapiens	16-27
1663723-1	1991	We have evaluated the effectiveness of daunorubicin against an SCCL cell line (NCI-H69) after conjugation to transferrin.	Daunorubicin	39-51	transferrin	Homo sapiens	109-120
1680550-5	1991	Chemosensitization of MDR1 mice to daunomycin and taxol, measured by a fall in WBC, is detectable at a dose as low as 0.01 mg/kg R-verapamil.	Daunorubicin	35-45	malic enzyme complex, mitochondrial	Mus musculus	22-26
1859877-6	1991	The complete remission rate and in vitro sensitivity to daunorubicin were both correlated with low expression (1 U, v 2 U or more) of mdr1.	Daunorubicin	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	134-138
1859877-8	1991	In vitro resistance to daunorubicin or other MDR-related drugs was associated with expression of 2 U or more of mdr1 in 11 of 11 cases, while specimens that were sensitive to these agents were negative for mdr1 expression in 5 of 11 cases, P = .03.	Daunorubicin	23-35	ATP binding cassette subfamily B member 1	Homo sapiens	112-116
1868977-3	1991	Transgenic mice that express the MDR1 gene in their bone marrow have been developed, and because of this expression these mice are resistant to the bone marrow-suppressive effects of daunomycin, doxorubicin, taxol, and several other anticancer drugs.	Daunorubicin	183-193	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	33-37
1742845-5	1991	In the MDR subline EMT6/AR1.0, much higher doses of CsA were required to effect optimal restoration of doxorubicin or daunorubicin accumulation.	Daunorubicin	118-130	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	52-55
1699657-5	1990	According to in vitro cytotoxic assay, the sensitivity of G-CSF-stimulated cells to intercalating (daunorubicin) and nonintercalating (etoposide) topo II-targeting drugs increased significantly, whereas no enhancement of sensitivity was observed with an alkylating agent (4-hydroperoxycyclophosphamide).	Daunorubicin	99-111	colony stimulating factor 3	Homo sapiens	58-63
1700978-9	1990	The RNA synthesis inhibitors, actinomycin D and daunomycin, prevented increased alpha 2M receptor expression when added up to 4 h after the CSF-1, but had no effect at 8 h. At 37 degrees C, uptake and digestion of 125I-alpha 2M-CH3NH2 was increased in BMMs treated with 1,000 units/ml CSF-1 for 18 h compared with untreated cells.	Daunorubicin	48-58	PZP, alpha-2-macroglobulin like	Mus musculus	80-88
1700978-9	1990	The RNA synthesis inhibitors, actinomycin D and daunomycin, prevented increased alpha 2M receptor expression when added up to 4 h after the CSF-1, but had no effect at 8 h. At 37 degrees C, uptake and digestion of 125I-alpha 2M-CH3NH2 was increased in BMMs treated with 1,000 units/ml CSF-1 for 18 h compared with untreated cells.	Daunorubicin	48-58	colony stimulating factor 1 (macrophage)	Mus musculus	140-145
1700978-9	1990	The RNA synthesis inhibitors, actinomycin D and daunomycin, prevented increased alpha 2M receptor expression when added up to 4 h after the CSF-1, but had no effect at 8 h. At 37 degrees C, uptake and digestion of 125I-alpha 2M-CH3NH2 was increased in BMMs treated with 1,000 units/ml CSF-1 for 18 h compared with untreated cells.	Daunorubicin	48-58	PZP, alpha-2-macroglobulin like	Mus musculus	219-227
1700978-9	1990	The RNA synthesis inhibitors, actinomycin D and daunomycin, prevented increased alpha 2M receptor expression when added up to 4 h after the CSF-1, but had no effect at 8 h. At 37 degrees C, uptake and digestion of 125I-alpha 2M-CH3NH2 was increased in BMMs treated with 1,000 units/ml CSF-1 for 18 h compared with untreated cells.	Daunorubicin	48-58	colony stimulating factor 1 (macrophage)	Mus musculus	285-290
1982999-2	1990	The results obtained show that: a) patients whose blasts express P-glycoprotein are resistant towards protocols including Doxorubicin, Daunorubicin, Etoposide, Mithramycin, Vincristine; b) P-glycoprotein can be expressed constitutively in some cases; c) P-glycoprotein does not appear to be the only mechanism responsible for resistance towards anthracyclines and Etoposide.	Daunorubicin	135-147	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
2120134-5	1990	Doxorubicin and daunorubicin increased the LPS response of TG-PEC by approximately 4-fold and the IFN gamma response by approximately 10-fold.	Daunorubicin	16-28	interferon gamma	Mus musculus	98-107
2143099-2	1990	Using a series of antifolate-resistant and colchicine-resistant Chinese hamster ovary cell lines obtained by single-step and stepwise selection protocols, we show that viable cell staining with fluoresceinated methotrexate and daunorubicin correlates well with drug resistance and expression of dihydrofolate reductase protein and the "classic" MDR phenotype in these cell lines.	Daunorubicin	227-239	dihydrofolate reductase	Cricetulus griseus	295-318
2200756-6	1990	Relocation of protein B23 in nucleoli was observed in cells of stationary growth after treatment with adriamycin or daunomycin at their subtoxic concentrations (10(-10) M).	Daunorubicin	116-126	nucleophosmin 1	Homo sapiens	22-25
2200756-7	1990	Adriamycin and daunomycin, at their toxic concentrations (greater than 5.0 x 10(-7) M), on the other hand, inhibited cell growth and induced B23 translocation from nucleoli to nucleoplasm in growing cells.	Daunorubicin	15-25	nucleophosmin 1	Homo sapiens	141-144
1972761-4	1990	In vitro drug uptake studies by on-line flow cytometry showed that in leukemia cells expressing either mdr1 or mdr3, the steady-state accumulation of daunorubicin could be significantly increased by addition of cyclosporine and, to a lesser extent, by verapamil.	Daunorubicin	150-162	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
1972761-4	1990	In vitro drug uptake studies by on-line flow cytometry showed that in leukemia cells expressing either mdr1 or mdr3, the steady-state accumulation of daunorubicin could be significantly increased by addition of cyclosporine and, to a lesser extent, by verapamil.	Daunorubicin	150-162	ATP binding cassette subfamily B member 4	Homo sapiens	111-115
2207063-1	1990	Results from a high-resolution deoxyribonuclease I (DNase I) footprinting titration procedure are described that identify preferred daunomycin binding sites within the 160 bp tyr T DNA fragment.	Daunorubicin	132-142	deoxyribonuclease 1	Homo sapiens	31-50
2207063-1	1990	Results from a high-resolution deoxyribonuclease I (DNase I) footprinting titration procedure are described that identify preferred daunomycin binding sites within the 160 bp tyr T DNA fragment.	Daunorubicin	132-142	deoxyribonuclease 1	Homo sapiens	52-59
2372507-2	1990	At relapse, a decrease of the intracellular accumulation of daunorubicin (DNR) as determined by real time flow cytometry was associated with a relative overexpression of RNA encoding for the multidrug resistance phenotype (MDR1), and by a decreased in vitro sensitivity to DNR of clonogenic AML cells (IC50 0.8-3.4 microM).	Daunorubicin	60-72	ATP binding cassette subfamily B member 1	Homo sapiens	223-227
2096913-2	1990	To this end, we have examined the factors influencing the synthesis of daunomycin-monoclonal antibody conjugates linked covalently by an acid-labile cis-aconitic spacer (which is considered to aid drug release from immunoconjugates in the lysosomes and thus enhance their cytotoxic potential).	Daunorubicin	71-81	activation induced cytidine deaminase	Homo sapiens	193-196
1696238-1	1990	The cytotoxic effect of the anticancer drug, Daunorubicin, combined with the anti human AFP horse antibody (Conjugate) on AFP-producing cells and non producing cells was studied in vitro.	Daunorubicin	45-57	alpha fetoprotein	Homo sapiens	122-125
2346308-6	1990	Using this procedure for daunorubicin coupling to monoclonal anti-CEA we found no significant polymerization of the conjugate and a full recovery of the pharmacological activity as tested in vitro on CEA producing human colon adenocarcinoma cells.	Daunorubicin	25-37	CEA cell adhesion molecule 3	Homo sapiens	66-69
2161816-4	1990	SDB-ethylenediamine enhanced the uptake of ADM and daunorubicin into V79/ADM and its parental cells, but it did not increase the uptake of 5-FU or peplomycin, indicating that different mechanisms operate for potentiation in the cases of the latter drugs, i.e., not simply an increase of intracellular drug uptake.	Daunorubicin	51-63	ADM	Cricetulus griseus	69-76
1967551-6	1990	LU-49888 labeling of Pgp was also inhibited by actinomycin D (45%), podophyllotoxin (47%), and amsacrine (82%), marginally by doxorubicin (25%), colchicine (22%), daunorubicin (18%), and etoposide (14%), but not by teniposide.	Daunorubicin	163-175	ATP binding cassette subfamily B member 1	Homo sapiens	21-24
1968051-4	1990	The purpose of our study was to find out whether P-glycoprotein inhibitors could increase the daunorubicin (DNR) accumulation in acute myelocytic leukemia (AML) cells, overexpressing the mdr1 gene.	Daunorubicin	94-106	ATP binding cassette subfamily B member 1	Homo sapiens	187-191
1968051-4	1990	The purpose of our study was to find out whether P-glycoprotein inhibitors could increase the daunorubicin (DNR) accumulation in acute myelocytic leukemia (AML) cells, overexpressing the mdr1 gene.	Daunorubicin	108-111	ATP binding cassette subfamily B member 1	Homo sapiens	187-191
2345065-1	1990	A number of fluorine containing derivatives of daunomycin and Adriamycin have been synthesised with a fluorine substituent located on the C-9 side chain.	Daunorubicin	47-57	complement C9	Homo sapiens	138-141
1706611-2	1990	P-glycoprotein is a molecule strongly associated with multi-drug resistance to certain cytostatic drugs, including adriamycin, vincristine, and daunorubicin.	Daunorubicin	144-156	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
2344828-1	1990	Intracellular pH (pHi) of mouse lymphoid leukemia P388 cells was measured at the wavelength of 518 and 570 nm of fluorescein: pHi of rubomycin-sensitive P388 cells was higher than pHi of the cells resistant to this antitumour antibiotic (6.98 +/- 0.04 and 6.63 +/- 0.03, respectively, P less than 0.001).	Daunorubicin	133-142	glucose-6-phosphate isomerase 1	Mus musculus	18-21
2344828-1	1990	Intracellular pH (pHi) of mouse lymphoid leukemia P388 cells was measured at the wavelength of 518 and 570 nm of fluorescein: pHi of rubomycin-sensitive P388 cells was higher than pHi of the cells resistant to this antitumour antibiotic (6.98 +/- 0.04 and 6.63 +/- 0.03, respectively, P less than 0.001).	Daunorubicin	133-142	glucose-6-phosphate isomerase 1	Mus musculus	126-129
2344828-1	1990	Intracellular pH (pHi) of mouse lymphoid leukemia P388 cells was measured at the wavelength of 518 and 570 nm of fluorescein: pHi of rubomycin-sensitive P388 cells was higher than pHi of the cells resistant to this antitumour antibiotic (6.98 +/- 0.04 and 6.63 +/- 0.03, respectively, P less than 0.001).	Daunorubicin	133-142	glucose-6-phosphate isomerase 1	Mus musculus	126-129
2144163-7	1990	The simultaneous administration of cyclophosphamide and daunorubicin at day 14, induced a LCK of 2.7, a value that was the sum of the LCKs of cyclophosphamide and daunorubicin alone.	Daunorubicin	56-68	LCK proto-oncogene, Src family tyrosine kinase	Rattus norvegicus	90-93
2144163-7	1990	The simultaneous administration of cyclophosphamide and daunorubicin at day 14, induced a LCK of 2.7, a value that was the sum of the LCKs of cyclophosphamide and daunorubicin alone.	Daunorubicin	163-175	LCK proto-oncogene, Src family tyrosine kinase	Rattus norvegicus	90-93
2232849-6	1990	The leukemic blasts expressed very high levels of a 180 kd p-glycoprotein associated with multidrug resistance and daunomycin efflux could be blocked by verapamil.	Daunorubicin	115-125	ATP binding cassette subfamily B member 1	Homo sapiens	59-73
18322072-4	2008	In our search for potential biomarkers for the occurrence of this side effect, we examined the activity of recombinant aldo-keto reductase enzymes, aldo-keto reductase (AKR) 1A1 and AKR1C2, with DAUN and DOX as substrates.	Daunorubicin	195-199	aldo-keto reductase family 1 member A1	Homo sapiens	148-177
18322072-4	2008	In our search for potential biomarkers for the occurrence of this side effect, we examined the activity of recombinant aldo-keto reductase enzymes, aldo-keto reductase (AKR) 1A1 and AKR1C2, with DAUN and DOX as substrates.	Daunorubicin	195-199	aldo-keto reductase family 1 member C2	Homo sapiens	182-188
34816536-4	2022	Toxicity of daunorubicin chemotherapy drug on NAGA transfected EPG85.257RDB cells was evaluated in comparison to control cells and no significant change was recorded.	Daunorubicin	12-24	alpha-N-acetylgalactosaminidase	Homo sapiens	46-50
34963561-0	2022	CREB/Sp1-mediated MCL1 expression and NFkappaB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells.	Daunorubicin	102-114	cAMP responsive element binding protein 1	Homo sapiens	0-4
34963561-0	2022	CREB/Sp1-mediated MCL1 expression and NFkappaB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells.	Daunorubicin	102-114	ATP binding cassette subfamily B member 1	Homo sapiens	56-61
34963561-4	2022	In addition, DNR induced NOX4-dependent ROS production, leading to the activation of p38 MAPK and inactivation of Akt and ERK.	Daunorubicin	13-16	NADPH oxidase 4	Homo sapiens	25-29
34963561-4	2022	In addition, DNR induced NOX4-dependent ROS production, leading to the activation of p38 MAPK and inactivation of Akt and ERK.	Daunorubicin	13-16	AKT serine/threonine kinase 1	Homo sapiens	114-117
34963561-4	2022	In addition, DNR induced NOX4-dependent ROS production, leading to the activation of p38 MAPK and inactivation of Akt and ERK.	Daunorubicin	13-16	mitogen-activated protein kinase 1	Homo sapiens	122-125
34963561-9	2022	In addition, DNR induced the expression of drug exporter ABCB1 in K562 cells through the p38 MAPK/NFkappaB-mediated pathway, while imatinib or ABT-199 inhibited the DNR-induced effect.	Daunorubicin	13-16	ATP binding cassette subfamily B member 1	Homo sapiens	57-62
34963561-9	2022	In addition, DNR induced the expression of drug exporter ABCB1 in K562 cells through the p38 MAPK/NFkappaB-mediated pathway, while imatinib or ABT-199 inhibited the DNR-induced effect.	Daunorubicin	165-168	ATP binding cassette subfamily B member 1	Homo sapiens	57-62
34963561-11	2022	Cumulatively, our data indicate that DNR induces MCL1 downregulation in K562 cells by promoting p38 MAPK-mediated dephosphorylation of CREB and inhibiting the Akt-ERK axis-mediated Sp1 protein stabilization.	Daunorubicin	37-40	cAMP responsive element binding protein 1	Homo sapiens	135-139
34963561-11	2022	Cumulatively, our data indicate that DNR induces MCL1 downregulation in K562 cells by promoting p38 MAPK-mediated dephosphorylation of CREB and inhibiting the Akt-ERK axis-mediated Sp1 protein stabilization.	Daunorubicin	37-40	AKT serine/threonine kinase 1	Homo sapiens	159-162
34963561-11	2022	Cumulatively, our data indicate that DNR induces MCL1 downregulation in K562 cells by promoting p38 MAPK-mediated dephosphorylation of CREB and inhibiting the Akt-ERK axis-mediated Sp1 protein stabilization.	Daunorubicin	37-40	mitogen-activated protein kinase 1	Homo sapiens	163-166
34896433-6	2022	Drug combination studies revealed the capability of alisertib to synergistically antagonize ABCC1-mediated resistance to daunorubicin.	Daunorubicin	121-133	ATP binding cassette subfamily C member 1	Homo sapiens	92-97
34959345-7	2021	We found that quercetin, quercetin-3-glucoside, narcissoside and ellagic acid inhibited the ATPase activity of Pgp and increased the accumulation of calcein and daunorubicin by Pgp-positive cells.	Daunorubicin	161-173	ATP binding cassette subfamily B member 1	Homo sapiens	177-180
34181204-1	2021	BACKGROUND AND OBJECTIVE: The phase III ALFA-0701 study demonstrated the efficacy and safety of gemtuzumab ozogamicin (GO) versus standard of care (SOC) chemotherapy (daunorubicin and cytarabine) for the treatment of adult patients with de novo CD33+ acute myeloid leukaemia (AML).	Daunorubicin	167-179	CD33 molecule	Homo sapiens	245-249
34562647-3	2021	METHODS: Herein, a chemical anticancer drug daunomycin (DNM), and a photosensitizer 5, 10, 15, 20-tetra (phenyl-4-N-methyl-4-pyridyl) porphyrin (TMPyP) were physically assembled with a novel DNA structure composed of an aptamer of vascular endothelial growth factor (VEGF) and a cytosine (C)-rich DNA fragment (gc-34).	Daunorubicin	44-54	vascular endothelial growth factor A	Mus musculus	231-265
34562647-3	2021	METHODS: Herein, a chemical anticancer drug daunomycin (DNM), and a photosensitizer 5, 10, 15, 20-tetra (phenyl-4-N-methyl-4-pyridyl) porphyrin (TMPyP) were physically assembled with a novel DNA structure composed of an aptamer of vascular endothelial growth factor (VEGF) and a cytosine (C)-rich DNA fragment (gc-34).	Daunorubicin	44-54	vascular endothelial growth factor A	Mus musculus	267-271
34751552-6	2021	In an in vitro system, we have reconstituted the enzymes in the daunorubicin/doxorubicin pathway involved in the biosynthesis of dTDP-l-daunosamine.	Daunorubicin	64-76	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	129-133
34517162-3	2021	The purpose of this study was to investigate the associations between multi-organ complications, focusing on the liver and intestine, and the serum concentrations of intestinal fatty acid-binding protein (I-FABP) and osteoprotegerin (OPG) in rabbits with daunorubicin-induced dilated cardiomyopathy (DCM).	Daunorubicin	255-267	tumor necrosis factor receptor superfamily member 11B	Oryctolagus cuniculus	217-232
34517162-3	2021	The purpose of this study was to investigate the associations between multi-organ complications, focusing on the liver and intestine, and the serum concentrations of intestinal fatty acid-binding protein (I-FABP) and osteoprotegerin (OPG) in rabbits with daunorubicin-induced dilated cardiomyopathy (DCM).	Daunorubicin	255-267	tumor necrosis factor receptor superfamily member 11B	Oryctolagus cuniculus	234-237
34492683-4	2021	IKZF1 knockout and heterozygous null cells displayed relative resistance to a number of common therapies for B-ALL including dexamethasone, asparaginase, and daunorubicin.	Daunorubicin	158-170	IKAROS family zinc finger 1	Homo sapiens	0-5
34339712-0	2021	Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib.	Daunorubicin	45-57	aldo-keto reductase family 1 member B10	Homo sapiens	14-21
34339712-7	2021	Subsequently, the ability of dasatinib to attenuate AKR1B10-mediated daunorubicin (Daun) resistance was determined in AKR1B10-overexpressing cells.	Daunorubicin	69-81	aldo-keto reductase family 1 member B10	Homo sapiens	52-59
34339712-7	2021	Subsequently, the ability of dasatinib to attenuate AKR1B10-mediated daunorubicin (Daun) resistance was determined in AKR1B10-overexpressing cells.	Daunorubicin	83-87	aldo-keto reductase family 1 member B10	Homo sapiens	52-59
34217736-0	2021	Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells.	Daunorubicin	151-163	ATP binding cassette subfamily B member 1	Homo sapiens	90-104
34217736-0	2021	Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells.	Daunorubicin	151-163	ATP binding cassette subfamily B member 1	Homo sapiens	106-110
34217736-0	2021	Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells.	Daunorubicin	151-163	ATP binding cassette subfamily B member 1	Homo sapiens	167-171
34402163-5	2021	BAG1-depleted cells show an increased sensitivity to the common chemotherapeutic agents, dexamethasone or daunorubicin, and to the BCL2 inhibitor ABT-737.	Daunorubicin	106-118	BAG cochaperone 1	Homo sapiens	0-4
34362484-8	2021	The escalated dose of daunorubicin had prolonged RFS (13 months vs not reached, P=0.022) and OS (23 months vs not reached, P=0.029) in the FLT3-ITD- AML patients.	Daunorubicin	22-34	fms related receptor tyrosine kinase 3	Homo sapiens	139-143
34251414-3	2021	In a phase 1 study of AML patients treated with G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no antisense-related toxicity was reported, and BCL2 downregulation occurred in patients achieving complete remission.	Daunorubicin	71-83	BCL2 apoptosis regulator	Homo sapiens	173-177
34095945-4	2021	Then, zwitterionic sulfobetaine (ZS) and CXCR4 antagonist peptide E5 were modified onto the surface of the nanoparticles via covalent bonding to fabricate a nanoplatform (denoted as HMPBs(DNR + AraC)@PEI-ZS-E5).	Daunorubicin	188-191	C-X-C motif chemokine receptor 4	Homo sapiens	41-46
34298882-6	2021	Measuring different BCL2-family proteins before and after treatment with daunorubicin revealed that PMPs downregulated the pro-apoptotic PUMA protein.	Daunorubicin	73-85	BCL2 apoptosis regulator	Homo sapiens	20-24
34298882-6	2021	Measuring different BCL2-family proteins before and after treatment with daunorubicin revealed that PMPs downregulated the pro-apoptotic PUMA protein.	Daunorubicin	73-85	BCL2 binding component 3	Homo sapiens	137-141
34108527-8	2021	Further, combined with the fixed-ratio liposomal formulation of daunorubicin and cytarabine, CPX-351, M3814 enhanced the efficacy against leukemia cells in vitro and in vivo without increasing hematopoietic toxicity, suggesting that DNA-PK inhibition could offer a novel clinical strategy for harnessing the anticancer potential of p53 in AML therapy.	Daunorubicin	64-76	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	233-239
34108527-8	2021	Further, combined with the fixed-ratio liposomal formulation of daunorubicin and cytarabine, CPX-351, M3814 enhanced the efficacy against leukemia cells in vitro and in vivo without increasing hematopoietic toxicity, suggesting that DNA-PK inhibition could offer a novel clinical strategy for harnessing the anticancer potential of p53 in AML therapy.	Daunorubicin	64-76	tumor protein p53	Homo sapiens	332-335
35461365-6	2022	ALOX5 mediates resistance to daunorubicin (DNR) and promotes AML cell survival and maintenance through its leukotriene (LT) synthetic capacity, specifically via modulating the synthesis of LTB4 and its binding to LTB receptor (BLTR).	Daunorubicin	29-41	arachidonate 5-lipoxygenase	Homo sapiens	0-5
35461365-6	2022	ALOX5 mediates resistance to daunorubicin (DNR) and promotes AML cell survival and maintenance through its leukotriene (LT) synthetic capacity, specifically via modulating the synthesis of LTB4 and its binding to LTB receptor (BLTR).	Daunorubicin	43-46	arachidonate 5-lipoxygenase	Homo sapiens	0-5
35596909-0	2022	Impact of DYRK1A Expression on TNNT2 Splicing and Daunorubicin Toxicity in Human iPSC-Derived Cardiomyocytes.	Daunorubicin	50-62	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	10-16
35596909-12	2022	DYRK1A over-expression ameliorated the impact of DAU on beating frequency.	Daunorubicin	49-52	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	0-6
35580565-3	2022	Here, we present the case of a 69-year-old woman with therapy-related nucleophosmin-1 (NPM1) and FLT3-internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia treated with induction and consolidation with CPX-351 (liposomal daunorubicin plus cytarabine) followed by off-label azacitidine maintenance who obtained a complete remission (CR) with persistent measurable residual disease.	Daunorubicin	238-250	fms related receptor tyrosine kinase 3	Homo sapiens	97-101
35580565-3	2022	Here, we present the case of a 69-year-old woman with therapy-related nucleophosmin-1 (NPM1) and FLT3-internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia treated with induction and consolidation with CPX-351 (liposomal daunorubicin plus cytarabine) followed by off-label azacitidine maintenance who obtained a complete remission (CR) with persistent measurable residual disease.	Daunorubicin	238-250	fms related receptor tyrosine kinase 3	Homo sapiens	131-135
35552383-5	2022	RESULTS: The topoisomerase-2 inhibitors, daunorubicin and mitoxantrone, were identified from the screen to upregulate PSMA protein expression in castration-resistant LNCaP95 cells; this result was validated in vitro in LNCaP, LNCaP95 and 22Rv1 cell lines, and in vivo using an mCRPC patient-derived xenograft model CP286 identified to have heterogeneous PSMA expression.	Daunorubicin	41-53	folate hydrolase 1	Homo sapiens	118-122
35552383-5	2022	RESULTS: The topoisomerase-2 inhibitors, daunorubicin and mitoxantrone, were identified from the screen to upregulate PSMA protein expression in castration-resistant LNCaP95 cells; this result was validated in vitro in LNCaP, LNCaP95 and 22Rv1 cell lines, and in vivo using an mCRPC patient-derived xenograft model CP286 identified to have heterogeneous PSMA expression.	Daunorubicin	41-53	folate hydrolase 1	Homo sapiens	354-358
35100472-5	2022	Furthermore, overexpression of CLDN6 enhanced cell-cell adhesion properties and attenuated sensitivity to anticancer drugs including doxorubicin, daunorubicin and cisplatin.	Daunorubicin	146-158	claudin 6	Homo sapiens	31-36
35119275-6	2022	Moreover, the addition of daunomycin, an inhibitor of Abeta aggregation, to the measurement solution suppresses the stepwise electrical response of the Abeta hydrogel-coated gate FET.	Daunorubicin	26-36	amyloid beta precursor protein	Homo sapiens	152-157
35207746-12	2022	We also used NCC-PMP1-C1 cells to screen drugs, which demonstrated a significant response to daunorubicin HCl, homoharringtonine, mitomycin C, and ponatinib.	Daunorubicin	93-109	peroxisomal biogenesis factor 19	Homo sapiens	17-21
2575381-3	1989	We found that MDR1 promoter could be activated directly on the addition of anticancer agents including vincristine, daunomycin, adriamycin and colchicine.	Daunorubicin	116-126	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
2573823-7	1989	P-glycoprotein labeling was inhibited by anticancer agents, vinblastine, vincristine, actinomycin D, and daunomycin, with half-maximal inhibition at 2.0, 2.3, 18, and 23 microM, respectively.	Daunorubicin	105-115	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
2475247-12	1989	However, ADR and DAU may be effective against skin tumor promotion if they are applied in combination with Ca2+ antagonists and at a time when they can inhibit the inductions of both ODC activity and DNA synthesis by TPA.	Daunorubicin	17-20	ornithine decarboxylase, structural 1	Mus musculus	183-186
2475247-12	1989	However, ADR and DAU may be effective against skin tumor promotion if they are applied in combination with Ca2+ antagonists and at a time when they can inhibit the inductions of both ODC activity and DNA synthesis by TPA.	Daunorubicin	17-20	promotion susceptibility QTL 1	Mus musculus	217-220
2573831-0	1989	Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia.	Daunorubicin	108-118	ATP binding cassette subfamily B member 1	Homo sapiens	49-53
2476405-0	1989	Overcoming effect of antibody against rat alpha-fetoprotein (AFP) on the growth of daunorubicin-resistant mutant rat ascites hepatoma cell line AH66.	Daunorubicin	83-95	alpha-fetoprotein	Rattus norvegicus	42-59
2476405-0	1989	Overcoming effect of antibody against rat alpha-fetoprotein (AFP) on the growth of daunorubicin-resistant mutant rat ascites hepatoma cell line AH66.	Daunorubicin	83-95	alpha-fetoprotein	Rattus norvegicus	61-64
2476405-1	1989	A daunorubicin (DNR)-resistant variant (AH66DR) of alpha-fetoprotein (AFP)-producing rat ascites hepatoma AH66 was established.	Daunorubicin	2-14	alpha-fetoprotein	Rattus norvegicus	51-68
2476405-1	1989	A daunorubicin (DNR)-resistant variant (AH66DR) of alpha-fetoprotein (AFP)-producing rat ascites hepatoma AH66 was established.	Daunorubicin	2-14	alpha-fetoprotein	Rattus norvegicus	70-73
2765667-5	1989	Overexpression of mdr-1/P-170 was heterogeneous within the population of malignant lymphoblasts as demonstrated by RNA in situ hybridization, immunohistochemistry, and drug uptake using daunomycin autofluorescence analysis.	Daunorubicin	186-196	ATP binding cassette subfamily B member 1	Homo sapiens	18-23
2788601-0	1989	Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells.	Daunorubicin	0-12	mucin 16, cell surface associated	Homo sapiens	45-50
2568172-2	1989	The MX2 cells are cross-resistant to etoposide, teniposide, bisantrene, dactinomycin, 4"-(9-acridinylamino)methanesulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloids melphalan and mitomycin C.	Daunorubicin	157-169	MX dynamin like GTPase 2	Homo sapiens	4-7
2568167-8	1989	The results of our studies demonstrate that inhibition of GSH synthesis in HL60/AR cells results in significant sensitization to daunorubicin and suggest that changes in the intracellular distribution of GSH/GST and/or increased drug retention may be involved in mediating this effect.	Daunorubicin	129-141	glutathione S-transferase kappa 1	Homo sapiens	208-211
2568355-9	1989	These results suggest that Gp170 is an ATP-dependent efflux pump which is responsible for the undirectional, energy-dependent transport of daunomycin and other drugs by rat liver into the bile.	Daunorubicin	139-149	ATP binding cassette subfamily B member 1	Homo sapiens	27-32
2665546-0	1989	Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V).	Daunorubicin	17-28	asparaginase and isoaspartyl peptidase 1	Homo sapiens	84-98
2665546-2	1989	The Dutch Childhood Leukemia Study Group (DCLSG) performed a phase III study-Study (ALL) V-to evaluate the effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for children (0-15 years) with standard risk acute lymphoblastic leukemia (ALL) (white blood cell [WBC] counts less than 50.10(9)/L, absence of mediastinal mass, and/or cerebromeningeal leukemia).	Daunorubicin	124-135	asparaginase and isoaspartyl peptidase 1	Homo sapiens	191-205
2567301-2	1989	NIH3T3 cells expressing a transfected MDR1 gene (NIH3T3-MDR) were treated with vinblastine or daunomycin.	Daunorubicin	94-104	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	38-42
2539902-1	1989	Our human T-cell leukemia line, CEM/VM-1, selected for resistance to VM-26 (teniposide), is cross-resistant to several drugs that interact with topoisomerase II, including VP-16 (etoposide), 4"-(9-acridinylamino)methanesulphon-m-anisidide, daunorubicin, and mitoxantrone.	Daunorubicin	240-252	host cell factor C1	Homo sapiens	172-177
2564628-10	1989	In contrast, daunorubicin increased VP-16 accumulation only in the sensitive MCF-7 cell line, whereas the efflux rate of VP-16 was not significantly changed in either cell line.	Daunorubicin	13-25	host cell factor C1	Homo sapiens	36-41
2563722-3	1989	Subline SW1573/50A with a 4- to 6-fold cross-resistance to daunorubicin (DNR) and vincristine (VCR) showed rather uniform positive staining for P-glycoprotein apparently at cytoplasmic sites.	Daunorubicin	59-71	ATP binding cassette subfamily B member 1	Homo sapiens	144-158
2563722-3	1989	Subline SW1573/50A with a 4- to 6-fold cross-resistance to daunorubicin (DNR) and vincristine (VCR) showed rather uniform positive staining for P-glycoprotein apparently at cytoplasmic sites.	Daunorubicin	73-76	ATP binding cassette subfamily B member 1	Homo sapiens	144-158
2914273-6	1989	Cepharanthine also potentiated daunomycin and vincristine (VCR) against HC-2-6 and HC-7-5 cells, and it almost completely overcame drug-resistance to daunomycin and vincristine in HC-7-5/VCR, a multidrug-resistant variant isolated after long exposure to vincristine of HC-7-5 cells in culture.	Daunorubicin	31-41	CYCS pseudogene 38	Homo sapiens	72-78
2914273-6	1989	Cepharanthine also potentiated daunomycin and vincristine (VCR) against HC-2-6 and HC-7-5 cells, and it almost completely overcame drug-resistance to daunomycin and vincristine in HC-7-5/VCR, a multidrug-resistant variant isolated after long exposure to vincristine of HC-7-5 cells in culture.	Daunorubicin	31-41	CYCS pseudogene 40	Homo sapiens	83-87
2914273-7	1989	The cellular accumulation of [3H]-daunomycin by HC-7-5 cells was about 70% that of HC-2-6 cells.	Daunorubicin	34-44	CYCS pseudogene 40	Homo sapiens	48-52
2910487-0	1989	Cyclosporin A and verapamil enhancement of daunorubicin-produced nucleolar protein B23 translocation in daunorubicin-resistant and -sensitive human and murine tumor cells.	Daunorubicin	43-55	nucleophosmin 1	Homo sapiens	83-86
2910487-0	1989	Cyclosporin A and verapamil enhancement of daunorubicin-produced nucleolar protein B23 translocation in daunorubicin-resistant and -sensitive human and murine tumor cells.	Daunorubicin	104-116	nucleophosmin 1	Homo sapiens	83-86
2910487-1	1989	It has recently been shown that anthracycline antibiotic-resistant tumor cells are less responsive to daunorubicin-stimulated B23 nucleolar phosphoprotein translocation than drug-sensitive cells.	Daunorubicin	102-114	nucleophosmin 1	Mus musculus	126-129
2536625-1	1989	Using ESR and spin-trapping techniques, it was found that synthetic 2-dimethylamino-3-chloro-1,4-naphthoquinone and the natural anticancer quinone daunomycin, when added to a system containing purified NADPH-cytochrome P-450 reductase, NADPH, ferric ions, and oxygen, (i) generated hydroxyl radicals and (ii) caused single-strand scission of supercoiled DNA of the plasmic pBR322.	Daunorubicin	147-157	cytochrome p450 oxidoreductase	Homo sapiens	202-234
2576974-3	1989	Our results also show that non-ionic oligonucleoside methylphosphonates, complementary to the initiation codon and 15 bases upstream of the mdr1 gene, can completely inhibit the synthesis of P-glycoprotein and partially increase the toxicity of daunorubicin.	Daunorubicin	245-257	ATP binding cassette subfamily B member 1	Homo sapiens	140-144
3229005-4	1988	Anthracyclines--doxorubicin, daunorubicin and aclacinomycin--inhibited calcium calmodulin-stimulated cyclic 3",5"-AMP (cAMP) nucleotide phosphodiesterase (EC.	Daunorubicin	29-41	calmodulin 1	Homo sapiens	79-89
2844190-2	1988	Daunorubicin was found to inhibit the phosphorylation of the 40 K PKC substrate induced by thrombin and 12-O-tetradecanoyl-phorbol-13-acetate as well as the phosphorylation of the 20 K protein induced by thrombin.	Daunorubicin	0-12	coagulation factor II, thrombin	Homo sapiens	91-99
2844190-2	1988	Daunorubicin was found to inhibit the phosphorylation of the 40 K PKC substrate induced by thrombin and 12-O-tetradecanoyl-phorbol-13-acetate as well as the phosphorylation of the 20 K protein induced by thrombin.	Daunorubicin	0-12	coagulation factor II, thrombin	Homo sapiens	204-212
3135332-5	1988	In combination with IFN-gamma, the daunomycin-mAb CL 207 conjugate displays a selective in vitro and in vivo toxic effect on tumor cells that express the 96-kDa MAA.	Daunorubicin	35-45	interferon gamma	Homo sapiens	20-29
2839377-1	1988	The hydroxyl radical has been spin trapped in microsomal and purified NADPH-cytochrome P-450 reductase systems in the presence of adriamycin, daunomycin and mitomycin C.	Daunorubicin	142-152	cytochrome p450 oxidoreductase	Homo sapiens	70-102
3176170-6	1988	The chloroquine and DNR accumulation in lysosomes inhibited activities of some lysosomal hydrolases tested: cathepsins B and D, N-acetyl-beta, D-glucosaminidase and acid phosphatase.	Daunorubicin	20-23	O-GlcNAcase	Homo sapiens	128-160
3340082-9	1988	Dissociation of daunomycin from four different synthetic polydeoxynucleotides (which did not contain the 5"-CA preferential daunomycin-binding site) exhibited dissociation rates characteristic of low affinity sites (3.3-4.8 sec-1).	Daunorubicin	16-26	galactoside 2-alpha-L-fucosyltransferase SEC1	Bos taurus	224-229
2892291-1	1987	Daunomycin coupled via an acid-sensitive spacer to monoclonal Thy-1.2-specific antibody was used to purge T lymphocytes from a 1:1 mixture of murine C57BL/6J bone marrow and spleen cells prior to engraftment in fully allogeneic, irradiated BALB/c recipients.	Daunorubicin	0-10	thymus cell antigen 1, theta	Mus musculus	62-69
2444108-3	1987	In rats, pronounced coexpression of vimentin and keratin was observed in chronic nephrosis induced by daunomycin, and the extent of coexpression seemed to increase with the incidence of altered collapsed and cystically dilated tubules and with the degree of tubular epithelial proliferation.	Daunorubicin	102-112	vimentin	Rattus norvegicus	36-44
2440563-0	1987	Therapeutic effect of treatment with polyclonal or monoclonal antibodies to alpha-fetoprotein that have been conjugated to daunomycin via a dextran bridge: studies with an alpha-fetoprotein-producing rat hepatoma tumor model.	Daunorubicin	123-133	alpha-fetoprotein	Rattus norvegicus	76-93
2440563-1	1987	Purified monoclonal mouse or polyclonal horse antibodies (Ab) to rat alpha-fetoprotein (AFP) were conjugated with daunomycin via a dextran bridge.	Daunorubicin	114-124	alpha-fetoprotein	Rattus norvegicus	69-86
2440563-1	1987	Purified monoclonal mouse or polyclonal horse antibodies (Ab) to rat alpha-fetoprotein (AFP) were conjugated with daunomycin via a dextran bridge.	Daunorubicin	114-124	alpha-fetoprotein	Rattus norvegicus	88-91
2440563-7	1987	There was a slight therapeutic effect with either antibody or daunomycin alone but treatment with the AFP Ab-daunomycin conjugates significantly prolonged survival and 60% of these treated animals were "tumor free" when sacrificed on day 100.	Daunorubicin	109-119	alpha-fetoprotein	Rattus norvegicus	102-105
2440563-8	1987	Serial quantitation of the concentration of AFP in the serum of the treated tumor-bearing or in the tumor-resected rats correlated with the therapeutic effectiveness of the Ab-daunomycin conjugates.	Daunorubicin	176-186	alpha-fetoprotein	Rattus norvegicus	44-47
2967076-0	1987	Inhibition of thymidylate synthase in intact L1210 cells by ara-C, daunomycin, hydroxyurea and 3,4-dihydroxybenzylamine.	Daunorubicin	67-77	thymidylate synthase	Mus musculus	14-34
2967076-1	1987	The use of an in situ assay for thymidylate synthase has shown that a variety of clinically important drugs, including arabinofuranosylcytosine, hydroxyurea, and daunomycin, inhibit thymidylate synthase in intact cells.	Daunorubicin	162-172	thymidylate synthase	Mus musculus	32-52
2967076-1	1987	The use of an in situ assay for thymidylate synthase has shown that a variety of clinically important drugs, including arabinofuranosylcytosine, hydroxyurea, and daunomycin, inhibit thymidylate synthase in intact cells.	Daunorubicin	162-172	thymidylate synthase	Mus musculus	182-202
3017783-1	1986	Conjugates of ovine prolactin and daunomycin were prepared for use as affinity-labelled drug carriers in cancer cells carrying the prolactin receptor.	Daunorubicin	34-44	prolactin receptor	Rattus norvegicus	131-149
3806571-7	1986	The Fe(III) chelate of daunomycin is however reduced by ferredoxin reductase and NADPH to the Fe(III) chelate of 7-deoxydaunomycinone, suggesting that quinone reduction of the chelate to the quinone methide has occurred.	Daunorubicin	23-33	ferredoxin reductase	Mus musculus	56-76
3707847-0	1986	Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells.	Daunorubicin	138-150	calmodulin 2	Mus musculus	12-22
3539383-1	1986	We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1).	Daunorubicin	19-31	interleukin 17F	Homo sapiens	57-71
3539383-1	1986	We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1).	Daunorubicin	19-31	interleukin 17F	Homo sapiens	57-60
2410001-0	1985	Suppression of human alpha-foetoprotein-producing hepatocellular carcinoma growth in nude mice by an anti alpha-foetoprotein antibody-daunorubicin conjugate with a poly-L-glutamic acid derivative as intermediate drug carrier.	Daunorubicin	134-146	alpha fetoprotein	Mus musculus	21-39
2410001-0	1985	Suppression of human alpha-foetoprotein-producing hepatocellular carcinoma growth in nude mice by an anti alpha-foetoprotein antibody-daunorubicin conjugate with a poly-L-glutamic acid derivative as intermediate drug carrier.	Daunorubicin	134-146	alpha fetoprotein	Mus musculus	106-124
3986001-5	1985	Exposure to daunorubicin was shown to be accompanied by a rapid induction of primarily DT-diaphorase and a slower induction of glutathione transferase.	Daunorubicin	12-24	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	87-100
2580485-1	1985	In order to increase the selective localization of anti-cancer drugs to the target tumor cells, polyclonal or monoclonal anti alpha-fetoprotein antibody (aAFP) was conjugated with anti-cancer drugs such as daunomycin (DM), adriamycin (AM) and mitomycin C (MMC) by chemical modification.	Daunorubicin	206-216	alpha-fetoprotein	Rattus norvegicus	126-143
3891121-1	1985	Daunorubicin uptake and metabolism were studied in vitro with human myeloid leukemia cell lines (KG1, ML1); erythroleukemia cell line (K562); and myeloblasts from two untreated patients with acute myelogenous leukemia (AML).	Daunorubicin	0-12	interleukin 17F	Homo sapiens	102-105
3859461-1	1985	On daunomycin treatment of a patient with promyelocytic leukemia, leukocyte elastase appeared in large amounts in the patient"s blood.	Daunorubicin	3-13	elastase, neutrophil expressed	Homo sapiens	66-84
4022191-1	1985	Two new of the spin-labeled analogues of Rubomycin were studied.	Daunorubicin	41-50	spindlin 1	Rattus norvegicus	15-19
6209394-1	1984	An anti-alpha-fetoprotein antibody-daunomycin conjugate.	Daunorubicin	35-45	alpha-fetoprotein	Rattus norvegicus	8-25
6209394-5	1984	Anti-AFP conjugate tended to be less cytotoxic than DM against the AFP-nonproducing rat ascites hepatoma AH272 cells, and in this case there was no difference between the cytotoxicities of anti-AFP conjugate and of normal conjugate.	Daunorubicin	52-54	alpha-fetoprotein	Rattus norvegicus	67-70
6209394-5	1984	Anti-AFP conjugate tended to be less cytotoxic than DM against the AFP-nonproducing rat ascites hepatoma AH272 cells, and in this case there was no difference between the cytotoxicities of anti-AFP conjugate and of normal conjugate.	Daunorubicin	52-54	alpha-fetoprotein	Rattus norvegicus	67-70
6505718-0	1984	Chemotherapy with daunorubicin-anti-CEA conjugates in human colon adenocarcinoma grafted in nude mice.	Daunorubicin	18-30	CEA cell adhesion molecule 3	Homo sapiens	36-39
6488165-8	1984	Results from this study indicate that in P388/DOX cells, the calmodulin inhibitor TFP is more effective with DAU than DOX, significantly less effective with ACM, and ineffective with AD32 and N-trifluoroacetyladriamycin.	Daunorubicin	109-112	calmodulin 2	Mus musculus	61-71
6206272-0	1984	An anti-alpha-fetoprotein antibody-daunorubicin conjugate with a novel poly-L-glutamic acid derivative as intermediate drug carrier.	Daunorubicin	35-47	alpha-fetoprotein	Rattus norvegicus	8-25
6206272-1	1984	In studies on antitumor antibody-cytotoxic drug conjugates as potential antitumor agents with improved tumor specificity, daunorubicin [(DM) daunomycin] was conjugated with an affinity-purified horse antibody to rat alpha-fetoprotein (AFP) with a novel derivative of poly-L-glutamic acid (PLGA) as the intermediate drug carrier.	Daunorubicin	122-134	alpha-fetoprotein	Rattus norvegicus	216-233
6206272-1	1984	In studies on antitumor antibody-cytotoxic drug conjugates as potential antitumor agents with improved tumor specificity, daunorubicin [(DM) daunomycin] was conjugated with an affinity-purified horse antibody to rat alpha-fetoprotein (AFP) with a novel derivative of poly-L-glutamic acid (PLGA) as the intermediate drug carrier.	Daunorubicin	122-134	alpha-fetoprotein	Rattus norvegicus	235-238
6689280-1	1983	Xanthine oxidase reduction of adriamycin (Am) and daunorubicin (Dm) to their respective 7-deoxy aglycones is inhibited by allopurinol.	Daunorubicin	50-62	xanthine dehydrogenase	Mus musculus	0-16
6850584-6	1983	These results strongly suggest the use of daunomycin or other cytotoxic drug:polyene fatty acid complexes in the therapy of human tumors producing alpha-fetoprotein.	Daunorubicin	42-52	alpha fetoprotein	Homo sapiens	147-164
6831444-3	1983	The UV-2237-ADMR line also exhibited increased resistance to N-trifluoroacetyladriamycin-24-valerate, daunorubicin, actinomycin D, amsacrine, mitomycin C, vinblastine, and vincristine but not to bleomycin.	Daunorubicin	102-114	G protein-coupled receptor 182	Mus musculus	12-16
6188454-2	1983	Of the enzymes assayed DT-diaphorase and glutathione-S-transferase showed a two-to-four fold increase in activity: higher concentrations of daunorubicin inactivated glutathione-S-transferase.	Daunorubicin	140-152	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	23-36
6188454-2	1983	Of the enzymes assayed DT-diaphorase and glutathione-S-transferase showed a two-to-four fold increase in activity: higher concentrations of daunorubicin inactivated glutathione-S-transferase.	Daunorubicin	140-152	hematopoietic prostaglandin D synthase	Rattus norvegicus	41-66
6188454-2	1983	Of the enzymes assayed DT-diaphorase and glutathione-S-transferase showed a two-to-four fold increase in activity: higher concentrations of daunorubicin inactivated glutathione-S-transferase.	Daunorubicin	140-152	hematopoietic prostaglandin D synthase	Rattus norvegicus	165-190
6188454-3	1983	Daunorubicin toxicity increased in the presence of dicoumarol, a specific inhibitor of DT-diaphorase.	Daunorubicin	0-12	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	87-100
6188454-4	1983	These results indicate that both DT-diaphorase and glutathione-S-transferase may be involved in the metabolism of daunorubicin.	Daunorubicin	114-126	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	33-46
6188454-4	1983	These results indicate that both DT-diaphorase and glutathione-S-transferase may be involved in the metabolism of daunorubicin.	Daunorubicin	114-126	hematopoietic prostaglandin D synthase	Rattus norvegicus	51-76
6200034-0	1983	Effect of a conjugate of daunomycin and purified polyclonal or monoclonal antibodies to rat alpha-fetoprotein on the growth of alpha-fetoprotein-producing tumor cells.	Daunorubicin	25-35	alpha-fetoprotein	Rattus norvegicus	127-144
6200034-2	1983	The monoclonal antibodies as well as horse anti-rat AFP antibodies were coupled via a dextran bridge to daunomycin.	Daunorubicin	104-114	alpha-fetoprotein	Rattus norvegicus	52-55
6200034-6	1983	Daunomycin conjugates with horse-anti-AFP and monoclonal mouse anti-AFP were capable of delaying the tumor development more efficiently than were the controls of antibodies or free drug, mixtures of drug with antibodies, and a conjugate of drug and normal Ig.	Daunorubicin	0-10	alpha-fetoprotein	Rattus norvegicus	38-41
6200034-6	1983	Daunomycin conjugates with horse-anti-AFP and monoclonal mouse anti-AFP were capable of delaying the tumor development more efficiently than were the controls of antibodies or free drug, mixtures of drug with antibodies, and a conjugate of drug and normal Ig.	Daunorubicin	0-10	alpha-fetoprotein	Rattus norvegicus	68-71
6317371-4	1983	However, for a number of these drugs, namely adriamycin, daunomycin, bleomycin, and dacarbazine, which are only weakly mutagenic at the HGPRT locus, a relatively strong and clear mutagenic response was observed at the AK locus.	Daunorubicin	57-67	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	136-141
6317371-4	1983	However, for a number of these drugs, namely adriamycin, daunomycin, bleomycin, and dacarbazine, which are only weakly mutagenic at the HGPRT locus, a relatively strong and clear mutagenic response was observed at the AK locus.	Daunorubicin	57-67	adenosine kinase	Cricetulus griseus	218-220
6762195-3	1982	CROP (cytosine arabinoside, daunorubicin, vincristine, prednisolone) produced CR in 41% of patients, 7 and 3 (cytosine arabinoside, daunorubicin) in 42% and 7 and 3 plus hydroxyurea in 52%.	Daunorubicin	28-40	LUC7 like 3 pre-mRNA splicing factor	Homo sapiens	0-4
6762195-3	1982	CROP (cytosine arabinoside, daunorubicin, vincristine, prednisolone) produced CR in 41% of patients, 7 and 3 (cytosine arabinoside, daunorubicin) in 42% and 7 and 3 plus hydroxyurea in 52%.	Daunorubicin	132-144	LUC7 like 3 pre-mRNA splicing factor	Homo sapiens	0-4
6185954-0	1982	Chemotherapy by intravenous administration of conjugates of daunomycin with monoclonal and conventional anti-rat alpha-fetoprotein antibodies.	Daunorubicin	60-70	alpha-fetoprotein	Rattus norvegicus	113-130
6185954-2	1982	The monoclonal antibodies as well as horse anti-rat AFP were coupled via a dextran bridge to daunomycin.	Daunorubicin	93-103	alpha-fetoprotein	Rattus norvegicus	52-55
6185954-6	1982	Daunomycin conjugates with horse anti-AFP and monoclonal mouse anti-AFP were capable of delaying the tumor development more efficiently than the controls of antibodies or free drug, mixtures of drug with antibodies, and a conjugate of drug and normal immunoglobulin.	Daunorubicin	0-10	alpha-fetoprotein	Rattus norvegicus	38-41
6185954-6	1982	Daunomycin conjugates with horse anti-AFP and monoclonal mouse anti-AFP were capable of delaying the tumor development more efficiently than the controls of antibodies or free drug, mixtures of drug with antibodies, and a conjugate of drug and normal immunoglobulin.	Daunorubicin	0-10	alpha-fetoprotein	Rattus norvegicus	68-71
6175912-1	1982	In our experimental work we intended to study the effect of certain anthracycline antibiotics, like Adriamycin, Daunomycin, Carminomycin on the RNA dependent DNA polymerase, i.e. reverse transcriptase (RT) system.	Daunorubicin	112-122	reverse transcriptase	Escherichia coli	179-200
6176999-0	1982	Effect of a conjugate of daunomycin and antibodies to rat alpha-fetoprotein on the growth of alpha-fetoprotein-producing tumor cells.	Daunorubicin	25-35	alpha-fetoprotein	Rattus norvegicus	93-110
6176999-1	1982	Daunomycin was covalently attached via a dextran bridge to specific antibodies against rat alpha-fetoprotein produced in a horse.	Daunorubicin	0-10	alpha-fetoprotein	Rattus norvegicus	91-108
7237450-0	1981	Improved antitumor activity of basic amino acid and dipeptide derivatives of daunorubicin on EL4 leukemia cells in mice.	Daunorubicin	77-89	epilepsy 4	Mus musculus	93-96
7237450-1	1981	Over thirty amino acid and peptide derivatives of the antitumor drug daunorubicin (DM) were tested for their potency to inhibit EL4 leukemia cell growth in mice.	Daunorubicin	69-81	epilepsy 4	Mus musculus	128-131
7245125-2	1981	Daunorubicin was shown to inhibit Collagen and Thrombin induced platelet aggregation and the intensity of inhibition on both drug concentration and the time of preincubation.	Daunorubicin	0-12	coagulation factor II, thrombin	Homo sapiens	47-55
7227969-1	1981	Daunomycin (DM), a potent chemotherapeutic agent, was linked to bovine thyrotropin (TSH) directly (TSH-DM) and indirectly (TSH-alpha-lactalbumin-DM) by covalent cross-linking methods.	Daunorubicin	0-10	glycoprotein hormones, alpha polypeptide	Bos taurus	123-132
7227969-1	1981	Daunomycin (DM), a potent chemotherapeutic agent, was linked to bovine thyrotropin (TSH) directly (TSH-DM) and indirectly (TSH-alpha-lactalbumin-DM) by covalent cross-linking methods.	Daunorubicin	12-14	glycoprotein hormones, alpha polypeptide	Bos taurus	123-132
7026686-2	1981	The anticancer drug, daunomycin (DM) was used as prototype and coupled to mercaptosuccinylated bovine serum albumin (MS, BSA) with N-(gamma-maleimidobutyryloxy)succinimide (GMBS).	Daunorubicin	21-31	albumin	Oryctolagus cuniculus	102-115
7440679-1	1980	A new solvent system composed of methanol-acidic water (pH 2.0 with phosphoric acid) has been developed for high-performance liquid chromatography of the daunorubicin complex from fermentation broth on a micro Bondapak C18 column.	Daunorubicin	154-166	Bardet-Biedl syndrome 9	Homo sapiens	219-222
7426629-0	1980	Proton nuclear magnetic resonance study of the self-complementary hexanucleotide d(pTpA)3 and its interaction with daunomycin.	Daunorubicin	115-125	protein phosphatase 2 phosphatase activator	Homo sapiens	83-87
6248123-1	1980	The superoxide free radical has been spin trapped in microsomal incubations containing adriamycin, daunorubicin, and mitomycin C.	Daunorubicin	99-111	spindlin 1	Homo sapiens	37-41
6929617-1	1980	The ventricular myocardium of CD1 mice given a single high dose (LD50) of daunorubicin (DNR) or its derivative, 4-demethoxydaunorubicin (4DD), was studied under the electron microscope.	Daunorubicin	74-86	CD1 antigen complex	Mus musculus	30-33
7424738-3	1980	The other major form of human brain enzyme, AR1, which is also NADPH-dependent, reduces both aldehyde and ketone-containing substrates, including vitamin K3 (menadione) and daunorubicin, a cancer chemotherapeutic agent.	Daunorubicin	173-185	transcription factor 20	Homo sapiens	44-47
527586-3	1979	At low daunomycin concentrations (1 and 2 muM) the rate of [3H]thymidine incorporation decreased progressively with the duration of exposure to the inhibitor.	Daunorubicin	7-17	latexin	Homo sapiens	42-45
527586-5	1979	At high daunomycin concentrations (12 muM) the rate of chain growth was also markedly reduced.	Daunorubicin	8-18	latexin	Homo sapiens	38-41
291472-2	1979	In the first patient (a 7-month-old female with acute monocytic leukemia) extremely young age and previous chemotherapy with a podophyllotoxin derivative, VP-16, may have prediposed the patient to fatal congestive heart failure at a total Daunorubicin dose of only 225 mg/m2.	Daunorubicin	239-251	host cell factor C1	Homo sapiens	155-160
528363-0	1979	Mechanism of action of the anthracycline anti-tumor antibiotics, doxorubicin, daunomycin and rubidazone: preferential inhibition of DNA polymerase alpha.	Daunorubicin	78-88	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	132-152
476691-3	1979	The derivatives, including Adriamycin, daunorubicin, and carminomycin, vary in structure at C-4 and C-13, with substitutions at C-14 and N and stereochemical differences at C-4".	Daunorubicin	39-51	complement C4A (Rodgers blood group)	Homo sapiens	92-95
490537-3	1979	Esterification of daunomycin at C-7 with beta-alanine was accomplished through the mixed anhydride of Z(OMe)-beta-alanine.	Daunorubicin	18-28	complement C7	Homo sapiens	32-35
708725-7	1978	Daunomycin was the most effective in decreasing the temperature of the phase transition and brought about a comparable reduction in the enthalpy of melting as AD32 and AD-14-OCTA.	Daunorubicin	0-10	AD14	Homo sapiens	168-178
911351-0	1977	Effect of daunomycin, adriamycin and its congener AD 32 on the activity of DNase I from bovine pancreas.	Daunorubicin	10-20	deoxyribonuclease 1	Bos taurus	75-82
616416-3	1977	On the other hand, combination of daunorubicin plus one of 8 agents (thio-TEPA, mitomycin-C, bleomycin, actinomycin-D, vinblastine, ancytabine, 6-mercaptopurine, and L-asparaginase) and 6 agents (cyclophosphamide, thio-TEPA, mitomycin-C, bleomycin, actinomycin-D, and vinblastine) provided synergism in alternate and simultaneous administration.	Daunorubicin	34-46	asparaginase and isoaspartyl peptidase 1	Homo sapiens	166-180
1008838-0	1976	Metabolism of daunorubicin by a barbiturate-sensitive aldehyde reductase from rat liver.	Daunorubicin	14-26	aldo-keto reductase family 1, member B7	Rattus norvegicus	54-72
1008838-1	1976	A barbiturate-sensitive aldehyde reductase was purified to homogeneity from rat liver and shown to metabolize the cancer-chemotherapeutic antibiotic daunorubicin.	Daunorubicin	149-161	aldo-keto reductase family 1, member B7	Rattus norvegicus	24-42
1009518-1	1976	Four new derivatives of daunorubicin, characterized by the absence of the methoxyl group at the C-4 position, have been obtained by chemical synthesis.	Daunorubicin	24-36	complement C4A (Rodgers blood group)	Homo sapiens	96-99
975021-0	1976	Fab dimers of antitumor immunoglobulins as covalent carriers of daunomycin.	Daunorubicin	64-74	FA complementation group B	Homo sapiens	0-3
975021-2	1976	Daunomycin was attatched to these (Fab)2 by covalent binding.	Daunorubicin	0-10	FA complementation group B	Homo sapiens	35-38
1271407-1	1976	Alterations in the C-9 side chain of the anthracycline antibiotics, adriamycin and daunorubicin, have a profound effect on antibiotic uptake and accumulation by cultured L1210 cells.	Daunorubicin	83-95	complement component 9	Mus musculus	19-22
1174142-8	1975	Although EAC RNA polymerases Ia, IIa, and IIb were inhibited by daunomycin, form IIa was preferentially affected.	Daunorubicin	64-74	ATPase, class II, type 9A	Mus musculus	33-36
1174142-8	1975	Although EAC RNA polymerases Ia, IIa, and IIb were inhibited by daunomycin, form IIa was preferentially affected.	Daunorubicin	64-74	ATPase, class II, type 9B	Mus musculus	42-45
34049223-10	2021	Finally, we validated Daunorubicin in a 3D transendothelial migration system and also in a in vivo model of advanced EC, demonstrating the ability of Daunorubicin to inhibit the proliferation of ANXA2-overexpressing tumor cells.	Daunorubicin	22-34	annexin A2	Homo sapiens	195-200
34049223-10	2021	Finally, we validated Daunorubicin in a 3D transendothelial migration system and also in a in vivo model of advanced EC, demonstrating the ability of Daunorubicin to inhibit the proliferation of ANXA2-overexpressing tumor cells.	Daunorubicin	150-162	annexin A2	Homo sapiens	195-200
33982799-0	2021	NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.	Daunorubicin	65-77	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	0-4
33982799-0	2021	NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.	Daunorubicin	65-77	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	29-33
33982799-0	2021	NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.	Daunorubicin	65-77	BCL2 like 1	Homo sapiens	38-44
33982799-3	2021	DNR-induced apoptosis in U937 cells accompanied by downregulation of MCL1 and BCL2L1, upregulation of Phorbol-12-myristate-13-acetate-induced protein 1 (NOXA), and mitochondrial depolarization.	Daunorubicin	0-3	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	69-73
33982799-3	2021	DNR-induced apoptosis in U937 cells accompanied by downregulation of MCL1 and BCL2L1, upregulation of Phorbol-12-myristate-13-acetate-induced protein 1 (NOXA), and mitochondrial depolarization.	Daunorubicin	0-3	BCL2 like 1	Homo sapiens	78-84
33982799-3	2021	DNR-induced apoptosis in U937 cells accompanied by downregulation of MCL1 and BCL2L1, upregulation of Phorbol-12-myristate-13-acetate-induced protein 1 (NOXA), and mitochondrial depolarization.	Daunorubicin	0-3	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	153-157
33982799-4	2021	DNR induced NOX4-mediated reactive reactive oxygen species (ROS) production, which in turn inactivated Akt and simultaneously activated p38 mitogen-activated protein kinase (MAPK).	Daunorubicin	0-3	NADPH oxidase 4	Homo sapiens	12-16
33982799-4	2021	DNR induced NOX4-mediated reactive reactive oxygen species (ROS) production, which in turn inactivated Akt and simultaneously activated p38 mitogen-activated protein kinase (MAPK).	Daunorubicin	0-3	AKT serine/threonine kinase 1	Homo sapiens	103-106
33982799-4	2021	DNR induced NOX4-mediated reactive reactive oxygen species (ROS) production, which in turn inactivated Akt and simultaneously activated p38 mitogen-activated protein kinase (MAPK).	Daunorubicin	0-3	mitogen-activated protein kinase 14	Homo sapiens	136-179
33982799-8	2021	Restoration of MCL1 or BCL2L1 expression alleviated DNR-induced mitochondrial depolarization and cell death.	Daunorubicin	52-55	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	15-19
33982799-8	2021	Restoration of MCL1 or BCL2L1 expression alleviated DNR-induced mitochondrial depolarization and cell death.	Daunorubicin	52-55	BCL2 like 1	Homo sapiens	23-29
33982799-9	2021	Furthermore, ABT-199 (a BCL2 inhibitor) synergistically enhanced the cytotoxicity of DNR in AML cell lines.	Daunorubicin	85-88	BCL2 apoptosis regulator	Homo sapiens	24-28
33982799-11	2021	Collectively, these results indicate that the upregulation of NOXA expression through the NOX4-ROS-p38 MAPK-GSK3beta-CREB axis results in the degradation of MCL1 and BCL2L1 in DNR-treated U937 and HL-60 cells.	Daunorubicin	176-179	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	62-66
33982799-11	2021	Collectively, these results indicate that the upregulation of NOXA expression through the NOX4-ROS-p38 MAPK-GSK3beta-CREB axis results in the degradation of MCL1 and BCL2L1 in DNR-treated U937 and HL-60 cells.	Daunorubicin	176-179	NADPH oxidase 4	Homo sapiens	90-94
33982799-11	2021	Collectively, these results indicate that the upregulation of NOXA expression through the NOX4-ROS-p38 MAPK-GSK3beta-CREB axis results in the degradation of MCL1 and BCL2L1 in DNR-treated U937 and HL-60 cells.	Daunorubicin	176-179	glycogen synthase kinase 3 alpha	Homo sapiens	108-116
33982799-11	2021	Collectively, these results indicate that the upregulation of NOXA expression through the NOX4-ROS-p38 MAPK-GSK3beta-CREB axis results in the degradation of MCL1 and BCL2L1 in DNR-treated U937 and HL-60 cells.	Daunorubicin	176-179	cAMP responsive element binding protein 1	Homo sapiens	117-121
33982799-11	2021	Collectively, these results indicate that the upregulation of NOXA expression through the NOX4-ROS-p38 MAPK-GSK3beta-CREB axis results in the degradation of MCL1 and BCL2L1 in DNR-treated U937 and HL-60 cells.	Daunorubicin	176-179	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	157-161
33982799-11	2021	Collectively, these results indicate that the upregulation of NOXA expression through the NOX4-ROS-p38 MAPK-GSK3beta-CREB axis results in the degradation of MCL1 and BCL2L1 in DNR-treated U937 and HL-60 cells.	Daunorubicin	176-179	BCL2 like 1	Homo sapiens	166-172
33976256-0	2021	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.	Daunorubicin	84-96	isocitrate dehydrogenase (NADP(+)) 2	Homo sapiens	0-4
33969374-0	2021	LncRNA UCA1 elevates the resistance of human leukaemia cells to daunorubicin by the PI3K/AKT pathway via sponging miR-613.	Daunorubicin	64-76	urothelial cancer associated 1	Homo sapiens	7-11
33969374-0	2021	LncRNA UCA1 elevates the resistance of human leukaemia cells to daunorubicin by the PI3K/AKT pathway via sponging miR-613.	Daunorubicin	64-76	AKT serine/threonine kinase 1	Homo sapiens	89-92
33969374-0	2021	LncRNA UCA1 elevates the resistance of human leukaemia cells to daunorubicin by the PI3K/AKT pathway via sponging miR-613.	Daunorubicin	64-76	microRNA 613	Homo sapiens	114-121
33969374-9	2021	DNR constrained viability, cell cycle progression, invasion, and facilitated apoptosis of HL-60 and U-937 cells in a dose-dependent manner, but these impacts mediated by DNR were reverted after UCA1 overexpression.	Daunorubicin	0-3	urothelial cancer associated 1	Homo sapiens	194-198
33969374-9	2021	DNR constrained viability, cell cycle progression, invasion, and facilitated apoptosis of HL-60 and U-937 cells in a dose-dependent manner, but these impacts mediated by DNR were reverted after UCA1 overexpression.	Daunorubicin	170-173	urothelial cancer associated 1	Homo sapiens	194-198
33969374-11	2021	MiR-613 inhibitor reversed DNR treatment-mediated effects on viability, cell cycle progression, apoptosis, and invasion of HL-60 and U-937 cells, but these impacts mediated by miR-613 inhibitor were counteracted after UCA1 inhibition.	Daunorubicin	27-30	microRNA 613	Homo sapiens	0-7
33969374-11	2021	MiR-613 inhibitor reversed DNR treatment-mediated effects on viability, cell cycle progression, apoptosis, and invasion of HL-60 and U-937 cells, but these impacts mediated by miR-613 inhibitor were counteracted after UCA1 inhibition.	Daunorubicin	27-30	microRNA 613	Homo sapiens	176-183
33969374-11	2021	MiR-613 inhibitor reversed DNR treatment-mediated effects on viability, cell cycle progression, apoptosis, and invasion of HL-60 and U-937 cells, but these impacts mediated by miR-613 inhibitor were counteracted after UCA1 inhibition.	Daunorubicin	27-30	urothelial cancer associated 1	Homo sapiens	218-222
33969374-12	2021	The inactivation of the PI3K/AKT pathway caused by DNR treatment was reversed after miR-613 inhibitor introduction, but this influence mediated by miR-613 inhibitor was offset after UCA1 knockdown.	Daunorubicin	51-54	AKT serine/threonine kinase 1	Homo sapiens	29-32
33969374-12	2021	The inactivation of the PI3K/AKT pathway caused by DNR treatment was reversed after miR-613 inhibitor introduction, but this influence mediated by miR-613 inhibitor was offset after UCA1 knockdown.	Daunorubicin	51-54	microRNA 613	Homo sapiens	84-91
33969374-13	2021	In conclusion, UCA1 upregulation facilitated the resistance of acute leukemia cells to DNR via the PI3K/AKT pathway by sponging miR-613.	Daunorubicin	87-90	urothelial cancer associated 1	Homo sapiens	15-19
33879127-11	2021	Expression of apoptotic proteins, including Bcl-2, Bax, caspase 3 and FADD, indicated that daunorubicin potentially induced both extrinsic and intrinsic apoptosis in both CCRF-CEM and MOLT-4 cells, but only extrinsic apoptosis in SUP-B15 cells.	Daunorubicin	91-103	BCL2 apoptosis regulator	Homo sapiens	44-49
33879127-11	2021	Expression of apoptotic proteins, including Bcl-2, Bax, caspase 3 and FADD, indicated that daunorubicin potentially induced both extrinsic and intrinsic apoptosis in both CCRF-CEM and MOLT-4 cells, but only extrinsic apoptosis in SUP-B15 cells.	Daunorubicin	91-103	BCL2 associated X, apoptosis regulator	Homo sapiens	51-54
33879127-11	2021	Expression of apoptotic proteins, including Bcl-2, Bax, caspase 3 and FADD, indicated that daunorubicin potentially induced both extrinsic and intrinsic apoptosis in both CCRF-CEM and MOLT-4 cells, but only extrinsic apoptosis in SUP-B15 cells.	Daunorubicin	91-103	caspase 3	Homo sapiens	56-65
33879127-11	2021	Expression of apoptotic proteins, including Bcl-2, Bax, caspase 3 and FADD, indicated that daunorubicin potentially induced both extrinsic and intrinsic apoptosis in both CCRF-CEM and MOLT-4 cells, but only extrinsic apoptosis in SUP-B15 cells.	Daunorubicin	91-103	Fas associated via death domain	Homo sapiens	70-74
33879127-13	2021	These differences could be attributed to the lack of functional p53 in coordinating the cells response following cytotoxic treatment with daunorubicin, which appears to delay apoptosis and utilises alternative signalling mechanisms that need to be further explored.	Daunorubicin	138-150	tumor protein p53	Homo sapiens	64-67
33782537-6	2021	MTSS1 expression was regulated by promoter methylation, and reduced by cytosine arabinoside and the anthracycline daunorubicin.	Daunorubicin	114-126	MTSS I-BAR domain containing 1	Homo sapiens	0-5
33531064-6	2021	METHODS: By utilizing the unique nature of mass cytometry for single cell multiparameter analysis, we have explored the proteomic effect and intracellular signaling response in individual leukemic cells with internal tandem duplication of FLT3 (FLT3-ITD) after midostaurin treatment in combination with daunorubicin or cytarabine.	Daunorubicin	303-315	fms related receptor tyrosine kinase 3	Homo sapiens	239-243
33531064-6	2021	METHODS: By utilizing the unique nature of mass cytometry for single cell multiparameter analysis, we have explored the proteomic effect and intracellular signaling response in individual leukemic cells with internal tandem duplication of FLT3 (FLT3-ITD) after midostaurin treatment in combination with daunorubicin or cytarabine.	Daunorubicin	303-315	fms related receptor tyrosine kinase 3	Homo sapiens	245-249
33531064-10	2021	Interestingly, the surface localization of FLT3 receptor increased in vivo on the blast cell population of two AML patients during day 3 of induction therapy (daunorubicin; once/day from day 1-3 and cytarabine; twice/day from day 1-7).	Daunorubicin	159-171	fms related receptor tyrosine kinase 3	Homo sapiens	43-47
32880787-4	2021	Here, we present evidence that cancer cells overexpressing Trx undergo enhanced apoptosis in response to daunomycin.	Daunorubicin	105-115	thioredoxin 1	Rattus norvegicus	59-62
32880787-6	2021	However, rat embryonic cardiomyocytes (H9c2 cells) overexpressing Trx were protected against daunomycin-mediated apoptosis, but H9c2 cells with decreased levels of active Trx showed enhanced apoptosis in response to daunomycin.	Daunorubicin	93-103	thioredoxin 1	Rattus norvegicus	66-69
33305533-15	2021	For MyHC-IIa, gene expression was down-regulated by ~2.6-fold and ~4.5-fold in Daun and Etop treatment, respectively (P < 0.0001).	Daunorubicin	79-83	myosin, heavy polypeptide 2, skeletal muscle, adult	Mus musculus	4-12
32679023-5	2021	METHODS: THP-1 leukemic cells were treated with EGCG and Daunorubicin (DNR) and cell viability was analyzed.	Daunorubicin	57-69	GLI family zinc finger 2	Homo sapiens	9-14
32679023-0	2021	Activation of Myosin Phosphatase by Epigallocatechin-Gallate Sensitizes THP-1 Leukemic Cells to Daunorubicin.	Daunorubicin	96-108	GLI family zinc finger 2	Homo sapiens	72-77
32679023-5	2021	METHODS: THP-1 leukemic cells were treated with EGCG and Daunorubicin (DNR) and cell viability was analyzed.	Daunorubicin	71-74	GLI family zinc finger 2	Homo sapiens	9-14
32679023-8	2021	EGCG plus DNR decreased the phosphorylation level of MYPT1pT696, which was accompanied by prominent dephosphorylation of pRb.	Daunorubicin	10-13	RB transcriptional corepressor 1	Homo sapiens	121-124
32679023-9	2021	In addition, significant dephosphorylation of merlin was observed when EGCG and DNR were applied together.	Daunorubicin	80-83	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	46-52
33025066-0	2021	Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism.	Daunorubicin	95-107	aldo-keto reductase family 1 member C3	Homo sapiens	24-47
33025066-4	2021	Here, we report that midostaurin is a potent inhibitor of Dau inactivation mediated by AKR1C3 in both its recombinant form as well as during its overexpression in a transfected cell model.	Daunorubicin	58-61	aldo-keto reductase family 1 member C3	Homo sapiens	87-93
32880751-14	2021	Furthermore, WTAP made AML cells resistant to daunorubicin.	Daunorubicin	46-58	WT1 associated protein	Homo sapiens	13-17
33270982-8	2021	We showed that miR-15a-5p and miR-21-5p overexpression decreased apoptosis induced by cytarabine and/or daunorubicin.	Daunorubicin	104-116	microRNA 215	Homo sapiens	30-39
33967147-8	2021	After the standard induction therapy with daunorubicin and cytarabine, the number of myeloblasts in the bone marrow decreased, and the amplified MYC signals disappeared.	Daunorubicin	42-54	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	145-148
33938176-0	2021	HDAC8 promotes daunorubicin resistance of human acute myeloid leukemia cells via regulation of IL-6 and IL-8.	Daunorubicin	15-27	histone deacetylase 8	Homo sapiens	0-5
33938176-0	2021	HDAC8 promotes daunorubicin resistance of human acute myeloid leukemia cells via regulation of IL-6 and IL-8.	Daunorubicin	15-27	interleukin 6	Homo sapiens	95-99
33938176-0	2021	HDAC8 promotes daunorubicin resistance of human acute myeloid leukemia cells via regulation of IL-6 and IL-8.	Daunorubicin	15-27	C-X-C motif chemokine ligand 8	Homo sapiens	104-108
33938176-2	2021	We found that the expression of histone deacetylase 8 (HDAC8) was increased in daunorubicin (DNR) resistant AML cells, while targeted inhibition of HDAC8 by its specific siRNA or inhibitor can restore sensitivity of DNR treatment .	Daunorubicin	79-91	histone deacetylase 8	Homo sapiens	32-53
33938176-2	2021	We found that the expression of histone deacetylase 8 (HDAC8) was increased in daunorubicin (DNR) resistant AML cells, while targeted inhibition of HDAC8 by its specific siRNA or inhibitor can restore sensitivity of DNR treatment .	Daunorubicin	79-91	histone deacetylase 8	Homo sapiens	55-60
33938176-2	2021	We found that the expression of histone deacetylase 8 (HDAC8) was increased in daunorubicin (DNR) resistant AML cells, while targeted inhibition of HDAC8 by its specific siRNA or inhibitor can restore sensitivity of DNR treatment .	Daunorubicin	79-91	histone deacetylase 8	Homo sapiens	148-153
33938176-2	2021	We found that the expression of histone deacetylase 8 (HDAC8) was increased in daunorubicin (DNR) resistant AML cells, while targeted inhibition of HDAC8 by its specific siRNA or inhibitor can restore sensitivity of DNR treatment .	Daunorubicin	93-96	histone deacetylase 8	Homo sapiens	32-53
33938176-2	2021	We found that the expression of histone deacetylase 8 (HDAC8) was increased in daunorubicin (DNR) resistant AML cells, while targeted inhibition of HDAC8 by its specific siRNA or inhibitor can restore sensitivity of DNR treatment .	Daunorubicin	93-96	histone deacetylase 8	Homo sapiens	55-60
33938176-2	2021	We found that the expression of histone deacetylase 8 (HDAC8) was increased in daunorubicin (DNR) resistant AML cells, while targeted inhibition of HDAC8 by its specific siRNA or inhibitor can restore sensitivity of DNR treatment .	Daunorubicin	93-96	histone deacetylase 8	Homo sapiens	148-153
33938176-2	2021	We found that the expression of histone deacetylase 8 (HDAC8) was increased in daunorubicin (DNR) resistant AML cells, while targeted inhibition of HDAC8 by its specific siRNA or inhibitor can restore sensitivity of DNR treatment .	Daunorubicin	216-219	histone deacetylase 8	Homo sapiens	32-53
33938176-2	2021	We found that the expression of histone deacetylase 8 (HDAC8) was increased in daunorubicin (DNR) resistant AML cells, while targeted inhibition of HDAC8 by its specific siRNA or inhibitor can restore sensitivity of DNR treatment .	Daunorubicin	216-219	histone deacetylase 8	Homo sapiens	55-60
33938176-2	2021	We found that the expression of histone deacetylase 8 (HDAC8) was increased in daunorubicin (DNR) resistant AML cells, while targeted inhibition of HDAC8 by its specific siRNA or inhibitor can restore sensitivity of DNR treatment .	Daunorubicin	216-219	histone deacetylase 8	Homo sapiens	148-153
33938176-4	2021	While recombinant IL-6 (rIL-6) and rIL-8 can reverse si-HDAC8-resored DNR sensitivity of AML cells.	Daunorubicin	70-73	interleukin 6	Homo sapiens	18-22
33938176-4	2021	While recombinant IL-6 (rIL-6) and rIL-8 can reverse si-HDAC8-resored DNR sensitivity of AML cells.	Daunorubicin	70-73	interleukin 6	Rattus norvegicus	24-29
33938176-4	2021	While recombinant IL-6 (rIL-6) and rIL-8 can reverse si-HDAC8-resored DNR sensitivity of AML cells.	Daunorubicin	70-73	histone deacetylase 8	Homo sapiens	56-61
33938176-7	2021	Collectively, our data suggested that HDAC8 promotes DNR resistance of human AML cells via regulation of IL-6 and IL-8.	Daunorubicin	53-56	histone deacetylase 8	Homo sapiens	38-43
33938176-7	2021	Collectively, our data suggested that HDAC8 promotes DNR resistance of human AML cells via regulation of IL-6 and IL-8.	Daunorubicin	53-56	interleukin 6	Homo sapiens	105-109
33938176-7	2021	Collectively, our data suggested that HDAC8 promotes DNR resistance of human AML cells via regulation of IL-6 and IL-8.	Daunorubicin	53-56	C-X-C motif chemokine ligand 8	Homo sapiens	114-118
33322571-4	2020	In this regard, we demonstrated that Bruton"s tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib efficiently prevented daunorubicin (Dau) inactivation mediated by AKR1C3 in both its recombinant form as well as during its overexpression in cancer cells.	Daunorubicin	129-141	Bruton tyrosine kinase	Homo sapiens	37-61
33322571-4	2020	In this regard, we demonstrated that Bruton"s tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib efficiently prevented daunorubicin (Dau) inactivation mediated by AKR1C3 in both its recombinant form as well as during its overexpression in cancer cells.	Daunorubicin	129-141	Bruton tyrosine kinase	Homo sapiens	63-66
33322571-4	2020	In this regard, we demonstrated that Bruton"s tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib efficiently prevented daunorubicin (Dau) inactivation mediated by AKR1C3 in both its recombinant form as well as during its overexpression in cancer cells.	Daunorubicin	129-141	aldo-keto reductase family 1 member C3	Homo sapiens	173-179
33322571-4	2020	In this regard, we demonstrated that Bruton"s tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib efficiently prevented daunorubicin (Dau) inactivation mediated by AKR1C3 in both its recombinant form as well as during its overexpression in cancer cells.	Daunorubicin	143-146	Bruton tyrosine kinase	Homo sapiens	37-61
33322571-4	2020	In this regard, we demonstrated that Bruton"s tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib efficiently prevented daunorubicin (Dau) inactivation mediated by AKR1C3 in both its recombinant form as well as during its overexpression in cancer cells.	Daunorubicin	143-146	Bruton tyrosine kinase	Homo sapiens	63-66
33322571-4	2020	In this regard, we demonstrated that Bruton"s tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib efficiently prevented daunorubicin (Dau) inactivation mediated by AKR1C3 in both its recombinant form as well as during its overexpression in cancer cells.	Daunorubicin	143-146	aldo-keto reductase family 1 member C3	Homo sapiens	173-179
33167906-9	2020	RESULTS: Prolonged in vitro daunorubicin exposure induced activating ABCB1 promoter translocations in human THP-1 AML cells, similar to those recently described in recurrent high-grade serous ovarian and breast cancers.	Daunorubicin	28-40	ATP binding cassette subfamily B member 1	Homo sapiens	69-74
32621953-0	2020	The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.	Daunorubicin	99-111	carbonyl reductase 1	Homo sapiens	165-185
32621953-13	2020	RESULTS: Y6(10 mug/ml or 55 mg/kg) decreased the expression of HIF-1alpha and CBR1 at both the mRNA and protein levels during combined drug therapy in vitro as well as in vivo, thereby inhibiting formation of the metabolite DNRol from DNR, with the mechanisms being related to PI3K/AKT and MEK/ERK signaling inhibition.	Daunorubicin	224-227	hypoxia inducible factor 1 subunit alpha	Homo sapiens	63-73
32621953-15	2020	CONCLUSIONS: Y6 has the ability to inhibit CBR1 expression through the coordinate inhibition of PI3K/AKT and MEK/ERK signaling, then synergistically enhances the antitumor effect and reduces the cardiotoxicity of DNR.	Daunorubicin	213-216	carbonyl reductase 1	Homo sapiens	43-47
33114555-0	2020	Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3.	Daunorubicin	47-59	aldo-keto reductase family 1 member C3	Homo sapiens	81-87
33120845-13	2020	LESSONS: APL patients with STAT5B-RARa is not only resistant to ATRA, but also to conventional combination chemotherapy such as daunorubicin and cytarabine/idarubicin and cytarabine or other regimens.	Daunorubicin	128-140	signal transducer and activator of transcription 5B	Homo sapiens	27-33
33120845-13	2020	LESSONS: APL patients with STAT5B-RARa is not only resistant to ATRA, but also to conventional combination chemotherapy such as daunorubicin and cytarabine/idarubicin and cytarabine or other regimens.	Daunorubicin	128-140	retinoic acid receptor alpha	Homo sapiens	34-38
33071281-6	2020	Treatment with daunorubicin (DNR), one of the main chemotherapeutics for AML, upregulated P2X7RB expression while reducing P2X7RA mRNA in AML blasts.	Daunorubicin	15-27	purinergic receptor P2X 7	Homo sapiens	90-96
33071281-6	2020	Treatment with daunorubicin (DNR), one of the main chemotherapeutics for AML, upregulated P2X7RB expression while reducing P2X7RA mRNA in AML blasts.	Daunorubicin	15-27	purinergic receptor P2X 7	Homo sapiens	123-129
33071281-6	2020	Treatment with daunorubicin (DNR), one of the main chemotherapeutics for AML, upregulated P2X7RB expression while reducing P2X7RA mRNA in AML blasts.	Daunorubicin	29-32	purinergic receptor P2X 7	Homo sapiens	90-96
33071281-6	2020	Treatment with daunorubicin (DNR), one of the main chemotherapeutics for AML, upregulated P2X7RB expression while reducing P2X7RA mRNA in AML blasts.	Daunorubicin	29-32	purinergic receptor P2X 7	Homo sapiens	123-129
33071281-7	2020	Interestingly, DNR administration also caused ATP release from AML blasts suggesting that, following chemotherapy, activation of the receptor isoforms via their agonist will be responsible for the differential survival of blasts overexpressing P2X7RA versus P2X7RB.	Daunorubicin	15-18	purinergic receptor P2X 7	Homo sapiens	244-250
33071281-7	2020	Interestingly, DNR administration also caused ATP release from AML blasts suggesting that, following chemotherapy, activation of the receptor isoforms via their agonist will be responsible for the differential survival of blasts overexpressing P2X7RA versus P2X7RB.	Daunorubicin	15-18	purinergic receptor P2X 7	Homo sapiens	258-264
33071281-8	2020	Indeed, AML blasts expressing high levels of P2X7RA were more prone to cell death if exposed to DNR, while those overexpressing P2X7RB were more vital and even protected against DNR toxicity.	Daunorubicin	96-99	purinergic receptor P2X 7	Homo sapiens	45-51
33071281-8	2020	Indeed, AML blasts expressing high levels of P2X7RA were more prone to cell death if exposed to DNR, while those overexpressing P2X7RB were more vital and even protected against DNR toxicity.	Daunorubicin	178-181	purinergic receptor P2X 7	Homo sapiens	128-134
33071281-10	2020	P2X7RA facilitation of DNR toxicity was in part due to increased uptake of the drug inside the cell that was lost upon P2X7RB expression.	Daunorubicin	23-26	purinergic receptor P2X 7	Homo sapiens	0-6
33071281-10	2020	P2X7RA facilitation of DNR toxicity was in part due to increased uptake of the drug inside the cell that was lost upon P2X7RB expression.	Daunorubicin	23-26	purinergic receptor P2X 7	Homo sapiens	119-125
33071281-11	2020	Finally, in an AML xenograft model administration of DNR or the P2X7R antagonist, AZ10606120 significantly reduced leukemic growth and coadministration of the drugs proved more efficacious than single treatment as it reduced both P2X7RA and P2X7RB levels and downmodulated c-myc oncogene.	Daunorubicin	53-56	purinergic receptor P2X 7	Homo sapiens	230-236
33071281-11	2020	Finally, in an AML xenograft model administration of DNR or the P2X7R antagonist, AZ10606120 significantly reduced leukemic growth and coadministration of the drugs proved more efficacious than single treatment as it reduced both P2X7RA and P2X7RB levels and downmodulated c-myc oncogene.	Daunorubicin	53-56	purinergic receptor P2X 7	Homo sapiens	241-247
33071281-11	2020	Finally, in an AML xenograft model administration of DNR or the P2X7R antagonist, AZ10606120 significantly reduced leukemic growth and coadministration of the drugs proved more efficacious than single treatment as it reduced both P2X7RA and P2X7RB levels and downmodulated c-myc oncogene.	Daunorubicin	53-56	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	273-278
32945392-0	2020	Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells.	Daunorubicin	84-96	CREB binding protein	Homo sapiens	15-21
32945392-9	2020	Downregulation of CREBBP increased the IC50 value of daunorubicin; however, no significant affects were observed on the IC50 values of vincristine and L-asparaginase.	Daunorubicin	53-65	CREB binding protein	Homo sapiens	18-24
32945456-7	2020	In addition, CD9 knockdown could suppress cell proliferation, adhesion, migration and invasion, and promote apoptosis and the efficacy of chemotherapeutic drugs (such as vincristine, daunorubicin, cyclophosphamide and dexamethasone) and the tyrosine kinase inhibitor imatinib in SUP-B15 cells.	Daunorubicin	183-195	CD9 molecule	Homo sapiens	13-16
33067936-11	2020	DNR down-regulated protein expression of BCL-2 (P<0.05) and up-regulated cleaved Caspase-3 (P<0.05).	Daunorubicin	0-3	BCL2 apoptosis regulator	Homo sapiens	41-46
33067936-11	2020	DNR down-regulated protein expression of BCL-2 (P<0.05) and up-regulated cleaved Caspase-3 (P<0.05).	Daunorubicin	0-3	caspase 3	Homo sapiens	81-90
32938995-0	2020	SHOC2 scaffold protein modulates daunorubicin-induced cell death through p53 modulation in lymphoid leukemia cells.	Daunorubicin	33-45	tumor protein p53	Homo sapiens	73-76
32588086-4	2020	In the present study, we investigated the influence of these anticancer drugs on the reductive Dau metabolism mediated by the aldo-keto reductases AKR1A1, 1B10, 1C3, and 7A2 and carbonyl reductase 1 (CBR1).	Daunorubicin	95-98	aldo-keto reductase family 1 member A1	Homo sapiens	147-153
32588086-4	2020	In the present study, we investigated the influence of these anticancer drugs on the reductive Dau metabolism mediated by the aldo-keto reductases AKR1A1, 1B10, 1C3, and 7A2 and carbonyl reductase 1 (CBR1).	Daunorubicin	95-98	carbonyl reductase 1	Homo sapiens	178-198
32588086-4	2020	In the present study, we investigated the influence of these anticancer drugs on the reductive Dau metabolism mediated by the aldo-keto reductases AKR1A1, 1B10, 1C3, and 7A2 and carbonyl reductase 1 (CBR1).	Daunorubicin	95-98	carbonyl reductase 1	Homo sapiens	200-204
32588086-8	2020	Further, the combination of 1 microM ATRA with different concentrations of Dau demonstrated synergistic effects in HCT116 and KG1a human cells expressing AKR1C3.	Daunorubicin	75-78	aldo-keto reductase family 1 member C3	Homo sapiens	154-160
32588086-9	2020	Our results suggest that ATRA-mediated inhibition of AKR1C3 can contribute to the mechanisms that are hidden beyond the beneficial clinical outcome of the ATRA-Dau combination.	Daunorubicin	160-163	aldo-keto reductase family 1 member C3	Homo sapiens	53-59
32525004-0	2020	Tetrandrine enhances glucocorticoid receptor translocation possibly via inhibition of P-glycoprotein in daunorubicin-resistant human T lymphoblastoid leukemia cells.	Daunorubicin	104-116	nuclear receptor subfamily 3 group C member 1	Homo sapiens	21-44
32525004-0	2020	Tetrandrine enhances glucocorticoid receptor translocation possibly via inhibition of P-glycoprotein in daunorubicin-resistant human T lymphoblastoid leukemia cells.	Daunorubicin	104-116	ATP binding cassette subfamily B member 1	Homo sapiens	86-100
32497550-6	2020	In subsequent drug combination experiments, we demonstrated the ability of entrectinib to synergize with daunorubicin in various ABCB1-expressing cellular models.	Daunorubicin	105-117	abcb1	None	129-134
32626988-6	2020	In addition, NL-101 enhanced DNR-induced cell apoptosis, as assessed by flow cytometry and as indicated by the upregulation of cleaved-poly (ADP-ribose) polymerase, cleaved-caspase-3, cleaved-caspase-7, BAD and BIM.	Daunorubicin	29-32	caspase 7	Mus musculus	192-201
31820302-0	2020	In Vivo Tumor Growth Inhibition and Antiangiogenic Effect of Cyclic NGR Peptide-Daunorubicin Conjugates Developed for Targeted Drug Delivery.	Daunorubicin	80-92	reticulon 4 receptor	Homo sapiens	68-71
32530018-3	2020	To ensure the drug release, the cathepsin B labile GFLG spacer was incorporated between the targeting peptide and the drug molecule (daunomycin), which significantly increased the hydrophobicity and thereby decreased the water solubility of the conjugates.	Daunorubicin	133-143	cathepsin B	Homo sapiens	32-43
32580307-0	2020	Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer.	Daunorubicin	35-45	pancreas protein 1	Mus musculus	89-95
32580307-9	2020	The most efficient conjugate was Dau=Aoa-GFLG-K(Dau=Aoa)SKAAKN-OH (conjugate 4) that also showed significant tumor growth inhibition on s.c. implanted PANC-1 tumor-bearing mice with negligible side effects.	Daunorubicin	33-36	pancreas protein 1	Mus musculus	151-157
32670766-8	2020	The T-hNP/SnMP enhances the chemo-therapeutic effect of daunorubicin and boosts immune response by reprogramming bone marrow myeloid cells resulting from the recruitment of the monocyte-lineage and induction of inflammatory genes.	Daunorubicin	56-68	kallikrein related peptidase 8	Homo sapiens	6-9
32362146-4	2020	GGP modified daunorubicin plus dioscin liposome has suitable particle size, narrow PDI, zeta potential of about -5 mV, long cycle effect, and enhanced cell uptake due to surface modification of GGP making the liposome could enter the inside of the tumor to fully exert its anti-tumor effect.	Daunorubicin	13-25	peptidyl arginine deiminase 1	Homo sapiens	83-86
32037927-0	2020	Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.	Daunorubicin	38-50	T-box transcription factor 22	Homo sapiens	52-55
32037927-3	2020	CPX-351 is a liposomal encapsulated formulation of cytarabine and daunorubicin in a 5:1 molar ratio that has been demonstrated to deliver synergistic ratiometric dosing of these drugs in pre-clinical studies.	Daunorubicin	66-78	T-box transcription factor 22	Homo sapiens	0-3
32037927-4	2020	Early phase studies noted the encapsulated formulation of CPX-351 led to the extended duration of detectable cytarabine and daunorubicin levels compared to conventional chemotherapy, which may contribute to prolonged cytopenias.	Daunorubicin	124-136	T-box transcription factor 22	Homo sapiens	58-61
32433559-5	2020	In-vitro, Kasumi-1 leukemic cell line, sorted by CD34 expression, showed increased apoptosis only in the CD34- subpopulation after exposure to cytosine arabinoside (Ara-C) or daunorubicin.	Daunorubicin	175-187	CD34 molecule	Homo sapiens	105-109
32429253-4	2020	Ex vivo response of primary AML blasts towards cytarabine (Ara C), daunorubicin (DNR), etoposide (VP16), and cladribine (2-CdA) was associated with the expression of 101, 345, 206, and 599 genes, respectively (p < 0.001, FDR 0.004-0.416).	Daunorubicin	67-79	cytidine deaminase	Homo sapiens	123-126
32429253-4	2020	Ex vivo response of primary AML blasts towards cytarabine (Ara C), daunorubicin (DNR), etoposide (VP16), and cladribine (2-CdA) was associated with the expression of 101, 345, 206, and 599 genes, respectively (p < 0.001, FDR 0.004-0.416).	Daunorubicin	81-84	cytidine deaminase	Homo sapiens	123-126
32203165-9	2020	Lastly, evaluation of survival signaling following daunorubicin treatment identified robust activation of p38 mitogen-activated protein kinase (MAPK) downstream of PKCalpha and beta1 integrin signaling when CD82 is overexpressed.	Daunorubicin	51-63	mitogen-activated protein kinase 14	Homo sapiens	106-142
32203165-9	2020	Lastly, evaluation of survival signaling following daunorubicin treatment identified robust activation of p38 mitogen-activated protein kinase (MAPK) downstream of PKCalpha and beta1 integrin signaling when CD82 is overexpressed.	Daunorubicin	51-63	protein kinase C alpha	Homo sapiens	164-172
32203165-9	2020	Lastly, evaluation of survival signaling following daunorubicin treatment identified robust activation of p38 mitogen-activated protein kinase (MAPK) downstream of PKCalpha and beta1 integrin signaling when CD82 is overexpressed.	Daunorubicin	51-63	integrin subunit beta 1	Homo sapiens	177-191
32098672-6	2020	After co-culture of NB4 and THP1 with MSCs pretreated with 3 MA or ATG5 knockdown respectively, the sensitivity of AML cell lines to daunorubicin and doxorubicin was improved in a dose- and time-dependent manner compared to controls.	Daunorubicin	133-145	GLI family zinc finger 2	Homo sapiens	28-32
32098672-6	2020	After co-culture of NB4 and THP1 with MSCs pretreated with 3 MA or ATG5 knockdown respectively, the sensitivity of AML cell lines to daunorubicin and doxorubicin was improved in a dose- and time-dependent manner compared to controls.	Daunorubicin	133-145	autophagy related 5	Homo sapiens	67-71
32232394-0	2020	TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt/beta-catenin signaling.	Daunorubicin	70-82	tripartite motif containing 31	Homo sapiens	0-6
32232394-0	2020	TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt/beta-catenin signaling.	Daunorubicin	70-82	Wnt family member 3A	Homo sapiens	95-98
32232394-0	2020	TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt/beta-catenin signaling.	Daunorubicin	70-82	catenin beta 1	Homo sapiens	99-111
32232394-10	2020	The IC50 of daunorubicin was significantly decreased in si-TRIM31 transfected cells.	Daunorubicin	12-24	tripartite motif containing 31	Homo sapiens	59-65
32232394-13	2020	Activation of Wnt/beta-catenin pathway by LiCl abolished the effects of si-TRIM31 on cell proliferation, apoptosis and sensitivity to daunorubicin in AML cells.	Daunorubicin	134-146	Wnt family member 3A	Homo sapiens	14-17
32232394-13	2020	Activation of Wnt/beta-catenin pathway by LiCl abolished the effects of si-TRIM31 on cell proliferation, apoptosis and sensitivity to daunorubicin in AML cells.	Daunorubicin	134-146	catenin beta 1	Homo sapiens	18-30
32232394-13	2020	Activation of Wnt/beta-catenin pathway by LiCl abolished the effects of si-TRIM31 on cell proliferation, apoptosis and sensitivity to daunorubicin in AML cells.	Daunorubicin	134-146	tripartite motif containing 31	Homo sapiens	75-81
32232394-14	2020	In conclusion, TRIM31 promoted leukemogenesis and chemoresistance to daunorubicin in AML.	Daunorubicin	69-81	tripartite motif containing 31	Homo sapiens	15-21
31954717-7	2020	The Km of Pgp-mediated ATP hydrolysis extracted from the kinetics curves was lower for DOX than DNR.	Daunorubicin	96-99	phosphoglycolate phosphatase	Mus musculus	10-13
31954717-9	2020	Acrylamide quenching of Pgp tryptophan fluorescence to probe the tertiary structure of Pgp suggested that DNR shifts Pgp to a "closed" conformation, while DOX shifts Pgp to an "intermediate" conformation.	Daunorubicin	106-109	phosphoglycolate phosphatase	Mus musculus	24-27
31954717-9	2020	Acrylamide quenching of Pgp tryptophan fluorescence to probe the tertiary structure of Pgp suggested that DNR shifts Pgp to a "closed" conformation, while DOX shifts Pgp to an "intermediate" conformation.	Daunorubicin	106-109	phosphoglycolate phosphatase	Mus musculus	87-90
31954717-9	2020	Acrylamide quenching of Pgp tryptophan fluorescence to probe the tertiary structure of Pgp suggested that DNR shifts Pgp to a "closed" conformation, while DOX shifts Pgp to an "intermediate" conformation.	Daunorubicin	106-109	phosphoglycolate phosphatase	Mus musculus	87-90
31954717-9	2020	Acrylamide quenching of Pgp tryptophan fluorescence to probe the tertiary structure of Pgp suggested that DNR shifts Pgp to a "closed" conformation, while DOX shifts Pgp to an "intermediate" conformation.	Daunorubicin	106-109	phosphoglycolate phosphatase	Mus musculus	87-90
31954717-11	2020	Analysis of AFM images revealed that DNR and DOX cause distinct and significant shifts in the conformational distribution of Pgp.	Daunorubicin	37-40	phosphoglycolate phosphatase	Mus musculus	125-128
32231067-6	2020	Drug combination experiments demonstrated that ensartinib synergistically potentiates the antiproliferative effects of daunorubicin, mitoxantrone, and docetaxel in ABCB1, ABCG2, and CYP3A4-overexpressing cellular models, respectively.	Daunorubicin	119-131	ATP binding cassette subfamily B member 1	Canis lupus familiaris	164-169
32231067-6	2020	Drug combination experiments demonstrated that ensartinib synergistically potentiates the antiproliferative effects of daunorubicin, mitoxantrone, and docetaxel in ABCB1, ABCG2, and CYP3A4-overexpressing cellular models, respectively.	Daunorubicin	119-131	ATP binding cassette subfamily G member 2	Canis lupus familiaris	171-176
32231067-6	2020	Drug combination experiments demonstrated that ensartinib synergistically potentiates the antiproliferative effects of daunorubicin, mitoxantrone, and docetaxel in ABCB1, ABCG2, and CYP3A4-overexpressing cellular models, respectively.	Daunorubicin	119-131	cytochrome P450 3A12	Canis lupus familiaris	182-188
33742970-3	2021	Knockdown of JMJD3 can decrease the proliferation of AML cells and increase the chemosensitivity of daunorubicin (DNR) and cytarabine (Ara-C).	Daunorubicin	100-112	lysine demethylase 6B	Homo sapiens	13-18
33742970-3	2021	Knockdown of JMJD3 can decrease the proliferation of AML cells and increase the chemosensitivity of daunorubicin (DNR) and cytarabine (Ara-C).	Daunorubicin	114-117	lysine demethylase 6B	Homo sapiens	13-18
31770110-3	2020	We show that exposure of leukemia cells to daunorubicin activated an integrated stress response-like transcriptional program to induce ABCB1 through remodeling and activation of an ATF4-bound, stress-responsive enhancer.	Daunorubicin	43-55	ATP binding cassette subfamily B member 1	Homo sapiens	135-140
31770110-3	2020	We show that exposure of leukemia cells to daunorubicin activated an integrated stress response-like transcriptional program to induce ABCB1 through remodeling and activation of an ATF4-bound, stress-responsive enhancer.	Daunorubicin	43-55	activating transcription factor 4	Homo sapiens	181-185
31770110-5	2020	In primary human AML, exposure of fresh blast cells to daunorubicin activated the stress-responsive enhancer and led to dose-dependent induction of ABCB1.	Daunorubicin	55-67	ATP binding cassette subfamily B member 1	Homo sapiens	148-153
32104283-7	2020	The results revealed that the protein expression levels of MRP1 and P-gp were downregulated by raised CD40L expression and that the combination of raised CD40L expression with daunorubicin (DNR), a drug from which ADM is derived, significantly increased the extent of cell apoptosis, indicating that drug resistance was effectively attenuated by CD40L.	Daunorubicin	176-188	ATP binding cassette subfamily C member 1	Homo sapiens	59-63
32104283-7	2020	The results revealed that the protein expression levels of MRP1 and P-gp were downregulated by raised CD40L expression and that the combination of raised CD40L expression with daunorubicin (DNR), a drug from which ADM is derived, significantly increased the extent of cell apoptosis, indicating that drug resistance was effectively attenuated by CD40L.	Daunorubicin	176-188	CD40 ligand	Homo sapiens	154-159
32104283-7	2020	The results revealed that the protein expression levels of MRP1 and P-gp were downregulated by raised CD40L expression and that the combination of raised CD40L expression with daunorubicin (DNR), a drug from which ADM is derived, significantly increased the extent of cell apoptosis, indicating that drug resistance was effectively attenuated by CD40L.	Daunorubicin	176-188	CD40 ligand	Homo sapiens	154-159
31462111-7	2020	Action mechanism studies showed that the R8GD modified daunorubicin liposomes plus R8GD modified emodin liposomes could downregulate some metastasis-related proteins, including MMP-2, VE-cad, TGF-beta1 and HIF-1alpha.	Daunorubicin	55-67	matrix metallopeptidase 2	Homo sapiens	177-182
31462111-7	2020	Action mechanism studies showed that the R8GD modified daunorubicin liposomes plus R8GD modified emodin liposomes could downregulate some metastasis-related proteins, including MMP-2, VE-cad, TGF-beta1 and HIF-1alpha.	Daunorubicin	55-67	transforming growth factor beta 1	Homo sapiens	192-201
31887299-0	2020	Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.	Daunorubicin	37-49	unc-51 like autophagy activating kinase 1	Homo sapiens	23-27
31887299-7	2020	Furthermore, ULK1 inhibition by a highly selective kinase inhibitor SBI-0206965 and shRNA enhanced cytotoxicity of DNR against AML cells.	Daunorubicin	115-118	unc-51 like autophagy activating kinase 1	Homo sapiens	13-17
31887299-8	2020	Independent of mTOR -ULK1 signaling pathway, activation of autophagy of DNR was proved to be mediated by AMPK (pThr172)/ULK1 pathway.	Daunorubicin	72-75	mechanistic target of rapamycin kinase	Homo sapiens	15-19
31887299-8	2020	Independent of mTOR -ULK1 signaling pathway, activation of autophagy of DNR was proved to be mediated by AMPK (pThr172)/ULK1 pathway.	Daunorubicin	72-75	unc-51 like autophagy activating kinase 1	Homo sapiens	21-25
31887299-8	2020	Independent of mTOR -ULK1 signaling pathway, activation of autophagy of DNR was proved to be mediated by AMPK (pThr172)/ULK1 pathway.	Daunorubicin	72-75	unc-51 like autophagy activating kinase 1	Homo sapiens	120-124
31887299-9	2020	CONCLUSIONS: These results revealed that pro-survival autophagy induced by ULK1 activation was one of the potential mechanisms of AML resistance to DNR.	Daunorubicin	148-151	unc-51 like autophagy activating kinase 1	Homo sapiens	75-79
31887299-10	2020	Targeting ULK1 selectively could be a promising therapeutic strategy to enhance sensitivity of DNR for AML therapy.	Daunorubicin	95-98	unc-51 like autophagy activating kinase 1	Homo sapiens	10-14
31787334-5	2020	The sR9-mediated heme oxygenase-1 siRNA (siHO-1) delivery efficiently enhanced apoptotic response to daunorubicin of AML cells and AML-targeted HO-1 silencing improved chemotherapy and prolonged survival in orthotopic myeloid leukemia model.	Daunorubicin	101-113	heme oxygenase 1	Homo sapiens	43-47
31614366-6	2020	Also, the increased daunomycin efflux capacity of our patient"s lymphocytes was successfully inhibited by fumitremorgin C, a specific ABCG2/BCRP inhibitor, and the patient"s level of thyroid-stimulating hormone increased by 248.6% after administration of intact levothyroxine tablets but decreased by 45.1% when tablets were crushed.	Daunorubicin	20-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	134-139
31614366-6	2020	Also, the increased daunomycin efflux capacity of our patient"s lymphocytes was successfully inhibited by fumitremorgin C, a specific ABCG2/BCRP inhibitor, and the patient"s level of thyroid-stimulating hormone increased by 248.6% after administration of intact levothyroxine tablets but decreased by 45.1% when tablets were crushed.	Daunorubicin	20-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	140-144
32021192-0	2020	Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment.	Daunorubicin	0-12	interleukin 3 receptor subunit alpha	Homo sapiens	50-55
32021192-4	2020	Many researches reported high expression of CD123 antigen on high-risk MDS cells, so we constructed a novel drug delivery system comprising daunorubicin-loaded CdTe QDs conjugated with anti-CD123 mAbs (DNR-CdTe-CD123) to develop targeted combination chemotherapy for MDS.	Daunorubicin	140-152	interleukin 3 receptor subunit alpha	Homo sapiens	44-57
32021192-4	2020	Many researches reported high expression of CD123 antigen on high-risk MDS cells, so we constructed a novel drug delivery system comprising daunorubicin-loaded CdTe QDs conjugated with anti-CD123 mAbs (DNR-CdTe-CD123) to develop targeted combination chemotherapy for MDS.	Daunorubicin	140-152	interleukin 3 receptor subunit alpha	Homo sapiens	44-49
32021192-4	2020	Many researches reported high expression of CD123 antigen on high-risk MDS cells, so we constructed a novel drug delivery system comprising daunorubicin-loaded CdTe QDs conjugated with anti-CD123 mAbs (DNR-CdTe-CD123) to develop targeted combination chemotherapy for MDS.	Daunorubicin	140-152	interleukin 3 receptor subunit alpha	Homo sapiens	190-195
32021192-13	2020	In vivo experiments, DNR-CdTe-CD123 can effectively inhibit the tumor growth of MDS-bearing nude mice and reduce the side effects of DNR on myocardial cells.	Daunorubicin	21-24	interleukin 3 receptor, alpha chain	Mus musculus	30-35
32021192-14	2020	Conclusion: The system of DNR-CdTe-CD123 enhances the therapeutic effects and reduce the side effects of DNR, thus providing a novel platform for MDS treatment.	Daunorubicin	26-29	interleukin 3 receptor, alpha chain	Mus musculus	35-40
31222822-0	2020	MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2.	Daunorubicin	38-50	microRNA 33b	Homo sapiens	0-12
31222822-0	2020	MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2.	Daunorubicin	38-50	eukaryotic translation initiation factor 5A2	Homo sapiens	94-139
31222822-1	2020	In this study, we aimed to study the effect of miR-33b in regulating sensitivity to daunorubicin (DNR) in acute myelocytic leukemia (AML).	Daunorubicin	84-96	microRNA 33b	Homo sapiens	47-54
31222822-1	2020	In this study, we aimed to study the effect of miR-33b in regulating sensitivity to daunorubicin (DNR) in acute myelocytic leukemia (AML).	Daunorubicin	98-101	microRNA 33b	Homo sapiens	47-54
31222822-4	2020	MiR-33b mimic increased sensitivity of AML cells against DNR, while miR-33b inhibitor had the opposite effect.	Daunorubicin	57-60	microRNA 33b	Homo sapiens	0-7
31222822-7	2020	We also found that MCL-1 contributed to the regulation of DNR sensitivity, which was dependent on downregulation of eIF5A-2.	Daunorubicin	58-61	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	19-24
31222822-7	2020	We also found that MCL-1 contributed to the regulation of DNR sensitivity, which was dependent on downregulation of eIF5A-2.	Daunorubicin	58-61	eukaryotic translation initiation factor 5A2	Homo sapiens	116-123
31222822-8	2020	Finally, knockdown of eIF5A-2 eliminated the effects of miRNA-33b mimic or inhibitor on DNR sensitivity.	Daunorubicin	88-91	eukaryotic translation initiation factor 5A2	Homo sapiens	22-29
31613845-9	2020	Also, ABCC4 and ABCC6 had more expression with high doses of Daunorubicin and L-Asparginase.	Daunorubicin	61-73	ATP binding cassette subfamily C member 4	Homo sapiens	6-11
31613845-9	2020	Also, ABCC4 and ABCC6 had more expression with high doses of Daunorubicin and L-Asparginase.	Daunorubicin	61-73	ATP binding cassette subfamily C member 6	Homo sapiens	16-21
31201358-6	2020	KDM6A-null myeloid leukemia cells were more resistant to treatment with the chemotherapeutic agents cytarabine (AraC) and daunorubicin.	Daunorubicin	122-134	lysine demethylase 6A	Homo sapiens	0-5
31290701-0	2020	Glucosamine Reverses P-Glycoprotein-Mediated Multidrug Resistance in the Daunorubicin-Resistant Human Gastric Cancer Cells.	Daunorubicin	73-85	ATP binding cassette subfamily B member 1	Homo sapiens	21-35
31290701-2	2020	In this study, we aimed to evaluate the effects of GlcN for its cytotoxicity, MDR reversal effects and inhibitory effects on function and expression of P-glycoprotein (P-gp) transporter in the daunorubicin-resistant human gastric cancer cells.	Daunorubicin	193-205	ATP binding cassette subfamily B member 1	Homo sapiens	152-166
31290701-2	2020	In this study, we aimed to evaluate the effects of GlcN for its cytotoxicity, MDR reversal effects and inhibitory effects on function and expression of P-glycoprotein (P-gp) transporter in the daunorubicin-resistant human gastric cancer cells.	Daunorubicin	193-205	ATP binding cassette subfamily B member 1	Homo sapiens	168-172
31839031-0	2019	[Newly Diagnosed Acute Myeloid Leukemia Patients-Derived Bone Marrow Mesenchymal Stem Cells Suppress Daunorubicin Induced HL-60 Cell Apoptosis via Modulating Caspase-3/Survivin].	Daunorubicin	101-113	caspase 3	Homo sapiens	158-167
31839031-12	2019	CONCLUSION: MSCs can suppress Daunorubicin-induced HL-60 apoptosis via inhibiting Caspase-3 and maintaining survivin level.	Daunorubicin	30-42	caspase 3	Homo sapiens	82-91
32009807-1	2019	Purpose: The addition of midostaurin to standard chemotherapy (cytarabine and daunorubicin) has shown significant improvements in the survival of patients with acute myeloid leukemia with the FLT3 mutation (FLT3-AML).	Daunorubicin	78-90	fms related receptor tyrosine kinase 3	Homo sapiens	192-196
32009807-1	2019	Purpose: The addition of midostaurin to standard chemotherapy (cytarabine and daunorubicin) has shown significant improvements in the survival of patients with acute myeloid leukemia with the FLT3 mutation (FLT3-AML).	Daunorubicin	78-90	fms related receptor tyrosine kinase 3	Homo sapiens	207-211
31741714-4	2019	Overexpression of miR-143-3p in melanoma cells inhibits CD44 translation, which is accompanied by a reduced proliferation, migration and enhanced daunorubicin induced apoptosis of melanoma cells in vitro.	Daunorubicin	146-158	membrane associated ring-CH-type finger 8	Homo sapiens	18-21
31741714-4	2019	Overexpression of miR-143-3p in melanoma cells inhibits CD44 translation, which is accompanied by a reduced proliferation, migration and enhanced daunorubicin induced apoptosis of melanoma cells in vitro.	Daunorubicin	146-158	CD44 molecule (Indian blood group)	Homo sapiens	56-60
30991860-3	2019	We assessed aspects of ICD, as reflected by calreticulin expression, in primary human AML blasts and observed induction of surface calreticulin upon exposure to daunorubicin but not to cytarabine.	Daunorubicin	161-173	calreticulin	Homo sapiens	131-143
31672129-4	2019	CASE PRESENTATION: A 28-years-old woman in the 26th week of gestation diagnosed with FLT3/ITD-mutated AML, complete remission was induced by Daunorubicin and Cytarabine, and subsequently with 5-azacytidine (75 mg/m2 daily for 7 days) with no fetal hematological or toxicity issues.	Daunorubicin	141-153	fms related receptor tyrosine kinase 3	Homo sapiens	85-89
31506393-0	2019	Hexokinase II inhibition by 3-Bromopyruvate sensitizes myeloid leukemic cells K-562 to anti leukemic drug Daunorubicin.	Daunorubicin	106-118	hexokinase 2	Homo sapiens	0-13
31506393-7	2019	The combined treatment of 3-BP and DNR showed synergistic effect on the growth inhibition of K-562 and THP-1 cells.	Daunorubicin	35-38	GLI family zinc finger 2	Homo sapiens	103-108
31551083-3	2019	RESULTS: The Gamma histone H2AX (gammaH2AX) assay was used assess the effects of DNA-PK inhibitor NU7026 and RAD51 inhibitor RI-2 on repair of DNA-DSB following treatment with daunorubicin.	Daunorubicin	176-188	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	81-87
31551083-3	2019	RESULTS: The Gamma histone H2AX (gammaH2AX) assay was used assess the effects of DNA-PK inhibitor NU7026 and RAD51 inhibitor RI-2 on repair of DNA-DSB following treatment with daunorubicin.	Daunorubicin	176-188	RAD51 recombinase	Homo sapiens	109-114
31548507-4	2019	Indeed, molecular modeling of PLCgamma1 with SLP76 peptide and with previously reported inhibitors (ritonavir, anethole, daunorubicin, diflunisal, and rosiglitazone) facilitated the identification of the common critical residues (Gln805, Arg806, Asp808, Glu809, Asp825, Gly827, and Trp828) as well as the quantification of their interaction through binding energies calculations.	Daunorubicin	121-133	phospholipase C gamma 1	Homo sapiens	30-39
31548507-4	2019	Indeed, molecular modeling of PLCgamma1 with SLP76 peptide and with previously reported inhibitors (ritonavir, anethole, daunorubicin, diflunisal, and rosiglitazone) facilitated the identification of the common critical residues (Gln805, Arg806, Asp808, Glu809, Asp825, Gly827, and Trp828) as well as the quantification of their interaction through binding energies calculations.	Daunorubicin	121-133	lymphocyte cytosolic protein 2	Homo sapiens	45-50
31319147-2	2019	Here we described the development and specific targeting of daunorubicin (DNR)-loaded CD123/CD33 dual-antibody modified liposome, CD123/CD33-LP-DNR.	Daunorubicin	60-72	interleukin 3 receptor subunit alpha	Homo sapiens	86-91
31319147-2	2019	Here we described the development and specific targeting of daunorubicin (DNR)-loaded CD123/CD33 dual-antibody modified liposome, CD123/CD33-LP-DNR.	Daunorubicin	60-72	interleukin 3 receptor subunit alpha	Homo sapiens	130-135
31319147-2	2019	Here we described the development and specific targeting of daunorubicin (DNR)-loaded CD123/CD33 dual-antibody modified liposome, CD123/CD33-LP-DNR.	Daunorubicin	74-77	interleukin 3 receptor subunit alpha	Homo sapiens	86-91
31319147-2	2019	Here we described the development and specific targeting of daunorubicin (DNR)-loaded CD123/CD33 dual-antibody modified liposome, CD123/CD33-LP-DNR.	Daunorubicin	74-77	interleukin 3 receptor subunit alpha	Homo sapiens	130-135
31319147-4	2019	In this study, antibody mixture of CD123 and CD33 (1:1, molar ratio) were thiolated and coupled to Mal-PEG2000-DSPE, then the antibody-Mal-PEG2000-DSPE conjugations were inserted on the DNR-loaded PEGylated liposomes (PEG-LP-DNR) via a post insertion method to prepare CD123/CD33-LP-DNR (antibody/S100PC, molar ratio, 0.06%).	Daunorubicin	186-189	interleukin 3 receptor subunit alpha	Homo sapiens	35-40
31500399-2	2019	The aim of our work was to compare the cytotoxic/apoptotic activity of different GnRH-based, daunorubicin (Dau)-linked conjugates with or without butyrated Lys in position 4 (4Lys(Bu)) at a molecular level in a human colorectal carcinoma cell line.	Daunorubicin	93-105	gonadotropin releasing hormone 1	Homo sapiens	81-85
31500399-2	2019	The aim of our work was to compare the cytotoxic/apoptotic activity of different GnRH-based, daunorubicin (Dau)-linked conjugates with or without butyrated Lys in position 4 (4Lys(Bu)) at a molecular level in a human colorectal carcinoma cell line.	Daunorubicin	107-110	gonadotropin releasing hormone 1	Homo sapiens	81-85
31305009-10	2019	Knockout of P-gp by CRISPRCas9 overcame resistance to VCR and DNR in the P-gp-positive t(17;19)-ALL cell line.	Daunorubicin	62-65	phosphoglycolate phosphatase	Mus musculus	12-16
31305009-10	2019	Knockout of P-gp by CRISPRCas9 overcame resistance to VCR and DNR in the P-gp-positive t(17;19)-ALL cell line.	Daunorubicin	62-65	phosphoglycolate phosphatase	Mus musculus	73-77
31305009-11	2019	A combination of cyclosporine A with DNR prolonged survival of NSG mice inoculated with P-gp-positive t(17;19)-ALL cell line.	Daunorubicin	37-40	phosphoglycolate phosphatase	Mus musculus	88-92
31305009-12	2019	These findings indicate involvement of P-gp in resistance to VCR and DNR in Pgp positive t(17;19)-ALL cell lines.	Daunorubicin	69-72	phosphoglycolate phosphatase	Mus musculus	39-43
31305009-12	2019	These findings indicate involvement of P-gp in resistance to VCR and DNR in Pgp positive t(17;19)-ALL cell lines.	Daunorubicin	69-72	phosphoglycolate phosphatase	Mus musculus	76-79
31270818-0	2019	Pegfilgrastim and linagliptin potentiate chemoattraction of Ccr2 and Cd44 stem cells accompanied by alterations of cardiac Hgf, Igf-1 and Mcp-1 in daunorubicin cardiomyopathy.	Daunorubicin	147-159	mast cell protease 1-like 1	Rattus norvegicus	138-143
31270818-10	2019	DAU-induced upregulation of Mcp-1, Ccr2 and Cd44 was further potentiated by PFIL + LINA.	Daunorubicin	0-3	mast cell protease 1-like 1	Rattus norvegicus	28-33
31270818-10	2019	DAU-induced upregulation of Mcp-1, Ccr2 and Cd44 was further potentiated by PFIL + LINA.	Daunorubicin	0-3	C-C motif chemokine receptor 2	Rattus norvegicus	35-39
31270818-10	2019	DAU-induced upregulation of Mcp-1, Ccr2 and Cd44 was further potentiated by PFIL + LINA.	Daunorubicin	0-3	CD44 molecule (Indian blood group)	Rattus norvegicus	44-48
31100648-3	2019	Daunomycin was conjugated to the N-terminus of the peptide directly or through Cathepsin B cleavable spacers.	Daunorubicin	0-10	cathepsin B	Homo sapiens	79-90
31173171-0	2019	HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/beta-catenin signaling.	Daunorubicin	70-82	high mobility group AT-hook 2	Homo sapiens	0-5
31173171-0	2019	HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/beta-catenin signaling.	Daunorubicin	70-82	catenin beta 1	Homo sapiens	91-103
31055076-0	2019	Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.	Daunorubicin	0-12	C-type lectin domain family 12 member A	Homo sapiens	24-28
31055076-3	2019	We developed novel disulfide-crosslinked CLL1-targeting micelles (DC-CTM), which can deliver high concentrations of daunorubicin (DNR) into both bulk leukemia cells and LSCs.	Daunorubicin	116-128	C-type lectin domain family 12 member A	Homo sapiens	41-45
31055076-3	2019	We developed novel disulfide-crosslinked CLL1-targeting micelles (DC-CTM), which can deliver high concentrations of daunorubicin (DNR) into both bulk leukemia cells and LSCs.	Daunorubicin	130-133	C-type lectin domain family 12 member A	Homo sapiens	41-45
31418356-0	2019	[Relationship of PTEN/PI3K/AKT Signaling Pathway Protein Expression with Apoptosis and Drug-resistance of Children"s ALL Primary Cells Treated with Daunorubicin].	Daunorubicin	148-160	phosphatase and tensin homolog	Homo sapiens	17-21
31418356-0	2019	[Relationship of PTEN/PI3K/AKT Signaling Pathway Protein Expression with Apoptosis and Drug-resistance of Children"s ALL Primary Cells Treated with Daunorubicin].	Daunorubicin	148-160	AKT serine/threonine kinase 1	Homo sapiens	27-30
31418356-1	2019	OBJECTIVE: To investigate the relationship of PTEN/PI3K/AKT signaling pathway protein expression with apoptosis and drug-resistance of children"s ALL primary cells treated with daunorubicin (DNR).	Daunorubicin	177-189	phosphatase and tensin homolog	Homo sapiens	46-50
31418356-1	2019	OBJECTIVE: To investigate the relationship of PTEN/PI3K/AKT signaling pathway protein expression with apoptosis and drug-resistance of children"s ALL primary cells treated with daunorubicin (DNR).	Daunorubicin	177-189	AKT serine/threonine kinase 1	Homo sapiens	56-59
30470795-7	2019	Elevated MCL-1 or BCL-2 reduced sensitivity to daunorubicin but, surprisingly, not to bortezomib.	Daunorubicin	47-59	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	9-14
30470795-7	2019	Elevated MCL-1 or BCL-2 reduced sensitivity to daunorubicin but, surprisingly, not to bortezomib.	Daunorubicin	47-59	BCL2 apoptosis regulator	Homo sapiens	18-23
30470795-9	2019	Notable synergies were achieved by combining BH3 mimetics with daunorubicin: S63845 increased the sensitivity of both MCL-1 and BCL-2 overexpressing MLL-AF9 AMLs, and ABT-737 aided in killing those overexpressing BCL-2.	Daunorubicin	63-75	BCL2 apoptosis regulator	Homo sapiens	128-133
30470795-9	2019	Notable synergies were achieved by combining BH3 mimetics with daunorubicin: S63845 increased the sensitivity of both MCL-1 and BCL-2 overexpressing MLL-AF9 AMLs, and ABT-737 aided in killing those overexpressing BCL-2.	Daunorubicin	63-75	BCL2 apoptosis regulator	Homo sapiens	213-218
30470795-11	2019	Impressive synergistic responses were achieved for human MLL-fusion AML cell lines treated with daunorubicin plus either ABT-737, ABT-199 or S63845, and with ABT-199 plus S63845, with or without daunorubicin.	Daunorubicin	96-108	lysine methyltransferase 2A	Homo sapiens	57-60
31039321-7	2019	Mitoxantrone, daunorubicin, and vinorelbine are substrates of one or more of the ABCG2, ABCB1, or ABCC1 efflux transporters expressed to varying extents in the selected cell lines.	Daunorubicin	14-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	81-86
31039321-7	2019	Mitoxantrone, daunorubicin, and vinorelbine are substrates of one or more of the ABCG2, ABCB1, or ABCC1 efflux transporters expressed to varying extents in the selected cell lines.	Daunorubicin	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	88-93
31039321-7	2019	Mitoxantrone, daunorubicin, and vinorelbine are substrates of one or more of the ABCG2, ABCB1, or ABCC1 efflux transporters expressed to varying extents in the selected cell lines.	Daunorubicin	14-26	ATP binding cassette subfamily C member 1	Homo sapiens	98-103
30920135-5	2019	We also observed that stromal CYP3A4 expression is up-regulated by drugs commonly used in AML induction therapy, cytarabine, etoposide and daunorubicin, resulting in cross-resistance.	Daunorubicin	139-151	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
30849340-6	2019	In this study, inhibitory properties of these substances were examined with CBR1-mediated 2,3-hexanedione and DAUN reduction.	Daunorubicin	110-114	carbonyl reductase 1	Homo sapiens	76-80
30925062-3	2019	The best hit molecule-a thienopyrimidine-was a moderately potent, competitive inhibitor of the ABCC1-mediated transport of calcein AM which also sensitized ABCC1-overexpressing cells toward daunorubicin.	Daunorubicin	190-202	ATP binding cassette subfamily C member 1	Homo sapiens	95-100
30925062-3	2019	The best hit molecule-a thienopyrimidine-was a moderately potent, competitive inhibitor of the ABCC1-mediated transport of calcein AM which also sensitized ABCC1-overexpressing cells toward daunorubicin.	Daunorubicin	190-202	ATP binding cassette subfamily C member 1	Homo sapiens	156-161
30925062-5	2019	In addition, the thienopyrimidine could also sensitize ABCB1- as well as ABCG2-overexpressing cells toward daunorubicin and SN-38, respectively, in concentration ranges that qualified it as one of the ten best triple ABCC1/ABCB1/ABCG2 inhibitors in the literature.	Daunorubicin	107-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	73-78
30826329-0	2019	Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters.	Daunorubicin	93-105	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	179-182
30826329-3	2019	This phenomenon is often caused by pharmacokinetic mechanisms such as efflux of DAUN from cancer cells through ATP-binding cassette (ABC) transporters and its conversion to less cytostatic but more cardiotoxic daunorubicinol (DAUN-OL) by carbonyl reducing enzymes (CREs).	Daunorubicin	80-84	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	111-131
30826329-3	2019	This phenomenon is often caused by pharmacokinetic mechanisms such as efflux of DAUN from cancer cells through ATP-binding cassette (ABC) transporters and its conversion to less cytostatic but more cardiotoxic daunorubicinol (DAUN-OL) by carbonyl reducing enzymes (CREs).	Daunorubicin	80-84	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	133-136
30826329-9	2019	Moreover, these cells were sensitized to DAUN by both compounds as Chou-Talalay combination index analysis showed synergism in AKR1C3 transfected HCT-116, but not in empty vector transfected control cell line.	Daunorubicin	41-45	aldo-keto reductase family 1 member C3	Homo sapiens	127-133
30826329-10	2019	In conclusion, we propose AZD5438 and R547 as modulators of DAUN resistance that can prevent AKR1C3-mediated DAUN biotransformation to DAUN-OL.	Daunorubicin	60-64	aldo-keto reductase family 1 member C3	Homo sapiens	93-99
30826329-10	2019	In conclusion, we propose AZD5438 and R547 as modulators of DAUN resistance that can prevent AKR1C3-mediated DAUN biotransformation to DAUN-OL.	Daunorubicin	109-113	aldo-keto reductase family 1 member C3	Homo sapiens	93-99
31035631-4	2019	The cytotoxicity of daunorubicin (as a substrate of P-gp) to KB/MDR1 cells and the parental KB cells was measured in the presence or absence of flavonoids.	Daunorubicin	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
31035631-4	2019	The cytotoxicity of daunorubicin (as a substrate of P-gp) to KB/MDR1 cells and the parental KB cells was measured in the presence or absence of flavonoids.	Daunorubicin	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	64-68
30703376-9	2019	In conclusion, our results show a novel PI3K-independent effect of buparlisib that may improve therapeutic efficacy and safety of daunorubicin by preventing its metabolism by AKR1C3.	Daunorubicin	130-142	aldo-keto reductase family 1 member C3	Homo sapiens	175-181
30837363-0	2019	G-quadruplex forming region within WT1 promoter is selectively targeted by daunorubicin and mitoxantrone: A possible mechanism for anti-leukemic effect of drugs.	Daunorubicin	75-87	WT1 transcription factor	Homo sapiens	35-38
30688831-4	2019	MATERIALS AND METHODS: We evaluated the insulin-induced chemoresistance and AKT pathway activation by measuring cell proliferation, apoptosis, and other parameters in ALL cell lines (Jurkat and Reh cells), as well as in primary pediatric leukemic cell samples, after culture with insulin, the chemotherapeutic drugs daunorubicin (DNR), vincristine (VCR), and L-asparaginase (L-Asp), or anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody.	Daunorubicin	316-328	insulin	Homo sapiens	40-47
30559256-7	2019	IMPLICATIONS: RELA and PARP1 form a positive feedback loop to regulate DNA damage repair, simultaneous inhibition of NF-kappaB and PARP1 increases the antileukemic efficacy of daunorubicin in vitro and in vivo, broadening the use of PARP1 inhibitors.	Daunorubicin	176-188	RELA proto-oncogene, NF-kB subunit	Homo sapiens	14-18
30559256-7	2019	IMPLICATIONS: RELA and PARP1 form a positive feedback loop to regulate DNA damage repair, simultaneous inhibition of NF-kappaB and PARP1 increases the antileukemic efficacy of daunorubicin in vitro and in vivo, broadening the use of PARP1 inhibitors.	Daunorubicin	176-188	poly(ADP-ribose) polymerase 1	Homo sapiens	23-28
30559256-7	2019	IMPLICATIONS: RELA and PARP1 form a positive feedback loop to regulate DNA damage repair, simultaneous inhibition of NF-kappaB and PARP1 increases the antileukemic efficacy of daunorubicin in vitro and in vivo, broadening the use of PARP1 inhibitors.	Daunorubicin	176-188	nuclear factor kappa B subunit 1	Homo sapiens	117-126
30559256-7	2019	IMPLICATIONS: RELA and PARP1 form a positive feedback loop to regulate DNA damage repair, simultaneous inhibition of NF-kappaB and PARP1 increases the antileukemic efficacy of daunorubicin in vitro and in vivo, broadening the use of PARP1 inhibitors.	Daunorubicin	176-188	poly(ADP-ribose) polymerase 1	Homo sapiens	131-136
30559256-7	2019	IMPLICATIONS: RELA and PARP1 form a positive feedback loop to regulate DNA damage repair, simultaneous inhibition of NF-kappaB and PARP1 increases the antileukemic efficacy of daunorubicin in vitro and in vivo, broadening the use of PARP1 inhibitors.	Daunorubicin	176-188	poly(ADP-ribose) polymerase 1	Homo sapiens	131-136
30813936-12	2019	CONCLUSIONS: The delay in DSB repair and lower sensitivity to daunorubicin seen in the B lymphocyte derived SUP-B15 cells could be due to loss of function of p53 that may be correlated to increased expression of SOD2 and lower ROS production.	Daunorubicin	62-74	tumor protein p53	Homo sapiens	158-161
30813936-12	2019	CONCLUSIONS: The delay in DSB repair and lower sensitivity to daunorubicin seen in the B lymphocyte derived SUP-B15 cells could be due to loss of function of p53 that may be correlated to increased expression of SOD2 and lower ROS production.	Daunorubicin	62-74	superoxide dismutase 2	Homo sapiens	212-216
30622244-3	2019	In this study, we found that EPO suppresses p53-dependent apoptosis induced by genotoxic (daunorubicin, doxorubicin, and gamma-radiation) and non-genotoxic (nutlin-3a) agents and induces a senescence-like state in myeloid leukemia cells.	Daunorubicin	90-102	erythropoietin	Homo sapiens	29-32
30622244-3	2019	In this study, we found that EPO suppresses p53-dependent apoptosis induced by genotoxic (daunorubicin, doxorubicin, and gamma-radiation) and non-genotoxic (nutlin-3a) agents and induces a senescence-like state in myeloid leukemia cells.	Daunorubicin	90-102	tumor protein p53	Homo sapiens	44-47
30622244-7	2019	In addition, EPO antagonizes Mcl-1 protein degradation in daunorubicin-treated cells.	Daunorubicin	58-70	erythropoietin	Homo sapiens	13-16
30622244-7	2019	In addition, EPO antagonizes Mcl-1 protein degradation in daunorubicin-treated cells.	Daunorubicin	58-70	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	29-34
31072293-3	2019	OBJECTIVE: In the present work, we tested a new mechanistic insight on the AZD1208 (PIM-1 specific inhibitor) under interaction with chemotherapy agents such as Daunorubicin (DNR) and Vincristine (VCR).	Daunorubicin	161-173	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	84-89
31072293-3	2019	OBJECTIVE: In the present work, we tested a new mechanistic insight on the AZD1208 (PIM-1 specific inhibitor) under interaction with chemotherapy agents such as Daunorubicin (DNR) and Vincristine (VCR).	Daunorubicin	175-178	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	84-89
30113235-9	2019	There was significantly less daunorubicin taken up in the SR-BI knock-down cells across all drug concentrations and at all three time points, although there were no concentration-related trends.	Daunorubicin	29-41	scavenger receptor class B member 1	Homo sapiens	58-63
30745844-0	2019	miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis.	Daunorubicin	52-64	eukaryotic translation initiation factor 5A2	Homo sapiens	82-88
30745844-0	2019	miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis.	Daunorubicin	52-64	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	89-94
30339824-0	2019	Modeling drug-drug interactions of AZD1208 with Vincristine and Daunorubicin on ligand-extrusion binding TMD-domains of multidrug resistance P-glycoprotein (ABCB1).	Daunorubicin	64-76	ATP binding cassette subfamily B member 1	Homo sapiens	157-162
30339824-1	2019	In the present study, the molecular docking mechanism based on pharmacodynamic interactions between the ligands AZD1208 and recognized chemotherapy agents (Vincristine and Daunorubicin) with human ATP-binding cassette (ABC) transporters (ABCB1) was investigated.	Daunorubicin	172-184	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	197-217
30339824-1	2019	In the present study, the molecular docking mechanism based on pharmacodynamic interactions between the ligands AZD1208 and recognized chemotherapy agents (Vincristine and Daunorubicin) with human ATP-binding cassette (ABC) transporters (ABCB1) was investigated.	Daunorubicin	172-184	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	219-222
30339824-1	2019	In the present study, the molecular docking mechanism based on pharmacodynamic interactions between the ligands AZD1208 and recognized chemotherapy agents (Vincristine and Daunorubicin) with human ATP-binding cassette (ABC) transporters (ABCB1) was investigated.	Daunorubicin	172-184	ATP binding cassette subfamily B member 1	Homo sapiens	238-243
30598640-17	2018	Patients with RUNX1-RUNX1T1 gene fusion or without the ASXL1 gene mutation had a better chance of achieving CR when treated with cytarabine and daunorubicin induction chemotherapy.	Daunorubicin	144-156	RUNX family transcription factor 1	Homo sapiens	14-19
30598640-17	2018	Patients with RUNX1-RUNX1T1 gene fusion or without the ASXL1 gene mutation had a better chance of achieving CR when treated with cytarabine and daunorubicin induction chemotherapy.	Daunorubicin	144-156	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	20-27
30598640-17	2018	Patients with RUNX1-RUNX1T1 gene fusion or without the ASXL1 gene mutation had a better chance of achieving CR when treated with cytarabine and daunorubicin induction chemotherapy.	Daunorubicin	144-156	ASXL transcriptional regulator 1	Homo sapiens	55-60
30231297-3	2018	We demonstrate the MAIT cell-predominant CD8+ CD161++ subset to uniquely and efficiently efflux the cytotoxic anthracycline daunorubicin, retain function on daunorubicin exposure and demonstrate MDR1-dependent protection from daunorubicin-induced apoptosis.	Daunorubicin	124-136	CD8a molecule	Homo sapiens	41-44
30231297-3	2018	We demonstrate the MAIT cell-predominant CD8+ CD161++ subset to uniquely and efficiently efflux the cytotoxic anthracycline daunorubicin, retain function on daunorubicin exposure and demonstrate MDR1-dependent protection from daunorubicin-induced apoptosis.	Daunorubicin	157-169	CD8a molecule	Homo sapiens	41-44
30231297-3	2018	We demonstrate the MAIT cell-predominant CD8+ CD161++ subset to uniquely and efficiently efflux the cytotoxic anthracycline daunorubicin, retain function on daunorubicin exposure and demonstrate MDR1-dependent protection from daunorubicin-induced apoptosis.	Daunorubicin	157-169	CD8a molecule	Homo sapiens	41-44
30361682-6	2018	Furthermore, combined inhibition of Bcl-2/Bcl-XL and Mcl-1 could revert BMSC-mediated resistance against cytarabine + daunorubicin.	Daunorubicin	118-130	BCL2 apoptosis regulator	Homo sapiens	36-41
30361682-6	2018	Furthermore, combined inhibition of Bcl-2/Bcl-XL and Mcl-1 could revert BMSC-mediated resistance against cytarabine + daunorubicin.	Daunorubicin	118-130	BCL2 like 1	Homo sapiens	42-48
30361682-6	2018	Furthermore, combined inhibition of Bcl-2/Bcl-XL and Mcl-1 could revert BMSC-mediated resistance against cytarabine + daunorubicin.	Daunorubicin	118-130	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	53-58
30077642-6	2018	Furthermore, we demonstrated that the combination of daunorubicin with purvalanol A or roscovitine exhibited a synergistic effect in AKR1C3 overexpressing cells.	Daunorubicin	53-65	aldo-keto reductase family 1 member C3	Homo sapiens	133-139
29992508-8	2018	In subsequent experiments, pretreatment with dinaciclib (0.1 microM) significantly sensitized AKR1C3-overexpressing anthracycline-resistant cancer cells to daunorubicin.	Daunorubicin	156-168	aldo-keto reductase family 1 member C3	Homo sapiens	94-100
30157922-4	2018	METHODS: We established an oncogenic N-MYC-driven B-ALL mouse model, which were subsequently treated with common chemotherapy drug cytarabine (Ara-C) and daunorubicin (DNR).	Daunorubicin	154-166	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	37-42
30197523-4	2018	The purpose of this study was to construct a triple-regulated oncolytic adenovirus carrying a PDCD5 gene expression cassette (SG611-PDCD5) and explore the combined antitumor efficacy of SG611-PDCD5 in combination with low dose daunorubicin on leukemic cells.	Daunorubicin	227-239	programmed cell death 5	Homo sapiens	94-99
30197523-11	2018	In vitro treatment with SG611-PDCD5 in combination with low-dose daunorubicin elicited more potent anti-proliferative and proapoptotic effects in leukemic cells in a dose-dependent manner.	Daunorubicin	65-77	programmed cell death 5	Homo sapiens	30-35
30197523-15	2018	Conclusion: The findings suggest that combined treatment with SG611-PDCD5 and daunorubicin may be a promising strategy for enhancing chemosensitivity and thus lowering the dose-related toxicity of daunorubicin in leukemia therapy.	Daunorubicin	197-209	programmed cell death 5	Homo sapiens	68-73
30132679-8	2018	The CDK9 inhibitors alvocidib, atuveciclib, and TG02 have completed phase 1/2 clinical trials, with results available for the alvocidib trial showing improved complete remission rates (70% vs 46%; P = .003) for alvocidib in combination with cytarabine and mitoxantrone, versus cytarabine/daunorubicin, in patients with newly diagnosed AML.	Daunorubicin	288-300	cyclin dependent kinase 9	Homo sapiens	4-8
29673999-7	2018	The ribociclib-induced ABCB1 and ABCG2 inhibition further reversed daunorubicin and mitoxantrone resistance in MDCKII and human MCF-7 breast carcinoma cell lines, indicating a synergistic antiproliferative effect, without affecting ABCB1 or ABCG2 expression.	Daunorubicin	67-79	ATP binding cassette subfamily B member 1	Canis lupus familiaris	23-28
29673999-7	2018	The ribociclib-induced ABCB1 and ABCG2 inhibition further reversed daunorubicin and mitoxantrone resistance in MDCKII and human MCF-7 breast carcinoma cell lines, indicating a synergistic antiproliferative effect, without affecting ABCB1 or ABCG2 expression.	Daunorubicin	67-79	ATP binding cassette subfamily G member 2	Canis lupus familiaris	33-38
29358668-7	2018	eIF2alpha phosphorylation induced by mitoxantrone, a prototype ICD-inducing anthracyline, was mediated by eIF2alpha kinase-3 (EIF2AK3).	Daunorubicin	76-88	eukaryotic translation initiation factor 2A	Mus musculus	0-9
29358668-7	2018	eIF2alpha phosphorylation induced by mitoxantrone, a prototype ICD-inducing anthracyline, was mediated by eIF2alpha kinase-3 (EIF2AK3).	Daunorubicin	76-88	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	106-124
29358668-7	2018	eIF2alpha phosphorylation induced by mitoxantrone, a prototype ICD-inducing anthracyline, was mediated by eIF2alpha kinase-3 (EIF2AK3).	Daunorubicin	76-88	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	126-133
29870138-10	2018	Daunorubicin, mycophenolic acid, and pyrvinium could potentially target the hub gene CHEK1 directly.	Daunorubicin	0-12	checkpoint kinase 1	Homo sapiens	85-90
30065619-14	2018	Knockdown the expression of coilin increased the sensitivity to daunorubicin and inhibited the expression of p27 in Reh cells, and led to increased apoptosis.	Daunorubicin	64-76	coilin	Homo sapiens	28-34
30065619-18	2018	Reduction of coilin expression was sufficient to increase the sensitivity of leukemic cells to daunorubicin treatments, and during which possibly involved functions of p27 in cell cycle regulation and its effects on cell apoptosis.	Daunorubicin	95-107	coilin	Homo sapiens	13-19
30065619-18	2018	Reduction of coilin expression was sufficient to increase the sensitivity of leukemic cells to daunorubicin treatments, and during which possibly involved functions of p27 in cell cycle regulation and its effects on cell apoptosis.	Daunorubicin	95-107	zinc ribbon domain containing 2	Homo sapiens	168-171
30061855-8	2018	Importantly, small molecules pentamidine and daunorubicin were able to rescue cardiac phenotypes by releasing Muscleblind from sequestration.	Daunorubicin	45-57	muscleblind	Drosophila melanogaster	110-121
30013686-0	2018	Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells.	Daunorubicin	131-143	gonadotropin releasing hormone 1	Homo sapiens	85-89
30013686-6	2018	Sixteen different previously developed GnRH-conjugates containing doxorubicin, daunorubicin and methotrexate were investigated in this study.	Daunorubicin	79-91	gonadotropin releasing hormone 1	Homo sapiens	39-43
29196978-0	2018	The Role of Soluble Epoxide Hydrolase Enzyme on Daunorubicin-Mediated Cardiotoxicity.	Daunorubicin	48-60	epoxide hydrolase 2	Homo sapiens	12-37
29196978-2	2018	However, the ability of daunorubicin (DNR) to induce cardiotoxicity through the modulation of CYP and its associated AA metabolites has not been investigated yet.	Daunorubicin	24-36	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
29705536-0	2018	High dose daunorubicin: New standard of care for FLT3 ITD mutant AML.	Daunorubicin	10-22	fms related receptor tyrosine kinase 3	Homo sapiens	49-53
29955397-0	2018	BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death.	Daunorubicin	107-119	delta/notch like EGF repeat containing	Homo sapiens	0-3
29955397-4	2018	Daunorubicin alone causes a dose- and time-dependent increase in S100A8 and S100A9 protein levels in AML cell lines which is overcome by cotreatment with JQ1.	Daunorubicin	0-12	S100 calcium binding protein A8	Homo sapiens	65-71
29955397-4	2018	Daunorubicin alone causes a dose- and time-dependent increase in S100A8 and S100A9 protein levels in AML cell lines which is overcome by cotreatment with JQ1.	Daunorubicin	0-12	S100 calcium binding protein A9	Homo sapiens	76-82
29955397-5	2018	This suggests that JQ1 synergises with daunorubicin in causing apoptosis via suppression of S100A8 and S100A9 levels.	Daunorubicin	39-51	S100 calcium binding protein A8	Homo sapiens	92-98
29955397-5	2018	This suggests that JQ1 synergises with daunorubicin in causing apoptosis via suppression of S100A8 and S100A9 levels.	Daunorubicin	39-51	S100 calcium binding protein A9	Homo sapiens	103-109
29378418-3	2018	CPX-351, a novel liposomal formulation which encapsulates cytarabine and daunorubicin in 5:1 molar ratio, has shown promising efficacy, leading to recent US FDA approval for front-line therapy for patients with therapy-related AML and AML with myelodysplasia-related changes based on a large multicenter Phase III clinical trial.	Daunorubicin	73-85	T-box transcription factor 22	Homo sapiens	0-3
29765472-0	2018	Development of novel cyclic NGR peptide-daunomycin conjugates with dual targeting property.	Daunorubicin	40-50	reticulon 4 receptor	Homo sapiens	28-31
29765472-4	2018	Therefore, we developed novel cyclic NGR peptide-daunomycin conjugates in which Lys was replaced by different amino acids (Ala, Leu, Nle, Pro, Ser).	Daunorubicin	49-59	reticulon 4 receptor	Homo sapiens	37-40
29690909-11	2018	Mechanistically, daunorubicin increased the expression of NKG2D and DNAM-1 ligands on KG1a; blocking of these pathways attenuated DNT-mediated cytotoxicity.	Daunorubicin	17-29	killer cell lectin like receptor K1	Homo sapiens	58-63
29690909-11	2018	Mechanistically, daunorubicin increased the expression of NKG2D and DNAM-1 ligands on KG1a; blocking of these pathways attenuated DNT-mediated cytotoxicity.	Daunorubicin	17-29	CD226 molecule	Homo sapiens	68-74
29690909-11	2018	Mechanistically, daunorubicin increased the expression of NKG2D and DNAM-1 ligands on KG1a; blocking of these pathways attenuated DNT-mediated cytotoxicity.	Daunorubicin	17-29	5', 3'-nucleotidase, cytosolic	Homo sapiens	130-133
29592894-6	2018	We also identified a drug - daunorubicin hydrochloride - that directly binds to CUG repeats and alleviates Mbl sequestration in Drosophila DM1 cardiomyocytes, resulting in mis-splicing rescue and cardiac function recovery.	Daunorubicin	28-54	muscleblind	Drosophila melanogaster	107-110
29592894-6	2018	We also identified a drug - daunorubicin hydrochloride - that directly binds to CUG repeats and alleviates Mbl sequestration in Drosophila DM1 cardiomyocytes, resulting in mis-splicing rescue and cardiac function recovery.	Daunorubicin	28-54	tarsal-less 1A	Drosophila melanogaster	139-142
29719573-0	2018	Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.	Daunorubicin	67-79	gonadotropin releasing hormone 1	Homo sapiens	80-84
29719573-7	2018	For comparative purpose, six novel daunorubicin-GnRH-III bioconjugates have been synthesized and biochemically characterized in which 6Asp was replaced by D-Asp, D-Glu and D-Trp.	Daunorubicin	35-47	gonadotropin releasing hormone 1	Homo sapiens	48-52
29473342-8	2018	DCK knockout by genome editing with a CRISPR-Cas9 system in an Ara-C-sensitive-ALL cell line induced marked resistance to Ara-C, but not to vincristine and daunorubicin, indicating the involvement of DCK expression in the Ara-C sensitivity of BCP-ALL.	Daunorubicin	156-168	deoxycytidine kinase	Homo sapiens	0-3
29339439-5	2018	Combined treatment with a PARP inhibitor and daunorubicin had an additive effect on the killing of IDH1/2MUT AML cells.	Daunorubicin	45-57	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	99-103
29339439-6	2018	We provide evidence that the therapy sensitivity of IDH1/2MUT cells was caused by D2HG-mediated downregulation of expression of the DNA damage response gene ATM and not by altered redox responses due to metabolic alterations in IDH1/2MUT cells.Conclusions:IDH1/2MUT AML cells are sensitive to PARP inhibitors as monotherapy but especially when combined with a DNA-damaging agent, such as daunorubicin, whereas concomitant administration of IDH1/2MUT inhibitors during cytotoxic therapy decrease the efficacy of both agents in IDH1/2MUT AML.	Daunorubicin	388-400	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	52-56
29339439-6	2018	We provide evidence that the therapy sensitivity of IDH1/2MUT cells was caused by D2HG-mediated downregulation of expression of the DNA damage response gene ATM and not by altered redox responses due to metabolic alterations in IDH1/2MUT cells.Conclusions:IDH1/2MUT AML cells are sensitive to PARP inhibitors as monotherapy but especially when combined with a DNA-damaging agent, such as daunorubicin, whereas concomitant administration of IDH1/2MUT inhibitors during cytotoxic therapy decrease the efficacy of both agents in IDH1/2MUT AML.	Daunorubicin	388-400	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	52-61
28901327-8	2018	Daun02 is an inactive prodrug that is converted to the inhibitory molecule daunorubicin by beta-gal.	Daunorubicin	75-87	galactosidase, beta 1	Mus musculus	91-99
29238994-8	2018	KEY-FINDINGS: Compound 1 increased the DNA accumulation to 6.5-fold and decreased the DNM efflux to approximately 1/2 in the overexpressing P-gp cell line.	Daunorubicin	86-89	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	140-144
29222131-8	2018	CBR3 polymorphism increased HF risk from daunorubicin and idarubicin to a greater extent as compared with doxorubicin.	Daunorubicin	41-53	carbonyl reductase 3	Homo sapiens	0-4
28956104-0	2018	Daunorubicin conjugated with alpha-fetoprotein selectively eliminates myeloid-derived suppressor cells (MDSCs) and inhibits experimental tumor growth.	Daunorubicin	0-12	alpha fetoprotein	Mus musculus	29-46
28956104-6	2018	AFP conjugated to daunorubicin (AFP-DR) and DR alone showed similar in vitro cytotoxicity against the granulocytic MDSC subpopulation.	Daunorubicin	18-30	alpha fetoprotein	Mus musculus	0-3
28956104-6	2018	AFP conjugated to daunorubicin (AFP-DR) and DR alone showed similar in vitro cytotoxicity against the granulocytic MDSC subpopulation.	Daunorubicin	18-30	alpha fetoprotein	Mus musculus	32-35
29025907-5	2018	As a result, SIRT6 depletion compromises the ability of leukemia cells to repair DNA double-strand breaks that, in turn, increases their sensitivity to daunorubicin and Ara-C, both in vitro and in vivo In contrast, low SIRT6 levels observed in normal CD34+ hematopoietic progenitors explain their weaker sensitivity to genotoxic stress.	Daunorubicin	152-164	sirtuin 6	Homo sapiens	13-18
29312358-5	2017	DCs cultured with daunorubicin-treated AML cells upregulated indoleamine 2,3-dioxygenase 1 (IDO1), which induced anti-leukemia Tregs.	Daunorubicin	18-30	indoleamine 2,3-dioxygenase 1	Mus musculus	61-90
29312358-5	2017	DCs cultured with daunorubicin-treated AML cells upregulated indoleamine 2,3-dioxygenase 1 (IDO1), which induced anti-leukemia Tregs.	Daunorubicin	18-30	indoleamine 2,3-dioxygenase 1	Mus musculus	92-96
29312358-6	2017	These data were confirmed in vivo as daunorubicin-treated mice show an increase in extracellular ATP levels with increased number of Tregs, expressing PD-1 and IDO1+CD39+ DCs.	Daunorubicin	37-49	indoleamine 2,3-dioxygenase 1	Mus musculus	160-164
29079042-7	2017	MDR1 efflux kinetics also revealed that the maximum velocity and the pump affinity to daunorubicin were uncompetitively decreased.	Daunorubicin	86-98	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
29039532-0	2017	Puerarin attenuates the daunorubicin-induced apoptosis of H9c2 cells by activating the PI3K/Akt signaling pathway via the inhibition of Ca2+ influx.	Daunorubicin	24-36	AKT serine/threonine kinase 1	Rattus norvegicus	92-95
29163680-0	2017	Yi-qi-yang-yin-tang increases the sensitivity of KG1a leukemia stem cells to daunorubicin by promoting cell cycle progression and regulating the expression of PTEN, TOPOII and mTOR.	Daunorubicin	77-89	phosphatase and tensin homolog	Homo sapiens	159-163
29163680-0	2017	Yi-qi-yang-yin-tang increases the sensitivity of KG1a leukemia stem cells to daunorubicin by promoting cell cycle progression and regulating the expression of PTEN, TOPOII and mTOR.	Daunorubicin	77-89	mechanistic target of rapamycin kinase	Homo sapiens	176-180
29016119-5	2017	The best compound was active in a very low micromolar concentration range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP (BCRP) cells.	Daunorubicin	137-149	ATP binding cassette subfamily B member 1	Homo sapiens	151-155
29016119-5	2017	The best compound was active in a very low micromolar concentration range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP (BCRP) cells.	Daunorubicin	137-149	ATP binding cassette subfamily C member 1	Homo sapiens	160-164
29016119-5	2017	The best compound was active in a very low micromolar concentration range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP (BCRP) cells.	Daunorubicin	137-149	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
29016119-5	2017	The best compound was active in a very low micromolar concentration range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP (BCRP) cells.	Daunorubicin	137-149	ATP binding cassette subfamily C member 1	Homo sapiens	211-215
29016119-5	2017	The best compound was active in a very low micromolar concentration range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP (BCRP) cells.	Daunorubicin	137-149	ATP binding cassette subfamily G member 2	Canis lupus familiaris	222-234
29016119-5	2017	The best compound was active in a very low micromolar concentration range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP (BCRP) cells.	Daunorubicin	137-149	ATP binding cassette subfamily G member 2	Canis lupus familiaris	230-234
29016119-6	2017	Additionally, the compound is a noncompetitive inhibitor of daunorubicin (MRP1), calcein AM (P-gp), and pheophorbide A (BCRP) transport.	Daunorubicin	60-72	ATP binding cassette subfamily C member 1	Homo sapiens	74-78
29116110-0	2017	Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.	Daunorubicin	66-78	protein phosphatase 2 phosphatase activator	Homo sapiens	22-26
29116110-0	2017	Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.	Daunorubicin	66-78	microRNA 181b-1	Homo sapiens	132-142
28574300-0	2017	Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia.	Daunorubicin	63-75	interleukin 3 receptor subunit alpha	Homo sapiens	5-10
28574300-8	2017	Daunorubicin (DNR)-loaded H-CD123-NS demonstrated a 2.45- and 3.22-fold higher cytotoxicity, compared to DNR-loaded NS in NB4 and THP-1 cells, respectively.	Daunorubicin	0-12	interleukin 3 receptor subunit alpha	Homo sapiens	28-33
28574300-8	2017	Daunorubicin (DNR)-loaded H-CD123-NS demonstrated a 2.45- and 3.22-fold higher cytotoxicity, compared to DNR-loaded NS in NB4 and THP-1 cells, respectively.	Daunorubicin	14-17	interleukin 3 receptor subunit alpha	Homo sapiens	28-33
29085463-10	2017	The MTT cell proliferation and cytotoxicity assay revealed that TNFalpha + TGFbeta-1 treatment significantly increased cell proliferation and daunorubicin resistance, but not gemcitabine resistance.	Daunorubicin	142-154	tumor necrosis factor	Homo sapiens	64-72
29085463-10	2017	The MTT cell proliferation and cytotoxicity assay revealed that TNFalpha + TGFbeta-1 treatment significantly increased cell proliferation and daunorubicin resistance, but not gemcitabine resistance.	Daunorubicin	142-154	transforming growth factor beta 1	Homo sapiens	75-84
29037126-0	2017	DACT1 overexpression inhibits proliferation, enhances apoptosis, and increases daunorubicin chemosensitivity in KG-1alpha cells.	Daunorubicin	79-91	dishevelled binding antagonist of beta catenin 1	Homo sapiens	0-5
29037126-6	2017	Furthermore, the viability of KG-1alpha cells transfected with DACT1 was significantly reduced when treated with daunorubicin.	Daunorubicin	113-125	dishevelled binding antagonist of beta catenin 1	Homo sapiens	63-68
29070105-1	2017	OBJECTIVE: To investigate the mechanism of reversing drug resistance of K562/D cells to daunorubicin by Embelin and its relationship with P-gp and MDR1 mRNA.	Daunorubicin	88-100	phosphoglycolate phosphatase	Homo sapiens	138-142
29070105-1	2017	OBJECTIVE: To investigate the mechanism of reversing drug resistance of K562/D cells to daunorubicin by Embelin and its relationship with P-gp and MDR1 mRNA.	Daunorubicin	88-100	ATP binding cassette subfamily B member 1	Homo sapiens	147-151
28173641-4	2017	Two adamantyl derivatives tested in this study increased the cytotoxicity of daunomycin (DNM) in P-gp overexpressed cell line by inhibiting P-gp efflux function.	Daunorubicin	77-87	phosphoglycolate phosphatase	Rattus norvegicus	97-101
28173641-4	2017	Two adamantyl derivatives tested in this study increased the cytotoxicity of daunomycin (DNM) in P-gp overexpressed cell line by inhibiting P-gp efflux function.	Daunorubicin	77-87	phosphoglycolate phosphatase	Rattus norvegicus	140-144
28173641-4	2017	Two adamantyl derivatives tested in this study increased the cytotoxicity of daunomycin (DNM) in P-gp overexpressed cell line by inhibiting P-gp efflux function.	Daunorubicin	89-92	phosphoglycolate phosphatase	Rattus norvegicus	97-101
28173641-4	2017	Two adamantyl derivatives tested in this study increased the cytotoxicity of daunomycin (DNM) in P-gp overexpressed cell line by inhibiting P-gp efflux function.	Daunorubicin	89-92	phosphoglycolate phosphatase	Rattus norvegicus	140-144
28583331-4	2017	On the basis of the daunorubicin (DNR) loaded PEGylated liposomes (DNR-LP), a post-insertion method was applied to covalently attach the anti-CD123 mAb onto the surface of the liposomes to obtain the anti-CD123 mAb modified immunoliposomes (CD123-ILP).	Daunorubicin	20-32	interleukin 3 receptor subunit alpha	Homo sapiens	142-147
28583810-0	2017	Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma.	Daunorubicin	34-46	lactotransferrin	Mus musculus	22-24
28583810-4	2017	In this study, we developed a kind of lactoferrin (Lf) modified daunorubicin plus honokiol liposomes to transport antitumor drugs across BBB, eliminate the VM channels and block tumor cell invasion.	Daunorubicin	64-76	lactotransferrin	Mus musculus	38-49
28583810-4	2017	In this study, we developed a kind of lactoferrin (Lf) modified daunorubicin plus honokiol liposomes to transport antitumor drugs across BBB, eliminate the VM channels and block tumor cell invasion.	Daunorubicin	64-76	lactotransferrin	Mus musculus	51-53
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	Daunorubicin	52-64	lactotransferrin	Mus musculus	40-42
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	Daunorubicin	52-64	caspase 3	Mus musculus	122-131
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	Daunorubicin	52-64	matrix metallopeptidase 2	Mus musculus	186-191
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	Daunorubicin	52-64	matrix metallopeptidase 9	Mus musculus	193-198
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	Daunorubicin	52-64	cadherin 5	Mus musculus	200-211
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	Daunorubicin	52-64	PTK2 protein tyrosine kinase 2	Mus musculus	216-219
28583810-9	2017	Therefore, Lf modified daunorubicin plus honokiol liposomes could be used as a potential therapy for treatment of brain glioma.	Daunorubicin	23-35	lactotransferrin	Mus musculus	11-13
28851949-6	2017	In silico functional assessment further supported this relationship - rs9327264 in PLCE1 (P = 0.0080) and ATP2B1 expression (P = 0.0079) were both significantly associated with daunorubicin IC50 values in a panel of lymphoblastoid cell lines.	Daunorubicin	177-189	phospholipase C epsilon 1	Homo sapiens	83-88
28851949-6	2017	In silico functional assessment further supported this relationship - rs9327264 in PLCE1 (P = 0.0080) and ATP2B1 expression (P = 0.0079) were both significantly associated with daunorubicin IC50 values in a panel of lymphoblastoid cell lines.	Daunorubicin	177-189	ATPase plasma membrane Ca2+ transporting 1	Homo sapiens	106-112
28632487-9	2017	Significant interaction between the treatment arm and the FLT3-ITD mutation was found, and high-dose daunorubicin was more effective than idarubicin in patients with FLT3-ITD mutation.	Daunorubicin	101-113	fms related receptor tyrosine kinase 3	Homo sapiens	58-62
28632487-9	2017	Significant interaction between the treatment arm and the FLT3-ITD mutation was found, and high-dose daunorubicin was more effective than idarubicin in patients with FLT3-ITD mutation.	Daunorubicin	101-113	fms related receptor tyrosine kinase 3	Homo sapiens	166-170
29201109-4	2017	The cleavage of poly ADP-ribose polymerase (PARP) demonstrated by daunorubicin and doxorubicin treatment of the cells, suggest that the apoptotic process is PARP dependent.	Daunorubicin	66-78	poly(ADP-ribose) polymerase 1	Homo sapiens	16-42
29201109-4	2017	The cleavage of poly ADP-ribose polymerase (PARP) demonstrated by daunorubicin and doxorubicin treatment of the cells, suggest that the apoptotic process is PARP dependent.	Daunorubicin	66-78	poly(ADP-ribose) polymerase 1	Homo sapiens	44-48
29201109-4	2017	The cleavage of poly ADP-ribose polymerase (PARP) demonstrated by daunorubicin and doxorubicin treatment of the cells, suggest that the apoptotic process is PARP dependent.	Daunorubicin	66-78	poly(ADP-ribose) polymerase 1	Homo sapiens	157-161
28277825-7	2017	RESULTS: In vitro results showed that WGA modified daunorubicin anti-resistant liposomes exhibited suitable physicochemical properties, significantly increased intracellular uptake in both MCF-7 cells and MCF-7/ADR cells, and circumvented the multidrug resistance via inhibiting P-gp.	Daunorubicin	51-63	phosphoglycolate phosphatase	Homo sapiens	279-283
28487980-3	2017	Compared with treatment alone, co-exposure of cells to bortezomib and daunorubicin resulted in a significant increase in cell death in the Jurkat cells, as evidenced by the increased percentage of Annexin V-positive cells, the formation of apoptotic bodies.	Daunorubicin	70-82	annexin A5	Homo sapiens	197-206
28487980-6	2017	Co-treatment with bortezomib and daunorubicin markedly enhanced the activation of caspase-3, -8 and -9, which was reversed by the pan-caspase inhibitor, Z-VAD-FMK.	Daunorubicin	33-45	caspase 3	Homo sapiens	82-102
28487980-7	2017	In addition, cotreatment with bortezomib and daunorubicin enhanced the collapse of mitochondrial transmembrane potential and upregulated the proapoptotic protein, B-cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim), but not Bcl-2 or Bcl-extra large.	Daunorubicin	45-57	BCL2 apoptosis regulator	Homo sapiens	163-180
28487980-7	2017	In addition, cotreatment with bortezomib and daunorubicin enhanced the collapse of mitochondrial transmembrane potential and upregulated the proapoptotic protein, B-cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim), but not Bcl-2 or Bcl-extra large.	Daunorubicin	45-57	BCL2 apoptosis regulator	Homo sapiens	182-187
28487980-7	2017	In addition, cotreatment with bortezomib and daunorubicin enhanced the collapse of mitochondrial transmembrane potential and upregulated the proapoptotic protein, B-cell lymphoma 2 (Bcl-2)-interacting mediator of cell death (Bim), but not Bcl-2 or Bcl-extra large.	Daunorubicin	45-57	BCL2 apoptosis regulator	Homo sapiens	239-244
28978059-6	2017	Targeting 6PGD and NADPH production was sufficient to block growth of AML cell lines resistant to the chemotherapeutics daunorubicin and cytarabine.	Daunorubicin	120-132	phosphogluconate dehydrogenase	Homo sapiens	10-14
28978059-6	2017	Targeting 6PGD and NADPH production was sufficient to block growth of AML cell lines resistant to the chemotherapeutics daunorubicin and cytarabine.	Daunorubicin	120-132	2,4-dienoyl-CoA reductase 1	Homo sapiens	19-24
28588271-0	2017	PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.	Daunorubicin	44-56	protein phosphatase 2 phosphatase activator	Homo sapiens	0-4
28588271-0	2017	PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.	Daunorubicin	44-56	microRNA 181b-1	Homo sapiens	110-120
28575020-4	2017	We synthesized small cyclic NGR peptide-daunomycin conjugates using NGR peptides of varying stability (c[KNGRE]-NH2, Ac-c[CNGRC]-NH2 and the thioether bond containing c[CH2-CO-NGRC]-NH2, c[CH2-CO-KNGRC]-NH2).	Daunorubicin	40-50	reticulon 4 receptor	Homo sapiens	28-31
28575020-4	2017	We synthesized small cyclic NGR peptide-daunomycin conjugates using NGR peptides of varying stability (c[KNGRE]-NH2, Ac-c[CNGRC]-NH2 and the thioether bond containing c[CH2-CO-NGRC]-NH2, c[CH2-CO-KNGRC]-NH2).	Daunorubicin	40-50	reticulon 4 receptor	Homo sapiens	68-71
28440407-0	2017	Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.	Daunorubicin	79-91	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	11-56
28440407-1	2017	The present study aimed to investigate the association between the genetic polymorphism of cytochrome P450 family 3 subfamily A member 5 (CYP3A5) and the activity of CYP3A and plasma concentrations of daunorubicin (DNR) in patients with acute leukemia.	Daunorubicin	201-213	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	91-136
28440407-1	2017	The present study aimed to investigate the association between the genetic polymorphism of cytochrome P450 family 3 subfamily A member 5 (CYP3A5) and the activity of CYP3A and plasma concentrations of daunorubicin (DNR) in patients with acute leukemia.	Daunorubicin	201-213	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	138-144
28440407-1	2017	The present study aimed to investigate the association between the genetic polymorphism of cytochrome P450 family 3 subfamily A member 5 (CYP3A5) and the activity of CYP3A and plasma concentrations of daunorubicin (DNR) in patients with acute leukemia.	Daunorubicin	201-213	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-143
28440407-1	2017	The present study aimed to investigate the association between the genetic polymorphism of cytochrome P450 family 3 subfamily A member 5 (CYP3A5) and the activity of CYP3A and plasma concentrations of daunorubicin (DNR) in patients with acute leukemia.	Daunorubicin	215-218	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	91-136
28440407-1	2017	The present study aimed to investigate the association between the genetic polymorphism of cytochrome P450 family 3 subfamily A member 5 (CYP3A5) and the activity of CYP3A and plasma concentrations of daunorubicin (DNR) in patients with acute leukemia.	Daunorubicin	215-218	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	138-144
28440407-1	2017	The present study aimed to investigate the association between the genetic polymorphism of cytochrome P450 family 3 subfamily A member 5 (CYP3A5) and the activity of CYP3A and plasma concentrations of daunorubicin (DNR) in patients with acute leukemia.	Daunorubicin	215-218	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-143
28505160-8	2017	AML cell lines stably overexpressing NRF2 showed increased resistance to ATO, Dnr and Ara-C and increased expression of downstream targets.	Daunorubicin	78-81	NFE2 like bZIP transcription factor 2	Homo sapiens	37-41
28498861-9	2017	Cav-3 expression in the heart was unchanged at three weeks of daunorubicin and increased in nine week treated rabbits when compared to control hearts.	Daunorubicin	62-74	caveolin-3	Oryctolagus cuniculus	0-5
28498861-11	2017	Activated beta-1 (beta1) integrin and the membrane repair protein MG53 were increased after nine weeks of daunorubicin vs. controls with no change at the three week time point.	Daunorubicin	106-118	tripartite motif-containing protein 72	Oryctolagus cuniculus	66-70
28498861-12	2017	The results suggest a potential pathophysiological role for Cav3, integrins and membrane repair in daunorubicin-induced heart failure.	Daunorubicin	99-111	caveolin-3	Oryctolagus cuniculus	60-64
29744416-2	2017	The present study outlines the fabrication of daunorubicin hydrochloride-loaded poly (epsilon-caprolactone) (PCL) fibrous membranes by melt electrospinning for potential application in localized tumor therapy.	Daunorubicin	46-72	PHD finger protein 1	Homo sapiens	109-112
29744416-8	2017	Therefore, PCL melt electrospun fibrous membranes loaded with daunorubicin hydrochloride may be used in the local administration of oncotherapy.	Daunorubicin	62-88	PHD finger protein 1	Homo sapiens	11-14
26552712-12	2017	Finally, ABT-737 synergistically enhanced the cytotoxic effect of cytarabine and daunorubicin in CD34+ AML cells.	Daunorubicin	81-93	CD34 molecule	Homo sapiens	97-101
28381182-0	2017	Involvement of miR-125a in resistance to daunorubicin by inhibiting apoptosis in leukemia cell lines.	Daunorubicin	41-53	microRNA 125a	Homo sapiens	15-23
28381182-1	2017	In this study, we investigated whether miR-125a participated in the resistance of the leukemia cell lines to the chemotherapeutic agent daunorubicin.	Daunorubicin	136-148	microRNA 125a	Homo sapiens	39-47
28381182-4	2017	We also showed that miR-125a mediated daunorubicin resistance in leukemia cell lines through the decrease of GRK2 and Puma which were proved to be direct targets of miR-125a.	Daunorubicin	38-50	microRNA 125a	Homo sapiens	20-28
28381182-4	2017	We also showed that miR-125a mediated daunorubicin resistance in leukemia cell lines through the decrease of GRK2 and Puma which were proved to be direct targets of miR-125a.	Daunorubicin	38-50	microRNA 125a	Homo sapiens	165-173
28300219-4	2017	We found that doxorubicin and related anthracycline agents (e.g., daunorubicin, idarubicin, and epirubicin) significantly upregulated the expression of death receptors (DRs) (TNFR1, Fas, DR4 and DR5) in iPS-derived cardiomyocytes at both protein and mRNA levels.	Daunorubicin	66-78	TNF receptor superfamily member 1A	Homo sapiens	175-180
28300219-4	2017	We found that doxorubicin and related anthracycline agents (e.g., daunorubicin, idarubicin, and epirubicin) significantly upregulated the expression of death receptors (DRs) (TNFR1, Fas, DR4 and DR5) in iPS-derived cardiomyocytes at both protein and mRNA levels.	Daunorubicin	66-78	TNF receptor superfamily member 10a	Homo sapiens	187-190
28300219-4	2017	We found that doxorubicin and related anthracycline agents (e.g., daunorubicin, idarubicin, and epirubicin) significantly upregulated the expression of death receptors (DRs) (TNFR1, Fas, DR4 and DR5) in iPS-derived cardiomyocytes at both protein and mRNA levels.	Daunorubicin	66-78	TNF receptor superfamily member 10b	Homo sapiens	195-198
27826122-7	2017	Interestingly, ALDH1A1 transcripts were highest in the ALDHneg leukemic cells and, in studies with leukemic cell lines, exposure to an inhibitor of ALDH activity variably affected sensitivity to daunorubicin.	Daunorubicin	195-207	aldehyde dehydrogenase 1 family member A1	Homo sapiens	15-22
27707884-0	2017	Ikaros 6 protects acute lymphoblastic leukemia cells against daunorubicin-induced apoptosis by activating the Akt-FoxO1 pathway.	Daunorubicin	61-73	AKT serine/threonine kinase 1	Homo sapiens	110-113
27707884-0	2017	Ikaros 6 protects acute lymphoblastic leukemia cells against daunorubicin-induced apoptosis by activating the Akt-FoxO1 pathway.	Daunorubicin	61-73	forkhead box O1	Homo sapiens	114-119
27707884-7	2017	Upon treatment with daunorubicin, Nalm-6/Ik6 cells exhibited a statistically significant reduction in apoptosis, with increased expression of p-Akt and p-FoxO1.	Daunorubicin	20-32	AKT serine/threonine kinase 1	Homo sapiens	144-147
27707884-7	2017	Upon treatment with daunorubicin, Nalm-6/Ik6 cells exhibited a statistically significant reduction in apoptosis, with increased expression of p-Akt and p-FoxO1.	Daunorubicin	20-32	forkhead box O1	Homo sapiens	154-159
27707884-11	2017	In conclusion, Ik6, the upstream factor of Akt-FoxO1 pathway, can protect ALL cells against daunorubicin-induced apoptosis and can potentially be explored as a therapeutic target in the treatment of patients with ALL.	Daunorubicin	92-104	AKT serine/threonine kinase 1	Homo sapiens	43-46
27707884-11	2017	In conclusion, Ik6, the upstream factor of Akt-FoxO1 pathway, can protect ALL cells against daunorubicin-induced apoptosis and can potentially be explored as a therapeutic target in the treatment of patients with ALL.	Daunorubicin	92-104	forkhead box O1	Homo sapiens	47-52
27821506-7	2017	Multidrug-effluxing CD4+CD161+ T cells were enriched within the viral-specific Th1 repertoire of healthy donors and patients with acute myeloid leukemia (AML) and survived exposure to daunorubicin chemotherapy in vitro.	Daunorubicin	184-196	CD4 molecule	Homo sapiens	20-23
27821506-7	2017	Multidrug-effluxing CD4+CD161+ T cells were enriched within the viral-specific Th1 repertoire of healthy donors and patients with acute myeloid leukemia (AML) and survived exposure to daunorubicin chemotherapy in vitro.	Daunorubicin	184-196	killer cell lectin like receptor B1	Homo sapiens	24-29
27821506-7	2017	Multidrug-effluxing CD4+CD161+ T cells were enriched within the viral-specific Th1 repertoire of healthy donors and patients with acute myeloid leukemia (AML) and survived exposure to daunorubicin chemotherapy in vitro.	Daunorubicin	184-196	negative elongation factor complex member C/D	Homo sapiens	79-82
27865002-5	2017	One example (5 d) efficiently induced apoptosis in vincristine- and daunorubicin-resistant P-glycoprotein overexpressing Nalm-6 leukemia cells.	Daunorubicin	68-80	ATP binding cassette subfamily B member 1	Homo sapiens	91-105
27974700-5	2017	Cytarabine downregulated TNTs and inhibited NF-kappaB alone and in combination with daunorubicin, providing additional support for involvement of the NF-kappaB pathway in TNT formation.	Daunorubicin	84-96	nuclear factor kappa B subunit 1	Homo sapiens	150-159
28030834-7	2017	We found that inhibition of both HDAC1 and HDAC2 was necessary to decrease the expression of BRCA1, CHK1, and RAD51, enhance cytarabine- or daunorubicin-induced DNA damage and apoptosis, and abrogate cytarabine- or daunorubicin-induced cell cycle checkpoint activation in AML cells.	Daunorubicin	140-152	histone deacetylase 1	Homo sapiens	33-38
28030834-7	2017	We found that inhibition of both HDAC1 and HDAC2 was necessary to decrease the expression of BRCA1, CHK1, and RAD51, enhance cytarabine- or daunorubicin-induced DNA damage and apoptosis, and abrogate cytarabine- or daunorubicin-induced cell cycle checkpoint activation in AML cells.	Daunorubicin	140-152	histone deacetylase 2	Homo sapiens	43-48
28030834-7	2017	We found that inhibition of both HDAC1 and HDAC2 was necessary to decrease the expression of BRCA1, CHK1, and RAD51, enhance cytarabine- or daunorubicin-induced DNA damage and apoptosis, and abrogate cytarabine- or daunorubicin-induced cell cycle checkpoint activation in AML cells.	Daunorubicin	140-152	BRCA1 DNA repair associated	Homo sapiens	93-98
28030834-7	2017	We found that inhibition of both HDAC1 and HDAC2 was necessary to decrease the expression of BRCA1, CHK1, and RAD51, enhance cytarabine- or daunorubicin-induced DNA damage and apoptosis, and abrogate cytarabine- or daunorubicin-induced cell cycle checkpoint activation in AML cells.	Daunorubicin	215-227	histone deacetylase 1	Homo sapiens	33-38
28030834-7	2017	We found that inhibition of both HDAC1 and HDAC2 was necessary to decrease the expression of BRCA1, CHK1, and RAD51, enhance cytarabine- or daunorubicin-induced DNA damage and apoptosis, and abrogate cytarabine- or daunorubicin-induced cell cycle checkpoint activation in AML cells.	Daunorubicin	215-227	histone deacetylase 2	Homo sapiens	43-48
28030834-7	2017	We found that inhibition of both HDAC1 and HDAC2 was necessary to decrease the expression of BRCA1, CHK1, and RAD51, enhance cytarabine- or daunorubicin-induced DNA damage and apoptosis, and abrogate cytarabine- or daunorubicin-induced cell cycle checkpoint activation in AML cells.	Daunorubicin	215-227	BRCA1 DNA repair associated	Homo sapiens	93-98
28030834-7	2017	We found that inhibition of both HDAC1 and HDAC2 was necessary to decrease the expression of BRCA1, CHK1, and RAD51, enhance cytarabine- or daunorubicin-induced DNA damage and apoptosis, and abrogate cytarabine- or daunorubicin-induced cell cycle checkpoint activation in AML cells.	Daunorubicin	215-227	checkpoint kinase 1	Homo sapiens	100-104
28030834-7	2017	We found that inhibition of both HDAC1 and HDAC2 was necessary to decrease the expression of BRCA1, CHK1, and RAD51, enhance cytarabine- or daunorubicin-induced DNA damage and apoptosis, and abrogate cytarabine- or daunorubicin-induced cell cycle checkpoint activation in AML cells.	Daunorubicin	215-227	RAD51 recombinase	Homo sapiens	110-115
27810353-5	2017	In this work we present certain pyrrolo[3,2-d]pyrimidine derivatives with variations at positions 4 and 5 and purine analogs with variations at position 6 as novel activators of MRP1-mediated transport of the MRP1 substrate calcein AM and the anticancer drug daunorubicin in low nanomolar concentration range.	Daunorubicin	259-271	ATP binding cassette subfamily C member 1	Canis lupus familiaris	178-182
27810353-5	2017	In this work we present certain pyrrolo[3,2-d]pyrimidine derivatives with variations at positions 4 and 5 and purine analogs with variations at position 6 as novel activators of MRP1-mediated transport of the MRP1 substrate calcein AM and the anticancer drug daunorubicin in low nanomolar concentration range.	Daunorubicin	259-271	ATP binding cassette subfamily C member 1	Canis lupus familiaris	209-213
28728446-3	2017	We synthesised two polymer conjugates of phospholipase C (PLC) and A2 (PLA2) and evaluated their ability to trigger anthracycline release from the clinically used liposomes, Caelyx  and DaunoXome .	Daunorubicin	186-195	phospholipase A2 group IIA	Homo sapiens	71-75
28728446-6	2017	Incubation with dextrin-PLA2 triggered significantly less daunomycin release than HPMA copolymer-PLC, but when dextrin-PLA2 was pre-incubated with alpha-amylase, the rate of daunomycin release increased.	Daunorubicin	58-68	phospholipase A2 group IIA	Homo sapiens	24-28
28728446-6	2017	Incubation with dextrin-PLA2 triggered significantly less daunomycin release than HPMA copolymer-PLC, but when dextrin-PLA2 was pre-incubated with alpha-amylase, the rate of daunomycin release increased.	Daunorubicin	174-184	phospholipase A2 group IIA	Homo sapiens	24-28
28728446-6	2017	Incubation with dextrin-PLA2 triggered significantly less daunomycin release than HPMA copolymer-PLC, but when dextrin-PLA2 was pre-incubated with alpha-amylase, the rate of daunomycin release increased.	Daunorubicin	174-184	phospholipase A2 group IIA	Homo sapiens	119-123
28728446-8	2017	Dextrin-PLA2 potentiated the cytotoxicity of DaunoXome  to MCF-7 cells to a greater extent than free PLA2, while combining dextrin-PLA2 with Caelyx  resulted in antagonism, even in the presence of alpha-amylase, presumably due to steric hindrance by PEG.	Daunorubicin	45-54	phospholipase A2 group IIA	Homo sapiens	8-12
27697501-3	2016	The potency of these compounds to modulate Pgp-mediated MDR was evaluated through daunorubicin accumulation and potentiation of doxorubicin cytotoxicity in K562/R7 multidrug resistant cells overexpressing Pgp.	Daunorubicin	82-94	ATP binding cassette subfamily B member 1	Homo sapiens	43-46
27994664-10	2016	Interestingly, expression of NPM1mA could upregulate Bax and downregulate Bcl-2 at mRNA and protein levels in THP-1 cells when treated with DNR or Ara-C.	Daunorubicin	140-143	nucleophosmin 1	Homo sapiens	29-33
27592051-9	2016	Simultaneously, while high-dose daunorubicin significantly decreased PPARbeta/delta and PPARgama mRNA, ramipril normalized these abnormalities.	Daunorubicin	32-44	peroxisome proliferator-activated receptor delta	Rattus norvegicus	69-77
27809838-11	2016	PfRuvB3.is inhibited by doxorubicin, daunorubicin and netropsin, known DNA helicase inhibitors.	Daunorubicin	37-49	helicase for meiosis 1	Homo sapiens	75-83
27506315-3	2016	Canine carbonyl reductase 1 (cbr1) catalyzes the reduction of daunorubicin into daunorubicinol.	Daunorubicin	62-74	carbonyl reductase [NADPH] 1	Canis lupus familiaris	7-27
27506315-3	2016	Canine carbonyl reductase 1 (cbr1) catalyzes the reduction of daunorubicin into daunorubicinol.	Daunorubicin	62-74	carbonyl reductase [NADPH] 1	Canis lupus familiaris	29-33
27759041-3	2016	Notably, daunorubicin-resistant HL-60 cells (HL-60R) have a prominent cytosolic PCNA localization due to increased nuclear export compared to daunorubicin-sensitive HL-60 cells (HL-60S).	Daunorubicin	9-21	proliferating cell nuclear antigen	Homo sapiens	80-84
27472927-4	2016	In Cell Counting Kit-8 and flow cytometric assays, SG611-VSTM1 exhibited more potent anti-proliferative and pro-apoptotic effects in leukemic cells compared with SG611 and exerted synergistic cytotoxicity with low-dose daunorubicin (DNR) in vitro.	Daunorubicin	219-231	V-set and transmembrane domain containing 1	Homo sapiens	57-62
27472927-4	2016	In Cell Counting Kit-8 and flow cytometric assays, SG611-VSTM1 exhibited more potent anti-proliferative and pro-apoptotic effects in leukemic cells compared with SG611 and exerted synergistic cytotoxicity with low-dose daunorubicin (DNR) in vitro.	Daunorubicin	233-236	V-set and transmembrane domain containing 1	Homo sapiens	57-62
27564097-7	2016	The decrease in MRP1 correlated with decreased cellular drug export activity, and increased level of MDR1 correlated with increased export of daunorubicin.	Daunorubicin	142-154	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
27103402-0	2016	Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.	Daunorubicin	125-137	BCL2 like 11	Homo sapiens	20-23
27103402-0	2016	Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.	Daunorubicin	125-137	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	27-32
27103402-8	2016	Combining conventional chemotherapeutic agent cytarabine or daunorubicin with ABT-199 resulted in increased DNA damage along with decreased Mcl-1 protein levels, compared with ABT-199 alone, and synergistic induction of cell death in both AML cell lines and primary patient samples obtained from AML patients at diagnosis.	Daunorubicin	60-72	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	140-145
27103402-9	2016	CONCLUSIONS: Our results demonstrate that sequestration of Bim by Mcl-1 is a mechanism of intrinsic ABT-199 resistance and supports the clinical development of ABT-199 in combination with cytarabine or daunorubicin for the treatment of AML.	Daunorubicin	202-214	BCL2 like 11	Homo sapiens	59-62
27103402-9	2016	CONCLUSIONS: Our results demonstrate that sequestration of Bim by Mcl-1 is a mechanism of intrinsic ABT-199 resistance and supports the clinical development of ABT-199 in combination with cytarabine or daunorubicin for the treatment of AML.	Daunorubicin	202-214	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	66-71
29342347-2	2016	In this study, a series of carboxymethyl chitosan/daunorubicin (CMCS/DNR) conjugates with macromolecular carriers of different molecular weights (MWs) were prepared and structurally characterized by Fourier transform infrared spectroscopy (FT-IR) and 1H-NMR spectroscopy.	Daunorubicin	50-62	G protein signaling modulator 2	Homo sapiens	64-68
27374090-4	2016	Indeed, co-treatment with the pan-Pim kinase inhibitor AZD1208 or expression of a kinase-dead Pim-1 mutant sensitized FLT3-ITD cell lines to apoptosis triggered by chemotherapy drugs including the topoisomerase 2 inhibitors daunorubicin, etoposide and mitoxantrone, but not the nucleoside analog cytarabine.	Daunorubicin	224-236	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	34-37
27374090-4	2016	Indeed, co-treatment with the pan-Pim kinase inhibitor AZD1208 or expression of a kinase-dead Pim-1 mutant sensitized FLT3-ITD cell lines to apoptosis triggered by chemotherapy drugs including the topoisomerase 2 inhibitors daunorubicin, etoposide and mitoxantrone, but not the nucleoside analog cytarabine.	Daunorubicin	224-236	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	94-99
27374090-4	2016	Indeed, co-treatment with the pan-Pim kinase inhibitor AZD1208 or expression of a kinase-dead Pim-1 mutant sensitized FLT3-ITD cell lines to apoptosis triggered by chemotherapy drugs including the topoisomerase 2 inhibitors daunorubicin, etoposide and mitoxantrone, but not the nucleoside analog cytarabine.	Daunorubicin	224-236	fms related receptor tyrosine kinase 3	Homo sapiens	118-122
27268085-0	2016	Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia.	Daunorubicin	7-19	fms related receptor tyrosine kinase 3	Homo sapiens	38-42
27367964-5	2016	When the prodrug Daun02 is injected into the brains of these rats 90 min after a behavior (e.g., drug-seeking) or cue exposure, then Daun02 is converted into daunorubicin by beta-gal, which selectively inactivates Fos- and beta-gal-expressing neurons that were activated 90 min before the Daun02 injection.	Daunorubicin	158-170	galactosidase, beta 1	Rattus norvegicus	174-182
27367964-5	2016	When the prodrug Daun02 is injected into the brains of these rats 90 min after a behavior (e.g., drug-seeking) or cue exposure, then Daun02 is converted into daunorubicin by beta-gal, which selectively inactivates Fos- and beta-gal-expressing neurons that were activated 90 min before the Daun02 injection.	Daunorubicin	158-170	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	214-217
27367964-5	2016	When the prodrug Daun02 is injected into the brains of these rats 90 min after a behavior (e.g., drug-seeking) or cue exposure, then Daun02 is converted into daunorubicin by beta-gal, which selectively inactivates Fos- and beta-gal-expressing neurons that were activated 90 min before the Daun02 injection.	Daunorubicin	158-170	galactosidase, beta 1	Rattus norvegicus	223-231
27563402-2	2016	Combination treatment with the nontoxic AKR1C3 inhibitors and etoposide or daunorubicin in acute myeloid leukemia cell lines, elicits a potent adjuvant effect, potentiating the cytotoxicity of etoposide by up to 6.25-fold and the cytotoxicity of daunorubicin by &gt;10-fold.	Daunorubicin	246-258	aldo-keto reductase family 1 member C3	Homo sapiens	40-46
27233074-0	2016	Targeting Notch-1 positive acute leukemia cells by novel fucose-bound liposomes carrying daunorubicin.	Daunorubicin	89-101	notch receptor 1	Homo sapiens	10-17
26663398-4	2016	Functional studies in vitro determined that four AML-directed chemotherapeutics (cytarabine, daunorubicin, etoposide, and mitoxantrone) are substrates for OATP1B1 and the mouse ortholog Oatp1b2.	Daunorubicin	93-105	solute carrier organic anion transporter family member 1B1	Homo sapiens	155-162
26663398-4	2016	Functional studies in vitro determined that four AML-directed chemotherapeutics (cytarabine, daunorubicin, etoposide, and mitoxantrone) are substrates for OATP1B1 and the mouse ortholog Oatp1b2.	Daunorubicin	93-105	solute carrier organic anion transporter family, member 1b2	Mus musculus	186-193
27176825-0	2016	Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling.	Daunorubicin	135-147	interleukin 17A	Homo sapiens	25-31
27176825-0	2016	Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling.	Daunorubicin	135-147	AKT serine/threonine kinase 1	Homo sapiens	170-173
27176825-10	2016	Additionally, IL-17A promoted resistance to daunorubicin via activation of Akt signaling and the PI3K/Akt inhibitor LY294002 or perifosine almost completely rescued daunorubicin-induced cell death in B-ALL cells.	Daunorubicin	44-56	interleukin 17A	Homo sapiens	14-20
27176825-10	2016	Additionally, IL-17A promoted resistance to daunorubicin via activation of Akt signaling and the PI3K/Akt inhibitor LY294002 or perifosine almost completely rescued daunorubicin-induced cell death in B-ALL cells.	Daunorubicin	165-177	interleukin 17A	Homo sapiens	14-20
27176825-10	2016	Additionally, IL-17A promoted resistance to daunorubicin via activation of Akt signaling and the PI3K/Akt inhibitor LY294002 or perifosine almost completely rescued daunorubicin-induced cell death in B-ALL cells.	Daunorubicin	165-177	AKT serine/threonine kinase 1	Homo sapiens	102-105
27176825-11	2016	CONCLUSIONS: Our findings suggest that elevated Th17 cells secrete IL-17A by which promotes the proliferation and resistance to daunorubicin in B-ALL cells through activation of Akt signaling.	Daunorubicin	128-140	interleukin 17A	Homo sapiens	67-73
27176825-11	2016	CONCLUSIONS: Our findings suggest that elevated Th17 cells secrete IL-17A by which promotes the proliferation and resistance to daunorubicin in B-ALL cells through activation of Akt signaling.	Daunorubicin	128-140	AKT serine/threonine kinase 1	Homo sapiens	178-181
27119567-7	2016	IL-27 also decreased the responsiveness of the leukemic cells to chemotherapeutic drugs, cytarabine and daunorubicin.	Daunorubicin	104-116	interleukin 27	Homo sapiens	0-5
26755712-6	2016	Patients with FLT3-ITD (24%),DNMT3A(24%), and NPM1(26%) mutant AML all benefited from HD daunorubicin (HR, 0.61,P= .009; HR, 0.62,P= .02; and HR, 0.50,P= .002; respectively).	Daunorubicin	89-101	DNA methyltransferase 3 alpha	Homo sapiens	29-35
26755712-6	2016	Patients with FLT3-ITD (24%),DNMT3A(24%), and NPM1(26%) mutant AML all benefited from HD daunorubicin (HR, 0.61,P= .009; HR, 0.62,P= .02; and HR, 0.50,P= .002; respectively).	Daunorubicin	89-101	nucleophosmin 1	Homo sapiens	46-50
26836364-3	2016	The compound library was evaluated for its ability to inhibit P-gp-mediated daunomycin efflux in MDR cells.	Daunorubicin	76-86	ATP binding cassette subfamily B member 1	Homo sapiens	62-66
25146322-5	2016	RESULTS: We first show that daunorubicin, the active product of Daun02 metabolism by beta-galactosidase, decreases the activity of MSNs in rat brain slices and that Daun02 strongly decreases the excitability of rat MSN primary cultures expressing beta-galactosidase upon D1 dopamine receptor stimulation.	Daunorubicin	28-40	galactosidase, beta 1	Rattus norvegicus	85-103
25146322-5	2016	RESULTS: We first show that daunorubicin, the active product of Daun02 metabolism by beta-galactosidase, decreases the activity of MSNs in rat brain slices and that Daun02 strongly decreases the excitability of rat MSN primary cultures expressing beta-galactosidase upon D1 dopamine receptor stimulation.	Daunorubicin	28-40	moesin	Rattus norvegicus	131-134
26861753-0	2016	The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin.	Daunorubicin	95-107	solute carrier family 22 member 1	Homo sapiens	37-41
26861753-3	2016	Using the high-grade serous ovarian cancer cell line TOV2223G, we show that OCT1 mediated the high affinity (Km ~ 5 muM) uptake of daunorubicin into the cells, and that micromolar amounts of choline completely abolished the drug entry.	Daunorubicin	131-143	solute carrier family 22 member 1	Homo sapiens	76-80
26861753-4	2016	OCT1 downregulation by shRNA impaired daunorubicin uptake into the TOV2223G cells, and these cells were significantly more resistant to the drug in comparison to the control shRNA.	Daunorubicin	38-50	solute carrier family 22 member 1	Homo sapiens	0-4
26727128-4	2016	Daunorubicin- or rebeccamycin-induced enhancement of the TJ barrier function partly rescued attenuation of the barrier function by the inflammatory cytokines TNF-alpha and IFN-gamma.	Daunorubicin	0-12	tumor necrosis factor	Homo sapiens	158-167
26727128-4	2016	Daunorubicin- or rebeccamycin-induced enhancement of the TJ barrier function partly rescued attenuation of the barrier function by the inflammatory cytokines TNF-alpha and IFN-gamma.	Daunorubicin	0-12	interferon gamma	Homo sapiens	172-181
26727128-5	2016	Daunorubicin and rebeccamycin increased claudin-5 expression and the product was distributed in the actin cytoskeleton fraction, which was enriched with TJ proteins.	Daunorubicin	0-12	claudin 5	Homo sapiens	40-49
26727128-6	2016	Caffeine, which is an inhibitor of ataxia telangiectasia mutated protein (ATM) and ataxia telangiectasia mutated and Rad3-related protein (ATR), and the Chk1 inhibitor inhibited the TER increases induced by daunorubicin and rebeccamycin, whereas a Chk2 inhibitor did not.	Daunorubicin	207-219	ATM serine/threonine kinase	Homo sapiens	35-72
26727128-6	2016	Caffeine, which is an inhibitor of ataxia telangiectasia mutated protein (ATM) and ataxia telangiectasia mutated and Rad3-related protein (ATR), and the Chk1 inhibitor inhibited the TER increases induced by daunorubicin and rebeccamycin, whereas a Chk2 inhibitor did not.	Daunorubicin	207-219	checkpoint kinase 1	Homo sapiens	153-157
26727128-9	2016	Our results suggest that Chk1 activation by daunorubicin and rebeccamycin induced claudin-5 expression and enhanced TJ barrier function in Caco-2 cell monolayer, which suggests a link between DNA damage and TJ integrity in the human intestine.	Daunorubicin	44-56	checkpoint kinase 1	Homo sapiens	25-29
26727128-9	2016	Our results suggest that Chk1 activation by daunorubicin and rebeccamycin induced claudin-5 expression and enhanced TJ barrier function in Caco-2 cell monolayer, which suggests a link between DNA damage and TJ integrity in the human intestine.	Daunorubicin	44-56	claudin 5	Homo sapiens	82-91
26870340-0	2016	Internal tandem duplication and tyrosine kinase domain mutations in FLT3 alter the response to daunorubicin in Ba/F3 cells.	Daunorubicin	95-107	FMS-like tyrosine kinase 3	Mus musculus	68-72
26870340-4	2016	As a result, the 50% effective dose for daunorubicin was significantly higher in both Ba/F3-FLT3-ITD clones, and also in one of the two Ba/F3-FLT3-TKD clones when cells were cultured without IL-3.	Daunorubicin	40-52	FMS-like tyrosine kinase 3	Mus musculus	92-96
26870340-4	2016	As a result, the 50% effective dose for daunorubicin was significantly higher in both Ba/F3-FLT3-ITD clones, and also in one of the two Ba/F3-FLT3-TKD clones when cells were cultured without IL-3.	Daunorubicin	40-52	FMS-like tyrosine kinase 3	Mus musculus	142-146
26870340-4	2016	As a result, the 50% effective dose for daunorubicin was significantly higher in both Ba/F3-FLT3-ITD clones, and also in one of the two Ba/F3-FLT3-TKD clones when cells were cultured without IL-3.	Daunorubicin	40-52	interleukin 3	Mus musculus	191-195
26870340-6	2016	Collectively, these results indicate that ITD and TKD mutations in FLT3 may confer daunorubicin resistance in Ba/F3 cells.	Daunorubicin	83-95	FMS-like tyrosine kinase 3	Mus musculus	67-71
26300056-9	2015	Moreover, dinaciclib significantly inhibited ABCC1-mediated efflux of daunorubicin (EC50=18 muM).	Daunorubicin	70-82	ATP binding cassette subfamily C member 1	Homo sapiens	45-50
26708874-7	2015	Besides, when treated with daunorubicin, the apoptosis rate of RYBP shRNA group was lower than that of NC group, while the inhibitive rate had no significant difference.	Daunorubicin	27-39	RING1 and YY1 binding protein	Homo sapiens	63-67
26529431-8	2015	In addition, cellular studies demonstrated a significant inhibition of the AKR1B10-mediated reduction of daunorubicin in intact cells by these inhibitors without a considerable cytotoxic effect.	Daunorubicin	105-117	aldo-keto reductase family 1 member B10	Homo sapiens	75-82
26512957-2	2015	Although previous studies have reported transcriptional upregulation of nSMase2 in response to daunorubicin, through Sp1 and Sp3 transcription factors, the role of the DNA damage pathway in regulating nSMase2 remains unclear.	Daunorubicin	95-107	sphingomyelin phosphodiesterase 3	Homo sapiens	72-79
26512957-2	2015	Although previous studies have reported transcriptional upregulation of nSMase2 in response to daunorubicin, through Sp1 and Sp3 transcription factors, the role of the DNA damage pathway in regulating nSMase2 remains unclear.	Daunorubicin	95-107	Sp3 transcription factor	Homo sapiens	125-128
26301700-2	2015	The drug delivery system is based on apoferritin as delivery vehicles to encapsulate the anticancer drug daunomycin (DN) and alleviate the side effect.	Daunorubicin	105-115	ferritin heavy chain 1	Homo sapiens	37-48
26301700-2	2015	The drug delivery system is based on apoferritin as delivery vehicles to encapsulate the anticancer drug daunomycin (DN) and alleviate the side effect.	Daunorubicin	117-119	ferritin heavy chain 1	Homo sapiens	37-48
26301700-4	2015	The negatively charged poly-l-aspartic acid (PLAA) was further introduced into the apoferritin to absorb the positively charged DN.	Daunorubicin	128-130	ferritin heavy chain 1	Homo sapiens	83-94
26291333-6	2015	FD18 (1 muM) can increase accumulation of doxorubicin by 2.7-fold, daunorubicin (2.1-fold), and rhodamine 123 (5.2-fold) in LCC6MDR.	Daunorubicin	67-79	latexin	Homo sapiens	8-11
26265695-3	2015	Furthermore, CHD4 depletion renders AML blasts more sensitive both in vitro and in vivo to genotoxic agents used in clinical therapy: daunorubicin (DNR) and cytarabine (ara-C).	Daunorubicin	134-146	chromodomain helicase DNA binding protein 4	Mus musculus	13-17
25765813-4	2015	In addition, the ability of NADPH-cytochrome P450 reductase and carbonyl reductase-1 to reduce the ketone groups of the drugs haloperidol and daunorubicin was examined.	Daunorubicin	142-154	cytochrome p450 oxidoreductase	Rattus norvegicus	28-59
25765813-4	2015	In addition, the ability of NADPH-cytochrome P450 reductase and carbonyl reductase-1 to reduce the ketone groups of the drugs haloperidol and daunorubicin was examined.	Daunorubicin	142-154	carbonyl reductase 1	Rattus norvegicus	64-84
25765813-5	2015	Under the conditions applied, a pronounced reductive metabolism was only observed for daunorubicin in the presence of microsomal NADPH-cytochrome P450 reductase.	Daunorubicin	86-98	cytochrome p450 oxidoreductase	Rattus norvegicus	129-160
25701955-0	2015	Overexpression of Hiwi Inhibits the Cell Growth of Chronic Myeloid Leukemia K562 Cells and Enhances Their Chemosensitivity to Daunomycin.	Daunorubicin	126-136	piwi like RNA-mediated gene silencing 1	Homo sapiens	18-22
25701955-5	2015	Additionally, Hiwi upregulation enhanced the chemosensitivity of CML cells to daunomycin.	Daunorubicin	78-88	piwi like RNA-mediated gene silencing 1	Homo sapiens	14-18
26072060-0	2015	Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFkappaB p65 mediated inflammation.	Daunorubicin	23-35	angiotensin II receptor, type 1a	Rattus norvegicus	73-77
26072060-0	2015	Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFkappaB p65 mediated inflammation.	Daunorubicin	23-35	mitogen activated protein kinase 3	Rattus norvegicus	79-85
26072060-0	2015	Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFkappaB p65 mediated inflammation.	Daunorubicin	23-35	synaptotagmin 1	Rattus norvegicus	95-98
26308531-0	2015	Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin.	Daunorubicin	107-119	musashi RNA binding protein 2	Homo sapiens	0-9
26308531-8	2015	Finally, Msi2 silencing in AML cells also enhanced their chemosensitivity to daunorubicin.	Daunorubicin	77-89	musashi RNA binding protein 2	Homo sapiens	9-13
26609475-0	2015	3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cells.	Daunorubicin	25-37	solute carrier family 16 member 1	Homo sapiens	71-100
26268310-8	2015	The EZH2 inhibitor DZNep used in combination with Daunoblastine was synergistic in inducing growth inhibition and increasing the apoptosis in T-ALL Jurkat cells at 48 and 72 h paralleled by EZH2 decreased expression.	Daunorubicin	50-63	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	4-8
26268310-8	2015	The EZH2 inhibitor DZNep used in combination with Daunoblastine was synergistic in inducing growth inhibition and increasing the apoptosis in T-ALL Jurkat cells at 48 and 72 h paralleled by EZH2 decreased expression.	Daunorubicin	50-63	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	190-194
26314425-0	2015	[Effects of Garcinia Acid Combined with Daunorubicin on Expression of Pregnane X Receptor in Leukemia Cell Line K562/A02].	Daunorubicin	40-52	nuclear receptor subfamily 1 group I member 2	Homo sapiens	70-89
26125482-6	2015	We observed reproducible transport of two substrates, daunorubicin and verapamil, by an average of 11-12 A through the plane of the membrane as P-gp progressed through a catalytic cycle.	Daunorubicin	54-66	ATP binding cassette subfamily B member 1	Homo sapiens	144-148
26328012-0	2015	Unbalanced upregulation of ryanodine receptor 2 plays a particular role in early development of daunorubicin cardiomyopathy.	Daunorubicin	96-108	ryanodine receptor 2	Rattus norvegicus	27-47
26328012-12	2015	DAU administration was associated with a twofold upregulation of RyR2 (P&lt;0.05), but not of other examined Ca(2+) regulating proteins remained.	Daunorubicin	0-3	ryanodine receptor 2	Rattus norvegicus	65-69
26328012-15	2015	In conclusion, unbalanced RyR2 overexpression plays a particular role in early development of daunorubicin cardiomyopathy characterized by discrepant in situ versus in vitro cardiac performance.	Daunorubicin	94-106	ryanodine receptor 2	Rattus norvegicus	26-30
25986678-9	2015	Both flavopiridol and SNS-032 showed synergistic antiproliferative effects in combination with relevant ABC transporter substrates such as daunorubicin and topotecan in cancer cells.	Daunorubicin	139-151	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	104-107
25918240-6	2015	The enzyme kinetics of "wild-type" canine cbr1 (cbr1 D218) and a variant isoform (cbr1 V218) were characterized with the substrates daunorubicin and menadione, as well as the flavonoid inhibitor rutin.	Daunorubicin	132-144	carbonyl reductase [NADPH] 1	Canis lupus familiaris	42-46
25918240-9	2015	Rutin acted as a competitive inhibitor for the reduction of daunorubicin (cbr1 D218 Ki: 1.84 +- 1.02 muM, cbr1 V218 Ki: 1.38 +- 0.47 muM).	Daunorubicin	60-72	carbonyl reductase [NADPH] 1	Canis lupus familiaris	74-78
25918240-10	2015	These studies show that canine cbr1 metabolizes daunorubicin and provide the necessary foundation to characterize the role of cbr1 in the variable pharmacodynamics of anthracyclines in canine cancer patients.	Daunorubicin	48-60	carbonyl reductase [NADPH] 1	Canis lupus familiaris	31-35
25541467-6	2015	Interestingly, CBR1 is one of the most effective human reductases in converting the anthracycline anti-tumor drug daunorubicin to daunorubicinol.	Daunorubicin	114-126	carbonyl reductase 1	Homo sapiens	15-19
25541467-8	2015	Thus, inhibition of CBR1 may increase the efficacy of daunorubicin in cancer tissue and simultaneously decrease its cardiotoxicity.	Daunorubicin	54-66	carbonyl reductase 1	Homo sapiens	20-24
26125799-1	2015	We evaluated the effects of down-regulated heme oxygenase (HO)-1 expression on the proliferation of the acute myelocytic leukemia Kasumi-1 cell line by using the HO-1 inhibitor zinc protoporphyrin IX (ZnPPIX) in combination with daunorubicin (DNR), and evaluated the mechanism.	Daunorubicin	229-241	heme oxygenase 1	Homo sapiens	43-64
25697484-8	2015	Both Aa and Ap attenuated daunorubicin-stimulated activation of the DNA damage response (DDR) as reflected on the levels of gammaH2AX, p-Kap-1 and p-Chk-1.	Daunorubicin	26-38	tripartite motif containing 28	Homo sapiens	137-142
25697484-8	2015	Both Aa and Ap attenuated daunorubicin-stimulated activation of the DNA damage response (DDR) as reflected on the levels of gammaH2AX, p-Kap-1 and p-Chk-1.	Daunorubicin	26-38	checkpoint kinase 1	Homo sapiens	149-154
25795919-8	2015	Strikingly, NPM1 mutant downregulation by ATO/ATRA was shown to potentiate response to the anthracyclin daunorubicin.	Daunorubicin	104-116	nucleophosmin 1	Homo sapiens	12-16
26028971-7	2015	Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo.	Daunorubicin	124-136	BCL2 apoptosis regulator	Homo sapiens	14-18
26028971-7	2015	Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo.	Daunorubicin	124-136	BCL2 apoptosis regulator	Homo sapiens	35-39
26028971-7	2015	Abrogation of Bcl2 activity by the Bcl2-specific inhibitor ABT 737 led to cell death in the presence of both cytarabine and daunorubicin, demonstrating that the cell adhesion-mediated drug resistance induced by Bcl2 and p27(Kip1) in the scaffold was similar to that seen in vivo.	Daunorubicin	124-136	BCL2 apoptosis regulator	Homo sapiens	35-39
25736313-7	2015	Ectopic overexpression of INPP4B conferred leukemic resistance to cytosine arabinoside (ara-C), daunorubicin, and etoposide.	Daunorubicin	96-108	inositol polyphosphate-4-phosphatase type II B	Homo sapiens	26-32
25695368-4	2015	Four compounds from this series were discovered as potent chemosensitizers for MDR1-G185 NIH-3T3 murine cells (3, 4, 6, and 7), showing higher efficacies than the classical P-glycoprotein inhibitor verapamil, a first-generation chemosensitizer, when reversing resistance to daunomycin and vinblastine at the lowest concentration tested of 1 muM.	Daunorubicin	274-284	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	79-83
25695368-4	2015	Four compounds from this series were discovered as potent chemosensitizers for MDR1-G185 NIH-3T3 murine cells (3, 4, 6, and 7), showing higher efficacies than the classical P-glycoprotein inhibitor verapamil, a first-generation chemosensitizer, when reversing resistance to daunomycin and vinblastine at the lowest concentration tested of 1 muM.	Daunorubicin	274-284	ATP binding cassette subfamily B member 1	Homo sapiens	173-187
25849454-8	2015	In a growth assay, Pgp-9 increased resistance to the fungicides ketoconazole, actinomycin D, valinomycin and daunorubicin, but not to the anthelmintic fungicide thiabendazole.	Daunorubicin	109-121	PGP	Canis lupus familiaris	19-22
25854646-3	2015	The overexpression of BCRP contributes to the resistance of several chemotherapeutic drugs, such as topotecan, methotrexate, mitoxantrone, doxorubicin and daunorubicin.	Daunorubicin	155-167	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	22-26
25776492-4	2015	The accumulation of daunorubicin or rhodamine 123, fluorescent substrates of P-glycoprotein, in KB/MDR1 cells increased in the presence of caffeic acid phenetyl ester (CAPE), licochalcone A, anacardic acid, celastrol, xanthohumol, magnolol, and honokiol in a concentration-dependent manner.	Daunorubicin	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	77-91
25776492-4	2015	The accumulation of daunorubicin or rhodamine 123, fluorescent substrates of P-glycoprotein, in KB/MDR1 cells increased in the presence of caffeic acid phenetyl ester (CAPE), licochalcone A, anacardic acid, celastrol, xanthohumol, magnolol, and honokiol in a concentration-dependent manner.	Daunorubicin	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	99-103
25498972-0	2015	Collateral sensitivity to cold stress and differential BCL-2 family expression in new daunomycin-resistant lymphoblastoid cell lines.	Daunorubicin	86-96	BCL2 apoptosis regulator	Homo sapiens	55-60
26027258-6	2015	However, the results of inhibitor analysis of input of Pgp-dependent mechanisms of accumulation of rodamin-123 by leukocytes differ the data received under application of daunorubicin that reflects differences of their intracellular binding sites.	Daunorubicin	171-183	phosphoglycolate phosphatase	Homo sapiens	55-58
25676275-0	2015	Analysis of the impact of extracellular acidity on the expression and activity of P-glycoprotein and on the P-glycoprotein-mediated cytotoxicity of daunorubicin in cancer cell by microfluidic chip technology.	Daunorubicin	148-160	ATP binding cassette subfamily B member 1	Homo sapiens	108-122
25676275-1	2015	OBJECTIVE: To explore the impact of extracellular acidic environment on the expression and activity of P-glycoprotein (P-gp) and on the P-gp-mediated cytotoxicity of daunomycin in cancer cells by using microfluidic chip technology.	Daunorubicin	166-176	ATP binding cassette subfamily B member 1	Homo sapiens	136-140
25609961-4	2015	Daunorubicin (DNR) was loaded into poly (lactic-co-glycolic acid) (PLGA)-poly-L-lysine (PLL)-polyethylene glycol (PEG)-transferrin (Tf) NPs to construct DNR-PLGA-PLL-PEG-Tf-NPs (DNR-loaded NPs) as a DDS.	Daunorubicin	0-12	transferrin	Homo sapiens	119-130
26279420-0	2015	Sodium Ferulate Prevents Daunorubicin--Induced Apoptosis in H9c2 Cells via Inhibition of the ERKs Pathway.	Daunorubicin	25-37	mitogen activated protein kinase 3	Rattus norvegicus	93-97
26279420-2	2015	The activation of the extracellular regulated protein kinases (ERKs) pathway is responsible for the pro-apoptosis effect of DNR Sodium ferulate (SF) has recently been found to attenuate both DNR-induced cardiotoxicity and mitochondrial apoptosis in juvenile rats.	Daunorubicin	124-127	mitogen activated protein kinase 3	Rattus norvegicus	63-67
25351635-0	2015	Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor.	Daunorubicin	18-30	gonadotropin releasing hormone receptor	Homo sapiens	133-153
25351635-8	2015	The antiproliferative effect of both Dau-GnRH-III and Dau-[4Lys(Ac)]-GnRH-III was counteracted by the simultaneous treatment of the cells with Antide, an antagonist of the GnRH-R.	Daunorubicin	37-40	gonadotropin releasing hormone receptor	Homo sapiens	172-178
25351635-10	2015	These data demonstrate that in CRPC cells, daunorubicin-GnRH-III derivative bioconjugates: i) inhibit tumor cell proliferation, by triggering the apoptosis process; ii) exert their antitumor effect through the activation of the type I GnRH-R expressed on these cells.	Daunorubicin	43-55	gonadotropin releasing hormone receptor	Homo sapiens	235-241
26016240-9	2015	The mechanism of SF preventing daunorubicin-induced cardiotoxicity in juvenile rats is relevant to inhabited cardiac Troponin I expression.	Daunorubicin	31-43	troponin I3, cardiac type	Rattus norvegicus	109-127
25226230-8	2014	Imaging and scWestern analysis of single glioblastoma cells dosed with the chemotherapeutic daunomycin showed both apoptotic (cleaved caspase 8- and annexin V-positive) and living cells.	Daunorubicin	92-102	caspase 8	Homo sapiens	134-143
25115303-11	2014	Expression of the codon-harmonized full-length ABCB5 DNA conferred increased resistance, relative to the host yeast strain, to the putative substrates rhodamine 123, daunorubicin, tetramethylrhodamine, FK506, or clorgyline.	Daunorubicin	166-178	ATP binding cassette subfamily B member 5	Homo sapiens	47-52
25119182-14	2014	FMO3-H1/H3 genotype was associated with lower daunorubicin clearance than FMO3-H1/H1, p = 0.00829.	Daunorubicin	46-58	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	0-4
25119182-15	2014	GSTP1*B/*B genotype was also associated with lower daunorubicin clearance compared to GSTP1*A/*A, p = 0.0347.	Daunorubicin	51-63	glutathione S-transferase pi 1	Homo sapiens	0-5
25119182-18	2014	We found suggestive associations between FMO3 and GSTP1 haplotypes with daunorubicin PK that could potentially affect efficacy and toxicity.	Daunorubicin	72-84	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	41-45
25119182-18	2014	We found suggestive associations between FMO3 and GSTP1 haplotypes with daunorubicin PK that could potentially affect efficacy and toxicity.	Daunorubicin	72-84	glutathione S-transferase pi 1	Homo sapiens	50-55
24743520-0	2014	Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells.	Daunorubicin	80-92	aldo-keto reductase family 1 member C1	Homo sapiens	35-41
24743520-0	2014	Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells.	Daunorubicin	80-92	aldo-keto reductase family 1 member C3	Homo sapiens	46-52
24769118-7	2014	In the follow-up cellular studies, stylopine significantly inhibited the AKR1C3-mediated reduction of daunorubicin in intact cells without considerable cytotoxic effects.	Daunorubicin	102-114	aldo-keto reductase family 1 member C3	Homo sapiens	73-79
24903378-9	2014	In addition, chloroform extract had the ability to inhibit human P-glycoprotein-mediated daunorubicin in K562/R7 leukaemic cells in a dose-dependent manner compared to the positive control, cyclosporin A.	Daunorubicin	89-101	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
24954033-0	2014	Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.	Daunorubicin	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	83-88
24954033-0	2014	Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.	Daunorubicin	14-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	93-98
24954033-8	2014	However, the K562/DoxDR05 and K562/ABCG2-Z cells significantly decreased the intracellular levels of DRN and nilotinib, respectively, thereby mediating significant resistances to these drugs.	Daunorubicin	101-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	35-40
24832494-4	2014	Furthermore, the intracellular reduction of daunorubicin and idarubicin was examined by employing the transfection of A549, HeLa, MCF7 and HCT 116 cancer cells with an AKR1C3 encoding vector.	Daunorubicin	44-56	aldo-keto reductase family 1 member C3	Homo sapiens	168-174
24832494-5	2014	To investigate the participation of AKR1C3 in anthracycline resistance, we conducted MTT cytotoxicity assays with these cells, and observed that AKR1C3 significantly contributes to the resistance of cancer cells to daunorubicin and idarubicin, whereas this resistance was reversible by the simultaneous administration of 2"-hydroxyflavanone, a specific AKR1C3 inhibitor.	Daunorubicin	215-227	aldo-keto reductase family 1 member C3	Homo sapiens	36-42
24832494-5	2014	To investigate the participation of AKR1C3 in anthracycline resistance, we conducted MTT cytotoxicity assays with these cells, and observed that AKR1C3 significantly contributes to the resistance of cancer cells to daunorubicin and idarubicin, whereas this resistance was reversible by the simultaneous administration of 2"-hydroxyflavanone, a specific AKR1C3 inhibitor.	Daunorubicin	215-227	aldo-keto reductase family 1 member C3	Homo sapiens	145-151
24832494-5	2014	To investigate the participation of AKR1C3 in anthracycline resistance, we conducted MTT cytotoxicity assays with these cells, and observed that AKR1C3 significantly contributes to the resistance of cancer cells to daunorubicin and idarubicin, whereas this resistance was reversible by the simultaneous administration of 2"-hydroxyflavanone, a specific AKR1C3 inhibitor.	Daunorubicin	215-227	aldo-keto reductase family 1 member C3	Homo sapiens	145-151
24832494-8	2014	Therefore, we suggest that the induction of AKR1C3 following exposure to daunorubicin and idarubicin, which seems to be dependent on endogenous AKR1C3 expression, eventually might potentiate an intrinsic resistance given by the normal expression of AKR1C3.	Daunorubicin	73-85	aldo-keto reductase family 1 member C3	Homo sapiens	44-50
24832494-8	2014	Therefore, we suggest that the induction of AKR1C3 following exposure to daunorubicin and idarubicin, which seems to be dependent on endogenous AKR1C3 expression, eventually might potentiate an intrinsic resistance given by the normal expression of AKR1C3.	Daunorubicin	73-85	aldo-keto reductase family 1 member C3	Homo sapiens	144-150
24832494-8	2014	Therefore, we suggest that the induction of AKR1C3 following exposure to daunorubicin and idarubicin, which seems to be dependent on endogenous AKR1C3 expression, eventually might potentiate an intrinsic resistance given by the normal expression of AKR1C3.	Daunorubicin	73-85	aldo-keto reductase family 1 member C3	Homo sapiens	144-150
24832494-9	2014	In conclusion, our data suggest a substantial impact of AKR1C3 on the metabolism of daunorubicin and idarubicin, which affects their pharmacokinetic and pharmacodynamic behavior.	Daunorubicin	84-96	aldo-keto reductase family 1 member C3	Homo sapiens	56-62
24832494-10	2014	In addition, we demonstrate that the reduction of daunorubicin and idarubicin, which is catalyzed by AKR1C3, contributes to the resistance of cancer cells to anthracycline treatment.	Daunorubicin	50-62	aldo-keto reductase family 1 member C3	Homo sapiens	101-107
24839008-0	2014	Knockdown of RLIP76 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to daunorubicin in U937 leukemia cells.	Daunorubicin	129-141	ralA binding protein 1	Homo sapiens	13-19
24839008-8	2014	Finally, knockdown of RLIP76 in U937 cells also enhanced their chemosensitivity to daunorubicin.	Daunorubicin	83-95	ralA binding protein 1	Homo sapiens	22-28
24830852-7	2014	Daunorubicin (DNR) demonstrated a 2.2- and 3.5-fold higher cytotoxicity with the HL formulation and a 1.2- and 2.0-fold higher cytotoxicity with the LL formulation compared to the unmodified liposomal formulation in THP-1 and NB4 cells, respectively.	Daunorubicin	0-12	GLI family zinc finger 2	Homo sapiens	216-221
24830852-7	2014	Daunorubicin (DNR) demonstrated a 2.2- and 3.5-fold higher cytotoxicity with the HL formulation and a 1.2- and 2.0-fold higher cytotoxicity with the LL formulation compared to the unmodified liposomal formulation in THP-1 and NB4 cells, respectively.	Daunorubicin	14-17	GLI family zinc finger 2	Homo sapiens	216-221
24595806-9	2014	Folate deprivation markedly increased growth inhibitory effects of the established MRP1 substrates daunorubicin (~twofold), doxorubicin (~fivefold), and methotrexate (~83-fold) in MRP1-overexpressing cells, proportional to MRP1 expression.	Daunorubicin	99-111	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
24595806-9	2014	Folate deprivation markedly increased growth inhibitory effects of the established MRP1 substrates daunorubicin (~twofold), doxorubicin (~fivefold), and methotrexate (~83-fold) in MRP1-overexpressing cells, proportional to MRP1 expression.	Daunorubicin	99-111	ATP binding cassette subfamily B member 1	Homo sapiens	180-184
24595806-9	2014	Folate deprivation markedly increased growth inhibitory effects of the established MRP1 substrates daunorubicin (~twofold), doxorubicin (~fivefold), and methotrexate (~83-fold) in MRP1-overexpressing cells, proportional to MRP1 expression.	Daunorubicin	99-111	ATP binding cassette subfamily B member 1	Homo sapiens	180-184
24720529-9	2014	Increasing/decreasing miR-210 expression using agomir/antagomir could enhance or reduce the response of Reh cells and RS4;11 cells to daunorubicin/dexamethasone/L-asparaginase and daunorubicin/dexamethasone/vincristine, respectively.	Daunorubicin	134-146	microRNA 210	Homo sapiens	22-29
24720529-9	2014	Increasing/decreasing miR-210 expression using agomir/antagomir could enhance or reduce the response of Reh cells and RS4;11 cells to daunorubicin/dexamethasone/L-asparaginase and daunorubicin/dexamethasone/vincristine, respectively.	Daunorubicin	180-192	microRNA 210	Homo sapiens	22-29
24424270-1	2014	Daunorubicin (DNR) is an effective inhibitor of an array of proteins involved in neovascularization, including VEGF and PDGF.	Daunorubicin	0-12	vascular endothelial growth factor A	Homo sapiens	111-115
24424270-1	2014	Daunorubicin (DNR) is an effective inhibitor of an array of proteins involved in neovascularization, including VEGF and PDGF.	Daunorubicin	14-17	vascular endothelial growth factor A	Homo sapiens	111-115
24626403-1	2014	In this paper, a novel daunorubicin (DNR)-loaded MUC1 aptamer-near infrared (NIR) CuInS2 quantum dot (DNR-MUC1-QDs) conjugates were developed, which can be used as a targeted cancer imaging and sensing system.	Daunorubicin	23-35	mucin 1, cell surface associated	Homo sapiens	49-53
24626403-1	2014	In this paper, a novel daunorubicin (DNR)-loaded MUC1 aptamer-near infrared (NIR) CuInS2 quantum dot (DNR-MUC1-QDs) conjugates were developed, which can be used as a targeted cancer imaging and sensing system.	Daunorubicin	23-35	mucin 1, cell surface associated	Homo sapiens	106-110
24626403-7	2014	The quenched fluorescence intensity of MUC1-QDs was proportional to the concentration of DNR in the concentration ranges of 33-88 nmol L(-1).	Daunorubicin	89-92	mucin 1, cell surface associated	Homo sapiens	39-43
24356818-8	2014	The liposomal daunorubicin, administered 1 hour after EGFR-targeted photoimmunotherapy, was homogeneously distributed, allowing delivery to tiny surviving nests of EGFR-negative Balb3T3/DsRed cells, resulting in prolonged survival of mice.	Daunorubicin	14-26	epidermal growth factor receptor	Mus musculus	54-58
24356818-8	2014	The liposomal daunorubicin, administered 1 hour after EGFR-targeted photoimmunotherapy, was homogeneously distributed, allowing delivery to tiny surviving nests of EGFR-negative Balb3T3/DsRed cells, resulting in prolonged survival of mice.	Daunorubicin	14-26	epidermal growth factor receptor	Mus musculus	164-168
24396448-0	2014	Adenovirus-mediated delivery of the human IFN-gamma gene potentiates the cytotoxicity of daunorubicin against leukemic cells through downregulation of the alpha4beta1 integrin/ILK/apoptosis pathway.	Daunorubicin	89-101	interferon gamma	Homo sapiens	42-51
24396448-0	2014	Adenovirus-mediated delivery of the human IFN-gamma gene potentiates the cytotoxicity of daunorubicin against leukemic cells through downregulation of the alpha4beta1 integrin/ILK/apoptosis pathway.	Daunorubicin	89-101	integrin linked kinase	Homo sapiens	176-179
24729214-3	2014	Treating R3327-AT1, Pgp-positive tumor cells at pH 7.4 with daunorubicin, cisplatin or docetaxel led to marked apoptosis induction and cell death.	Daunorubicin	60-72	angiotensin II receptor, type 1a	Rattus norvegicus	15-18
24729214-3	2014	Treating R3327-AT1, Pgp-positive tumor cells at pH 7.4 with daunorubicin, cisplatin or docetaxel led to marked apoptosis induction and cell death.	Daunorubicin	60-72	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	20-23
24729214-5	2014	Inhibiting Pgp with verapamil reversed the acidosis-induced chemoresistance against daunorubicin and docetaxel.	Daunorubicin	84-96	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	11-14
24729214-10	2014	Since daunorubicin and docetaxel (but not cisplatin) are substrates of the Pgp, these results underline the influence of the tumor acidosis on the Pgp-mediated chemoresistance which can be counteracted by inhibition of the drug transporter.	Daunorubicin	6-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	75-78
24729214-10	2014	Since daunorubicin and docetaxel (but not cisplatin) are substrates of the Pgp, these results underline the influence of the tumor acidosis on the Pgp-mediated chemoresistance which can be counteracted by inhibition of the drug transporter.	Daunorubicin	6-18	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	147-150
24530422-0	2014	Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA ligase IV transcription of daunorubicin-resistant leukemia cell lines.	Daunorubicin	83-95	DNA ligase 4	Homo sapiens	52-65
24899604-1	2014	OBJECTIVES: The aim of this study was to observe the effects of bortezomib (PS341) on the expression of NF-kappaB (nuclear factor-kappa B), IkappaB (inhibitor kB) and P-gp (P-glycoprotein) of K562 cells induced by daunorubicin (K562/DNR).	Daunorubicin	214-226	nuclear factor kappa B subunit 1	Homo sapiens	104-113
24248633-11	2014	The sevoflurane and DRB groups induced increased caspase 3/7 activation compared with untreated cells.	Daunorubicin	20-23	caspase 3	Homo sapiens	49-58
24376706-0	2013	Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro.	Daunorubicin	122-134	ATP binding cassette subfamily B member 1	Homo sapiens	52-57
24376706-3	2013	Four of the compounds inhibited efflux of two ABCB1 substrates, Hoechst 33342 and daunorubicin, in MDCKII-ABCB1 cells: Olomoucine II most strongly, followed by roscovitine, purvalanol A, and flavopiridol.	Daunorubicin	82-94	ATP binding cassette subfamily B member 1	Homo sapiens	46-51
24376706-3	2013	Four of the compounds inhibited efflux of two ABCB1 substrates, Hoechst 33342 and daunorubicin, in MDCKII-ABCB1 cells: Olomoucine II most strongly, followed by roscovitine, purvalanol A, and flavopiridol.	Daunorubicin	82-94	ATP binding cassette subfamily B member 1	Homo sapiens	106-111
24376706-6	2013	We further revealed that the strongest ABCB1 inhibitors (purvalanol A, olomoucine II and roscovitine) synergistically potentiate the antiproliferative effect of daunorubicin, a commonly used anticancer drug and ABCB1 substrate, in MDCKII-ABCB1 cells as well as in human carcinoma HCT-8 and HepG2 cells.	Daunorubicin	161-173	ATP binding cassette subfamily B member 1	Homo sapiens	39-44
24376706-6	2013	We further revealed that the strongest ABCB1 inhibitors (purvalanol A, olomoucine II and roscovitine) synergistically potentiate the antiproliferative effect of daunorubicin, a commonly used anticancer drug and ABCB1 substrate, in MDCKII-ABCB1 cells as well as in human carcinoma HCT-8 and HepG2 cells.	Daunorubicin	161-173	ATP binding cassette subfamily B member 1	Homo sapiens	211-216
24376706-6	2013	We further revealed that the strongest ABCB1 inhibitors (purvalanol A, olomoucine II and roscovitine) synergistically potentiate the antiproliferative effect of daunorubicin, a commonly used anticancer drug and ABCB1 substrate, in MDCKII-ABCB1 cells as well as in human carcinoma HCT-8 and HepG2 cells.	Daunorubicin	161-173	ATP binding cassette subfamily B member 1	Homo sapiens	211-216
24376706-7	2013	We suggest that this pronounced synergism is at least partly caused by (i) CDKi-mediated inhibition of ABCB1 transporter leading to increased intracellular retention of daunorubicin and (ii) native cytotoxic activity of the CDKi.	Daunorubicin	169-181	ATP binding cassette subfamily B member 1	Homo sapiens	103-108
24321497-8	2013	EWS/WT1 expression in wild-type MEFs conferred resistance to cell-cycle arrest after irradiation and daunorubicin induced apoptosis.	Daunorubicin	101-113	Ewing sarcoma breakpoint region 1	Mus musculus	0-3
24321497-8	2013	EWS/WT1 expression in wild-type MEFs conferred resistance to cell-cycle arrest after irradiation and daunorubicin induced apoptosis.	Daunorubicin	101-113	WT1 transcription factor	Mus musculus	4-7
24220583-3	2013	Expression of ARNT in TG-sensitive cells made these cells resistant to both TG and daunorubicin.	Daunorubicin	83-95	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	14-18
24266510-6	2013	Most common drugs like sorafenib, doxorubicin and daunorubicin have been used widely for treatment of HCC.	Daunorubicin	50-62	HCC	Homo sapiens	102-105
24273552-0	2013	A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor.	Daunorubicin	21-33	cytochrome p450 oxidoreductase	Homo sapiens	116-135
24273552-4	2013	Here, using a multi-SNP based approach, we examined 60 genes coding for proteins involved in drug metabolism and efflux and identified the P450 oxidoreductase (POR) gene to be most strongly associated with daunorubicin induced cardiotoxicity in a population of acute myeloid leukemia (AML) patients (FDR adjusted p-value of 0.15).	Daunorubicin	206-218	cytochrome p450 oxidoreductase	Homo sapiens	139-158
24273552-4	2013	Here, using a multi-SNP based approach, we examined 60 genes coding for proteins involved in drug metabolism and efflux and identified the P450 oxidoreductase (POR) gene to be most strongly associated with daunorubicin induced cardiotoxicity in a population of acute myeloid leukemia (AML) patients (FDR adjusted p-value of 0.15).	Daunorubicin	206-218	cytochrome p450 oxidoreductase	Homo sapiens	160-163
24273552-5	2013	In this sample of cancer patients, variation in the POR gene is estimated to account for some 11.6% of the variability in the drop of left ventricular ejection fraction (LVEF) after daunorubicin treatment, compared to the estimated 13.2% accounted for by the cumulative dose and ethnicity.	Daunorubicin	182-194	cytochrome p450 oxidoreductase	Homo sapiens	52-55
24244429-8	2013	Our results establish a novel mechanism underlying the cooperative antileukemic activities of these drug combinations in which panobinostat suppresses expression of BRCA1, CHK1, and RAD51 to enhance cytarabine and daunorubicin sensitivities in AML cells.	Daunorubicin	214-226	RAD51 recombinase	Mus musculus	182-187
24062304-8	2013	Importantly, to elicit drug resistance via lysosomes, the cytotoxic chemotherapeutics (e.g. DOX, daunorubicin, or vinblastine) were required to be Pgp substrates and also ionized at lysosomal pH (pH 5), resulting in them being sequestered and trapped in lysosomes.	Daunorubicin	97-109	ATP binding cassette subfamily B member 1	Homo sapiens	147-150
24179544-5	2013	The Eca109/ABCG2 esophageal cancer cells with ABCG2 gene overexpression were resistant to adriamycin (ADM), daunorubicin (DNR) and mitoxantrone (MIT), which indicated that ABCG2 may be associated with drug resistance in esophageal cancer.	Daunorubicin	108-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	11-16
24179544-5	2013	The Eca109/ABCG2 esophageal cancer cells with ABCG2 gene overexpression were resistant to adriamycin (ADM), daunorubicin (DNR) and mitoxantrone (MIT), which indicated that ABCG2 may be associated with drug resistance in esophageal cancer.	Daunorubicin	108-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	46-51
24179544-5	2013	The Eca109/ABCG2 esophageal cancer cells with ABCG2 gene overexpression were resistant to adriamycin (ADM), daunorubicin (DNR) and mitoxantrone (MIT), which indicated that ABCG2 may be associated with drug resistance in esophageal cancer.	Daunorubicin	108-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	46-51
24283803-10	2013	Baseline and daunorubicin-induced STAT3 activation was hampered upon CK2 blockade.	Daunorubicin	13-25	signal transducer and activator of transcription 3	Homo sapiens	34-39
24283803-12	2013	CK2 negative regulation of the protein levels of tumor suppressor p53 and activation of the STAT3 anti-apoptotic pathway might antagonize apoptosis and could be involved in acute myeloid leukemia cell resistance to daunorubicin.	Daunorubicin	215-227	tumor protein p53	Homo sapiens	66-69
24283803-12	2013	CK2 negative regulation of the protein levels of tumor suppressor p53 and activation of the STAT3 anti-apoptotic pathway might antagonize apoptosis and could be involved in acute myeloid leukemia cell resistance to daunorubicin.	Daunorubicin	215-227	signal transducer and activator of transcription 3	Homo sapiens	92-97
23896410-6	2013	Our studies suggest that enhanced targeting of AML cells by the combination of dasatinib with daunorubicin may be related to inhibition of AKT-mediated human mouse double minute 2 homolog phosphorylation, resulting in enhanced p53 activity in AML cells.	Daunorubicin	94-106	AKT serine/threonine kinase 1	Homo sapiens	139-142
23896410-6	2013	Our studies suggest that enhanced targeting of AML cells by the combination of dasatinib with daunorubicin may be related to inhibition of AKT-mediated human mouse double minute 2 homolog phosphorylation, resulting in enhanced p53 activity in AML cells.	Daunorubicin	94-106	transformation related protein 53, pseudogene	Mus musculus	227-230
23792590-3	2013	Exposure to daunomycin at clinically relevant concentrations (25-250 nM) caused dissociation of wild-type H1.1 as well as 4 H1 point mutants from DNA, followed by their accumulation in nucleoli and aggregation of chromatin.	Daunorubicin	12-22	H1.1 linker histone, cluster member	Homo sapiens	106-110
23792590-6	2013	Dissociation of the H1.1 linker histones and subsequent loss of higher order chromatin structures may constitute an important component of the mechanism of cytotoxicity of daunomycin.	Daunorubicin	172-182	H1.1 linker histone, cluster member	Homo sapiens	20-24
23841896-0	2013	Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen.	Daunorubicin	52-64	transformation related protein 53	Mus musculus	11-14
23841896-4	2013	METHODS: Mice with wild type or deleted Trp53 were treated with the daunorubicin (DNR) for three consecutive days.	Daunorubicin	68-80	transformation related protein 53	Mus musculus	40-45
23841896-4	2013	METHODS: Mice with wild type or deleted Trp53 were treated with the daunorubicin (DNR) for three consecutive days.	Daunorubicin	82-85	transformation related protein 53	Mus musculus	40-45
23874683-5	2013	ShRNA knockdown of GATA1 in the megakaryocytic cell line Meg-01 resulted in significantly increased cytarabine (ara-C) and daunorubicin anti-proliferative sensitivities and decreased Bcl-xL transcript and protein levels.	Daunorubicin	123-135	GATA binding protein 1	Homo sapiens	19-24
23874683-5	2013	ShRNA knockdown of GATA1 in the megakaryocytic cell line Meg-01 resulted in significantly increased cytarabine (ara-C) and daunorubicin anti-proliferative sensitivities and decreased Bcl-xL transcript and protein levels.	Daunorubicin	123-135	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	57-60
23332453-6	2013	In addition, adipose tissue explants protected ALL cells against daunorubicin and vincristine.	Daunorubicin	65-77	WD and tetratricopeptide repeats 1	Mus musculus	13-20
23467984-2	2013	The aim of this study was to assess whether the induction of MAPK-mediated effects contributes to the therapeutic value of combination sorafenib and daunorubicin (DNR) treatment.	Daunorubicin	149-161	mitogen-activated protein kinase 3	Homo sapiens	61-65
23434423-0	2013	Synthesis, enzymatic stability and in vitro cytostatic effect of Daunorubicin-GnRH-III derivative dimers.	Daunorubicin	65-77	gonadotropin releasing hormone 1	Homo sapiens	78-82
23434423-5	2013	The daunorubicin-GnRH-III derivative dimers were partly digested by alpha-chymotrypsin; however, they had increased stability compared to the corresponding monomers, making them potential candidates for oral administration.	Daunorubicin	4-16	gonadotropin releasing hormone 1	Homo sapiens	17-21
23434423-7	2013	All daunorubicin-GnRH-III derivative dimers exerted slightly increased in vitro cytostatic effect (IC50 values in low muM range) than the corresponding monomeric bioconjugates.	Daunorubicin	4-16	gonadotropin releasing hormone 1	Homo sapiens	17-21
23263202-11	2013	In addition, the concentration-dependent induction of apoptosis in response to treatment with the cytostatic drugs cytarabine or daunorubicin was significantly reduced in TRAF6-depleted MV4-11 cells.	Daunorubicin	129-141	TNF receptor associated factor 6	Homo sapiens	171-176
23228943-7	2013	Moreover, AMPK inhibition in MLL-rearranged cell lines synergistically enhanced the antiproliferative effects of vincristine, daunorubicin, cytarabine, dexamethasone and L-asparaginase in most of the evaluated conditions.	Daunorubicin	126-138	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	10-14
23228943-7	2013	Moreover, AMPK inhibition in MLL-rearranged cell lines synergistically enhanced the antiproliferative effects of vincristine, daunorubicin, cytarabine, dexamethasone and L-asparaginase in most of the evaluated conditions.	Daunorubicin	126-138	lysine methyltransferase 2A	Homo sapiens	29-32
23295225-11	2013	GSNO treatment of CBR1 resulted in a 2-5-fold decrease in kcat with menadione, 4-benzoylpyridine, 2,3-hexanedione, daunorubicin and 1,4-naphthoquinone.	Daunorubicin	115-127	carbonyl reductase 1	Homo sapiens	18-22
23400406-4	2013	Towards this goal, a series of Benzopyranes and Benzopyrano[3,4b][1,4]oxazines have been synthesized and pharmacologically tested for their ability to inhibit P-gp mediated daunomycin efflux.	Daunorubicin	173-183	ATP binding cassette subfamily B member 1	Homo sapiens	159-163
23484690-1	2013	The aim of this study was to observe the inhibitory effect of daunorubicin on KG1a cells and the expression of Eps8 which is a novel tumor-associated antigen with its full name epidermal growth factor receptor pathway substrate 8 (Eps8), and to explore the effect of daunorubicin on Eps8 expression in KG1a cells at mRNA and protein levels.	Daunorubicin	267-279	epidermal growth factor receptor pathway substrate 8	Homo sapiens	111-115
23484690-1	2013	The aim of this study was to observe the inhibitory effect of daunorubicin on KG1a cells and the expression of Eps8 which is a novel tumor-associated antigen with its full name epidermal growth factor receptor pathway substrate 8 (Eps8), and to explore the effect of daunorubicin on Eps8 expression in KG1a cells at mRNA and protein levels.	Daunorubicin	267-279	epidermal growth factor receptor pathway substrate 8	Homo sapiens	231-235
23484690-1	2013	The aim of this study was to observe the inhibitory effect of daunorubicin on KG1a cells and the expression of Eps8 which is a novel tumor-associated antigen with its full name epidermal growth factor receptor pathway substrate 8 (Eps8), and to explore the effect of daunorubicin on Eps8 expression in KG1a cells at mRNA and protein levels.	Daunorubicin	267-279	epidermal growth factor receptor pathway substrate 8	Homo sapiens	231-235
23484690-4	2013	Daunorubicin could reduce the mRNA and protein levels of Eps8 expression in dose and time dependent manners in KG1a cells (r = 0.979, P &lt; 0.05).	Daunorubicin	0-12	epidermal growth factor receptor pathway substrate 8	Homo sapiens	57-61
23484690-5	2013	It is concluded that with the increasing of concentration and time of daunorubicin acting on KG1a cells, the cell proliferative inhibitory effect increased and the expression of Eps8 decreased, suggesting that the inhibitory effect of daunorubicin on KG1a cell proliferation is realized through downregulation of Eps8 expression.	Daunorubicin	70-82	epidermal growth factor receptor pathway substrate 8	Homo sapiens	178-182
23484690-5	2013	It is concluded that with the increasing of concentration and time of daunorubicin acting on KG1a cells, the cell proliferative inhibitory effect increased and the expression of Eps8 decreased, suggesting that the inhibitory effect of daunorubicin on KG1a cell proliferation is realized through downregulation of Eps8 expression.	Daunorubicin	70-82	epidermal growth factor receptor pathway substrate 8	Homo sapiens	313-317
23484690-5	2013	It is concluded that with the increasing of concentration and time of daunorubicin acting on KG1a cells, the cell proliferative inhibitory effect increased and the expression of Eps8 decreased, suggesting that the inhibitory effect of daunorubicin on KG1a cell proliferation is realized through downregulation of Eps8 expression.	Daunorubicin	235-247	epidermal growth factor receptor pathway substrate 8	Homo sapiens	178-182
23484690-5	2013	It is concluded that with the increasing of concentration and time of daunorubicin acting on KG1a cells, the cell proliferative inhibitory effect increased and the expression of Eps8 decreased, suggesting that the inhibitory effect of daunorubicin on KG1a cell proliferation is realized through downregulation of Eps8 expression.	Daunorubicin	235-247	epidermal growth factor receptor pathway substrate 8	Homo sapiens	313-317
32260820-3	2013	Cellular treatment with DNR-loaded GGN remarkably reduced drug resistant-related P-gp expression and activated apoptosis-related caspase protein expression in KA cells.	Daunorubicin	24-27	phosphoglycolate phosphatase	Mus musculus	81-85
23036589-0	2013	Evidence for the binding affinity of daunomycin to HMGB1 protein in chromatin and in solution.	Daunorubicin	37-47	high mobility group box 1	Homo sapiens	51-56
23036589-1	2013	In this study the interaction of daunomycin with HMGB1 nonhistone chromatin protein in the chromatin context using hydroxyapatite (HAP) column chromatography and free in solution was investigated employing fluorescence, circular dichroism spectroscopy and thermal denaturation techniques.	Daunorubicin	33-43	high mobility group box 1	Homo sapiens	49-54
23036589-2	2013	The results demonstrate that HMGB1 fraction eluted from HAP column contained the most amount of daunomycin.	Daunorubicin	96-106	high mobility group box 1	Homo sapiens	29-34
23036589-3	2013	Upon addition of daunomycin to HMGB1 solution, fluorescence emission intensity was dependent on the drug concentration used whereas the ellipticity in CD spectra was decreased at both 205 and 220 nm extremes implying that quenching of the drug with the HMGB1 chromospheres alters secondary structure of the protein.	Daunorubicin	17-27	high mobility group box 1	Homo sapiens	31-36
23036589-3	2013	Upon addition of daunomycin to HMGB1 solution, fluorescence emission intensity was dependent on the drug concentration used whereas the ellipticity in CD spectra was decreased at both 205 and 220 nm extremes implying that quenching of the drug with the HMGB1 chromospheres alters secondary structure of the protein.	Daunorubicin	17-27	high mobility group box 1	Homo sapiens	253-258
23036589-4	2013	Although daunomycin slightly increased the melting point of HMGB1, but exhibited a significant hyperchromicity at low concentrations and hypochromicity at higher concentrations of daunomycin.	Daunorubicin	9-19	high mobility group box 1	Homo sapiens	60-65
23036589-5	2013	The results suggest that daunomycin binds to HMGB1 protein which may influence its interaction with DNA in nucleosomes and other cellular processes.	Daunorubicin	25-35	high mobility group box 1	Homo sapiens	45-50
23103446-7	2013	Importantly, cells with downregulated expression of P-gp gradually lost their ability to decrease the intracellular level of nilotinib although they still significantly decreased the intracellular level of daunorubicin (DNR).	Daunorubicin	206-218	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
23457546-3	2013	Here, we show that a human myeloid cell line constitutively overexpressing EVI1 after infection with a retroviral vector (U937_EVI1) was partially resistant to etoposide and daunorubicin as compared to empty vector infected control cells (U937_vec).	Daunorubicin	174-186	MDS1 and EVI1 complex locus	Homo sapiens	75-79
23457546-4	2013	Similarly, inducible expression of EVI1 in HL-60 cells decreased their sensitivity to daunorubicin.	Daunorubicin	86-98	MDS1 and EVI1 complex locus	Homo sapiens	35-39
22562609-0	2012	Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.	Daunorubicin	43-55	carbonyl reductase 1	Homo sapiens	0-20
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	74-86	carbonyl reductase 1	Homo sapiens	108-134
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	74-86	carbonyl reductase 1	Homo sapiens	136-140
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	74-86	carbonyl reductase 3	Homo sapiens	145-149
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	74-86	carbonyl reductase 1	Homo sapiens	280-284
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	74-86	carbonyl reductase 3	Homo sapiens	289-293
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	183-195	carbonyl reductase 1	Homo sapiens	108-134
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	183-195	carbonyl reductase 1	Homo sapiens	136-140
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	183-195	carbonyl reductase 3	Homo sapiens	145-149
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	183-195	carbonyl reductase 1	Homo sapiens	280-284
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	183-195	carbonyl reductase 3	Homo sapiens	289-293
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	183-195	carbonyl reductase 1	Homo sapiens	108-134
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	183-195	carbonyl reductase 1	Homo sapiens	136-140
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	183-195	carbonyl reductase 3	Homo sapiens	145-149
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	183-195	carbonyl reductase 1	Homo sapiens	280-284
22562609-1	2012	PURPOSE: The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients.	Daunorubicin	183-195	carbonyl reductase 3	Homo sapiens	289-293
22562609-4	2012	RESULTS: Increased expression of CBR1 significantly reduced the in vitro cytotoxicity of daunorubicin and also positively correlated with intracellular DOL levels.	Daunorubicin	89-101	carbonyl reductase 1	Homo sapiens	33-37
22562609-5	2012	Polymorphisms in CBR1 and CBR3 did not show any association with intracellular daunorubicin or DOL levels, but there was a trend towards significant increase in plasma daunorubicin systemic exposure in patients with a variant genotype for CBR1 polymorphism rs25678.	Daunorubicin	168-180	carbonyl reductase 1	Homo sapiens	239-243
22562609-6	2012	CONCLUSIONS: This pilot study suggests that CBR1 RNA expression may be helpful in identifying AML patients at risk of developing resistance or toxicity to daunorubicin due to increased formation of DOL.	Daunorubicin	155-167	carbonyl reductase 1	Homo sapiens	44-48
23203067-5	2012	Daunomycin, doxorubicin, thioridazine, and trifluoperazine showed strong affinity to the S1 site, which is a central cavity formed between three domains of CASQ2.	Daunorubicin	0-10	calsequestrin 2	Canis lupus familiaris	156-161
22982121-2	2012	To better understand the individual importance of each enzyme in the reduction and to provide deeper insight into the binding at atomic level we performed molecular docking and dynamics simulations of DAUN and DOX into the active sites of human carbonyl reductase 1 (CBR1) and human aldehyde reductase (AKR1A1).	Daunorubicin	201-205	carbonyl reductase 1	Homo sapiens	245-265
22982121-2	2012	To better understand the individual importance of each enzyme in the reduction and to provide deeper insight into the binding at atomic level we performed molecular docking and dynamics simulations of DAUN and DOX into the active sites of human carbonyl reductase 1 (CBR1) and human aldehyde reductase (AKR1A1).	Daunorubicin	201-205	carbonyl reductase 1	Homo sapiens	267-271
22982121-2	2012	To better understand the individual importance of each enzyme in the reduction and to provide deeper insight into the binding at atomic level we performed molecular docking and dynamics simulations of DAUN and DOX into the active sites of human carbonyl reductase 1 (CBR1) and human aldehyde reductase (AKR1A1).	Daunorubicin	201-205	aldo-keto reductase family 1 member A1	Homo sapiens	283-301
22982121-2	2012	To better understand the individual importance of each enzyme in the reduction and to provide deeper insight into the binding at atomic level we performed molecular docking and dynamics simulations of DAUN and DOX into the active sites of human carbonyl reductase 1 (CBR1) and human aldehyde reductase (AKR1A1).	Daunorubicin	201-205	aldo-keto reductase family 1 member A1	Homo sapiens	303-309
22197725-5	2012	The presence of CLL1-targeting peptides on the surface of the nanomicelles enabled the improved binding and delivery of substantially more daunorubicin into the cells expressing CLL1 and CD34(+) leukemic cells compared with unmodified nanomicelles.	Daunorubicin	139-151	C-type lectin domain family 12 member A	Homo sapiens	16-20
22197725-5	2012	The presence of CLL1-targeting peptides on the surface of the nanomicelles enabled the improved binding and delivery of substantially more daunorubicin into the cells expressing CLL1 and CD34(+) leukemic cells compared with unmodified nanomicelles.	Daunorubicin	139-151	C-type lectin domain family 12 member A	Homo sapiens	178-182
22197725-5	2012	The presence of CLL1-targeting peptides on the surface of the nanomicelles enabled the improved binding and delivery of substantially more daunorubicin into the cells expressing CLL1 and CD34(+) leukemic cells compared with unmodified nanomicelles.	Daunorubicin	139-151	CD34 molecule	Homo sapiens	187-191
22868178-3	2012	Their abilities to inhibit P-glycoprotein-mediated daunorubicin efflux in K562/R7 human leukemic cells overexpressing P-glycoprotein were evaluated versus progesterone.	Daunorubicin	51-63	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
22855599-4	2012	In multivariate analysis, controlled for prognostic baseline characteristics and daunorubicin dose, CD25(POS) patients had inferior complete remission rates (P = .0005) and overall survival (P &lt; .0001) compared with CD25(NEG) cases.	Daunorubicin	81-93	interleukin 2 receptor subunit alpha	Homo sapiens	100-104
23087807-8	2012	Furthermore, the monoclonal antibody against LRP significantly increased daunorubicin acumulation (P=0.004) in the nuclei of leukemic blast cells with LRP positivity in more than 10% of the cells.	Daunorubicin	73-85	major vault protein	Homo sapiens	45-48
23087807-8	2012	Furthermore, the monoclonal antibody against LRP significantly increased daunorubicin acumulation (P=0.004) in the nuclei of leukemic blast cells with LRP positivity in more than 10% of the cells.	Daunorubicin	73-85	major vault protein	Homo sapiens	151-154
23087807-9	2012	An LRP reversing agent, PAK-104P, was found to increase the daunorubicin content with marginal significance (P=0.060).	Daunorubicin	60-72	major vault protein	Homo sapiens	3-6
22864744-5	2012	[(3)H]daunomycin uptake into MPMVs was diminished after SNP pretreatment in the presence of an ATP-regenerating system, indicating that the functional activity of P-gp was impaired after exposure to SNP.	Daunorubicin	6-16	phosphoglycolate phosphatase	Mus musculus	163-167
22659796-8	2012	Metformin and rosiglitazone enhanced daunorubicin-induced apoptosis, while insulin, aspart and glargine antagonized daunorubicin-induced apoptosis.	Daunorubicin	116-128	insulin	Homo sapiens	75-82
22145750-1	2012	INTRODUCTION: To study the effect of bortezomib alone or in combination with daunorubicin (DNR) on an mdr1 single-factor drug-resistant leukemia cell line K562/MDR1, a multifactor-resistant cell line K562/A02, a drug-sensitive cell line K562, and primary cells from acute myeloid leukemia patients.	Daunorubicin	77-89	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
22967388-0	2012	[Effect of proliferation inhibition and PTEN gene expression induced by decitabine combined with daunorubicin on HL-60 cell line].	Daunorubicin	97-109	phosphatase and tensin homolog	Homo sapiens	40-44
22554523-0	2012	Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand.	Daunorubicin	27-39	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	18-23
22554523-4	2012	We identified daunorubicin as a potent sensitizer of TRAIL-induced apoptosis in MCF-7 cells.	Daunorubicin	14-26	TNF superfamily member 10	Homo sapiens	53-58
22554523-7	2012	By immunoblotting, we found that daunorubicin treatment induced loss of the anti-apoptotic protein, Mcl-1, in breast cancer cells.	Daunorubicin	33-45	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	100-105
22252735-6	2012	By means of small-molecule kinase inhibitors and transfection of cells with the genes of the components of these pathways, c-Jun and AKT, we confirm that JNK signalling pathway is proapoptotic, whereas AKT is antiapoptotic in daunorubicin-induced muscle cells.	Daunorubicin	226-238	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	123-128
22252735-6	2012	By means of small-molecule kinase inhibitors and transfection of cells with the genes of the components of these pathways, c-Jun and AKT, we confirm that JNK signalling pathway is proapoptotic, whereas AKT is antiapoptotic in daunorubicin-induced muscle cells.	Daunorubicin	226-238	AKT serine/threonine kinase 1	Homo sapiens	133-136
22252735-6	2012	By means of small-molecule kinase inhibitors and transfection of cells with the genes of the components of these pathways, c-Jun and AKT, we confirm that JNK signalling pathway is proapoptotic, whereas AKT is antiapoptotic in daunorubicin-induced muscle cells.	Daunorubicin	226-238	mitogen-activated protein kinase 8	Homo sapiens	154-157
22252735-6	2012	By means of small-molecule kinase inhibitors and transfection of cells with the genes of the components of these pathways, c-Jun and AKT, we confirm that JNK signalling pathway is proapoptotic, whereas AKT is antiapoptotic in daunorubicin-induced muscle cells.	Daunorubicin	226-238	AKT serine/threonine kinase 1	Homo sapiens	202-205
22417203-9	2012	High-dose daunorubicin, as compared with standard-dose daunorubicin, improved the rate of survival among patients with DNMT3A or NPM1 mutations or MLL translocations (P=0.001) but not among patients with wild-type DNMT3A, NPM1, and MLL (P=0.67).	Daunorubicin	10-22	DNA methyltransferase 3 alpha	Homo sapiens	119-125
22417203-9	2012	High-dose daunorubicin, as compared with standard-dose daunorubicin, improved the rate of survival among patients with DNMT3A or NPM1 mutations or MLL translocations (P=0.001) but not among patients with wild-type DNMT3A, NPM1, and MLL (P=0.67).	Daunorubicin	10-22	nucleophosmin 1	Homo sapiens	129-133
22417203-9	2012	High-dose daunorubicin, as compared with standard-dose daunorubicin, improved the rate of survival among patients with DNMT3A or NPM1 mutations or MLL translocations (P=0.001) but not among patients with wild-type DNMT3A, NPM1, and MLL (P=0.67).	Daunorubicin	10-22	lysine methyltransferase 2A	Homo sapiens	147-150
22417203-9	2012	High-dose daunorubicin, as compared with standard-dose daunorubicin, improved the rate of survival among patients with DNMT3A or NPM1 mutations or MLL translocations (P=0.001) but not among patients with wild-type DNMT3A, NPM1, and MLL (P=0.67).	Daunorubicin	10-22	DNA methyltransferase 3 alpha	Homo sapiens	214-220
22417203-9	2012	High-dose daunorubicin, as compared with standard-dose daunorubicin, improved the rate of survival among patients with DNMT3A or NPM1 mutations or MLL translocations (P=0.001) but not among patients with wild-type DNMT3A, NPM1, and MLL (P=0.67).	Daunorubicin	10-22	nucleophosmin 1	Homo sapiens	222-226
22417203-9	2012	High-dose daunorubicin, as compared with standard-dose daunorubicin, improved the rate of survival among patients with DNMT3A or NPM1 mutations or MLL translocations (P=0.001) but not among patients with wild-type DNMT3A, NPM1, and MLL (P=0.67).	Daunorubicin	10-22	lysine methyltransferase 2A	Homo sapiens	232-235
22285729-0	2012	miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2.	Daunorubicin	73-85	BCL2 apoptosis regulator	Homo sapiens	99-104
22829255-6	2012	Heterologously expressed MCL-1 substituted for FLT3 signaling by conferring resistance of hematopoietic cells to antileukemia drugs such as cytarabine and daunorubicin, and to the proapoptotic BH3 mimetic ABT-737.	Daunorubicin	155-167	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	25-30
22829255-6	2012	Heterologously expressed MCL-1 substituted for FLT3 signaling by conferring resistance of hematopoietic cells to antileukemia drugs such as cytarabine and daunorubicin, and to the proapoptotic BH3 mimetic ABT-737.	Daunorubicin	155-167	fms related receptor tyrosine kinase 3	Homo sapiens	47-51
22058208-8	2012	Furthermore, re-expression of TWIST2 resulted in increased sensitivity to the chemotherapeutic agents etoposide, daunorubicin and dexamethasone and TWIST2 hypermethylation was almost invariably found in relapsed adult acute lymphoblastic leukemia (91% of samples hypermethylated).	Daunorubicin	113-125	twist family bHLH transcription factor 2	Homo sapiens	30-36
22147501-0	2012	Doxorubicin- and daunorubicin-induced regulation of Ca2+ and H+ fluxes through human bax inhibitor-1 reconstituted into membranes.	Daunorubicin	17-29	transmembrane BAX inhibitor motif containing 6	Homo sapiens	85-100
22147501-2	2012	We examined the effect of doxorubicin (DXR) and daunorubicin (DNR), which are clinically important anthracycline compounds, on the functional regulation of BI-1 reconstituted into membranes.	Daunorubicin	48-60	transmembrane BAX inhibitor motif containing 6	Homo sapiens	156-160
22115891-3	2012	It was evidenced that at high NADPH concentration (500 muM) anthracyclines having non-modified quinone structure: doxorubicin (DOX), daunorubicin (DR) and idarubicin (IDA) were susceptible upon CPR catalysis to undergo a multi-stage chemical transformation concerning their chromophore part.	Daunorubicin	133-145	cytochrome p450 oxidoreductase	Homo sapiens	194-197
22199276-10	2011	CONCLUSION: As(2)O(3) and arsenic acid inhibit proliferation and induce apoptosis in MOLT-4 and daunorubicine-resistant MOLT-4/DNR cells via glutathione-depletion and subsequent caspase-3/7 activation.	Daunorubicin	96-109	caspase 3	Homo sapiens	178-187
22101268-4	2011	BMAL1 deficient fibroblasts had an increased sensitivity to hydrogen peroxide treatment, and reduced sensitivity to DNA damaging anticancer drugs etoposide and daunorubicin.	Daunorubicin	160-172	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	0-5
20635168-2	2011	The transduction of adenovirus vectors encoding HA117 conferred breast cancer cell line 4T1 MDR not only to MRP1 substrate drugs but also to MRP1 non-substrate drugs and the MDR strength of HA117 was similar to that of multidrug resistance-associated protein-1 (MRP1) for MRP1 substrate, but HA117 had no daunorubicin-excretion function.	Daunorubicin	305-317	regulator of G protein signaling 6	Homo sapiens	48-53
22081665-9	2011	However, DNMT3A exon 23+ patients had better median DFS (not reached vs 11.6 months, p=0.009) and OS (not reached vs 14.3 months, p=0.005) as compared to DNMT3A exon 23- patients when treated with idarubicin, whereas patients treated with daunorubicin had similar outcome regardless the DNMT3A status.	Daunorubicin	239-251	DNA methyltransferase 3 alpha	Homo sapiens	9-15
22035293-8	2011	P-glycoprotein function and drug sensitivity were analyzed by Daunorubicin accumulation and MTT assays.	Daunorubicin	62-74	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-14
21333751-0	2011	Fe3O4 nanoparticles with daunorubicin induce apoptosis through caspase 8-PARP pathway and inhibit K562 leukemia cell-induced tumor growth in vivo.	Daunorubicin	25-37	caspase 8	Homo sapiens	63-72
21333751-0	2011	Fe3O4 nanoparticles with daunorubicin induce apoptosis through caspase 8-PARP pathway and inhibit K562 leukemia cell-induced tumor growth in vivo.	Daunorubicin	25-37	poly(ADP-ribose) polymerase 1	Homo sapiens	73-77
21697274-1	2011	Our aim was to examine the molecular basis for acute effects of the anthracycline daunorubicin on cardiac ryanodine receptor (RyR2) channels and cardiac calsequestrin (CSQ2).	Daunorubicin	82-94	ryanodine receptor 2	Homo sapiens	126-130
21697274-5	2011	We show that 0.5 to 10 muM daunorubicin increases the activity of RyR2 channels after 5 to 10 min and that activity then declines to very low levels when channels are exposed to daunorubicin concentrations of &gt;= 2.5 muM for a further 10 to 20 min.	Daunorubicin	27-39	ryanodine receptor 2	Homo sapiens	66-70
21697274-5	2011	We show that 0.5 to 10 muM daunorubicin increases the activity of RyR2 channels after 5 to 10 min and that activity then declines to very low levels when channels are exposed to daunorubicin concentrations of &gt;= 2.5 muM for a further 10 to 20 min.	Daunorubicin	178-190	ryanodine receptor 2	Homo sapiens	66-70
21697274-6	2011	Extensive dissection of these effects shows for the first time that the activation results from a redox-independent binding of daunorubicin to the RyR2 complex.	Daunorubicin	127-139	ryanodine receptor 2	Homo sapiens	147-151
21697274-7	2011	Novel data include the demonstration of daunorubicin binding to RyR2.	Daunorubicin	40-52	ryanodine receptor 2	Homo sapiens	64-68
21697274-10	2011	We also present novel data showing that CSQ2 modifies the response of RyR2 to daunorubicin, but that the response of RyR2 is not dependent on daunorubicin binding to CSQ2.	Daunorubicin	78-90	ryanodine receptor 2	Homo sapiens	70-74
21697274-11	2011	We suggest that binding of daunorubicin to RyR2 and CSQ2, and oxidation of RyR2, are all likely to contribute to anthracycline-induced cardiotoxicity during chemotherapy.	Daunorubicin	27-39	ryanodine receptor 2	Homo sapiens	43-47
21911919-4	2011	This study aims to analyse the role of HO-1 in regulating apoptosis in AML cells in response to two front-line chemotherapeutic agents used for AML, cytarabine and daunorubicin.	Daunorubicin	164-176	heme oxygenase 1	Homo sapiens	39-43
21911919-5	2011	Here we show that HO-1 expression in AML samples was increased in response to both cytarabine and daunorubicin treatment, and micro RNA (miRNA) silenced HO-1 expression in combination with either daunorubicin or cytarabine induced a greater apoptotic responses in AML cells.	Daunorubicin	98-110	heme oxygenase 1	Homo sapiens	18-22
21911919-7	2011	However, ROS-dependent induction of HO-1 was limiting the apoptotic response that is seen in AML towards cytarabine and daunorubicin treatment.	Daunorubicin	120-132	heme oxygenase 1	Homo sapiens	36-40
21441950-4	2011	We show here that the anthracyclines doxorubicin, daunorubicin and epirubicin further increase the amounts of mutant p53 mRNA and protein in cancer cells.	Daunorubicin	50-62	tumor protein p53	Homo sapiens	117-120
21287651-6	2011	However, the MDR1 2667A/893Thr variant interestingly showed a significant decrease of efflux activity for both digoxin and daunorubicin compared with those of 893Ala and 893Ser variants.	Daunorubicin	123-135	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
21591994-3	2011	AREAS COVERED: In vitro, Pgp-mediated transport (efflux) of amonafide from myeloblasts obtained from patients with secondary acute myeloid leukemia (sAML) was significantly less than efflux of daunorubicin.	Daunorubicin	193-205	ATP binding cassette subfamily B member 1	Homo sapiens	25-28
21641880-1	2011	A sensitive assay for direct determination of intracellular level of daunorubicin (DRN) in resistant leukemia cells with overexpressed P-glycoprotein has been developed.	Daunorubicin	69-81	ATP binding cassette subfamily B member 1	Homo sapiens	135-149
21641880-1	2011	A sensitive assay for direct determination of intracellular level of daunorubicin (DRN) in resistant leukemia cells with overexpressed P-glycoprotein has been developed.	Daunorubicin	83-86	ATP binding cassette subfamily B member 1	Homo sapiens	135-149
21622622-6	2011	To further determine the biological importance of this mechanism, we employed RNA oligonucleotides to redirect caspase 9 pre-mRNA splicing in favor of caspase 9b expression, which resulted in an increase in the IC(50) of non-small cell lung cancer (NSCLC) cells to daunorubicin, cisplatinum, and paclitaxel.	Daunorubicin	265-277	caspase 9	Homo sapiens	111-120
21622622-6	2011	To further determine the biological importance of this mechanism, we employed RNA oligonucleotides to redirect caspase 9 pre-mRNA splicing in favor of caspase 9b expression, which resulted in an increase in the IC(50) of non-small cell lung cancer (NSCLC) cells to daunorubicin, cisplatinum, and paclitaxel.	Daunorubicin	265-277	caspase 9	Homo sapiens	151-160
21622622-8	2011	Finally, these studies showed that caspase 9 RNA splicing was a major mechanism for the synergistic effects of combination therapy with daunorubicin and erlotinib.	Daunorubicin	136-148	caspase 9	Homo sapiens	35-44
21679421-6	2011	RESULTS: In this study we report the creation of the cell line OCI-AML3DNR, which over-expresses Pgp but not BCRP or multidrug resistance-associated protein (MRP), through prolonged treatment of OCI-AML3 cells with daunorubicin.	Daunorubicin	215-227	ATP binding cassette subfamily B member 1	Homo sapiens	97-100
21464611-0	2011	Doxorubicin and daunorubicin induce processing and release of interleukin-1beta through activation of the NLRP3 inflammasome.	Daunorubicin	16-28	interleukin 1 beta	Mus musculus	62-79
21464611-0	2011	Doxorubicin and daunorubicin induce processing and release of interleukin-1beta through activation of the NLRP3 inflammasome.	Daunorubicin	16-28	NLR family, pyrin domain containing 3	Mus musculus	106-111
21464611-9	2011	Furthermore, doxorubicin and daunorubicin induced the processing and release of IL-1beta from LPS-primed BMDM by providing danger signals that lead to assembly and activation of the inflammasome.	Daunorubicin	29-41	interleukin 1 beta	Mus musculus	80-88
21464611-10	2011	The release of IL-1beta required the expression of ASC, caspase-1, and NLRP3, demonstrating that doxorubicin and daunorubicin-induced inflammation is mediated by the NLRP3 inflammasome.	Daunorubicin	113-125	interleukin 1 beta	Mus musculus	15-23
21464611-10	2011	The release of IL-1beta required the expression of ASC, caspase-1, and NLRP3, demonstrating that doxorubicin and daunorubicin-induced inflammation is mediated by the NLRP3 inflammasome.	Daunorubicin	113-125	steroid sulfatase	Mus musculus	51-54
21464611-10	2011	The release of IL-1beta required the expression of ASC, caspase-1, and NLRP3, demonstrating that doxorubicin and daunorubicin-induced inflammation is mediated by the NLRP3 inflammasome.	Daunorubicin	113-125	caspase 1	Mus musculus	56-65
21464611-10	2011	The release of IL-1beta required the expression of ASC, caspase-1, and NLRP3, demonstrating that doxorubicin and daunorubicin-induced inflammation is mediated by the NLRP3 inflammasome.	Daunorubicin	113-125	NLR family, pyrin domain containing 3	Mus musculus	71-76
21464611-10	2011	The release of IL-1beta required the expression of ASC, caspase-1, and NLRP3, demonstrating that doxorubicin and daunorubicin-induced inflammation is mediated by the NLRP3 inflammasome.	Daunorubicin	113-125	NLR family, pyrin domain containing 3	Mus musculus	166-171
21520400-5	2011	It is demonstrated that ImageStream assessment of receptor-mediated (TNFalpha) and drug (Daunorubicin, DNR)-induced NF-kappaB translocation in leukemic cell lines correlates well with microscopy analysis and Western blot analysis.	Daunorubicin	89-101	nuclear factor kappa B subunit 1	Homo sapiens	116-125
21729547-0	2011	[Effect of different concentrations of bortezomib on the expression of ERK, JNK and P38 in daunorubicin-resistant K562 cells].	Daunorubicin	91-103	mitogen-activated protein kinase 1	Homo sapiens	71-74
21729547-0	2011	[Effect of different concentrations of bortezomib on the expression of ERK, JNK and P38 in daunorubicin-resistant K562 cells].	Daunorubicin	91-103	mitogen-activated protein kinase 8	Homo sapiens	76-79
21729547-0	2011	[Effect of different concentrations of bortezomib on the expression of ERK, JNK and P38 in daunorubicin-resistant K562 cells].	Daunorubicin	91-103	mitogen-activated protein kinase 14	Homo sapiens	84-87
21729547-1	2011	The aim of this study was to investigate the effect of proteasome inhibitor bortezomib on the expression of ERK, JNK, and P38 in daunorubicin (DNR)-resistant K562 cells and its mechanism.	Daunorubicin	129-141	mitogen-activated protein kinase 1	Homo sapiens	108-111
21729547-1	2011	The aim of this study was to investigate the effect of proteasome inhibitor bortezomib on the expression of ERK, JNK, and P38 in daunorubicin (DNR)-resistant K562 cells and its mechanism.	Daunorubicin	129-141	mitogen-activated protein kinase 8	Homo sapiens	113-116
21729547-1	2011	The aim of this study was to investigate the effect of proteasome inhibitor bortezomib on the expression of ERK, JNK, and P38 in daunorubicin (DNR)-resistant K562 cells and its mechanism.	Daunorubicin	129-141	mitogen-activated protein kinase 14	Homo sapiens	122-125
21595920-0	2011	Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.	Daunorubicin	62-74	BCL2 apoptosis regulator	Homo sapiens	31-36
21595920-2	2011	CD34+ AML cells are 10-15-fold more resistant to daunorubicin (DNR) than CD34- AML cells.	Daunorubicin	49-61	CD34 molecule	Homo sapiens	0-4
21242186-7	2011	Resistance to vincristine and daunorubicin was characterized by an approximately 20-fold up-regulation of miR-125b, miR-99a and miR-100 (P(FDR)&lt;=0.002).	Daunorubicin	30-42	microRNA 99a	Homo sapiens	116-123
21242186-7	2011	Resistance to vincristine and daunorubicin was characterized by an approximately 20-fold up-regulation of miR-125b, miR-99a and miR-100 (P(FDR)&lt;=0.002).	Daunorubicin	30-42	microRNA 100	Homo sapiens	128-135
21432770-6	2011	Immunohistochemical analysis showed ICAM-1 staining in many aortas from both saline and daunorubicin-treated rabbits without any relationship to the anthracycline treatment.	Daunorubicin	88-100	ICAM-1	Oryctolagus cuniculus	36-42
24800340-0	2011	Effect of doxorubicin and daunorubicin on the activity of acetylcholinesterase in acute lymphoblastic leukamia.	Daunorubicin	26-38	acetylcholinesterase (Cartwright blood group)	Homo sapiens	58-78
21336027-6	2011	Although, daunorubicin and doxorubicin also inhibited the DNA helicase activity of pea MCM6, but with less efficiency; however, these could not inhibit the ATPase activity.	Daunorubicin	10-22	minichromosome maintenance complex component 6	Homo sapiens	87-91
21062083-5	2011	Mitosomal daunorubicin plus amlodipine were about 97 nm, selectively accumulated in mitochondria, induced the swelling and disruption of mitochondria, dissipated the mitochondrial membrane potential, released a large amount of cytochrome C by translocation, cleaved Bid, and initiated a cascade of caspase 8 and 3 reactions.	Daunorubicin	10-22	cytochrome c, somatic	Homo sapiens	227-239
21062083-5	2011	Mitosomal daunorubicin plus amlodipine were about 97 nm, selectively accumulated in mitochondria, induced the swelling and disruption of mitochondria, dissipated the mitochondrial membrane potential, released a large amount of cytochrome C by translocation, cleaved Bid, and initiated a cascade of caspase 8 and 3 reactions.	Daunorubicin	10-22	BH3 interacting domain death agonist	Homo sapiens	266-269
21062083-5	2011	Mitosomal daunorubicin plus amlodipine were about 97 nm, selectively accumulated in mitochondria, induced the swelling and disruption of mitochondria, dissipated the mitochondrial membrane potential, released a large amount of cytochrome C by translocation, cleaved Bid, and initiated a cascade of caspase 8 and 3 reactions.	Daunorubicin	10-22	caspase 8	Homo sapiens	298-307
21128658-3	2011	In this study, HAV6 peptide derived from the EC1 domain of E-cadherin was found to enhance the permeation of 14C-mannitol and [3H(G)]-daunomycin through the blood-brain barrier of the in situ rat brain perfusion model.	Daunorubicin	134-144	cadherin 1	Rattus norvegicus	59-69
21187093-0	2011	Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line.	Daunorubicin	39-51	microRNA 21	Homo sapiens	15-21
21187093-0	2011	Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line.	Daunorubicin	39-51	phosphatase and tensin homolog	Homo sapiens	66-70
21187093-2	2011	In this study, we investigated whether miR-21 mediated resistance of the leukaemia cell line K562 to the chemotherapeutic agent daunorubicin (DNR).	Daunorubicin	128-140	microRNA 21	Homo sapiens	39-45
21445777-10	2011	Extracellular acidosis in vivo decreased caspase 3-activity after daunorubicin treatment by 30%indicating a reduced chemosensitivity.	Daunorubicin	66-78	caspase 3	Rattus norvegicus	41-50
21052994-10	2011	Three days of daunorubicin treatment resulted in enhanced antigen expression by tumor cells, in turn inducing co-cultured antigen-specific T cells to secrete Interleukin-2 and Interferon-gamma.	Daunorubicin	14-26	interleukin 2	Homo sapiens	158-171
21052994-10	2011	Three days of daunorubicin treatment resulted in enhanced antigen expression by tumor cells, in turn inducing co-cultured antigen-specific T cells to secrete Interleukin-2 and Interferon-gamma.	Daunorubicin	14-26	interferon gamma	Homo sapiens	176-192
21269564-1	2011	In this study, we applied D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) hydrochloride as a chemical inhibitor for glucosylceramide synthase (GCS) and tetrandrine (Tet) for P-glycoprotein (P-gp) to reverse daunorubicin (DNR) resistance of human leukemia cell line K562/A02.	Daunorubicin	226-238	UDP-glucose ceramide glucosyltransferase	Homo sapiens	135-160
20209493-8	2011	Attenuation of endogenous Rab4 levels in K562ADR by RNA interference enhanced the expression of P-gp in the cell surface, and reduced the uptake of DNM.	Daunorubicin	148-151	RAB4A, member RAS oncogene family	Homo sapiens	26-30
21968975-6	2011	Interestingly, depleting intracellular GSH contents can hyper-sensitize the MRP1-cDNA transfected BHK cells to daunomycin, but not the adriamycin-selected H69AR cells.	Daunorubicin	111-121	ATP binding cassette subfamily C member 1	Homo sapiens	76-80
21968975-8	2011	We hypothesized that knocking down the expression of Bcl2 could hyper-sensitize H69AR cells to daunomycin.	Daunorubicin	95-105	BCL2 apoptosis regulator	Homo sapiens	53-57
21968975-9	2011	Interestingly, infection of H69AR cells with retroviral particles harboring Bcl2 interfering RNAi not only reduced the expression of Bcl2, but also many factors that contribute to MDR, such as Bcl-xl, MRP1 and ABCC3, etc., leading to the MDR H69AR cells more sensitive to daunomycin than the parental H69 cell.	Daunorubicin	272-282	BCL2 apoptosis regulator	Homo sapiens	76-80
21282968-1	2011	BACKGROUND: To circumvent the problem of transporting anticancer drugs across the blood-brain barrier (BBB) to target brain tumors, we have previously developed dual-targeting daunorubicin liposomes modified with 4-aminophenyl-alpha-D-manno-pyranoside and transferrin molecules.	Daunorubicin	176-188	transferrin	Mus musculus	256-267
22110660-10	2011	Increased basal apoptosis and sensitivities to ara-C, daunorubicin, and VP-16 accompanied by down-regulated Bcl-2 were also detected in the CMK GATA1 shRNA knockdown clones.	Daunorubicin	54-66	cytidine/uridine monophosphate kinase 1	Homo sapiens	140-143
22110660-10	2011	Increased basal apoptosis and sensitivities to ara-C, daunorubicin, and VP-16 accompanied by down-regulated Bcl-2 were also detected in the CMK GATA1 shRNA knockdown clones.	Daunorubicin	54-66	GATA binding protein 1	Homo sapiens	144-149
20670211-13	2010	Our results support that CR1 is the most important enzyme for conversion of DNR to DOL in AML cells.	Daunorubicin	76-79	carbonyl reductase 1	Homo sapiens	25-28
20729274-8	2010	CBR1 activity for daunorubicin was 1.7-fold higher in DS samples than in non-DS samples (3.8 +- 0.1 versus 2.3 +- 0.2 nmol daunol/min   mg, respectively; p = 0.050).	Daunorubicin	18-30	carbonyl reductase 1	Homo sapiens	0-4
20837989-8	2010	These findings suggest that ns-SNPs in human AKR1C3, AKR1C4, and AKR7A2 significantly decrease the in vitro metabolism of DOX and DAUN.	Daunorubicin	130-134	aldo-keto reductase family 1 member C3	Homo sapiens	45-51
20837989-8	2010	These findings suggest that ns-SNPs in human AKR1C3, AKR1C4, and AKR7A2 significantly decrease the in vitro metabolism of DOX and DAUN.	Daunorubicin	130-134	aldo-keto reductase family 1 member C4	Homo sapiens	53-59
20837989-8	2010	These findings suggest that ns-SNPs in human AKR1C3, AKR1C4, and AKR7A2 significantly decrease the in vitro metabolism of DOX and DAUN.	Daunorubicin	130-134	aldo-keto reductase family 7 member A2	Homo sapiens	65-71
20427086-0	2010	A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.	Daunorubicin	72-84	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	89-94
21176351-1	2010	The study was aimed to investigate the effects of bortezomib (BTZ) on the expression of ERK, JNK and P38 in daunorubicin (DNR)-resistant K562 cells (K562/DNR) and to clarify the molecular mechanism of BTZ in reversing the drug-resistance in leukemic cells.	Daunorubicin	108-120	mitogen-activated protein kinase 1	Homo sapiens	88-91
21176351-1	2010	The study was aimed to investigate the effects of bortezomib (BTZ) on the expression of ERK, JNK and P38 in daunorubicin (DNR)-resistant K562 cells (K562/DNR) and to clarify the molecular mechanism of BTZ in reversing the drug-resistance in leukemic cells.	Daunorubicin	108-120	mitogen-activated protein kinase 8	Homo sapiens	93-96
21176351-1	2010	The study was aimed to investigate the effects of bortezomib (BTZ) on the expression of ERK, JNK and P38 in daunorubicin (DNR)-resistant K562 cells (K562/DNR) and to clarify the molecular mechanism of BTZ in reversing the drug-resistance in leukemic cells.	Daunorubicin	108-120	mitogen-activated protein kinase 14	Homo sapiens	101-104
21176352-8	2010	The cell growth inhibition rate in 50 nmol/L and 100 nmol/L rapamycin plus daunorubicin (DNR) group was more than that in DNR alone group (p &lt; 0.05), especially when DNR was added at 24 hours interval after RAP.	Daunorubicin	75-87	LDL receptor related protein associated protein 1	Homo sapiens	210-213
21223737-0	2010	[Influence of arsenic trioxide and daunorubicin on the expression of annexin II and fibrinolytic activity in NB4 cells].	Daunorubicin	35-47	annexin A2	Homo sapiens	69-79
21223737-1	2010	OBJECTIVE: To study the expression of annexin II (AnnII) and the fibrinolytic activity in NB4 cells and their alterations in the presence of arsenic trioxide (ATO) and daunorubicin (DNR).	Daunorubicin	168-180	annexin A2	Homo sapiens	50-55
21223737-1	2010	OBJECTIVE: To study the expression of annexin II (AnnII) and the fibrinolytic activity in NB4 cells and their alterations in the presence of arsenic trioxide (ATO) and daunorubicin (DNR).	Daunorubicin	182-185	annexin A2	Homo sapiens	38-48
21223737-2	2010	METHODS: Leukemia cell line NB4 was treated with ATO or DNR for 24 ~ 72 h. Cell surface expression of AnnII and its mRNA were analysed by flow cytometry and real time PCR, respectively, the fibrinolytic activity by chromogenic assay.	Daunorubicin	56-59	annexin A2	Homo sapiens	102-107
21187919-8	2010	Furthermore, the combination of MNP-Fe3O4 with adriamycin or daunorubicin increased p53 protein levels and decreased NF-kappaB protein levels more than adriamycin or daunorubicin alone, indicating that MNP-Fe3O4 could enhance the effect of chemotherapeutic drugs on p53 and NF-kappaB.	Daunorubicin	61-73	tumor protein p53	Homo sapiens	84-87
21187919-8	2010	Furthermore, the combination of MNP-Fe3O4 with adriamycin or daunorubicin increased p53 protein levels and decreased NF-kappaB protein levels more than adriamycin or daunorubicin alone, indicating that MNP-Fe3O4 could enhance the effect of chemotherapeutic drugs on p53 and NF-kappaB.	Daunorubicin	61-73	nuclear factor kappa B subunit 1	Homo sapiens	117-126
21187919-8	2010	Furthermore, the combination of MNP-Fe3O4 with adriamycin or daunorubicin increased p53 protein levels and decreased NF-kappaB protein levels more than adriamycin or daunorubicin alone, indicating that MNP-Fe3O4 could enhance the effect of chemotherapeutic drugs on p53 and NF-kappaB.	Daunorubicin	61-73	tumor protein p53	Homo sapiens	266-269
21187919-8	2010	Furthermore, the combination of MNP-Fe3O4 with adriamycin or daunorubicin increased p53 protein levels and decreased NF-kappaB protein levels more than adriamycin or daunorubicin alone, indicating that MNP-Fe3O4 could enhance the effect of chemotherapeutic drugs on p53 and NF-kappaB.	Daunorubicin	61-73	nuclear factor kappa B subunit 1	Homo sapiens	274-283
20705604-6	2010	Nonporphyrin substrates of ABCG2, such as mitoxantrone, doxo/daunorubicin, and riboflavin, do not bind to ECL3.	Daunorubicin	61-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	27-32
21036735-5	2010	Exposure to either DNR or Ara-C resulted in modest increases in CRIM1 levels in HL60R0.5.	Daunorubicin	19-22	cysteine rich transmembrane BMP regulator 1	Homo sapiens	64-69
19967559-1	2010	Breast cancer resistance protein (BCRP/ABCG2), an ATP-binding cassette half transporter, confers multidrug resistance (MDR) to a series of antitumor agents such as mitoxantrone, daunorubicin, SN-38, and topotecan, and often limits the efficacy of chemotherapy.	Daunorubicin	178-190	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-32
19967559-1	2010	Breast cancer resistance protein (BCRP/ABCG2), an ATP-binding cassette half transporter, confers multidrug resistance (MDR) to a series of antitumor agents such as mitoxantrone, daunorubicin, SN-38, and topotecan, and often limits the efficacy of chemotherapy.	Daunorubicin	178-190	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	34-38
19967559-1	2010	Breast cancer resistance protein (BCRP/ABCG2), an ATP-binding cassette half transporter, confers multidrug resistance (MDR) to a series of antitumor agents such as mitoxantrone, daunorubicin, SN-38, and topotecan, and often limits the efficacy of chemotherapy.	Daunorubicin	178-190	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	39-44
20608983-3	2010	Here, we report that loss of the type 2A-related serine/threonine protein phosphatase Sit4p renders yeast cells sensitive to cycloheximide, azoles, daunorubicin and rhodamine 6G.	Daunorubicin	148-160	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	86-91
21302442-8	2010	Compared with control group and single drug (DNR or Bor) group, there were obvious increase of apoptosis ratio and obvious decrease of Bcl-2 in the group of DNR 100 nmol/L combined with Bor 20 nmol/L after 24 h or 48 h cultivation (P &lt; 0.05).	Daunorubicin	45-48	BCL2 apoptosis regulator	Homo sapiens	135-140
21302442-8	2010	Compared with control group and single drug (DNR or Bor) group, there were obvious increase of apoptosis ratio and obvious decrease of Bcl-2 in the group of DNR 100 nmol/L combined with Bor 20 nmol/L after 24 h or 48 h cultivation (P &lt; 0.05).	Daunorubicin	157-160	BCL2 apoptosis regulator	Homo sapiens	135-140
21122325-0	2010	[NT-pro-BNP in the evaluation of daunorubicin-indued cardiotoxicity in acute childhood leukemia].	Daunorubicin	33-45	natriuretic peptide B	Homo sapiens	8-11
21122325-1	2010	OBJECTIVE: To evaluate the sensitivity of NT-pro-BNP in daunorubicin (DNR) induced myocardial damage by monitoring the level of NT-pro-BNP and myocardial enzymes (CK, CKMB) before and after DNR treatment in childhood acute leukemia (AL) and performing control study.	Daunorubicin	56-68	natriuretic peptide B	Homo sapiens	49-52
21122325-1	2010	OBJECTIVE: To evaluate the sensitivity of NT-pro-BNP in daunorubicin (DNR) induced myocardial damage by monitoring the level of NT-pro-BNP and myocardial enzymes (CK, CKMB) before and after DNR treatment in childhood acute leukemia (AL) and performing control study.	Daunorubicin	70-73	natriuretic peptide B	Homo sapiens	49-52
20683966-1	2010	UNLABELLED: Human carbonyl reductase 1 (CBR1) converts the antitumor drug and anthracycline daunorubicin (DNR) into the alcohol metabolite daunorubicinol (DNROL) with significantly reduced antitumor activity and cardiotoxicity, and this limits the clinical use of DNR.	Daunorubicin	106-109	carbonyl reductase 1	Homo sapiens	18-38
20683966-1	2010	UNLABELLED: Human carbonyl reductase 1 (CBR1) converts the antitumor drug and anthracycline daunorubicin (DNR) into the alcohol metabolite daunorubicinol (DNROL) with significantly reduced antitumor activity and cardiotoxicity, and this limits the clinical use of DNR.	Daunorubicin	106-109	carbonyl reductase 1	Homo sapiens	40-44
20642825-7	2010	The drug-excretion activity of HA117 and MDR1 were determined by daunorubicin (DNR) efflux assay.	Daunorubicin	65-77	regulator of G protein signaling 6	Homo sapiens	31-36
20642825-7	2010	The drug-excretion activity of HA117 and MDR1 were determined by daunorubicin (DNR) efflux assay.	Daunorubicin	65-77	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
20682982-2	2010	The ability of these compounds to revert MDR was evaluated on daunorubicin-resistant K562 cells, by measuring the intracellular accumulation of rhodamine 123, a fluorescent probe of Pgp transport activity.	Daunorubicin	62-74	ATP binding cassette subfamily B member 1	Homo sapiens	182-185
20557448-7	2010	Transfection of MDCK cells with sheep P-gp resulted in 10- to 50-fold resistance to the cytotoxic P-gp substrates colchicin and daunorubicin, and in reduced digoxin accumulation.	Daunorubicin	128-140	multidrug resistance protein 1	Ovis aries	38-42
20557448-7	2010	Transfection of MDCK cells with sheep P-gp resulted in 10- to 50-fold resistance to the cytotoxic P-gp substrates colchicin and daunorubicin, and in reduced digoxin accumulation.	Daunorubicin	128-140	multidrug resistance protein 1	Ovis aries	98-102
22069634-3	2010	P-glycoprotein mediates resistance to various classes of anticancer drugs including vinblastine, daunorubicin, and paclitaxel, by actively extruding the drugs from the cells.	Daunorubicin	97-109	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
20399647-3	2010	Their abilities to inhibit P-glycoprotein-mediated daunorubicin efflux in K562/R7 human leukemic cells overexpressing P-glycoprotein were evaluated versus progesterone.	Daunorubicin	51-63	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
19763573-8	2010	PSC833 (5 microM) also decreased the intracellular accumulation of fluorescent Pgp substrates such as rhodamine 123 and daunorubicin in SK-MES-1/DX1000 cells.	Daunorubicin	120-132	ATP binding cassette subfamily B member 1	Homo sapiens	79-82
19943768-3	2010	In this study, sgc8, an aptamer for protein tyrosine kinase-7 (PTK7), was used for specific delivery of daunorubicin to Molt-4 cells (PTK7(+)).	Daunorubicin	104-116	protein tyrosine kinase 7 (inactive)	Homo sapiens	36-61
19943768-3	2010	In this study, sgc8, an aptamer for protein tyrosine kinase-7 (PTK7), was used for specific delivery of daunorubicin to Molt-4 cells (PTK7(+)).	Daunorubicin	104-116	protein tyrosine kinase 7 (inactive)	Homo sapiens	63-67
19943768-3	2010	In this study, sgc8, an aptamer for protein tyrosine kinase-7 (PTK7), was used for specific delivery of daunorubicin to Molt-4 cells (PTK7(+)).	Daunorubicin	104-116	protein tyrosine kinase 7 (inactive)	Homo sapiens	134-138
19943768-4	2010	Flow cytometric experiments showed that aptamer-daunorubicin complex was internalized effectively to Molt-4 cells (PTK7(+)), but not to U266 cells (PTK7(-)).	Daunorubicin	48-60	protein tyrosine kinase 7 (inactive)	Homo sapiens	115-119
19657712-4	2010	This strongly suggests that TOP2A gene amplification is a predictive factor for anthracyline-based regimens.	Daunorubicin	80-92	DNA topoisomerase II alpha	Homo sapiens	28-33
20127688-6	2010	Knockdown of DJ-1 and MTA2, a core component of the NuRD complex, had a similar and pro-apoptotic effect on the transcriptional- and p53-dependent cell death induced by daunorubicin.	Daunorubicin	169-181	Parkinsonism associated deglycase	Homo sapiens	13-17
20127688-6	2010	Knockdown of DJ-1 and MTA2, a core component of the NuRD complex, had a similar and pro-apoptotic effect on the transcriptional- and p53-dependent cell death induced by daunorubicin.	Daunorubicin	169-181	metastasis associated 1 family member 2	Homo sapiens	22-26
20127688-6	2010	Knockdown of DJ-1 and MTA2, a core component of the NuRD complex, had a similar and pro-apoptotic effect on the transcriptional- and p53-dependent cell death induced by daunorubicin.	Daunorubicin	169-181	tumor protein p53	Homo sapiens	133-136
19914848-1	2010	We examined the effect of the anthracyclines aclarubicin, bleomycin, daunorubicin, doxorubicin and idarubicin on human gamma- and beta-globin promoter activity in an in vitro luciferase assay, ex vivo in erythroid cultures and in vivo in transgenic mice carrying the human gamma-globin gene.	Daunorubicin	69-81	hemoglobin subunit gamma 1	Homo sapiens	119-141
19914848-5	2010	Daunorubicin induced HbF in thalassaemic cells ex vivo with the highest statistical significance and, importantly and in contrast to the clinical HbF inducer hydroxyurea, showed specific induction of gamma-globin without associated induction of alpha-globin.	Daunorubicin	0-12	hemoglobin subunit gamma 1	Homo sapiens	200-212
19914848-6	2010	Daunorubicin was screened in transgenic mice carrying the human (A)gamma-globin gene, and it resulted in increased (A)gamma-globin mRNA levels.	Daunorubicin	0-12	hemoglobin subunit gamma 1	Homo sapiens	64-79
19914848-6	2010	Daunorubicin was screened in transgenic mice carrying the human (A)gamma-globin gene, and it resulted in increased (A)gamma-globin mRNA levels.	Daunorubicin	0-12	hemoglobin subunit gamma 1	Homo sapiens	65-79
20007405-11	2010	These findings suggest that commonly occurring ns-SNPs in human CBR3 significantly alter the in vitro metabolism of DOX and DAUN.	Daunorubicin	124-128	carbonyl reductase 3	Homo sapiens	64-68
20335952-5	2010	The study aimed at determination if Q sensitizes cells resistant to daunorubicin (DB) through its effect on P-gp expression and action.	Daunorubicin	82-84	ATP binding cassette subfamily B member 1	Homo sapiens	108-112
19799948-2	2010	For overcoming these hurdles, the dual-targeting daunorubicin liposomes were developed by conjugating with p-aminophenyl-alpha-D-manno-pyranoside (MAN) and transferrin (TF) for transporting drug across the BBB and then targeting brain glioma.	Daunorubicin	49-61	transferrin	Homo sapiens	156-167
19799948-2	2010	For overcoming these hurdles, the dual-targeting daunorubicin liposomes were developed by conjugating with p-aminophenyl-alpha-D-manno-pyranoside (MAN) and transferrin (TF) for transporting drug across the BBB and then targeting brain glioma.	Daunorubicin	49-61	transferrin	Homo sapiens	169-171
20150614-5	2010	Treatment of the cells with disulfide-linked ODN liposomes resulted in efficient Bcl-2 down-regulation greater than that with hydrophobized disulfide-linked ODN and consistent with that of cellular growth inhibition and the sensitization to daunorubicin in KB cells.	Daunorubicin	241-253	BCL2 apoptosis regulator	Homo sapiens	81-86
21133625-8	2010	The association of CC genotype with clinical variables in ALL indicated that the CC genotype with high expression might be eliminating antileukemic drugs (anthracyclines, Daunorubicin, Vincristeine, Mitoxanthrone) which are P-gp substrates, leading to lower intra cellular drug concentrations and a poor prognosis.	Daunorubicin	171-183	phosphoglycolate phosphatase	Homo sapiens	224-228
20185911-9	2010	The P-gp pump function, measured by daunorubicin exclusion, was also reduced by DFO treatment.	Daunorubicin	36-48	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
19786507-12	2010	Extrapolating these results to other Abcg2 substrates (e.g., daunorubicin and doxorubicin) indicates that the brain uptake of these agents may be affected if they are administered concomitantly with oxycodone.	Daunorubicin	61-73	ATP binding cassette subfamily G member 2	Rattus norvegicus	37-42
19499569-3	2010	Morin, phloretin, biochanin A, chalcone, and silymarin significantly increased DNM accumulation by greater than 2.5-fold, suggesting they are P-gp inhibitors.	Daunorubicin	79-82	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	142-146
20001229-6	2010	DMPH decreased the phosphorylation of ERK and inhibited daunorubicin-induced ERK activation.	Daunorubicin	56-68	mitogen-activated protein kinase 1	Homo sapiens	77-80
20024113-5	2009	Six compounds from these series (, , , , and ) showed an effectiveness that was similar to (or higher than) the classical Pgp reversal agent verapamil for the reversal of resistance to daunomycin and vinblastine.	Daunorubicin	185-195	ATP binding cassette subfamily B member 1	Homo sapiens	122-125
20019844-8	2009	Remarkably, mimicking cytotoxic bolus drug treatment through 12- to 24-hour pulse exposure of ABCG2-silenced leukemia cells, to clinically relevant concentrations of the chemotherapeutic agents daunorubicin and mitoxantrone, resulted in a marked transcriptional up-regulation of ABCG2.	Daunorubicin	194-206	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	94-99
19698806-0	2009	Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin.	Daunorubicin	149-161	sphingomyelin phosphodiesterase 3	Homo sapiens	30-56
19698806-4	2009	Here, we analyzed the mechanism of NSMase2 gene expression by the anti-cancer drug, daunorubicin (DA).	Daunorubicin	84-96	sphingomyelin phosphodiesterase 3	Homo sapiens	35-42
19698806-4	2009	Here, we analyzed the mechanism of NSMase2 gene expression by the anti-cancer drug, daunorubicin (DA).	Daunorubicin	98-100	sphingomyelin phosphodiesterase 3	Homo sapiens	35-42
19777523-5	2009	Most of them were able to stimulate P-gp-mediated efflux of daunorubicin and rhodamine 123 in a concentration-dependent manner, but some compounds also displayed weak inhibitory effects.	Daunorubicin	60-72	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
19725919-5	2009	Chemotherapeutic drugs that intercalate into DNA and inhibit topoisomerase II such as Doxorubicin, Daunorubicin and Mitoxantrone stimulate NF-kappaB DNA binding and transcriptional activity prior to induction of cell death.	Daunorubicin	99-111	nuclear factor kappa B subunit 1	Homo sapiens	139-148
19725919-6	2009	Importantly, specific inhibition of drug-induced NF-kappaB activation by IkappaBalpha-SR or RNA interference against p65 significantly reduces apoptosis upon treatment with Doxorubicin, Daunorubicin or Mitoxantrone.	Daunorubicin	186-198	nuclear factor kappa B subunit 1	Homo sapiens	49-58
19725919-6	2009	Importantly, specific inhibition of drug-induced NF-kappaB activation by IkappaBalpha-SR or RNA interference against p65 significantly reduces apoptosis upon treatment with Doxorubicin, Daunorubicin or Mitoxantrone.	Daunorubicin	186-198	NFKB inhibitor alpha	Homo sapiens	73-85
19725919-6	2009	Importantly, specific inhibition of drug-induced NF-kappaB activation by IkappaBalpha-SR or RNA interference against p65 significantly reduces apoptosis upon treatment with Doxorubicin, Daunorubicin or Mitoxantrone.	Daunorubicin	186-198	RELA proto-oncogene, NF-kB subunit	Homo sapiens	117-120
19840446-0	2009	[Effect of tetrandrine combined with daunorubicin on expressions of P21 and P-gp in K562/A02 cells].	Daunorubicin	37-49	H3 histone pseudogene 16	Homo sapiens	68-71
19840446-0	2009	[Effect of tetrandrine combined with daunorubicin on expressions of P21 and P-gp in K562/A02 cells].	Daunorubicin	37-49	phosphoglycolate phosphatase	Homo sapiens	76-80
19639341-8	2009	Staining for activated caspase-3 has demonstrated immunopositive cells following DM administration both in the matrix and in the outer root sheath.	Daunorubicin	81-83	caspase 3	Rattus norvegicus	23-32
19299014-0	2009	siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53.	Daunorubicin	84-96	protein phosphatase 1 regulatory subunit 13 like	Homo sapiens	34-39
19625780-0	2009	The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.	Daunorubicin	113-125	fms related receptor tyrosine kinase 3	Homo sapiens	4-8
19657382-9	2009	From the approximately 37K drug-drug relationships, we discover relationships that aid in target and pathway deconvolution, such as 1) KCNMA1 as a potential molecular target of lobeline, and 2) both apoptotic DNA fragmentation and G2/M DNA damage checkpoint regulation as potential pathway targets of daunorubicin.	Daunorubicin	301-313	activation induced cytidine deaminase	Homo sapiens	83-86
19657382-9	2009	From the approximately 37K drug-drug relationships, we discover relationships that aid in target and pathway deconvolution, such as 1) KCNMA1 as a potential molecular target of lobeline, and 2) both apoptotic DNA fragmentation and G2/M DNA damage checkpoint regulation as potential pathway targets of daunorubicin.	Daunorubicin	301-313	potassium calcium-activated channel subfamily M alpha 1	Homo sapiens	135-141
19657571-8	2009	HL-60/A cells showed multi-drug resistance phenotype characteristic by cross-resistance to adriamycin, daunorubicin, and arabinosylcytosine, due to the expression of MRP.	Daunorubicin	103-115	ATP binding cassette subfamily C member 3	Homo sapiens	166-169
19657571-11	2009	Compared with the MRP expression level in the control group (nucleofected by control siRNA), the mRNA and protein expression levels of MRP in HL-60/A cells nucleofected by SKP2 siRNA were lower, and the latter cells were more sensitive to adriamycin, daunorubicin, and arabinosylcytosine.	Daunorubicin	251-263	ATP binding cassette subfamily C member 3	Homo sapiens	135-138
19657571-11	2009	Compared with the MRP expression level in the control group (nucleofected by control siRNA), the mRNA and protein expression levels of MRP in HL-60/A cells nucleofected by SKP2 siRNA were lower, and the latter cells were more sensitive to adriamycin, daunorubicin, and arabinosylcytosine.	Daunorubicin	251-263	S-phase kinase associated protein 2	Homo sapiens	172-176
19108889-2	2009	In preliminary experiments, blockade of P-gp for at least 12 h was required to reverse daunorubicin resistance.	Daunorubicin	87-99	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
18440836-5	2009	Cells were incubated with daunorubicin (a fluorescent drug extruded by P-gp) at 37 degrees C and 4 degrees C for 30 min.	Daunorubicin	26-38	ATP binding cassette subfamily B member 1	Homo sapiens	71-75
18440836-13	2009	CONCLUSIONS: Percentage of cells extruding daunorubicin in RCCC is elevated, indicating that P-gp activity may contribute to multidrug resistance in RCCC.	Daunorubicin	43-55	ATP binding cassette subfamily B member 1	Homo sapiens	93-97
19411853-4	2009	We have measured DDR as reported by activation of ATM through its phosphorylation on Ser 1981 (ATM-S1981(P)) concurrent with histone H2AX phosphorylation on Ser139 (gammaH2AX) in leukemic blast cells from the blood of twenty patients, 16 children/adolescents and 4 adults, diagnosed with acute leukemias and treated with topo2 inhibitors doxorubicin, daunomycin, mitoxantrone or idarubicin.	Daunorubicin	351-361	ATM serine/threonine kinase	Homo sapiens	50-53
19411853-4	2009	We have measured DDR as reported by activation of ATM through its phosphorylation on Ser 1981 (ATM-S1981(P)) concurrent with histone H2AX phosphorylation on Ser139 (gammaH2AX) in leukemic blast cells from the blood of twenty patients, 16 children/adolescents and 4 adults, diagnosed with acute leukemias and treated with topo2 inhibitors doxorubicin, daunomycin, mitoxantrone or idarubicin.	Daunorubicin	351-361	ATM serine/threonine kinase	Homo sapiens	95-98
19278995-0	2009	Mapping daunorubicin-binding Sites in the ATP-binding cassette transporter MsbA using site-specific quenching by spin labels.	Daunorubicin	8-20	ATP binding cassette subfamily A member 4	Homo sapiens	42-74
19435509-10	2009	There were no significant changes in K562/Ad-HA117 cells growth, while the drug sensitivities of K562/Ad-HA117 cells to Vincristine, Adriamycin, Etoposide, Daunorubicin, Mitomycin and Cyclophosphamide decreased 4.44, 7.18, 3.01, 9.53, 3.48 and 3.61 times than that of uninfected K562 cells, respectively (P &lt; 0.05).	Daunorubicin	156-168	regulator of G protein signaling 6	Homo sapiens	105-110
19442055-4	2009	Natural product, daunorubicin a toxic analogue of anthracycline is reduced to less toxic daunorubicinol by the AKR1B10, enzyme, which is overexpressed in most cases of smoking associate squamous cell carcinoma (SCC) and adenocarcinoma.	Daunorubicin	17-29	aldo-keto reductase family 1 member B10	Homo sapiens	111-118
19442055-4	2009	Natural product, daunorubicin a toxic analogue of anthracycline is reduced to less toxic daunorubicinol by the AKR1B10, enzyme, which is overexpressed in most cases of smoking associate squamous cell carcinoma (SCC) and adenocarcinoma.	Daunorubicin	17-29	serpin family B member 3	Homo sapiens	211-214
19442055-7	2009	This article presents the mechanism of daunorubicin action and a method to improve the effectiveness of daunorubicin by modulating the activity of AKR1B10.	Daunorubicin	39-51	aldo-keto reductase family 1 member B10	Homo sapiens	147-154
19442055-7	2009	This article presents the mechanism of daunorubicin action and a method to improve the effectiveness of daunorubicin by modulating the activity of AKR1B10.	Daunorubicin	104-116	aldo-keto reductase family 1 member B10	Homo sapiens	147-154
19204081-0	2009	Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.	Daunorubicin	123-135	carbonyl reductase 1	Homo sapiens	59-79
19028477-7	2009	The anticancer drug daunorubicin, which is currently used in the clinical treatment of various forms of cancer, is converted by AKR1B10 to daunorubicinol with a K(m) and k(cat) of 1.1+/-0.18 mM and 1.4+/-0.16 min(-1), respectively.	Daunorubicin	20-32	aldo-keto reductase family 1 member B10	Homo sapiens	128-135
19028477-8	2009	This carbonyl reducing activity of AKR1B10 decreases the anticancer effectiveness of daunorubicin.	Daunorubicin	85-97	aldo-keto reductase family 1 member B10	Homo sapiens	35-42
19214144-7	2009	None of these mutations had any effect on MRP1/ABCC1 expression and trafficking, but that Arg723Gln mutation significantly reduced MRP1/ABCC1-mediated resistance to daunorubicin, doxorubicin, etoposide, vinblastine, and vincristine.	Daunorubicin	165-177	ATP binding cassette subfamily C member 1	Homo sapiens	131-135
19214144-7	2009	None of these mutations had any effect on MRP1/ABCC1 expression and trafficking, but that Arg723Gln mutation significantly reduced MRP1/ABCC1-mediated resistance to daunorubicin, doxorubicin, etoposide, vinblastine, and vincristine.	Daunorubicin	165-177	multidrug resistance-associated protein 1	Cricetulus griseus	136-141
19282659-8	2009	By using this screening system, daunorubicin, doxorubicin and cytochalasin D, which enhanced the green fluorescent, were selected and then were confirmed to actually increase the expression of Melan-A/MART-1 mRNA and protein in human melanoma cells of MU89, MM96L(+) and SK-MEL-28, but also in low-antigen presenting cells such as MM96L(-), MUX, and A375.	Daunorubicin	32-44	melan-A	Homo sapiens	193-200
19282659-8	2009	By using this screening system, daunorubicin, doxorubicin and cytochalasin D, which enhanced the green fluorescent, were selected and then were confirmed to actually increase the expression of Melan-A/MART-1 mRNA and protein in human melanoma cells of MU89, MM96L(+) and SK-MEL-28, but also in low-antigen presenting cells such as MM96L(-), MUX, and A375.	Daunorubicin	32-44	melan-A	Homo sapiens	201-207
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Daunorubicin	321-331	colony stimulating factor 3	Homo sapiens	83-120
19138562-12	2009	Compared with other precursor B-ALL cells, BCR-ABL1-like cells were 73 times more resistant to L-asparaginase (p=0.001) and 1.6 times more resistant to daunorubicin (p=0.017), but toxicity of prednisolone and vincristine did not differ.	Daunorubicin	152-164	BCR activator of RhoGEF and GTPase	Homo sapiens	43-51
19118001-7	2009	In this drug-sensitive cellular background, MRP7 conferred high levels of resistance to docetaxel (46-fold), paclitaxel (116-fold), SN-38 (65-fold), daunorubicin (7.5-fold), etoposide (11-fold), and vincristine (56-fold).	Daunorubicin	149-161	ATP binding cassette subfamily C member 10	Homo sapiens	44-48
18924151-4	2009	Two new drug-resistant cell lines were generated following exposure to doxorubicin or daunorubicin and these upregulated MRP1 or P-glycoprotein expression, respectively.	Daunorubicin	86-98	ATP binding cassette subfamily C member 1	Homo sapiens	121-125
18924151-4	2009	Two new drug-resistant cell lines were generated following exposure to doxorubicin or daunorubicin and these upregulated MRP1 or P-glycoprotein expression, respectively.	Daunorubicin	86-98	ATP binding cassette subfamily B member 1	Homo sapiens	129-143
18674816-4	2009	Transient expression of pig7 in leukemic cells exhibited no evident effect on cell proliferation and differentiation, but could intensify inhibitory efficacy of etoposide (VP16) and daunorubicin (DNR).	Daunorubicin	182-194	lipopolysaccharide induced TNF factor	Homo sapiens	24-28
18674816-4	2009	Transient expression of pig7 in leukemic cells exhibited no evident effect on cell proliferation and differentiation, but could intensify inhibitory efficacy of etoposide (VP16) and daunorubicin (DNR).	Daunorubicin	196-199	lipopolysaccharide induced TNF factor	Homo sapiens	24-28
18972190-6	2009	RESULTS: The novel modulators showed activities as mdr reversers in a P-gp specific human cancer cell model with mainly increased uptake rates of daunorubicin into the drug-resistant cell line.	Daunorubicin	146-158	ATP binding cassette subfamily B member 1	Homo sapiens	70-74
18955043-3	2008	The accumulation of daunorubicin, a fluorescent substrate of P-glycoprotein, increased in the presence of auraptene and nobiletin in KB-C2 cells.	Daunorubicin	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	61-75
18785686-0	2008	Study of the interaction of aglycon of daunorubicin with human serum albumin by spectroscopy and modeling.	Daunorubicin	39-51	albumin	Homo sapiens	63-76
18785686-1	2008	The interaction between aglycon of daunorubicin (DNR-A) and human serum albumin (HSA) was investigated using fluorescence quenching and modeling.	Daunorubicin	35-47	albumin	Homo sapiens	66-85
18729196-2	2008	In vitro, extracellular acidosis (pH 6.6) activated p38 and ERK1/2 and thereby induced daunorubicin resistance via a pronounced activation of pGP.	Daunorubicin	87-99	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	142-145
18729196-4	2008	Intracellular acidification also induced daunorubicin resistance via activation of pGP, which was mediated by activation of p38 alone.	Daunorubicin	41-53	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	83-86
18729196-4	2008	Intracellular acidification also induced daunorubicin resistance via activation of pGP, which was mediated by activation of p38 alone.	Daunorubicin	41-53	mitogen activated protein kinase 14	Rattus norvegicus	124-127
18729196-6	2008	In vivo, the reduced extracellular pH of 6.6 was also able to induce daunorubicin resistance, which was abolished by inhibition of p38.	Daunorubicin	69-81	mitogen activated protein kinase 14	Rattus norvegicus	131-134
18755268-0	2008	Myosin phosphatase interacts with and dephosphorylates the retinoblastoma protein in THP-1 leukemic cells: its inhibition is involved in the attenuation of daunorubicin-induced cell death by calyculin-A.	Daunorubicin	156-168	GLI family zinc finger 2	Homo sapiens	85-90
18755268-3	2008	It is shown that pretreatment of THP-1 leukemic cells with calyculin-A (CL-A), a cell-permeable phosphatase inhibitor, attenuated daunorubicin (DNR)-induced cell death and resulted in increased pRb phosphorylation and protection against proteolytic degradation.	Daunorubicin	130-142	GLI family zinc finger 2	Homo sapiens	33-38
18755268-3	2008	It is shown that pretreatment of THP-1 leukemic cells with calyculin-A (CL-A), a cell-permeable phosphatase inhibitor, attenuated daunorubicin (DNR)-induced cell death and resulted in increased pRb phosphorylation and protection against proteolytic degradation.	Daunorubicin	144-147	GLI family zinc finger 2	Homo sapiens	33-38
18755268-3	2008	It is shown that pretreatment of THP-1 leukemic cells with calyculin-A (CL-A), a cell-permeable phosphatase inhibitor, attenuated daunorubicin (DNR)-induced cell death and resulted in increased pRb phosphorylation and protection against proteolytic degradation.	Daunorubicin	144-147	RB transcriptional corepressor 1	Homo sapiens	194-197
18723777-6	2008	Although there was a minimal effect on doxorubicin and daunorubicin, the MDR1-dependent resistance on vinblastine, vincristine, paclitaxel, and etoposide was reduced by approximately 5-fold.	Daunorubicin	55-67	ATP binding cassette subfamily B member 1	Homo sapiens	73-77
18634747-0	2008	Direct determination of intracellular daunorubicin in intact confluent monolayers of AT1 prostate carcinoma cells using a multiwell-multilabel counter.	Daunorubicin	38-50	angiotensin II receptor type 1	Homo sapiens	85-88
18634747-3	2008	Here we have evaluated the use of a multiwell-multilabel reader for the direct determination of the fluorescent cytostatic drug daunorubicin in a prostate carcinoma cell line (AT1 R-3327 Dunning prostate carcinoma cells) grown on 24-well plates.	Daunorubicin	128-140	angiotensin II receptor type 1	Homo sapiens	176-179
18204840-4	2008	RESULTS: The accumulation of daunorubicin, a fluorescent substrate of P-glycoprotein, increased in the presence of sesamin, ginkgolic acid, matairesinol, glycyrrhetinic acid, glabridin, and phyllodulcin in KB-C2 cells.	Daunorubicin	29-41	ATP binding cassette subfamily B member 1	Homo sapiens	70-84
18650843-8	2008	Short-term in vitro exposure of primary AML cells (n=29) to daunorubicin showed a strong correlation between the in vitro pharmacodymanic changes of phospho-JNK levels and the response of patients to standard induction chemotherapy (P=0.012).	Daunorubicin	60-72	mitogen-activated protein kinase 8	Homo sapiens	157-160
18657189-5	2008	[3H]Daunomycin binding to the ABCG2 R482G isoform was examined in the nucleotide-bound and post-hydrolytic conformations.	Daunorubicin	4-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	30-35
18493867-0	2008	Granulocyte colony stimulating factor increases drug resistance of leukaemic blast cells to daunorubicin.	Daunorubicin	92-104	colony stimulating factor 3	Homo sapiens	0-37
18493867-6	2008	In this study we investigated how G-CSF might influence the sensitivity of leukemic cells to daunorubicin induced cell death using MTT assay, flow cytometry and Western blot analysis.	Daunorubicin	93-105	colony stimulating factor 3	Homo sapiens	34-39
18493867-7	2008	After pretreatment of KG-1 leukaemic cells with G-CSF a moderate increase in the resistance of these cells to daunorubicin could be observed.	Daunorubicin	110-122	colony stimulating factor 3	Homo sapiens	48-53
18493867-9	2008	In addition, adjuvant treatment of AML patients with G-CSF in order to prevent neutropenia, or its use in priming regimens might result resistance to daunorubicin.	Daunorubicin	150-162	colony stimulating factor 3	Homo sapiens	53-58
18538911-9	2008	In co-culture medium, there was a 20-fold decrease in MIP-3alpha in daunorubicin-pretreated HS-5 cells and at least a 3-fold decrease in Ara-C-pretreated cells.	Daunorubicin	68-80	C-C motif chemokine ligand 20	Homo sapiens	54-64
18579125-2	2008	CBR1 was purified and kinetically characterised using daunorubicin as substrate.	Daunorubicin	54-66	carbonyl reductase 1	Homo sapiens	0-4
18579125-3	2008	CBR1-catalysed reduction of daunorubicin followed an apparent Michaelis-Menten kinetics with K(M)=85.2+/-26.7microM and V(max)=3490+/-220micromol/(mingprotein).	Daunorubicin	28-40	carbonyl reductase 1	Homo sapiens	0-4
18449627-1	2008	PURPOSE: Carbonyl reductase 1 (CBR1) reduces the anticancer anthracyclines doxorubicin and daunorubicin into the cardiotoxic metabolites doxorubicinol and daunorubicinol.	Daunorubicin	91-103	carbonyl reductase 1	Homo sapiens	9-29
18449627-1	2008	PURPOSE: Carbonyl reductase 1 (CBR1) reduces the anticancer anthracyclines doxorubicin and daunorubicin into the cardiotoxic metabolites doxorubicinol and daunorubicinol.	Daunorubicin	91-103	carbonyl reductase 1	Homo sapiens	31-35
18449627-8	2008	MonoHER acted as a competitive CBR1 inhibitor when using daunorubicin as a substrate Ki = 45 +/- 18 microM.	Daunorubicin	57-69	carbonyl reductase 1	Homo sapiens	31-35
18430410-4	2008	Moreover, Elongator deficiency causes increased basal and daunomycin-induced expression of the pro-survival serum- and glucocorticoid-induced protein kinase (SGK) gene through a p53-dependent pathway.	Daunorubicin	58-68	serum/glucocorticoid regulated kinase 1	Homo sapiens	158-161
18430410-4	2008	Moreover, Elongator deficiency causes increased basal and daunomycin-induced expression of the pro-survival serum- and glucocorticoid-induced protein kinase (SGK) gene through a p53-dependent pathway.	Daunorubicin	58-68	tumor protein p53	Homo sapiens	178-181
18280247-3	2008	The accumulation of daunorubicin or rhodamine 123, fluorescent substrates of P-gp, increased in the presence of guggulsterone in KB-C2 cells.	Daunorubicin	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
18341636-5	2008	AML samples with -17, which are more resistant to daunorubicin and cytarabine compared with samples without -17, were effectively killed by PRIMA-1.	Daunorubicin	50-62	proline rich membrane anchor 1	Homo sapiens	140-147
18451141-8	2008	Using 50 non-HapMap CEPH cell lines, single nucleotide polymorphisms generated through our model predicted 29% of the overall variation in daunorubicin sensitivity and the expression of CYP1B1 was significantly correlated with sensitivity to daunorubicin.	Daunorubicin	242-254	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	186-192
18299310-0	2008	Targeting MDR1 gene: synthesis and cellular study of modified daunomycin-triplex-forming oligonucleotide conjugates able to inhibit gene expression in resistant cell lines.	Daunorubicin	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	10-14
18299310-2	2008	In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance.	Daunorubicin	112-122	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
18299310-2	2008	In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance.	Daunorubicin	112-122	ATP binding cassette subfamily B member 1	Homo sapiens	49-63
18299310-2	2008	In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance.	Daunorubicin	112-122	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
18299310-2	2008	In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance.	Daunorubicin	124-127	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
18299310-2	2008	In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance.	Daunorubicin	124-127	ATP binding cassette subfamily B member 1	Homo sapiens	49-63
18299310-2	2008	In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance.	Daunorubicin	124-127	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
18249061-9	2008	The increased expression of MDR1 and BCRP1 in leukemic cells correlated with increased cellular daunorubicin resistance, which could be reversed by the ABC transporter inhibitors verapamil and PSC-833.	Daunorubicin	96-108	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
18249061-9	2008	The increased expression of MDR1 and BCRP1 in leukemic cells correlated with increased cellular daunorubicin resistance, which could be reversed by the ABC transporter inhibitors verapamil and PSC-833.	Daunorubicin	96-108	BCR pseudogene 1	Homo sapiens	37-42
18036655-0	2008	Binding of daunorubicin to human serum albumin using molecular modeling and its analytical application.	Daunorubicin	11-23	albumin	Homo sapiens	33-46
18036655-1	2008	This study was designed to examine the interaction of daunorubicin with human serum albumin (HSA) for the first time by fluorescence spectroscopy in combination with UV absorption and molecular modeling under simulative physiological conditions.	Daunorubicin	54-66	albumin	Homo sapiens	78-91
18283525-0	2008	Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells.	Daunorubicin	120-132	sphingosine kinase 1	Homo sapiens	16-36
18283525-2	2008	This alteration is supposed to change the cellular sphingolipid metabolites; however, positive correlations were observed between daunorubicin (DA)-IC50 and the SPHK1 message but not between DA-IC50 and NSMase2 messages, when 16 different leukemia cell lines were used to analyze the relationship between gene expressions and chemosensitivity against DA.	Daunorubicin	130-142	sphingosine kinase 1	Homo sapiens	161-166
18283525-2	2008	This alteration is supposed to change the cellular sphingolipid metabolites; however, positive correlations were observed between daunorubicin (DA)-IC50 and the SPHK1 message but not between DA-IC50 and NSMase2 messages, when 16 different leukemia cell lines were used to analyze the relationship between gene expressions and chemosensitivity against DA.	Daunorubicin	144-146	sphingosine kinase 1	Homo sapiens	161-166
18283525-6	2008	A SPHK inhibitor recovered the DA sensitivity of DA-resistant cells.	Daunorubicin	31-33	sphingosine kinase 1	Homo sapiens	2-6
17278123-3	2008	We present a case of advanced stage Burkitt lymphoma in an 8-year-old female with acquired immunodeficiency syndrome (AIDS), who was successfully treated with a 3 month course of modified CHOP-R (cyclophosphamide, daunorubicin, vincristine, prednisone, and rituximab) and HAART therapy.	Daunorubicin	214-226	DNA damage inducible transcript 3	Homo sapiens	188-192
17721914-7	2008	Antisense oligonucleotides targeting XIAP down-regulated the expression of XIAP and sensitized U937 cells to daunorubicin.	Daunorubicin	109-121	X-linked inhibitor of apoptosis	Homo sapiens	37-41
17721914-9	2008	The levels of phosphorylated Akt (Ser473) were elevated in U937/FN cells and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 suppressed XIAP expression and restored the chemosensitivity to daunorubicin.	Daunorubicin	201-213	AKT serine/threonine kinase 1	Homo sapiens	29-32
17721914-9	2008	The levels of phosphorylated Akt (Ser473) were elevated in U937/FN cells and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 suppressed XIAP expression and restored the chemosensitivity to daunorubicin.	Daunorubicin	201-213	fibronectin 1	Homo sapiens	64-66
18310528-0	2008	High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent.	Daunorubicin	30-42	ATP binding cassette subfamily B member 1	Homo sapiens	109-114
18094719-6	2008	In the K562pTet-on/ETS2 cells, ETS2 induction conferred differences in sensitivities to ara-C and daunorubicin, depending on GATA1 levels.	Daunorubicin	98-110	ETS proto-oncogene 2, transcription factor	Homo sapiens	31-35
18439867-4	2008	Here, we characterised the distribution of sequestered daunorubicin in commonly used leukaemia cell lines, HL-60, K562, KG1a and the multidrug resistant HL-60/ADR line, and related this to the spatial distribution of their endocytic organelles and microtubule networks.	Daunorubicin	55-67	aldo-keto reductase family 1 member B	Homo sapiens	159-162
18439867-6	2008	HL-60/ADR and K562 cells showed extensive clustering of early and recycling endosomes, late endosomes, lysosomes and daunorubicin to a juxtanuclear region but these cells lacked microtubule arrays.	Daunorubicin	117-129	aldo-keto reductase family 1 member B	Homo sapiens	6-9
17923246-12	2007	Furthermore, toxicity of the pgp substrate drug daunorubicin was enhanced following lovastatin preculture (p = 0.04).	Daunorubicin	48-60	ATP binding cassette subfamily B member 1	Homo sapiens	29-32
18089708-2	2007	Here, we report that the antineoplastic agents, daunorubicin hydrochloride, etoposide, and vincristine sulfate inhibited the ability of 1,25(OH)(2)D(3) to cause the accumulation of mRNA for kidney 25-hydroxyvitamin D(3) 24-hydroxylase (CYP24), an enzyme which catabolizes this hormone.	Daunorubicin	48-74	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	236-241
17659913-5	2007	Myeloid enriched BM cells from gadd45a and gadd45b deficient mice were observed to be more sensitive to ultraviolet radiation (UVC), VP-16, and daunorubicin (DNR)-induced apoptosis compared to wild-type (wt) cells.	Daunorubicin	144-156	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	43-50
17850057-3	2007	The screening was performed on the basis of the ability of sesquiterpenes to modulate the intracellular accumulation of the classical Pgp substrate daunorubicin.	Daunorubicin	148-160	ATP binding cassette subfamily B member 1	Homo sapiens	134-137
17917277-1	2007	We studied the effects of ginsenosides and their metabolites on daunorubicin transport in multidrug-resistant P-glycoprotein (P-gp)-overexpressing KB-C2 cells.	Daunorubicin	64-76	ATP binding cassette subfamily B member 1	Homo sapiens	110-124
17917277-1	2007	We studied the effects of ginsenosides and their metabolites on daunorubicin transport in multidrug-resistant P-glycoprotein (P-gp)-overexpressing KB-C2 cells.	Daunorubicin	64-76	ATP binding cassette subfamily B member 1	Homo sapiens	126-130
17917277-6	2007	Analysis of verapamil-stimulated ATPase activity in membrane vesicles expressing human P-gp suggested that the increased daunorubicin accumulation by M4 was at least partly due to ATPase inhibition of P-gp.	Daunorubicin	121-133	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
17917277-6	2007	Analysis of verapamil-stimulated ATPase activity in membrane vesicles expressing human P-gp suggested that the increased daunorubicin accumulation by M4 was at least partly due to ATPase inhibition of P-gp.	Daunorubicin	121-133	ATP binding cassette subfamily B member 1	Homo sapiens	201-205
17854304-3	2007	We developed tolerance to therapeutic concentrations of daunorubicin (DNR) and L-asparaginase (L-asp) in Jurkat (CD1a(-), sCD3(+)) and Sup T1 (CD1a(+), sCD3(-)) cell lines, having respective "mature" and "cortical" stages of developmental arrest.	Daunorubicin	56-68	CD1a molecule	Homo sapiens	113-117
17854304-3	2007	We developed tolerance to therapeutic concentrations of daunorubicin (DNR) and L-asparaginase (L-asp) in Jurkat (CD1a(-), sCD3(+)) and Sup T1 (CD1a(+), sCD3(-)) cell lines, having respective "mature" and "cortical" stages of developmental arrest.	Daunorubicin	56-68	CD1a molecule	Homo sapiens	143-147
17457659-7	2007	Moreover, ABCB1-mediated efflux of daunorubicin in K562/DOX cells could be blocked markedly by GA analogues in a dose-dependent fashion.	Daunorubicin	35-47	ATP binding cassette subfamily B member 1	Homo sapiens	10-15
17631493-6	2007	Formation of the last ring via C-1/C-18 aldol condensation does not require a dedicated fourth-ring cyclase, in contrast to the biosynthetic mechanism of other tetracyclic aromatic polyketides, such as daunorubicin and tetracenomycin.	Daunorubicin	202-214	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	31-39
17654249-4	2007	These results were similar to the profiles induced by daunorubicin, an activator of serine palmitoyl CoA transferase (SPT), suggesting that H2O2 stimulated the de novo synthetic pathway of ceramides.	Daunorubicin	54-66	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	84-116
17654249-4	2007	These results were similar to the profiles induced by daunorubicin, an activator of serine palmitoyl CoA transferase (SPT), suggesting that H2O2 stimulated the de novo synthetic pathway of ceramides.	Daunorubicin	54-66	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	118-121
17587482-3	2007	In cell-culture media, the cTnI and cTnT concentrations were concentration- and time-dependently increasing in response to daunorubicin exposure and were negatively exponentially related to cardiomyocyte viability.	Daunorubicin	123-135	troponin I3, cardiac type	Rattus norvegicus	27-31
17587482-3	2007	In cell-culture media, the cTnI and cTnT concentrations were concentration- and time-dependently increasing in response to daunorubicin exposure and were negatively exponentially related to cardiomyocyte viability.	Daunorubicin	123-135	troponin T2, cardiac type	Rattus norvegicus	36-40
17587482-4	2007	With 3microM daunorubicin, the relative increase of AUC of cTnT and cTnI was 2.4- and 5.3-fold higher than the increase of LDH activity, respectively.	Daunorubicin	13-25	troponin T2, cardiac type	Rattus norvegicus	59-63
17587482-4	2007	With 3microM daunorubicin, the relative increase of AUC of cTnT and cTnI was 2.4- and 5.3-fold higher than the increase of LDH activity, respectively.	Daunorubicin	13-25	troponin I3, cardiac type	Rattus norvegicus	68-72
17524504-7	2007	Furthermore, the intracellular accumulation of daunorubicin, a substrate for P-gp, increased significantly with an increased intracellular localisation of P-gp-EGFP.	Daunorubicin	47-59	phosphoglycolate phosphatase	Homo sapiens	77-81
17524504-7	2007	Furthermore, the intracellular accumulation of daunorubicin, a substrate for P-gp, increased significantly with an increased intracellular localisation of P-gp-EGFP.	Daunorubicin	47-59	phosphoglycolate phosphatase	Homo sapiens	155-164
17637191-2	2007	Both tannic acid and pentagalloylglucose markedly elevated the accumulation of P-gp substrates, rhodamine 123 and daunorubicin, by inhibiting their efflux.	Daunorubicin	114-126	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
17344335-1	2007	Human carbonyl reductase 1 (CBR1) metabolizes endogenous and xenobiotic substrates such as the fever mediator, prostaglandin E2 (PGE2), and the anticancer anthracycline drug, daunorubicin.	Daunorubicin	175-187	carbonyl reductase 1	Homo sapiens	6-26
17344335-1	2007	Human carbonyl reductase 1 (CBR1) metabolizes endogenous and xenobiotic substrates such as the fever mediator, prostaglandin E2 (PGE2), and the anticancer anthracycline drug, daunorubicin.	Daunorubicin	175-187	carbonyl reductase 1	Homo sapiens	28-32
17344335-5	2007	Kinetic studies revealed that the CBR1 V88 and CBR1 I88 isoforms have different maximal velocities for daunorubicin (V(max) CBR1 V88, 181 +/- 13 versus V(max) CBR1 I88, 121 +/- 12 nmol/min .	Daunorubicin	103-115	carbonyl reductase 1	Homo sapiens	34-38
17344335-5	2007	Kinetic studies revealed that the CBR1 V88 and CBR1 I88 isoforms have different maximal velocities for daunorubicin (V(max) CBR1 V88, 181 +/- 13 versus V(max) CBR1 I88, 121 +/- 12 nmol/min .	Daunorubicin	103-115	carbonyl reductase 1	Homo sapiens	47-51
17344335-5	2007	Kinetic studies revealed that the CBR1 V88 and CBR1 I88 isoforms have different maximal velocities for daunorubicin (V(max) CBR1 V88, 181 +/- 13 versus V(max) CBR1 I88, 121 +/- 12 nmol/min .	Daunorubicin	103-115	carbonyl reductase 1	Homo sapiens	47-51
17344335-5	2007	Kinetic studies revealed that the CBR1 V88 and CBR1 I88 isoforms have different maximal velocities for daunorubicin (V(max) CBR1 V88, 181 +/- 13 versus V(max) CBR1 I88, 121 +/- 12 nmol/min .	Daunorubicin	103-115	carbonyl reductase 1	Homo sapiens	47-51
17094122-5	2007	On daunorubicin transport, the relative IC(50) value (quinidine IC(50)/verapamil IC(50)) of human P-gp was 5.25 and those from other species ranged from 0.89 to 10.70.	Daunorubicin	3-15	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
17434463-6	2007	The functionality of efflux pumps (P-gp, Mrps and Bcrp) was demonstrated in the presence of specific inhibitors (PSC833, MK571 or Ko143, respectively) by (i) assessing the uptake of the common substrates rhodamine 123 and daunorubicin and (ii) evaluating apical to basolateral and basolateral to apical polarized transport of daunorubicin.	Daunorubicin	222-234	phosphoglycolate phosphatase	Rattus norvegicus	35-39
17434463-6	2007	The functionality of efflux pumps (P-gp, Mrps and Bcrp) was demonstrated in the presence of specific inhibitors (PSC833, MK571 or Ko143, respectively) by (i) assessing the uptake of the common substrates rhodamine 123 and daunorubicin and (ii) evaluating apical to basolateral and basolateral to apical polarized transport of daunorubicin.	Daunorubicin	326-338	phosphoglycolate phosphatase	Rattus norvegicus	35-39
17498302-9	2007	Daunorubicin (DNR) induced continuing down regulation of Hdm2 and Mcl-1 in both cell lines followed by apoptosis.	Daunorubicin	0-12	MDM2 proto-oncogene	Homo sapiens	57-61
17498302-9	2007	Daunorubicin (DNR) induced continuing down regulation of Hdm2 and Mcl-1 in both cell lines followed by apoptosis.	Daunorubicin	0-12	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	66-71
17498302-9	2007	Daunorubicin (DNR) induced continuing down regulation of Hdm2 and Mcl-1 in both cell lines followed by apoptosis.	Daunorubicin	14-17	MDM2 proto-oncogene	Homo sapiens	57-61
17498302-9	2007	Daunorubicin (DNR) induced continuing down regulation of Hdm2 and Mcl-1 in both cell lines followed by apoptosis.	Daunorubicin	14-17	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	66-71
17451600-7	2007	Transfection experiments demonstrated that LEDGF/p75 and p52b antagonized daunorubicin-induced and cAMP-induced apoptosis in an AML cell line.	Daunorubicin	74-86	PC4 and SFRS1 interacting protein 1	Homo sapiens	43-48
17451600-7	2007	Transfection experiments demonstrated that LEDGF/p75 and p52b antagonized daunorubicin-induced and cAMP-induced apoptosis in an AML cell line.	Daunorubicin	74-86	PC4 and SFRS1 interacting protein 1	Homo sapiens	49-52
17451600-8	2007	Also HEK-293 cells were protected against daunorubicin by LEDGF/p75 and p52b, whereas LEDGF/p52 splice variants lacking exon 6 had proapoptotic effects.	Daunorubicin	42-54	PC4 and SFRS1 interacting protein 1	Homo sapiens	58-63
17451600-8	2007	Also HEK-293 cells were protected against daunorubicin by LEDGF/p75 and p52b, whereas LEDGF/p52 splice variants lacking exon 6 had proapoptotic effects.	Daunorubicin	42-54	PC4 and SFRS1 interacting protein 1	Homo sapiens	64-67
17451600-8	2007	Also HEK-293 cells were protected against daunorubicin by LEDGF/p75 and p52b, whereas LEDGF/p52 splice variants lacking exon 6 had proapoptotic effects.	Daunorubicin	42-54	PC4 and SFRS1 interacting protein 1	Homo sapiens	72-75
17673002-0	2007	[Effects of daunorubicin on the expression of brain natriuretic peptide gene in myocardial cells: an in vitro experiment with cultured myocardial cells from rats].	Daunorubicin	12-24	natriuretic peptide B	Rattus norvegicus	46-71
17673002-1	2007	OBJECTIVE: To investigate the effects of daunorubicin (DNR) on the gene expression of brain natriuretic peptide (BNP) in myocardial cells.	Daunorubicin	41-53	natriuretic peptide B	Rattus norvegicus	86-111
17673002-1	2007	OBJECTIVE: To investigate the effects of daunorubicin (DNR) on the gene expression of brain natriuretic peptide (BNP) in myocardial cells.	Daunorubicin	41-53	natriuretic peptide B	Rattus norvegicus	113-116
17122416-2	2007	The stably expressed P-gp-EGFP from a clonal cell population was functional as a drug efflux pump, as demonstrated by the inhibition of daunorubicin accumulation and the conferring of resistance of the cells to colchicine and daunorubicin.	Daunorubicin	136-148	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
17122416-2	2007	The stably expressed P-gp-EGFP from a clonal cell population was functional as a drug efflux pump, as demonstrated by the inhibition of daunorubicin accumulation and the conferring of resistance of the cells to colchicine and daunorubicin.	Daunorubicin	226-238	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
17122416-7	2007	In functional studies it was shown that in parallel with the interruption of the traffic of P-gp-EGFP, cellular accumulation of the P-gp substrate daunorubicin was increased after cells were treated with actin inhibitors, and cell proliferation was inhibited to a greater extent than in the presence of daunorubicin alone.	Daunorubicin	147-159	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
17122416-7	2007	In functional studies it was shown that in parallel with the interruption of the traffic of P-gp-EGFP, cellular accumulation of the P-gp substrate daunorubicin was increased after cells were treated with actin inhibitors, and cell proliferation was inhibited to a greater extent than in the presence of daunorubicin alone.	Daunorubicin	147-159	ATP binding cassette subfamily B member 1	Homo sapiens	132-136
17122416-7	2007	In functional studies it was shown that in parallel with the interruption of the traffic of P-gp-EGFP, cellular accumulation of the P-gp substrate daunorubicin was increased after cells were treated with actin inhibitors, and cell proliferation was inhibited to a greater extent than in the presence of daunorubicin alone.	Daunorubicin	303-315	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
17122416-7	2007	In functional studies it was shown that in parallel with the interruption of the traffic of P-gp-EGFP, cellular accumulation of the P-gp substrate daunorubicin was increased after cells were treated with actin inhibitors, and cell proliferation was inhibited to a greater extent than in the presence of daunorubicin alone.	Daunorubicin	303-315	ATP binding cassette subfamily B member 1	Homo sapiens	132-136
17342096-3	2007	Cripto Mab synergistically enhanced sensitivity of the MDR cells to Pgp substrates epirubicin (EPI), daunorubicin (DAU) and non-Pgp substrates nucleoside analogue cytosine arabinoside (AraC).	Daunorubicin	101-113	teratocarcinoma-derived growth factor 1	Homo sapiens	0-6
17342096-3	2007	Cripto Mab synergistically enhanced sensitivity of the MDR cells to Pgp substrates epirubicin (EPI), daunorubicin (DAU) and non-Pgp substrates nucleoside analogue cytosine arabinoside (AraC).	Daunorubicin	115-118	teratocarcinoma-derived growth factor 1	Homo sapiens	0-6
16862171-2	2007	Here, we report that daunorubicin (DNR) activated acid CDase post-transcriptionally in established human (HepG2 cells) or mouse (Hepa1c1c7) hepatoma cell lines as well as in primary cells from murine liver tumors, but not in cultured mouse hepatocytes.	Daunorubicin	21-33	N-acylsphingosine amidohydrolase 1	Mus musculus	50-60
16636798-10	2007	Daunorubicin cytotoxicity was also increased seven to eight-fold in cells co-treated with XR9577 or WK-X-34 (10 muM).	Daunorubicin	0-12	latexin	Homo sapiens	112-115
16850318-1	2007	Two monoclonal antibodies (ADM-1-11 and 79-31 mAbs) were raised against daunomycin (DM) conjugated to bovine serum albumin via the cross-linker N-(gamma-maleimidobutyryloxy)succinimide.	Daunorubicin	72-82	Adrenal mass QTL 1	Rattus norvegicus	27-32
17143522-2	2007	Present studies in K562 human myelogenous leukemia show that RALBP1 overexpression confers broad resistance to multiple chemotherapy drugs including cisplatin, melphalan, doxorubicin, daunorubicin, vincristine, vinblastine, vinorelbine, and mitomycin-C.	Daunorubicin	184-196	ralA binding protein 1	Homo sapiens	61-67
17050779-7	2007	The feasibility of such a combinative treatment for in vivo multidrug resistance reversal was substantiated by the dramatic increase of daunorubicin accumulation in xenotransplanted Pgp+ tumors in response to a combined treatment with UIC2 and CsA, both administered at doses ineffective when applied alone.	Daunorubicin	136-148	ATP binding cassette subfamily B member 1	Homo sapiens	182-185
18261366-0	2007	Altered pharmacokinetics of daunorubicin in rats with CCl4-induced hepatic injury.	Daunorubicin	28-40	C-C motif chemokine ligand 4	Rattus norvegicus	54-58
18261366-1	2007	PURPOSE: The effect of CCl4-induced experimental hepatic injury (CCl4-EHI) on the pharmacokinetics of daunorubicin was investigated systemically in rats, in an attempt to elucidate the major determinants of the effect of CCl4-EHI on the pharmacokinetics of the drug.	Daunorubicin	102-114	C-C motif chemokine ligand 4	Rattus norvegicus	23-27
18261366-1	2007	PURPOSE: The effect of CCl4-induced experimental hepatic injury (CCl4-EHI) on the pharmacokinetics of daunorubicin was investigated systemically in rats, in an attempt to elucidate the major determinants of the effect of CCl4-EHI on the pharmacokinetics of the drug.	Daunorubicin	102-114	C-C motif chemokine ligand 4	Rattus norvegicus	65-69
18261366-1	2007	PURPOSE: The effect of CCl4-induced experimental hepatic injury (CCl4-EHI) on the pharmacokinetics of daunorubicin was investigated systemically in rats, in an attempt to elucidate the major determinants of the effect of CCl4-EHI on the pharmacokinetics of the drug.	Daunorubicin	102-114	C-C motif chemokine ligand 4	Rattus norvegicus	65-69
18261366-5	2007	RESULTS: The area under the plasma concentration-time curve (AUC) of daunorubicin was increased by 1.6 times, resulting in a 34% decrease in the systemic clearance (CL) in rats with CCl4-EHI.	Daunorubicin	69-81	C-C motif chemokine ligand 4	Rattus norvegicus	182-186
18261366-8	2007	CONCLUSIONS: CCl4-EHI appears to impair the hepatic metabolism of daunorubicin, thereby decreasing the CL and increasing the AUC of daunorubicin.	Daunorubicin	66-78	C-C motif chemokine ligand 4	Rattus norvegicus	13-17
18261366-8	2007	CONCLUSIONS: CCl4-EHI appears to impair the hepatic metabolism of daunorubicin, thereby decreasing the CL and increasing the AUC of daunorubicin.	Daunorubicin	132-144	C-C motif chemokine ligand 4	Rattus norvegicus	13-17
17274671-0	2007	Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance.	Daunorubicin	32-44	phosphoglycolate phosphatase	Homo sapiens	55-59
17204174-4	2006	CCK-8 cell viability assay was used to determine the effect of AS ODN of XIAP and MRP used alone or in combination on the chemotherapy sensitivity of HL-60/ADR cells to daunorubicin (DNR).	Daunorubicin	169-181	X-linked inhibitor of apoptosis	Homo sapiens	73-77
17204174-4	2006	CCK-8 cell viability assay was used to determine the effect of AS ODN of XIAP and MRP used alone or in combination on the chemotherapy sensitivity of HL-60/ADR cells to daunorubicin (DNR).	Daunorubicin	169-181	ATP binding cassette subfamily C member 3	Homo sapiens	82-85
17204177-1	2006	The aim of study was to investigate the combined effect of recombinant mutant human TRAIL (rmhTRAIL) with daunorubicin (DNR) or alone on K562 and U937 leukemia cell lines and its mechanism.	Daunorubicin	106-118	TNF superfamily member 10	Homo sapiens	84-89
16981002-4	2006	EXPERIMENTAL APPROACH: Plasma membranes from insect cells expressing ABCG2 were used to characterise binding of [3H]daunomycin to the multidrug transporter.	Daunorubicin	116-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	69-74
17090932-8	2006	The enhanced accumulation of daunomycin would therefore not have been due to P-gp inhibition, but instead to the increased daunomycin permeability of cell membranes caused by the emulsifiers.	Daunorubicin	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
16955376-2	2006	PROCEDURE: Pgp inhibition was measured by daunorubicin transport assays and fluorescence microscopy in resistant A2780/Adr cells treated with WK-X-34 and antisense.	Daunorubicin	42-54	phosphoglycolate phosphatase	Homo sapiens	11-14
17072096-8	2006	In conclusion, for the first time we demonstrated that TA increases the intestinal absorption of P-gp substrates Rho123 and daunorubicin, possibly by modulating the P-gp function without changing the expression level of P-gp in the rat intestine.	Daunorubicin	124-136	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	97-101
16856922-2	2006	Liposomal encapsulation makes daunorubicin (DNR) less sensitive to the efflux effect of P-glycoprotein (PGP), and in vitro data indicate that liposomal-encapsulated DNR (Daunoxome-DNX) is more toxic than DNR against ALL cell lines.	Daunorubicin	30-42	phosphoglycolate phosphatase	Homo sapiens	104-107
16856922-2	2006	Liposomal encapsulation makes daunorubicin (DNR) less sensitive to the efflux effect of P-glycoprotein (PGP), and in vitro data indicate that liposomal-encapsulated DNR (Daunoxome-DNX) is more toxic than DNR against ALL cell lines.	Daunorubicin	165-168	ATP binding cassette subfamily B member 1	Homo sapiens	88-102
16856922-2	2006	Liposomal encapsulation makes daunorubicin (DNR) less sensitive to the efflux effect of P-glycoprotein (PGP), and in vitro data indicate that liposomal-encapsulated DNR (Daunoxome-DNX) is more toxic than DNR against ALL cell lines.	Daunorubicin	165-168	phosphoglycolate phosphatase	Homo sapiens	104-107
16982329-10	2006	Within AML blast cells influenced by Flt3 signaling, selective inhibition of JNK by a small molecule inhibitor, led to proliferative inhibition, apoptosis, and sensitizing cells to the anthracycline, daunorubicin.	Daunorubicin	200-212	fms related receptor tyrosine kinase 3	Homo sapiens	37-41
16982329-10	2006	Within AML blast cells influenced by Flt3 signaling, selective inhibition of JNK by a small molecule inhibitor, led to proliferative inhibition, apoptosis, and sensitizing cells to the anthracycline, daunorubicin.	Daunorubicin	200-212	mitogen-activated protein kinase 8	Homo sapiens	77-80
16682957-4	2006	Cooperation between p53 and NF-kappaB was required for activation of COX-2 promoter in response to daunomycin, a DNA-damaging agent.	Daunorubicin	99-109	tumor protein p53	Homo sapiens	20-23
16682957-4	2006	Cooperation between p53 and NF-kappaB was required for activation of COX-2 promoter in response to daunomycin, a DNA-damaging agent.	Daunorubicin	99-109	nuclear factor kappa B subunit 1	Homo sapiens	28-37
16682957-4	2006	Cooperation between p53 and NF-kappaB was required for activation of COX-2 promoter in response to daunomycin, a DNA-damaging agent.	Daunorubicin	99-109	prostaglandin-endoperoxide synthase 2	Homo sapiens	69-74
16682957-5	2006	Pharmacological inhibition of Cox-2 enhanced apoptosis in response to daunomycin, in particular in cells containing active p53.	Daunorubicin	70-80	prostaglandin-endoperoxide synthase 2	Homo sapiens	30-35
16682957-5	2006	Pharmacological inhibition of Cox-2 enhanced apoptosis in response to daunomycin, in particular in cells containing active p53.	Daunorubicin	70-80	tumor protein p53	Homo sapiens	123-126
16844372-1	2006	We report a novel approach to enhance the efficient accumulation and utilization of anticancer drug daunorubicin on cancer cells through the combination with CdS nanoparticles.	Daunorubicin	100-112	CDP-diacylglycerol synthase 1	Homo sapiens	158-161
16844372-2	2006	Our observations using confocal fluorescence scanning microscopy as well as electrochemical analysis methods demonstrate that CdS nanoparticles can readily bind with daunorubicin on the external membrane of the targeted cells and facilitate the uptake of drug molecules in the human leukemia K562 cells.	Daunorubicin	166-178	CDP-diacylglycerol synthase 1	Homo sapiens	126-129
16542724-5	2006	Moreover, KT-5720 (at 5 mg/kg) sensitized the bone marrow of MDR1 transgenic mice model towards daunorubicin (at 8 mg/kg) without general toxic effects.	Daunorubicin	96-108	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	61-65
17052966-5	2006	After 48 and 72 hours treatment with daunorubicin and Ara-C, respectively, increased cell death was observed in THP-1 cells that were pretreated with FK866, as compared to cells exposed to antineoplastic drugs alone.	Daunorubicin	37-49	GLI family zinc finger 2	Homo sapiens	112-117
16790528-8	2006	Additionally, the specific down-regulation of SAP155 sensitized cells to undergo apoptosis in response to daunorubicin in a manner similar to ceramide.	Daunorubicin	106-118	splicing factor 3b subunit 1	Homo sapiens	46-52
16791269-5	2006	Leukaemic cells of T-ALL patients expressing higher levels of antiapoptotic p73 were more resistant to the DNA-damaging drug daunorubicin compared to cells of patients with low or negative expression or these isoforms (P(trend)=0.045).	Daunorubicin	125-137	tumor protein p73	Homo sapiens	76-79
16791269-6	2006	Interestingly, p73Deltaex2 was the most abundantly expressed antiapoptotic isoform in daunorubicin-resistant patient cells (44% of total p73).	Daunorubicin	86-98	tumor protein p73	Homo sapiens	15-18
16518407-5	2006	Knockdown of hARD1 also sensitized cells to daunorubicin-induced apoptosis, potentially pointing at the NATH-hARD1 acetyltransferase complex as a novel target for chemotherapy.	Daunorubicin	44-56	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	13-18
16518407-5	2006	Knockdown of hARD1 also sensitized cells to daunorubicin-induced apoptosis, potentially pointing at the NATH-hARD1 acetyltransferase complex as a novel target for chemotherapy.	Daunorubicin	44-56	N-alpha-acetyltransferase 15, NatA auxiliary subunit	Homo sapiens	104-108
16518407-5	2006	Knockdown of hARD1 also sensitized cells to daunorubicin-induced apoptosis, potentially pointing at the NATH-hARD1 acetyltransferase complex as a novel target for chemotherapy.	Daunorubicin	44-56	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	109-114
16646006-4	2006	In vitro inhibition of Pgp activity was evaluated using 99mTc-Sestamibi and daunorubicin accumulation in Pgp overexpressing human ovarian cancer cells (A2780/Adr) and its sensitive counterpart (A2780/wt).	Daunorubicin	76-88	ATP binding cassette subfamily B member 1	Homo sapiens	23-26
16646006-4	2006	In vitro inhibition of Pgp activity was evaluated using 99mTc-Sestamibi and daunorubicin accumulation in Pgp overexpressing human ovarian cancer cells (A2780/Adr) and its sensitive counterpart (A2780/wt).	Daunorubicin	76-88	ATP binding cassette subfamily B member 1	Homo sapiens	105-108
16458935-5	2006	The AML-2/DX100 cells were also resistant to other anticancer drugs, including daunorubicin and camptothecin, and the expression levels of the differentially regulated genes such as STMN1, MMP-2 and CTSG, were constantly maintained.	Daunorubicin	79-91	RUNX family transcription factor 3	Homo sapiens	4-9
16830181-3	2006	In an attempt at novel "transport engineering" using hMRP1 as a molecular pump, we established transgenic tobacco plants that showed clear resistance to cadmium and daunorubicin, although they were not resistant to etoposide, another known substrate of hMRP1.	Daunorubicin	165-177	ATP binding cassette subfamily C member 1	Homo sapiens	53-58
16407823-3	2006	In our study, both the adhesion of leukemic blasts to fibronectin and the addition of Wnt antagonists induced, independently, resistance of AML cells to daunorubicin in a cell survival assay.	Daunorubicin	153-165	fibronectin 1	Homo sapiens	54-65
16407823-6	2006	A link between the adhesion and the Wnt pathway was found, as adhesion of U937 on human osteoblasts, a component of the hematopoietic niche, triggered the secretion of the Wnt antagonist sFRP-1 and supported resistance to daunorubicin.	Daunorubicin	222-234	secreted frizzled related protein 1	Homo sapiens	187-193
16564522-4	2006	When MCF-7/R cells were transiently transfected with esiRNA of MDR1 (esiMDR1), the MDR1 mRNA was reduced by about 50%, drug accumulation increased by about 30%, and the IC50 for daunorubicin was reduced from 4.5 to 1.2 microM.	Daunorubicin	178-190	ATP binding cassette subfamily B member 1	Homo sapiens	63-67
16564522-4	2006	When MCF-7/R cells were transiently transfected with esiRNA of MDR1 (esiMDR1), the MDR1 mRNA was reduced by about 50%, drug accumulation increased by about 30%, and the IC50 for daunorubicin was reduced from 4.5 to 1.2 microM.	Daunorubicin	178-190	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
16609039-15	2006	Cytarabine and daunorubicin interfered with EPO signaling in F-MEL cells.	Daunorubicin	15-27	erythropoietin	Homo sapiens	44-47
16479196-5	2006	Before starting L-asparaginase treatment all patients had already demonstrated an increased thrombin generation shown by the elevated levels of prothrombin fragment 1+2 and thrombin antithrombin III, presumably due to therapy with prednisone, daunorubicin and vincristine.	Daunorubicin	243-255	coagulation factor II, thrombin	Homo sapiens	92-100
16381663-7	2006	Enzymatic efficiencies calculated as kcat/Km were more than 100 mM-1 min-1 for dolasetron and 1.3, 0.43, and 0.47 mM-1 min-1 for daunorubicin, oracin, and NNK, respectively.	Daunorubicin	129-141	CD59 molecule (CD59 blood group)	Homo sapiens	69-74
16381663-7	2006	Enzymatic efficiencies calculated as kcat/Km were more than 100 mM-1 min-1 for dolasetron and 1.3, 0.43, and 0.47 mM-1 min-1 for daunorubicin, oracin, and NNK, respectively.	Daunorubicin	129-141	CD59 molecule (CD59 blood group)	Homo sapiens	119-124
16503553-0	2006	The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma.	Daunorubicin	51-63	DNA damage inducible transcript 3	Homo sapiens	43-47
16112192-4	2006	Therefore, the present study was performed to evaluate whether stem cell factor-antibody (anti-SCF) can enhance the efficacy of the two main chemotherapeutic drugs used in AML therapy: cytarabine and daunorubicin at low doses in human-resistant CD34+ AML cells, in an attempt to identify a novel effective regimen with tolerable side-effects for elderly AML patients.	Daunorubicin	200-212	KIT ligand	Homo sapiens	95-98
16112192-6	2006	Anti-SCF has significantly enhanced the low dose cytarabine- and daunorubicin-induced apoptosis+necrosis in KG1a CD34+ AML cells from 12.0+/-1.7 to 40.9+/-5.9% and from 16.3+/-0.9 to 48.9+/-1.0%, respectively, p&lt;0.01.	Daunorubicin	65-77	KIT ligand	Homo sapiens	5-8
16112192-6	2006	Anti-SCF has significantly enhanced the low dose cytarabine- and daunorubicin-induced apoptosis+necrosis in KG1a CD34+ AML cells from 12.0+/-1.7 to 40.9+/-5.9% and from 16.3+/-0.9 to 48.9+/-1.0%, respectively, p&lt;0.01.	Daunorubicin	65-77	CD34 molecule	Homo sapiens	113-117
16112192-7	2006	It has also exerted its significant enhancement activity on the low dose cytarabine- and daunorubicin-induced apoptosis+necrosis in KG1a CD34+ AML cells in the presence of SCF, p&lt;0.05.	Daunorubicin	89-101	CD34 molecule	Homo sapiens	137-141
16112192-7	2006	It has also exerted its significant enhancement activity on the low dose cytarabine- and daunorubicin-induced apoptosis+necrosis in KG1a CD34+ AML cells in the presence of SCF, p&lt;0.05.	Daunorubicin	89-101	KIT ligand	Homo sapiens	172-175
16112192-8	2006	Anti-SCF has significantly enhanced the low dose cytarabine- and daunorubicin-induced bcl-2 reduction in KG1a CD34+ AML cells from 26.7+/-0.6 to 64.6+/-1.0% and from 59.8+/-3.1 to 80.1+/-7.9%, respectively, p&lt;0.01.	Daunorubicin	65-77	KIT ligand	Homo sapiens	5-8
16112192-8	2006	Anti-SCF has significantly enhanced the low dose cytarabine- and daunorubicin-induced bcl-2 reduction in KG1a CD34+ AML cells from 26.7+/-0.6 to 64.6+/-1.0% and from 59.8+/-3.1 to 80.1+/-7.9%, respectively, p&lt;0.01.	Daunorubicin	65-77	BCL2 apoptosis regulator	Homo sapiens	86-91
16112192-8	2006	Anti-SCF has significantly enhanced the low dose cytarabine- and daunorubicin-induced bcl-2 reduction in KG1a CD34+ AML cells from 26.7+/-0.6 to 64.6+/-1.0% and from 59.8+/-3.1 to 80.1+/-7.9%, respectively, p&lt;0.01.	Daunorubicin	65-77	CD34 molecule	Homo sapiens	110-114
16112192-10	2006	Anti-SCF has also significantly enhanced the low dose cytarabine- and daunorubicin-induced bcl-2 reduction in KG1a CD34+ AML cells in the presence of SCF, p&lt;0.05.	Daunorubicin	70-82	KIT ligand	Homo sapiens	5-8
16112192-10	2006	Anti-SCF has also significantly enhanced the low dose cytarabine- and daunorubicin-induced bcl-2 reduction in KG1a CD34+ AML cells in the presence of SCF, p&lt;0.05.	Daunorubicin	70-82	BCL2 apoptosis regulator	Homo sapiens	91-96
16112192-10	2006	Anti-SCF has also significantly enhanced the low dose cytarabine- and daunorubicin-induced bcl-2 reduction in KG1a CD34+ AML cells in the presence of SCF, p&lt;0.05.	Daunorubicin	70-82	CD34 molecule	Homo sapiens	115-119
16112192-10	2006	Anti-SCF has also significantly enhanced the low dose cytarabine- and daunorubicin-induced bcl-2 reduction in KG1a CD34+ AML cells in the presence of SCF, p&lt;0.05.	Daunorubicin	70-82	KIT ligand	Homo sapiens	150-153
16451059-0	2006	Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.	Daunorubicin	15-27	ATP binding cassette subfamily B member 1	Homo sapiens	91-95
16451059-5	2006	Molecular docking showed that the lead compound (3"-azidodaunorubicin, ADNR) averts P-gp binding, while daunorubicin (DNR) extensively interacts with multidrug-resistance (MDR) protein through H-bonds and electrostatic interactions.	Daunorubicin	57-69	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
16611407-5	2006	In parallel, the cytotoxic efficacy of daunorubicin showed pronounced reduction at low pH, an effect that was reversible on coincubation with a pGP inhibitor.	Daunorubicin	39-51	ATP binding cassette subfamily B member 1	Homo sapiens	144-147
16449206-0	2006	Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.	Daunorubicin	43-53	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	112-117
16174794-0	2006	Niemann-Pick C1 protein facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel vesicle-mediated pathway.	Daunorubicin	70-82	NPC intracellular cholesterol transporter 1	Homo sapiens	0-15
16289483-12	2005	Uptake studies with daunomycin and the P-gp inhibitor verapamil showed functional activity of P-gp.	Daunorubicin	20-30	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
16159878-3	2005	We show here that MCF-7 cells overexpressing thioredoxin (Trx) were more apoptotic in response to daunomycin.	Daunorubicin	98-108	thioredoxin	Homo sapiens	45-56
16159878-3	2005	We show here that MCF-7 cells overexpressing thioredoxin (Trx) were more apoptotic in response to daunomycin.	Daunorubicin	98-108	thioredoxin	Homo sapiens	58-61
16159878-5	2005	Enhanced generation of O2- in response to daunomycin inTrx-overexpressing MCF-7 cells was inhibited by diphenyleneiodonium chloride, a general NADPH reductase inhibitor, demonstrating that Trx provides reducing equivalents to a bioreductive enzyme for redox cycling of daunomycin.	Daunorubicin	42-52	thioredoxin	Homo sapiens	55-58
16159878-5	2005	Enhanced generation of O2- in response to daunomycin inTrx-overexpressing MCF-7 cells was inhibited by diphenyleneiodonium chloride, a general NADPH reductase inhibitor, demonstrating that Trx provides reducing equivalents to a bioreductive enzyme for redox cycling of daunomycin.	Daunorubicin	269-279	thioredoxin	Homo sapiens	55-58
16159878-8	2005	In addition, down-regulation of endogenous Trx expression by small interfering RNA resulted in decreased expression of caspase-7 and cleaved poly(ADP-ribose) polymerase expression in response to daunomycin.	Daunorubicin	195-205	thioredoxin	Homo sapiens	43-46
16159878-8	2005	In addition, down-regulation of endogenous Trx expression by small interfering RNA resulted in decreased expression of caspase-7 and cleaved poly(ADP-ribose) polymerase expression in response to daunomycin.	Daunorubicin	195-205	caspase 7	Homo sapiens	119-128
16159878-8	2005	In addition, down-regulation of endogenous Trx expression by small interfering RNA resulted in decreased expression of caspase-7 and cleaved poly(ADP-ribose) polymerase expression in response to daunomycin.	Daunorubicin	195-205	poly(ADP-ribose) polymerase 1	Homo sapiens	141-168
16339857-8	2005	Transport of daunorubicin was reduced by the P-gp inhibitors verapamil and quinacrine and also by the organic cation tetraethylammonium.	Daunorubicin	13-25	Multi drug resistance 65	Drosophila melanogaster	45-49
16327214-0	2005	Inhibitory action of daunorubicin on lipopolysaccharide-stimulated inducible-type nitric oxide synthase induction in alveolar macrophages.	Daunorubicin	21-33	nitric oxide synthase 2	Rattus norvegicus	67-103
16327214-1	2005	The purpose of this study was to investigate the effects of daunorubicin on lipopolysaccharide (LPS)-stimulated inducible-type nitric oxide synthase (iNOS) expression in macrophages.	Daunorubicin	60-72	nitric oxide synthase 2	Rattus norvegicus	112-148
16327214-1	2005	The purpose of this study was to investigate the effects of daunorubicin on lipopolysaccharide (LPS)-stimulated inducible-type nitric oxide synthase (iNOS) expression in macrophages.	Daunorubicin	60-72	nitric oxide synthase 2	Rattus norvegicus	150-154
16327214-2	2005	LPS-stimulated iNOS expression and NO production were significantly inhibited in alveolar macrophages from rats administrated daunorubicin (4 mg/kg body weight per day) for 5 consecutive days.	Daunorubicin	126-138	nitric oxide synthase 2	Rattus norvegicus	15-19
16327214-3	2005	Incubation of macrophages with daunorubicin at 1 muM but not at 0.1 and 0.5 muM significantly inhibited LPS-stimulated NO production and iNOS induction.	Daunorubicin	31-43	nitric oxide synthase 2	Rattus norvegicus	137-141
16327214-4	2005	Activation of extracellular regulated kinase (ERK) by LPS was markedly attenuated in both macrophages isolated from in vivo daunorubicin-treated rats and those incubated in vitro with daunorubicin at 1 microM.	Daunorubicin	124-136	Eph receptor B1	Rattus norvegicus	14-44
16327214-4	2005	Activation of extracellular regulated kinase (ERK) by LPS was markedly attenuated in both macrophages isolated from in vivo daunorubicin-treated rats and those incubated in vitro with daunorubicin at 1 microM.	Daunorubicin	124-136	Eph receptor B1	Rattus norvegicus	46-49
16327214-4	2005	Activation of extracellular regulated kinase (ERK) by LPS was markedly attenuated in both macrophages isolated from in vivo daunorubicin-treated rats and those incubated in vitro with daunorubicin at 1 microM.	Daunorubicin	184-196	Eph receptor B1	Rattus norvegicus	14-44
16327214-4	2005	Activation of extracellular regulated kinase (ERK) by LPS was markedly attenuated in both macrophages isolated from in vivo daunorubicin-treated rats and those incubated in vitro with daunorubicin at 1 microM.	Daunorubicin	184-196	Eph receptor B1	Rattus norvegicus	46-49
16327214-7	2005	These results suggest that in vivo treatment of rats with daunorubicin attenuates LPS-induced iNOS expression of macrophages through inhibition of ERK activation, while inhibition of iNOS induction by in vitro incubation with daunorubicin may be mainly due to its cytotoxicity.	Daunorubicin	58-70	nitric oxide synthase 2	Rattus norvegicus	94-98
16327214-7	2005	These results suggest that in vivo treatment of rats with daunorubicin attenuates LPS-induced iNOS expression of macrophages through inhibition of ERK activation, while inhibition of iNOS induction by in vitro incubation with daunorubicin may be mainly due to its cytotoxicity.	Daunorubicin	58-70	Eph receptor B1	Rattus norvegicus	147-150
16327214-7	2005	These results suggest that in vivo treatment of rats with daunorubicin attenuates LPS-induced iNOS expression of macrophages through inhibition of ERK activation, while inhibition of iNOS induction by in vitro incubation with daunorubicin may be mainly due to its cytotoxicity.	Daunorubicin	226-238	nitric oxide synthase 2	Rattus norvegicus	183-187
16170381-4	2005	BM cells from gadd45a- and gadd45b-deficient mice were observed to be more sensitive to ultraviolet radiation chemotherapy (UVC), VP-16 and daunorubicin (DNR)-induced apoptosis compared to wild-type (wt) cells.	Daunorubicin	140-152	growth arrest and DNA-damage-inducible 45 alpha	Mus musculus	14-21
16170381-4	2005	BM cells from gadd45a- and gadd45b-deficient mice were observed to be more sensitive to ultraviolet radiation chemotherapy (UVC), VP-16 and daunorubicin (DNR)-induced apoptosis compared to wild-type (wt) cells.	Daunorubicin	140-152	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	27-34
16170381-4	2005	BM cells from gadd45a- and gadd45b-deficient mice were observed to be more sensitive to ultraviolet radiation chemotherapy (UVC), VP-16 and daunorubicin (DNR)-induced apoptosis compared to wild-type (wt) cells.	Daunorubicin	154-157	growth arrest and DNA-damage-inducible 45 alpha	Mus musculus	14-21
16170381-4	2005	BM cells from gadd45a- and gadd45b-deficient mice were observed to be more sensitive to ultraviolet radiation chemotherapy (UVC), VP-16 and daunorubicin (DNR)-induced apoptosis compared to wild-type (wt) cells.	Daunorubicin	154-157	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	27-34
16255603-9	2005	The most effective inhibitor of aggregation of Abeta protein was daunomycin followed in descending order by 3-indolepropionic acid, melatonin, and then methysticin.	Daunorubicin	65-75	amyloid beta precursor protein	Homo sapiens	47-52
16343180-1	2005	Overexpression of breast cancer resistance protein (BCRP) and mitoxantrone (MX) resistance protein can confer resistance to a variety of cytostatic drugs, such as MX, topotecan (TPT), doxorubicin, and daunorubicin.	Daunorubicin	201-213	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	18-50
16343180-1	2005	Overexpression of breast cancer resistance protein (BCRP) and mitoxantrone (MX) resistance protein can confer resistance to a variety of cytostatic drugs, such as MX, topotecan (TPT), doxorubicin, and daunorubicin.	Daunorubicin	201-213	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	52-56
16264104-6	2005	Subsequent experiments tested the ability of stress-inducing drugs, anisomycin and daunorubicin, to promote apoptosis by stimulating an endogenous Fas-FasL pathway in OSEs.	Daunorubicin	83-95	Fas ligand	Bos taurus	151-155
16264104-8	2005	Treatment with anisomycin or daunorubicin in the presence of ZVAD increased expression of FasL mRNA and protein but did not alter expression of Fas mRNA or protein.	Daunorubicin	29-41	Fas ligand	Bos taurus	90-94
16264104-9	2005	Treatment of OSEs with a recombinant protein that blocks interaction of FasL with Fas (Fas:Fc) reduced apoptosis in response to anisomycin and daunorubicin, indicating that drug-induced apoptosis was mediated at least partially through endogenous Fas-FasL interactions.	Daunorubicin	143-155	Fas ligand	Bos taurus	72-76
16139251-2	2005	We examined the effects of three alkyl (n-butyl, n-octyl and n-dodecyl) gallates and their related compounds on the cellular accumulation and efflux of rhodamine 123 and daunorubicin in P-gp overexpressing KB-C2 cells.	Daunorubicin	170-182	ATP binding cassette subfamily B member 1	Homo sapiens	186-190
16139251-7	2005	The cytotoxicity of daunorubicin was recovered in the presence of alkyl gallates possibly due to their inhibition of P-gp function.	Daunorubicin	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	117-121
15985615-4	2005	We report that at pharmacologically relevant concentrations, salicylic acid stimulates oxidation of daunorubicin and doxorubicin by myeloperoxidase and lactoperoxidase systems and that efficacy of the process increases markedly on changing the pH from 7 to 5.	Daunorubicin	100-112	myeloperoxidase	Homo sapiens	132-147
16111844-5	2005	In the presence of NP-9, the apical uptake of daunomycin was increased, suggesting competitive inhibition between NP-9 and daunomycin in the efflux via the P-gp system.	Daunorubicin	46-56	phosphoglycolate phosphatase	Homo sapiens	156-160
16111844-5	2005	In the presence of NP-9, the apical uptake of daunomycin was increased, suggesting competitive inhibition between NP-9 and daunomycin in the efflux via the P-gp system.	Daunorubicin	123-133	phosphoglycolate phosphatase	Homo sapiens	156-160
15964731-0	2005	Interaction of daunomycin antibiotic with human serum albumin: investigation by resonant mirror biosensor technique, fluorescence spectroscopy and molecular modeling methods.	Daunorubicin	15-25	albumin	Homo sapiens	48-61
15964731-1	2005	Daunomycin (DM) is a clinically used antitumor anthracycline antibiotic, which is transported primarily by human serum albumin (HSA) in the blood.	Daunorubicin	0-10	albumin	Homo sapiens	113-126
16159384-7	2005	The ability of the proteasome inhibitor MG-132 to affect P-glycoprotein function was monitored by fluorescence due to accumulation of daunorubicin in P-glycoprotein overexpressing KB 8-5 cells.	Daunorubicin	134-146	ATP binding cassette subfamily B member 1	Homo sapiens	57-71
16159384-7	2005	The ability of the proteasome inhibitor MG-132 to affect P-glycoprotein function was monitored by fluorescence due to accumulation of daunorubicin in P-glycoprotein overexpressing KB 8-5 cells.	Daunorubicin	134-146	ATP binding cassette subfamily B member 1	Homo sapiens	150-164
16159384-10	2005	The proteasome inhibitor MG-132 caused a dose-dependent accumulation of daunorubicin in KB 8-5 cells that overexpress P-glycoprotein, suggesting that it blocked P-glycoprotein function.	Daunorubicin	72-84	ATP binding cassette subfamily B member 1	Homo sapiens	118-132
16159384-10	2005	The proteasome inhibitor MG-132 caused a dose-dependent accumulation of daunorubicin in KB 8-5 cells that overexpress P-glycoprotein, suggesting that it blocked P-glycoprotein function.	Daunorubicin	72-84	ATP binding cassette subfamily B member 1	Homo sapiens	161-175
16085187-9	2005	Anticancer anthracyclines (daunorubicin and doxorubicin) were, in contrast to the alkylating agents, not inhibitors but poor substrates of TrxR.	Daunorubicin	27-39	peroxiredoxin 5	Homo sapiens	139-143
16188140-7	2005	Compared with HL-60 and HL-60/pc cells, HL-60/CYP3A5 cells were statistically significantly resistant to daunorubicin, aclacinomycin A, vincristine and harringtonine (resistance multiples were 2.89, 2.01, 4.05 and 2.79 times, respectively, P &lt; 0.05), however the sensitivity to teniposide didn"t change (resistance multiple was 1.04 times).	Daunorubicin	105-117	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	46-52
16114498-5	2005	The accumulation of daunomycin (DNM), a P-gp substrate, was greater in the sensitive cells compared to the resistant cells, while the efflux of DNM was higher in the resistant cells compared to the sensitive cells over a period of 2 h. The IC50 value of DNM in the resistant cells was about 22 times higher than that in the sensitive cells, indicating an over-expression of P-gp in the resistant cells, MCF-7/ADR.	Daunorubicin	20-30	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
16114498-5	2005	The accumulation of daunomycin (DNM), a P-gp substrate, was greater in the sensitive cells compared to the resistant cells, while the efflux of DNM was higher in the resistant cells compared to the sensitive cells over a period of 2 h. The IC50 value of DNM in the resistant cells was about 22 times higher than that in the sensitive cells, indicating an over-expression of P-gp in the resistant cells, MCF-7/ADR.	Daunorubicin	32-35	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
16114498-5	2005	The accumulation of daunomycin (DNM), a P-gp substrate, was greater in the sensitive cells compared to the resistant cells, while the efflux of DNM was higher in the resistant cells compared to the sensitive cells over a period of 2 h. The IC50 value of DNM in the resistant cells was about 22 times higher than that in the sensitive cells, indicating an over-expression of P-gp in the resistant cells, MCF-7/ADR.	Daunorubicin	144-147	ATP binding cassette subfamily B member 1	Homo sapiens	374-378
16114498-5	2005	The accumulation of daunomycin (DNM), a P-gp substrate, was greater in the sensitive cells compared to the resistant cells, while the efflux of DNM was higher in the resistant cells compared to the sensitive cells over a period of 2 h. The IC50 value of DNM in the resistant cells was about 22 times higher than that in the sensitive cells, indicating an over-expression of P-gp in the resistant cells, MCF-7/ADR.	Daunorubicin	144-147	ATP binding cassette subfamily B member 1	Homo sapiens	374-378
16199376-2	2005	In vitro, these biotinylated immunoliposomes were used to by-pass P-glycoprotein in multidrug-resistant RBE4 brain capillary endothelial cells and thereby to achieve 2- to 3-fold higher intracellular accumulation of liposomal daunomycin as compared to free drug.	Daunorubicin	226-236	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	66-80
16199376-5	2005	Pharmacokinetics and tissue distribution studies in the rat revealed brain accumulation of daunomycin in OX26-immunoliposomes to higher levels as compared to brain uptake of free daunomycin, or daunomycin incorporated within pegylated liposomes or within unspecific IgG(2a) isotype control immunoliposomes.	Daunorubicin	91-101	gamma-2a immunoglobulin heavy chain	Rattus norvegicus	266-272
16117892-4	2005	RESULTS: Compared with HL-60/S, 20-40 micromol/L quercetin in vitro remarkably enhanced the sensitivity of HL-60/ADM cells to daunorubicin, down-regulated the expression of MRP(1) gene and its protein product MRP(1), restored the abnormal subcellular distribution of daunorubicin, so as to reverse MDR.	Daunorubicin	267-279	ATP binding cassette subfamily C member 1	Homo sapiens	173-179
15626738-6	2005	Overexpression of Bcl-x(L) was identified as the critical mediator of drug resistance and recapitulates the PTK inhibitor and daunorubicin-resistant phenotype in FLT3-ITD cells.	Daunorubicin	126-138	BCL2 like 1	Homo sapiens	18-26
15626738-6	2005	Overexpression of Bcl-x(L) was identified as the critical mediator of drug resistance and recapitulates the PTK inhibitor and daunorubicin-resistant phenotype in FLT3-ITD cells.	Daunorubicin	126-138	fms related receptor tyrosine kinase 3	Homo sapiens	162-166
15857279-2	2005	The intravitreal application of daunorubicin combined with CD95 ligand (CD95L) could provide a new therapeutic strategy.	Daunorubicin	32-44	Fas ligand	Bos taurus	72-77
15644429-5	2005	The screening identified 20 trimers of N-alkylglycine that increased the intracellular accumulation of daunomycin (DNM) in drug-resistant L1210R tumor cells that overexpressed the P-gp.	Daunorubicin	103-113	phosphoglycolate phosphatase	Mus musculus	180-184
15644429-5	2005	The screening identified 20 trimers of N-alkylglycine that increased the intracellular accumulation of daunomycin (DNM) in drug-resistant L1210R tumor cells that overexpressed the P-gp.	Daunorubicin	115-118	phosphoglycolate phosphatase	Mus musculus	180-184
15644429-6	2005	These compounds seem to act as P-gp antagonists, as evidenced by the augmentation of DNM accumulation in the L1210(P-gp) cell line, a drug-sensitive L1210 cell stably expressing the murine P-gp protein.	Daunorubicin	85-88	phosphoglycolate phosphatase	Mus musculus	31-35
15644429-6	2005	These compounds seem to act as P-gp antagonists, as evidenced by the augmentation of DNM accumulation in the L1210(P-gp) cell line, a drug-sensitive L1210 cell stably expressing the murine P-gp protein.	Daunorubicin	85-88	phosphoglycolate phosphatase	Mus musculus	115-119
15644429-6	2005	These compounds seem to act as P-gp antagonists, as evidenced by the augmentation of DNM accumulation in the L1210(P-gp) cell line, a drug-sensitive L1210 cell stably expressing the murine P-gp protein.	Daunorubicin	85-88	phosphoglycolate phosphatase	Mus musculus	115-119
15644429-7	2005	Similarly, several of the active N-trialkylglycines also produced an increment in DNM uptake in human HL60R cells, which primarily express the MRP1 protein.	Daunorubicin	82-85	ATP binding cassette subfamily C member 1	Homo sapiens	143-147
15854293-0	2005	[Influence of cytochrome C on apoptosis induced by daunorubicine in acute myeloid leukemia (AML) cells].	Daunorubicin	51-64	cytochrome c, somatic	Homo sapiens	14-26
15766280-3	2005	Membrane cholesterol controlled the ATPase activity of P-gp in a linear manner, whereas the P-gp-induced daunomycin efflux decreased nonlinearly with the depletion of membrane cholesterol.	Daunorubicin	105-115	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
15766280-6	2005	Finally, we showed that the decreased daunomycin efflux by P-gp due to the partial depletion of membrane cholesterol was responsible for the efficient chemosensitization of resistant CEM cells, which could be totally reversed after cholesterol repletion.	Daunorubicin	38-48	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
15688011-4	2005	While hypoxia induced p53 accumulation without expression of its responsive genes (bax and p21), daunomycin treatment restored p53 transactivation activity and cell cycle progression.	Daunorubicin	97-107	tumor protein p53	Homo sapiens	127-130
15688011-5	2005	We also demonstrated a role for Akt activation in daunomycin-induced protection through phosphorylation and inactivation of the Bcl-2 family proapoptotic factor Bad.	Daunorubicin	50-60	AKT serine/threonine kinase 1	Homo sapiens	32-35
15733908-2	2005	We compared the effects of attenuated neuregulin/erbB signaling and of daunorubicin on splicing of the Bcl-x gene and on mitochondrial activation of apoptosis in cardiomyocytes.	Daunorubicin	71-83	Bcl2-like 1	Rattus norvegicus	103-108
15733908-7	2005	Daunorubicin also caused Bcl-xS/Bcl-xL enhancement and mitochondrial apoptotic activation in cultured cardiomyocytes; this was attenuated by BH4-fusion protein or by neuregulin-1 and augmented by siRNA-mediated Bcl-xL lowering.	Daunorubicin	0-12	Bcl2-like 1	Rattus norvegicus	32-38
15733908-7	2005	Daunorubicin also caused Bcl-xS/Bcl-xL enhancement and mitochondrial apoptotic activation in cultured cardiomyocytes; this was attenuated by BH4-fusion protein or by neuregulin-1 and augmented by siRNA-mediated Bcl-xL lowering.	Daunorubicin	0-12	Bcl2-like 1	Rattus norvegicus	211-217
15649425-1	2005	The effects of dietary phytochemicals on P-glycoprotein function were investigated using human multidrug-resistant carcinoma KB-C2 cells and the fluorescent P-glycoprotein substrates daunorubicin and rhodamine 123.	Daunorubicin	183-195	ATP binding cassette subfamily B member 1	Homo sapiens	157-171
15639231-7	2005	The DNA interacting ligands nogalamycin, daunorubicin, actinomycin C1, and ethidium bromide were inhibitory to DNA unwinding (with K(i) values of 0.40, 2.21, 8.0, and 9.0 microM, respectively) and ATPase (with K(i) values of 0.43, 1.65, 4.6, and 7.0 microM, respectively) activities of the enzyme.	Daunorubicin	41-53	dynein axonemal heavy chain 8	Homo sapiens	197-203
15580299-2	2005	Cells cultured in the presence of EPO exhibited an elevated apoptotic response to cancer chemotherapeutic agents such as daunorubicin (Dauno) and vinblastine (VBL).	Daunorubicin	121-133	erythropoietin	Homo sapiens	34-37
15580299-2	2005	Cells cultured in the presence of EPO exhibited an elevated apoptotic response to cancer chemotherapeutic agents such as daunorubicin (Dauno) and vinblastine (VBL).	Daunorubicin	135-140	erythropoietin	Homo sapiens	34-37
15580299-4	2005	In vitro monotherapy with Dauno or VBL induced the degradation of IkappaBalpha, provoked the translocation of NF-kappaB p65/50 to the nucleus and stimulated the expression of an NF-kappaB-activatable reporter gene.	Daunorubicin	26-31	NFKB inhibitor alpha	Homo sapiens	66-78
15580299-4	2005	In vitro monotherapy with Dauno or VBL induced the degradation of IkappaBalpha, provoked the translocation of NF-kappaB p65/50 to the nucleus and stimulated the expression of an NF-kappaB-activatable reporter gene.	Daunorubicin	26-31	nuclear factor kappa B subunit 1	Homo sapiens	110-119
15580299-4	2005	In vitro monotherapy with Dauno or VBL induced the degradation of IkappaBalpha, provoked the translocation of NF-kappaB p65/50 to the nucleus and stimulated the expression of an NF-kappaB-activatable reporter gene.	Daunorubicin	26-31	RELA proto-oncogene, NF-kB subunit	Homo sapiens	120-123
15580299-4	2005	In vitro monotherapy with Dauno or VBL induced the degradation of IkappaBalpha, provoked the translocation of NF-kappaB p65/50 to the nucleus and stimulated the expression of an NF-kappaB-activatable reporter gene.	Daunorubicin	26-31	nuclear factor kappa B subunit 1	Homo sapiens	178-187
15331656-8	2005	Moreover, P-glycoprotein-mediated daunomycin resistance could only be marginally restored by KP1019 in serum-containing medium, also indicating an influence of serum proteins on the interaction between KP1019 and P-glycoprotein.	Daunorubicin	34-44	ATP binding cassette subfamily B member 1	Homo sapiens	10-24
15331656-8	2005	Moreover, P-glycoprotein-mediated daunomycin resistance could only be marginally restored by KP1019 in serum-containing medium, also indicating an influence of serum proteins on the interaction between KP1019 and P-glycoprotein.	Daunorubicin	34-44	ATP binding cassette subfamily B member 1	Homo sapiens	213-227
15304385-0	2004	Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.	Daunorubicin	49-61	fms related receptor tyrosine kinase 3	Homo sapiens	65-69
15498506-4	2004	In this work, three compounds that were shown to inhibit the MRP1-mediated efflux of daunorubicin (DNR) have been studied.	Daunorubicin	85-97	ATP binding cassette subfamily C member 1	Homo sapiens	61-65
15585622-9	2004	Pgp function was a prognostic factor in patients treated by daunorubicin and idarubicin but not by mitoxantrone.	Daunorubicin	60-72	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
15585622-10	2004	In contrast, BCRP expression was a prognostic factor in patients treated by daunorubicin and mitoxantrone but not by idarubicin.	Daunorubicin	76-88	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	13-17
15517563-9	2004	MXRG cells displayed the highest level of resistance to MXR, doxorubicin, and daunorubicin in the cytotoxicity assays.	Daunorubicin	78-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-3
15717737-4	2004	In randomized clinical trials, PLD induced higher response rates than did the conventional combination chemotherapy regimens, bleomycin + vincristine (BV) and BV + conventional doxorubicin (ABV); DNX produced a response rate comparable to that of ABV.	Daunorubicin	196-199	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	31-34
15717744-4	2004	Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi"s sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]).	Daunorubicin	254-266	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	228-231
15717744-4	2004	Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi"s sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]).	Daunorubicin	268-277	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	228-231
15717744-4	2004	Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi"s sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]).	Daunorubicin	279-282	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	228-231
15514562-4	2004	In accord with the fact that effector caspase-3 is responsible for PARP-1 cleavage, 4 microM concentrations of DAU and these TT bisquinones all maximally induce caspase-3 activity at 6 h in HL-60-S cells, an effect which persists when the drugs are removed after a 1-h pulse treatment.	Daunorubicin	111-114	caspase 3	Homo sapiens	38-47
15514562-4	2004	In accord with the fact that effector caspase-3 is responsible for PARP-1 cleavage, 4 microM concentrations of DAU and these TT bisquinones all maximally induce caspase-3 activity at 6 h in HL-60-S cells, an effect which persists when the drugs are removed after a 1-h pulse treatment.	Daunorubicin	111-114	caspase 3	Homo sapiens	161-170
15514562-5	2004	Since caspase-3 may be activated by initiator caspase-9 and -8, it is significant to show that such caspase activation cascade is induced by 4 microM DAU and TT bisquinones at 6 h in HL-60-S cells.	Daunorubicin	150-153	caspase 3	Homo sapiens	6-15
15514562-5	2004	Since caspase-3 may be activated by initiator caspase-9 and -8, it is significant to show that such caspase activation cascade is induced by 4 microM DAU and TT bisquinones at 6 h in HL-60-S cells.	Daunorubicin	150-153	caspase 9	Homo sapiens	46-62
15514562-5	2004	Since caspase-3 may be activated by initiator caspase-9 and -8, it is significant to show that such caspase activation cascade is induced by 4 microM DAU and TT bisquinones at 6 h in HL-60-S cells.	Daunorubicin	150-153	caspase 2	Homo sapiens	6-13
15514562-8	2004	The release of mitochondrial Cyt c is also detected within 6 h in HL-60-S cells treated with 4 microM DAU or TT bisquinones, a finding consistent with the fact that Cyt c is the apoptotic trigger that activates caspase-9.	Daunorubicin	102-105	cytochrome c, somatic	Homo sapiens	29-34
15514562-8	2004	The release of mitochondrial Cyt c is also detected within 6 h in HL-60-S cells treated with 4 microM DAU or TT bisquinones, a finding consistent with the fact that Cyt c is the apoptotic trigger that activates caspase-9.	Daunorubicin	102-105	cytochrome c, somatic	Homo sapiens	165-170
15514562-8	2004	The release of mitochondrial Cyt c is also detected within 6 h in HL-60-S cells treated with 4 microM DAU or TT bisquinones, a finding consistent with the fact that Cyt c is the apoptotic trigger that activates caspase-9.	Daunorubicin	102-105	caspase 9	Homo sapiens	211-220
15514562-10	2004	However, the mechanisms by which DAU and TT13 induce the release of mitochondrial Cyt c appear to be caspase-independent since they are both insensitive to similar pre-treatments with 100 microM of these specific caspase-2 and -8 inhibitors.	Daunorubicin	33-36	cytochrome c, somatic	Homo sapiens	82-87
15514562-10	2004	However, the mechanisms by which DAU and TT13 induce the release of mitochondrial Cyt c appear to be caspase-independent since they are both insensitive to similar pre-treatments with 100 microM of these specific caspase-2 and -8 inhibitors.	Daunorubicin	33-36	caspase 2	Homo sapiens	101-108
15514562-10	2004	However, the mechanisms by which DAU and TT13 induce the release of mitochondrial Cyt c appear to be caspase-independent since they are both insensitive to similar pre-treatments with 100 microM of these specific caspase-2 and -8 inhibitors.	Daunorubicin	33-36	caspase 2	Homo sapiens	213-229
15375375-4	2004	Depletion of MDR1 by si-MDR1 correlated with the increased sensitivity of the cells to cytotoxic agents and with the enhanced intracellular retention of daunorubicin (DNR).	Daunorubicin	153-165	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
15375375-4	2004	Depletion of MDR1 by si-MDR1 correlated with the increased sensitivity of the cells to cytotoxic agents and with the enhanced intracellular retention of daunorubicin (DNR).	Daunorubicin	153-165	ATP binding cassette subfamily B member 1	Homo sapiens	24-28
15375375-4	2004	Depletion of MDR1 by si-MDR1 correlated with the increased sensitivity of the cells to cytotoxic agents and with the enhanced intracellular retention of daunorubicin (DNR).	Daunorubicin	167-170	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
15375375-4	2004	Depletion of MDR1 by si-MDR1 correlated with the increased sensitivity of the cells to cytotoxic agents and with the enhanced intracellular retention of daunorubicin (DNR).	Daunorubicin	167-170	ATP binding cassette subfamily B member 1	Homo sapiens	24-28
15375376-5	2004	The reversal of MDR was accompanied by a complete suppression of MDR1/P-gp expression on mRNA and protein level, and by a considerable increased intracellular anthracyline accumulation in the anti-MDR1/P-gp shRNA-treated cells.	Daunorubicin	159-171	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
15375376-5	2004	The reversal of MDR was accompanied by a complete suppression of MDR1/P-gp expression on mRNA and protein level, and by a considerable increased intracellular anthracyline accumulation in the anti-MDR1/P-gp shRNA-treated cells.	Daunorubicin	159-171	phosphoglycolate phosphatase	Homo sapiens	202-206
15543344-6	2004	Treatment with increasing concentrations of daunorubicin or cytosine-beta-D-arabinofuranoside, two cytotoxic drugs commonly used in AML therapy, induced apoptosis and secondary necrosis of HL60 cells and resulted in marked decryption of TF PCA independent of de novo protein synthesis.	Daunorubicin	44-56	coagulation factor III, tissue factor	Homo sapiens	237-239
15466210-5	2004	Cytotoxicity assays using human MDR1-transfected NIH-3T3 cells allowed us to select the most potent sesquiterpenes reversing the in vitro resistance to daunomycin and vinblastine.	Daunorubicin	152-162	ATP binding cassette subfamily B member 1	Homo sapiens	32-36
15380050-7	2004	The effect of G-CSF, GM-CSF, IL3 and M-CSF on daunorubicin mediated cytotoxicity in K562 cells was measured using the MTT assay.	Daunorubicin	46-58	colony stimulating factor 3	Homo sapiens	14-19
15380050-7	2004	The effect of G-CSF, GM-CSF, IL3 and M-CSF on daunorubicin mediated cytotoxicity in K562 cells was measured using the MTT assay.	Daunorubicin	46-58	interleukin 3	Homo sapiens	29-32
15161671-4	2004	We now report that the levels of mRNAs encoding the cholesterol synthesis-regulating enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and the cholesterol-importing low-density lipoprotein (LDL) receptor were both increased by daunorubicin (DNR) or cytarabine (ARA-C) treatments in almost three fourths of cultured AML samples.	Daunorubicin	234-246	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	93-140
15161671-4	2004	We now report that the levels of mRNAs encoding the cholesterol synthesis-regulating enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and the cholesterol-importing low-density lipoprotein (LDL) receptor were both increased by daunorubicin (DNR) or cytarabine (ARA-C) treatments in almost three fourths of cultured AML samples.	Daunorubicin	234-246	low density lipoprotein receptor	Homo sapiens	172-210
15517865-7	2004	Within 24 h of treatment with paclitaxel, Bcl-2 formed a doublet at 26 kilodaltons and the expression was abrogated with daunorubicin and the combination of the two drugs as determined by Western blots.	Daunorubicin	121-133	BCL2 apoptosis regulator	Homo sapiens	42-47
15763945-5	2004	Similarly caspase-3 activity was significantly elevated in HCAECs treated with doxorubicin, daunorubicin, and idamycin.	Daunorubicin	92-104	caspase 3	Homo sapiens	10-19
15178484-2	2004	Here, the effect of acetaminophen on the metabolism of daunorubicin and doxorubicin by isolated enzymes lactoperoxidase and myeloperoxidase, and by myeloperoxidase-containing human leukemia HL-60 cells was investigated using spectrophotometric and EPR techniques.	Daunorubicin	55-67	myeloperoxidase	Homo sapiens	124-139
15178484-2	2004	Here, the effect of acetaminophen on the metabolism of daunorubicin and doxorubicin by isolated enzymes lactoperoxidase and myeloperoxidase, and by myeloperoxidase-containing human leukemia HL-60 cells was investigated using spectrophotometric and EPR techniques.	Daunorubicin	55-67	myeloperoxidase	Homo sapiens	148-163
15257929-0	2004	Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.	Daunorubicin	129-141	ATP binding cassette subfamily B member 1	Homo sapiens	21-35
15176077-2	2004	BITC, PEITC, and 1-NITC significantly increased the 2-h accumulation of DNM in MCF-7/ADR (P-gp overexpression), PANC-1 (MRP1 overexpression), and human colon adenocarcinoma Caco-2 cells (except for 1-NITC).	Daunorubicin	72-75	ATP binding cassette subfamily B member 1	Homo sapiens	90-94
15176077-2	2004	BITC, PEITC, and 1-NITC significantly increased the 2-h accumulation of DNM in MCF-7/ADR (P-gp overexpression), PANC-1 (MRP1 overexpression), and human colon adenocarcinoma Caco-2 cells (except for 1-NITC).	Daunorubicin	72-75	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
15194168-9	2004	Peripheral blood mononuclear cells were isolated by gradient centrifugation and incubated with daunorubicin (DNR) (a fluorescent drug extruded by P-gp).	Daunorubicin	95-107	ATP binding cassette subfamily B member 1	Homo sapiens	146-150
15194168-9	2004	Peripheral blood mononuclear cells were isolated by gradient centrifugation and incubated with daunorubicin (DNR) (a fluorescent drug extruded by P-gp).	Daunorubicin	109-112	ATP binding cassette subfamily B member 1	Homo sapiens	146-150
15126359-8	2004	FAK+ AML cells displayed significantly higher migration capacities and resistance to daunorubicin, compared with FAK- cells.	Daunorubicin	85-97	protein tyrosine kinase 2	Homo sapiens	0-3
15126359-10	2004	However, adhesion on fibronectin efficiently protected FAK- AML cells from daunorubicin-mediated killing, suggesting that cellular adhesion mediated-drug resistance is not mediated by FAK.	Daunorubicin	75-87	fibronectin 1	Homo sapiens	21-32
15126359-10	2004	However, adhesion on fibronectin efficiently protected FAK- AML cells from daunorubicin-mediated killing, suggesting that cellular adhesion mediated-drug resistance is not mediated by FAK.	Daunorubicin	75-87	protein tyrosine kinase 2	Homo sapiens	55-58
14766899-0	2004	Cytoprotective effect of glucosylceramide synthase inhibition against daunorubicin-induced apoptosis in human leukemic cell lines.	Daunorubicin	70-82	UDP-glucose ceramide glucosyltransferase	Homo sapiens	25-50
15121897-0	2004	DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene.	Daunorubicin	39-49	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	132-137
15121897-4	2004	The 11mer daunomycin-conjugated GT (dauno-GT11) TFO targeted a sequence upstream of the P2 promoter, a site known to be critical for transcription of the c-myc gene.	Daunorubicin	10-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	154-159
15121897-7	2004	The daunomycin-conjugated TFO inhibited transcription in vitro and reduced c-myc promoter activity in prostate and breast cancer cells.	Daunorubicin	4-14	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	75-80
15041471-3	2004	In this study we determined whether cellular folate status affected the functional activity of MRP1/ABCC1 mediated efflux of an established substrate, the anthracycline daunorubicin (DNR).	Daunorubicin	169-181	ATP binding cassette subfamily C member 1	Homo sapiens	95-99
15041471-3	2004	In this study we determined whether cellular folate status affected the functional activity of MRP1/ABCC1 mediated efflux of an established substrate, the anthracycline daunorubicin (DNR).	Daunorubicin	169-181	ATP binding cassette subfamily C member 1	Homo sapiens	100-105
15041471-3	2004	In this study we determined whether cellular folate status affected the functional activity of MRP1/ABCC1 mediated efflux of an established substrate, the anthracycline daunorubicin (DNR).	Daunorubicin	183-186	ATP binding cassette subfamily C member 1	Homo sapiens	95-99
15041471-3	2004	In this study we determined whether cellular folate status affected the functional activity of MRP1/ABCC1 mediated efflux of an established substrate, the anthracycline daunorubicin (DNR).	Daunorubicin	183-186	ATP binding cassette subfamily C member 1	Homo sapiens	100-105
15160935-4	2004	BCRP confers resistance to chemotherapeutic agents, such as mitoxantrone, doxorubicin and daunorubicin.	Daunorubicin	90-102	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-4
15053878-2	2004	Here, we demonstrate that NF-kappa B induced by cytotoxic stimuli, such as ultraviolet light (UV-C) and the chemotherapeutic drugs daunorubicin/doxorubicin, is functionally distinct to that seen with the inflammatory cytokine TNF and is an active repressor of antiapoptotic gene expression.	Daunorubicin	131-143	nuclear factor kappa B subunit 1	Homo sapiens	26-36
15053878-4	2004	Furthermore, UV-C and daunorubicin inhibit TNF-induced NF-kappa B transactivation, indicating that this is a dominant effect.	Daunorubicin	22-34	tumor necrosis factor	Homo sapiens	43-46
15053878-4	2004	Furthermore, UV-C and daunorubicin inhibit TNF-induced NF-kappa B transactivation, indicating that this is a dominant effect.	Daunorubicin	22-34	nuclear factor kappa B subunit 1	Homo sapiens	55-65
15053878-5	2004	Consistent with this, mechanistic studies reveal that UV-C and daunorubicin induce the association of RelA with histone deacetylases.	Daunorubicin	63-75	RELA proto-oncogene, NF-kB subunit	Homo sapiens	102-106
14750166-3	2004	The degree of intracellular accumulation of daunorubicin was related to the particular localization of P-gp-EGFP.	Daunorubicin	44-56	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
14750166-4	2004	Significant daunorubicin accumulation occurred in transfected cells when P-gp-EGFP was localized predominantly within the ER, and accumulation remained high when P-gp-EGFP was mainly localized in the Golgi.	Daunorubicin	12-24	ATP binding cassette subfamily B member 1	Homo sapiens	73-77
14750166-8	2004	Our study shows that P-gp-EGFP can be used to define the dynamics of P-gp traffic in a transient expression system, and demonstrates that localization of P-gp on the plasma membrane is associated with the highest level of resistance to daunorubicin accumulation in cells.	Daunorubicin	236-248	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
14750166-8	2004	Our study shows that P-gp-EGFP can be used to define the dynamics of P-gp traffic in a transient expression system, and demonstrates that localization of P-gp on the plasma membrane is associated with the highest level of resistance to daunorubicin accumulation in cells.	Daunorubicin	236-248	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
14750166-8	2004	Our study shows that P-gp-EGFP can be used to define the dynamics of P-gp traffic in a transient expression system, and demonstrates that localization of P-gp on the plasma membrane is associated with the highest level of resistance to daunorubicin accumulation in cells.	Daunorubicin	236-248	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
14985110-4	2004	On the other hand, the activity of P-glycoprotein, which was examined by measuring the accumulation of Rhodamine-123 and daunomycin, was increased by prolonged TBT treatment in a concentration-dependent manner (1-100 nM).	Daunorubicin	121-131	ATP binding cassette subfamily B member 1	Homo sapiens	35-49
15161018-3	2004	The only method allowing the detection of LRP activity is based on radio-labelled daunorubicin incorporation.	Daunorubicin	82-94	major vault protein	Homo sapiens	42-45
15161039-7	2004	The activity of MRP in 257P/MDR and its drug-sensitive derivative were studied in human stomach cancer cells by daunorubicin accumulation in a flow cytometer.	Daunorubicin	112-124	ATP binding cassette subfamily C member 1	Homo sapiens	16-19
14662759-7	2004	Consistent with this increased expression of cell survival genes, MEKK3 stable cells showed reduced activation of caspases 3 and 8 and poly(ADP-ribose) polymerase cleavage and dramatically increased resistance to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand, doxorubicin, daunorubicin, camptothecin, and paclitaxel.	Daunorubicin	304-316	mitogen-activated protein kinase kinase kinase 3	Homo sapiens	66-71
14973069-4	2004	We provide evidence that exposure of human leukemia cells to low concentrations of RSV (4-8 micro M) inhibits caspase activation, DNA fragmentation, and translocation of cytochrome c induced by hydrogen peroxide or anticancer drugs C2, vincristine, and daunorubicin.	Daunorubicin	253-265	cytochrome c, somatic	Homo sapiens	170-182
14643888-7	2004	Furthermore, Z-VAD-fmk treatment is able to completely inhibit the daunorubicin-induced apoptosis in A-431 cells, but only slightly blocks the daunorubicin-induced PARP cleavage, whereas BD-fmk can inhibit both daunorubicin-induced apoptosis and PARP cleavage completely.	Daunorubicin	143-155	poly (ADP-ribose) polymerase family, member 1	Mus musculus	164-168
14643888-7	2004	Furthermore, Z-VAD-fmk treatment is able to completely inhibit the daunorubicin-induced apoptosis in A-431 cells, but only slightly blocks the daunorubicin-induced PARP cleavage, whereas BD-fmk can inhibit both daunorubicin-induced apoptosis and PARP cleavage completely.	Daunorubicin	143-155	poly (ADP-ribose) polymerase family, member 1	Mus musculus	164-168
14757231-6	2004	In addition, the translocation of NBD-PC by proteoliposomes containing MRP1 protein is in a glutathione-dependent manner, similar to the process of translocating anticancer drugs such as daunorubicin.	Daunorubicin	187-199	ATP binding cassette subfamily C member 1	Homo sapiens	71-75
14754410-4	2004	Over-expression of ABCG2 in cell lines confers resistance on a wide variety of anticancer drugs including mitoxantrone, daunorubicin, doxorubicin, topotecan and epirubicin.	Daunorubicin	120-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	19-24
15141364-2	2004	The present study evaluated the mutagenic and recombinagenic properties of two anthracycline topoisomerase II (topo II) poisons, daunorubicin (DNR) and idarubicin (IDA), as well as the related topo II catalytic inhibitor aclarubicin (ACLA), using the wing Somatic Mutation and Recombination Test (SMART) in Drosophila melanogaster.	Daunorubicin	129-141	Topoisomerase 2	Drosophila melanogaster	111-118
14701777-1	2004	PURPOSE: Randomized comparisons of idarubicin (IDA) with daunorubicin (DNR) show that in adults with acute myeloid leukemia (AML), IDA achieves higher remission rates and longer remission durations.	Daunorubicin	57-69	alpha-L-iduronidase	Homo sapiens	131-134
15559760-0	2004	The ability of new sugar-modified derivatives of antitumor anthracycline, daunorubicin, to stimulate NAD(P)H oxidation in different cellular oxidoreductase systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase.	Daunorubicin	74-86	thioredoxin reductase 1	Homo sapiens	141-155
15559760-0	2004	The ability of new sugar-modified derivatives of antitumor anthracycline, daunorubicin, to stimulate NAD(P)H oxidation in different cellular oxidoreductase systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase.	Daunorubicin	74-86	cytochrome p450 oxidoreductase	Homo sapiens	185-216
15559760-3	2004	In this work the data on the ability of new amino sugar derivatives of daunorubicin to stimulate NAD(P)H oxidation in the above oxidoreductase systems are presented.	Daunorubicin	71-83	thioredoxin reductase 1	Homo sapiens	128-142
14654373-4	2003	Daunorubicin-induced activation of caspase-3 in cardiomyocytes was similarly inhibited by NRG-1beta.	Daunorubicin	0-12	caspase 3	Rattus norvegicus	35-44
14654373-5	2003	The phosphoinositol-3-kinase (PI3-kinase) inhibitor wortmannin prevented the effects of NRG-1beta on daunorubicin-induced apoptosis and activation of caspase-3.	Daunorubicin	101-113	caspase 3	Rattus norvegicus	150-159
14534356-1	2003	The apparent inhibition constant, Kapp, for the blockade of P-glycoprotein (P-gp) by four drugs, verapamil, cyclosporin A, XR9576 (tariquidar), and vinblastine, was measured by studying their ability to inhibit daunorubicin and calcein-AM efflux from four strains of Ehrlich cells with different levels of drug resistance and P-gp content.	Daunorubicin	211-223	phosphoglycolate phosphatase	Mus musculus	60-74
14534356-2	2003	For daunorubicin as a transport substrate, Kapp was independent of [P-gp] for verapamil but increased strictly linearly with [P-gp] for vinblastine, cyclosporin A, and XR9576.	Daunorubicin	4-16	phosphoglycolate phosphatase	Mus musculus	126-130
14612912-5	2003	Cells transfected with mutant ABCG2 were 13- to 71- fold resistant to the P-glycoprotein substrates doxorubicin, daunorubicin, epirubicin, bisantrene, and rhodamine 123 compared to cells transfected with wild-type ABCG2, which were only three- to four-fold resistant to these compounds.	Daunorubicin	113-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	30-35
14563488-0	2003	Bcl-2 overexpression prevents daunorubicin-induced apoptosis through inhibition of XIAP and Akt degradation.	Daunorubicin	30-42	BCL2 apoptosis regulator	Homo sapiens	0-5
14563488-0	2003	Bcl-2 overexpression prevents daunorubicin-induced apoptosis through inhibition of XIAP and Akt degradation.	Daunorubicin	30-42	X-linked inhibitor of apoptosis	Homo sapiens	83-87
14563488-0	2003	Bcl-2 overexpression prevents daunorubicin-induced apoptosis through inhibition of XIAP and Akt degradation.	Daunorubicin	30-42	AKT serine/threonine kinase 1	Homo sapiens	92-95
14563488-3	2003	Treatment with 3 microM DNR for 12 hr produced morphological features of apoptosis and DNA fragmentation in U937 cells, which was associated with caspase-3 activation and PLC-gamma 1 degradation.	Daunorubicin	24-27	caspase 3	Homo sapiens	146-155
14563488-3	2003	Treatment with 3 microM DNR for 12 hr produced morphological features of apoptosis and DNA fragmentation in U937 cells, which was associated with caspase-3 activation and PLC-gamma 1 degradation.	Daunorubicin	24-27	phospholipase C gamma 1	Homo sapiens	171-182
14618274-2	2003	In this study we used daunorubicin-treated Chinchilla rabbits as a model to investigate the relationship between left ventricular contractility and cTnT plasma concentrations.	Daunorubicin	22-34	troponin T2, cardiac type	Homo sapiens	148-152
14618274-6	2003	RESULTS: Cardiac contractility was significantly lower in seven surviving daunorubicin-treated animals than in control animals (745.7+/-69.3 vs 1393.4+/-25.5 kPa/s; P&lt;0.001), while cTnT plasma concentrations were significantly increased (medians 0.278 vs 0.000 ng/ml; P&lt;0.001).	Daunorubicin	74-86	troponin T2, cardiac type	Homo sapiens	184-188
14618274-7	2003	When the dP/dtmax values of individual daunorubicin-treated animals were plotted against the corresponding cTnT plasma concentrations, a close negative linear correlation was found (R=-0.910; P&lt;0.005; regression equation: dP/dtmax=-1861*cTnT+1234).	Daunorubicin	39-51	troponin T2, cardiac type	Homo sapiens	107-111
14618274-7	2003	When the dP/dtmax values of individual daunorubicin-treated animals were plotted against the corresponding cTnT plasma concentrations, a close negative linear correlation was found (R=-0.910; P&lt;0.005; regression equation: dP/dtmax=-1861*cTnT+1234).	Daunorubicin	39-51	troponin T2, cardiac type	Homo sapiens	240-244
14613996-1	2003	PURPOSE: Overexpression of the transporter ABCG2, also known as breast cancer resistance protein and mitoxantrone resistance protein, can confer resistance to a variety of cytostatic drugs, such as mitoxantrone, topotecan, doxorubicin, and daunorubicin.	Daunorubicin	240-252	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	43-48
14613996-1	2003	PURPOSE: Overexpression of the transporter ABCG2, also known as breast cancer resistance protein and mitoxantrone resistance protein, can confer resistance to a variety of cytostatic drugs, such as mitoxantrone, topotecan, doxorubicin, and daunorubicin.	Daunorubicin	240-252	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	64-96
14713364-0	2003	Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.	Daunorubicin	47-59	ATP binding cassette subfamily B member 1	Homo sapiens	23-37
14604468-5	2003	Some of these compounds inhibit the active P-gp-mediated efflux of the fluorescent markers LDS-751 and daunorubicin with low potency, with the most potent among them, phenethyl isothiocyanate, inhibiting transport of the LDS-751 substrate with an IC(50) of approximately 240 microM.	Daunorubicin	103-115	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
12888645-7	2003	Additionally, two typical p-glycoprotein substrates, daunomycin and verapamil, both inhibited choline accumulation.	Daunorubicin	53-63	ATP binding cassette subfamily B member 1	Homo sapiens	26-40
12948013-5	2003	RESULTS: In situ experimental results revealed that the extent to which the intestinal absorption is affected by P-gp was in the following order: quinidine &gt; ritonavir &gt; loperamide, verapamil, daunomycin &gt; digoxin, cyclosporin A &gt; dexamethasone, and vinblastine.	Daunorubicin	199-209	ATP binding cassette subfamily B member 1	Homo sapiens	113-117
12818351-5	2003	Expression of P-gp in this mutant confers cross-resistance to mitomycin C, tegafur, daunorubicin, rhodamine 6G, tetraphenylphosphonium bromide and ciprofloxacin.	Daunorubicin	84-96	phosphoglycolate phosphatase	Mus musculus	14-18
12824222-0	2003	Characterization of daunorubicin-induced apoptosis in retinal pigment epithelial cells: modulation by CD95L.	Daunorubicin	20-32	Fas ligand	Homo sapiens	102-107
12824222-1	2003	PURPOSE: To characterize daunorubicin-induced cell death in cultured human retinal pigment epithelial (RPE) cells and its modulation by CD95 ligand (CD95L).	Daunorubicin	25-37	Fas ligand	Homo sapiens	136-147
12824222-1	2003	PURPOSE: To characterize daunorubicin-induced cell death in cultured human retinal pigment epithelial (RPE) cells and its modulation by CD95 ligand (CD95L).	Daunorubicin	25-37	Fas ligand	Homo sapiens	149-154
12824222-8	2003	Daunorubicin-induced RPE cell apoptosis was associated with enhanced CD95 and CD95L expression.	Daunorubicin	0-12	Fas cell surface death receptor	Homo sapiens	69-73
12824222-8	2003	Daunorubicin-induced RPE cell apoptosis was associated with enhanced CD95 and CD95L expression.	Daunorubicin	0-12	Fas ligand	Homo sapiens	78-83
12824222-10	2003	In contrast, the cytotoxic effects of daunorubicin were synergistically enhanced by exogenous CD95L.	Daunorubicin	38-50	Fas ligand	Homo sapiens	94-99
12820137-5	2003	The in vivo canalicular excretion clearance (CL(exc)) of daunomycin was also decreased by 79% (p &lt; 0.01) in PCM rats, but the degree was more severe than would be expected from the 22% decrease in the expression of P-gp and the 33% decrease in the uptake of daunomycin (CL(int)).	Daunorubicin	57-67	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	218-222
12820137-7	2003	In summary, the canalicular excretion of P-gp substrates, such as daunomycin, might be reduced in patients with PCM via a mechanism involving the suppression of the expression of P-gp.	Daunorubicin	66-76	phosphoglycolate phosphatase	Homo sapiens	41-45
12820137-7	2003	In summary, the canalicular excretion of P-gp substrates, such as daunomycin, might be reduced in patients with PCM via a mechanism involving the suppression of the expression of P-gp.	Daunorubicin	66-76	phosphoglycolate phosphatase	Homo sapiens	179-183
12788478-4	2003	Similar to daunorubicin (DNR), mercury causes downregulation of GATA-4 mRNA expression.	Daunorubicin	11-23	GATA binding protein 4	Homo sapiens	64-70
12780785-4	2003	However, incubation with TRAIL combined with fludarabine, cytosine arabinoside or daunorubicin resulted in additive or super-additive apoptosis induction in approximately half of the isolates.	Daunorubicin	82-94	TNF superfamily member 10	Homo sapiens	25-30
12780785-6	2003	The ability of TRAIL and daunorubicin to induce super-additive apoptosis correlated with the ability of these agents to activate caspase 8 and to augment cellular levels of the truncated pro-apoptotic form of the BCL-2 family member BID.	Daunorubicin	25-37	caspase 8	Homo sapiens	129-138
12829023-6	2003	Peripheral blood mononuclear cells were isolated by gradient centrifugation and incubated with daunorubicin (a fluorescent drug extruded by P-gp).	Daunorubicin	95-107	ATP binding cassette subfamily B member 1	Homo sapiens	140-144
12859862-2	2003	METHODS: By using RT-PCR, immunohistochemistry and MTT assay, CYP3A5 mRNA and protein were detected in leukemia cell lines and acute leukemia patients, meanwhile transcriptional regulation of CYP3A5 induced by daunorubicin was observed.	Daunorubicin	210-222	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	62-68
12859862-2	2003	METHODS: By using RT-PCR, immunohistochemistry and MTT assay, CYP3A5 mRNA and protein were detected in leukemia cell lines and acute leukemia patients, meanwhile transcriptional regulation of CYP3A5 induced by daunorubicin was observed.	Daunorubicin	210-222	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	192-198
12859862-4	2003	RESULTS: CYP3A5 mRNA was detected in K562 and U937 cells, whose IC(50) values of daunorubicin were 2.1-fold higher than those of NB4 and HL-60 cells.	Daunorubicin	81-93	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	9-15
12859862-7	2003	Daunorubicin increased CYP3A5 mRNA level in K562/A02 and activated its transcription in HL-60/ADR.	Daunorubicin	0-12	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	23-29
12859862-7	2003	Daunorubicin increased CYP3A5 mRNA level in K562/A02 and activated its transcription in HL-60/ADR.	Daunorubicin	0-12	aldo-keto reductase family 1 member B	Homo sapiens	94-97
12859862-8	2003	HL-60/CYP3A5 cell was significantly resistant to daunorubicin and vincristine than HL-60 cells did (3.0 and 4.0 times, respectively).	Daunorubicin	49-61	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	6-12
12706238-9	2003	Consistently, first transport studies indicate that active exclusion of the chemotherapeutic drug daunorubicin from the central nervous system is mediated mainly by this new transporter compared to P-glycoprotein or MRP1.	Daunorubicin	98-110	ATP binding cassette subfamily B member 1	Homo sapiens	198-212
12706238-9	2003	Consistently, first transport studies indicate that active exclusion of the chemotherapeutic drug daunorubicin from the central nervous system is mediated mainly by this new transporter compared to P-glycoprotein or MRP1.	Daunorubicin	98-110	ATP binding cassette subfamily C member 1	Homo sapiens	216-220
12894558-2	2003	Drug resistance in human colon carcinoma (SW620 Ad300) and breast carcinoma (MCF-7/INT500, MCF-7/AD150 and MCF-7/TH) cell lines is predominantly due to overexpression of P-glycoprotein (P-gp) resulting in decreased daunorubicin (DNR) accumulation.	Daunorubicin	215-227	ATP binding cassette subfamily B member 1	Homo sapiens	170-184
12714083-1	2003	The interactions between daunorubicin and human serum albumin (HSA) were studied using the spectrofluorimetric method.	Daunorubicin	25-37	albumin	Homo sapiens	48-61
12704006-4	2003	The BCRP-overexpressing tumor cells are resistant to mitoxantrone, adriamycin, daunorubicin, etoposide, topotecan and irinotecan, but lack resistance to paclitaxel and vincristine.	Daunorubicin	79-91	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	4-8
12604704-5	2003	The flavonoids increased [(3)H]DNM accumulation in P-gp positive cells, but not P-gp negative cells, and these effects were both flavonoid concentration- and P-gp expression level-dependent.	Daunorubicin	31-34	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
12406911-0	2003	Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin.	Daunorubicin	81-93	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	30-35
12406911-1	2003	In light of the emerging concept of a protective function of the mitogen-activated protein kinase (MAPK) pathway under stress conditions, we investigated the influence of the anthracycline daunorubicin (DNR) on MAPK signaling and its possible contribution to DNR-induced cytotoxicity.	Daunorubicin	189-201	mitogen-activated protein kinase 3	Homo sapiens	211-215
12406911-1	2003	In light of the emerging concept of a protective function of the mitogen-activated protein kinase (MAPK) pathway under stress conditions, we investigated the influence of the anthracycline daunorubicin (DNR) on MAPK signaling and its possible contribution to DNR-induced cytotoxicity.	Daunorubicin	203-206	mitogen-activated protein kinase 3	Homo sapiens	211-215
12468531-9	2003	Furthermore, expression of the GATA-4 mutant (S105A) suppresses HGF-mediated protection of cells against daunorubicin-induced apoptosis.	Daunorubicin	105-117	GATA binding protein 4	Rattus norvegicus	31-37
12468531-9	2003	Furthermore, expression of the GATA-4 mutant (S105A) suppresses HGF-mediated protection of cells against daunorubicin-induced apoptosis.	Daunorubicin	105-117	hepatocyte growth factor	Rattus norvegicus	64-67
12536201-8	2003	Combined RNAi for c-raf and bcl-2 induced apoptosis in HL-60, U937, and THP-1 cells and increased chemosensitivity to etoposide and daunorubicin.	Daunorubicin	132-144	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	18-23
12536201-8	2003	Combined RNAi for c-raf and bcl-2 induced apoptosis in HL-60, U937, and THP-1 cells and increased chemosensitivity to etoposide and daunorubicin.	Daunorubicin	132-144	BCL2 apoptosis regulator	Homo sapiens	28-33
12647012-0	2003	Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells.	Daunorubicin	105-117	phosphoglycolate phosphatase	Homo sapiens	89-93
12647012-1	2003	PURPOSE: To investigate the effects of arsenic trioxide (As(2)O(3)) on human T-lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 (MOLT-4/DNR) cells.	Daunorubicin	136-148	phosphoglycolate phosphatase	Homo sapiens	120-124
12532374-1	2003	The purpose of this study was to identify the effects of dietary flavonoids, which are present in fruits, vegetables, and plant-derived beverages, on the transport of daunomycin (DNM) and vinblastine (VBL) in Panc-1 cells.	Daunorubicin	167-177	dynamin 1	Homo sapiens	179-182
12527808-5	2003	Treatment of HL-1 cardiac muscle cells or isolated adult rat ventricular myocytes with anthracyclines such as daunorubicin and doxorubicin decreased the level of GATA-4 DNA-binding activity.	Daunorubicin	110-122	GATA binding protein 4	Rattus norvegicus	162-168
12527911-3	2003	We observed that NF-kappaB or P-glycoprotein inhibition in the HCT15 colon cancer cells led to increased apoptotic cell death in response to daunomycin treatment.	Daunorubicin	141-151	nuclear factor kappa B subunit 1	Homo sapiens	17-26
12527911-4	2003	Interestingly, NF-kappaB inhibition through transfection of a plasmid coding for a mutated IkappaB-alpha inhibitor increased daunomycin cell uptake.	Daunorubicin	125-135	nuclear factor kappa B subunit 1	Homo sapiens	15-24
12527911-4	2003	Interestingly, NF-kappaB inhibition through transfection of a plasmid coding for a mutated IkappaB-alpha inhibitor increased daunomycin cell uptake.	Daunorubicin	125-135	NFKB inhibitor alpha	Homo sapiens	91-104
12708479-4	2003	Transport experiments using LLC-GA5-COL150 cell monolayers demonstrated that this effect of carvedilol was due to the inhibition of MDR1-mediated transport of vinblastine, paclitaxel, doxorubicin and daunorubicin.	Daunorubicin	200-212	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	132-136
12655365-1	2003	We show that treating human trisomic fibroblasts with anthracyclines - aclarubicin, daunorubicin and idarubicin - leads to certain changes in these cells; namely the activation of caspase 3, morphological changes and an increase in the level of intracellular calcium.	Daunorubicin	84-96	caspase 3	Homo sapiens	180-189
14640900-5	2003	In this work, we investigated the effects of daunorubicin and quercetin on mitochondrial enzyme activities such as ATPase, glutathione peroxidase (GPx) and glutathione reductase (GR).	Daunorubicin	45-57	glutathione-disulfide reductase	Rattus norvegicus	156-177
14640900-7	2003	The activity of ATPase and GR were significantly increased after daunorubicin application.	Daunorubicin	65-77	glutathione-disulfide reductase	Rattus norvegicus	27-29
12528795-6	2003	For example, expression of the newly described half transporter BCRP is related to daunorubicin resistance (p &lt; 0.05).	Daunorubicin	83-95	BCR pseudogene 1	Homo sapiens	64-68
12351644-3	2002	NF-kappaB was activated in HepG2 cells shortly after therapeutic doses of ionizing radiation or daunorubicin treatment that translated into up-regulation of kappaB-dependent genes.	Daunorubicin	96-108	nuclear factor kappa B subunit 1	Homo sapiens	0-9
12406551-0	2002	Induction of poly(ADP-ribose) polymerase-1 cleavage by antitumor triptycene bisquinones in wild-type and daunorubicin-resistant HL-60 cell lines.	Daunorubicin	105-117	poly(ADP-ribose) polymerase 1	Homo sapiens	13-42
12520735-1	2002	BACKGROUND &amp; OBJECTIVE: The previous study has identified two novel antisense oligonucleotides (AS-ODN) of new target point in the translation initiation and the coding region of bcl-2 mRNA that could increase the sensitivity of HL-60 and K562 cells lines to etoposide, daunorubicin, and araninosyl cytosine (Ara-C).	Daunorubicin	274-286	BCL2 apoptosis regulator	Homo sapiens	183-188
12434406-9	2002	If this occurs in the gastrointestinal epithelial cells, the repeated administration of berberine may reduce the gastrointestinal absorption of P-gp substrates including chemotherapeutic agents such as daunomycin.	Daunorubicin	202-212	ATP binding cassette subfamily B member 1	Homo sapiens	144-148
12435813-4	2002	We show that PKCzeta overexpression resulted in delayed apoptosis and significant resistance to both 1-beta-D-arabinofuranosylcytosine (ara-C) and daunorubicin (DNR), but there was no significant protection against cell-permeant C(6)-CER.	Daunorubicin	147-159	protein kinase C zeta	Homo sapiens	13-20
12435813-4	2002	We show that PKCzeta overexpression resulted in delayed apoptosis and significant resistance to both 1-beta-D-arabinofuranosylcytosine (ara-C) and daunorubicin (DNR), but there was no significant protection against cell-permeant C(6)-CER.	Daunorubicin	161-164	protein kinase C zeta	Homo sapiens	13-20
12164785-3	2002	Daunorubicin only affected wild-type yeast strains at very high concentrations; however, erg6 mutant strains (but not pdr1, pdr3 or pdr5 strains) were sensitive to daunorubicin at low micromolar concentrations.	Daunorubicin	164-176	sterol 24-C-methyltransferase	Saccharomyces cerevisiae S288C	89-93
12164785-4	2002	In Delta erg6 strains, daunorubicin inhibited the galactose-induced transcription by Gal4p in a specific manner, since the transcription of identical reporters driven by other activators (either constitutive or inducible) was not inhibited.	Daunorubicin	23-35	sterol 24-C-methyltransferase	Saccharomyces cerevisiae S288C	9-13
12164785-4	2002	In Delta erg6 strains, daunorubicin inhibited the galactose-induced transcription by Gal4p in a specific manner, since the transcription of identical reporters driven by other activators (either constitutive or inducible) was not inhibited.	Daunorubicin	23-35	galactose-responsive transcription factor GAL4	Saccharomyces cerevisiae S288C	85-90
12164785-6	2002	Furthermore, daunorubicin inhibited the growth in galactose and the transcriptional induction of resident Gal4p-driven genes upon galactose addition, two processes absolutely dependent on Gal4p function.	Daunorubicin	13-25	galactose-responsive transcription factor GAL4	Saccharomyces cerevisiae S288C	106-111
12164785-6	2002	Furthermore, daunorubicin inhibited the growth in galactose and the transcriptional induction of resident Gal4p-driven genes upon galactose addition, two processes absolutely dependent on Gal4p function.	Daunorubicin	13-25	galactose-responsive transcription factor GAL4	Saccharomyces cerevisiae S288C	188-193
12410571-0	2002	Resistance of bcr-abl-positive acute lymphoblastic leukemia to daunorubicin is not mediated by mdr1 gene expression.	Daunorubicin	63-75	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	14-21
12410571-9	2002	The median LD(50) of daunorubicin (concentration lethal to 50% of the leukemic blasts) differed significantly between bcr-abl-positive and -negative patients (P = 0.018).	Daunorubicin	21-33	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	118-125
12410571-10	2002	This in vitro study suggests that bcr-abl-positive ALL is relatively resistant to daunorubicin, but this resistance is not mediated through mdr1 gene expression.	Daunorubicin	82-94	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	34-41
12414644-5	2002	Analysis of the drug sensitivity of MRP6-transfected cells revealed low levels of resistance to several natural product agents, including etoposide, teniposide, doxorubicin, and daunorubicin.	Daunorubicin	178-190	ATP binding cassette subfamily C member 6	Homo sapiens	36-40
12642689-2	2002	We have observed that exogenous expression of MRITalpha1/cFLIP(L) isoform also protects against cell death induced by a diverse group of chemotherapeutic drugs with different mechanisms of action, including doxorubicin, etoposide, cytosine arabinoside, daunorubicin, chlorambucil and cisplatin.	Daunorubicin	253-265	CASP8 and FADD like apoptosis regulator	Homo sapiens	57-62
12385892-0	2002	Daunorubicin- and Ara-C-induced interphasic apoptosis of human type II leukemia cells is caspase-8-independent.	Daunorubicin	0-12	caspase 8	Homo sapiens	89-98
12151395-4	2002	Treatment of HCT116/p21(-/-) cells with daunomycin resulted in a reduction of the mitochondrial membrane potential and in activation of caspase-9, whereas no such changes were observed in HCT116/p21(+/+) cells, providing evidence that p21(WAF1) exerts an antagonistic effect on the mitochondrial pathway of apoptosis.	Daunorubicin	40-50	cyclin dependent kinase inhibitor 1A	Homo sapiens	20-23
12151395-4	2002	Treatment of HCT116/p21(-/-) cells with daunomycin resulted in a reduction of the mitochondrial membrane potential and in activation of caspase-9, whereas no such changes were observed in HCT116/p21(+/+) cells, providing evidence that p21(WAF1) exerts an antagonistic effect on the mitochondrial pathway of apoptosis.	Daunorubicin	40-50	caspase 9	Homo sapiens	136-145
12151395-4	2002	Treatment of HCT116/p21(-/-) cells with daunomycin resulted in a reduction of the mitochondrial membrane potential and in activation of caspase-9, whereas no such changes were observed in HCT116/p21(+/+) cells, providing evidence that p21(WAF1) exerts an antagonistic effect on the mitochondrial pathway of apoptosis.	Daunorubicin	40-50	cyclin dependent kinase inhibitor 1A	Homo sapiens	239-243
12151395-5	2002	Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-alpha reduced the sensitivity of HCT116/p21(-/-) cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21(+/+) cells.	Daunorubicin	188-198	tumor protein p53	Homo sapiens	22-25
12151395-5	2002	Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-alpha reduced the sensitivity of HCT116/p21(-/-) cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21(+/+) cells.	Daunorubicin	188-198	tumor protein p53	Homo sapiens	104-107
12151395-5	2002	Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-alpha reduced the sensitivity of HCT116/p21(-/-) cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21(+/+) cells.	Daunorubicin	188-198	cyclin dependent kinase inhibitor 1A	Homo sapiens	170-173
12151395-5	2002	Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-alpha reduced the sensitivity of HCT116/p21(-/-) cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21(+/+) cells.	Daunorubicin	188-198	BCL2 associated X, apoptosis regulator	Homo sapiens	232-235
12151395-5	2002	Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-alpha reduced the sensitivity of HCT116/p21(-/-) cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21(+/+) cells.	Daunorubicin	188-198	BCL2 apoptosis regulator	Homo sapiens	236-241
12206990-0	2002	Ara-C- and daunorubicin-induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts.	Daunorubicin	11-23	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	47-50
12206990-5	2002	Under Ara-C and daunorubicin (DNR) treatment, Lyn is rapidly activated and translocated into rafts.	Daunorubicin	16-28	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	46-49
12425469-0	2002	Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine.	Daunorubicin	88-98	ATP binding cassette subfamily B member 1	Homo sapiens	41-55
12425469-0	2002	Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine.	Daunorubicin	88-98	ATP binding cassette subfamily C member 1	Homo sapiens	61-65
12425469-12	2002	Our results indicate that certain dietary ITCs inhibit the P-gp- and the MRP1-mediated efflux of DNM and VBL in MDR cancer cells and suggest the potential for diet-drug interactions.	Daunorubicin	97-100	ATP binding cassette subfamily C member 1	Homo sapiens	73-77
12115804-9	2002	To test this hypothesis, we examined the ability of nontoxic concentrations of CPT to sensitize MRP1-overexpressing cells to daunorubicin (DNR).	Daunorubicin	125-137	ATP binding cassette subfamily C member 1	Homo sapiens	96-100
12222768-6	2002	It suggested that the upregulation of bax mediated by daunorubicin could lead to the onset of apoptosis, and therefore contribute to its therapeutic mechanisms for the treatment of PVR.	Daunorubicin	54-66	BCL2 associated X, apoptosis regulator	Homo sapiens	38-41
12145683-2	2002	Transfection and enforced expression of BCRP in drug-sensitive cells confers resistance to mitoxantrone, doxorubicin, daunorubicin and topotecan.	Daunorubicin	118-130	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	40-44
12136248-2	2002	In order to gain further insighte into these mechanisms, a P-glycoprotein-mediated multidrug-resistant phenotype induced by daunorubicin-selection and an alternative drug resistance due to treatment with mitoxantrone were investigated in pancreatic carcinoma-derived cells.	Daunorubicin	124-136	ATP binding cassette subfamily B member 1	Homo sapiens	59-73
12032660-5	2002	In parallel, we found that, by inhibiting degradation of I kappa B, hGH gene transfer diminished NF-kappa B entry into the nuclei of U937 cells exposed to daunorubicin.	Daunorubicin	155-167	nuclear factor kappa B subunit 1	Homo sapiens	97-107
12107549-2	2002	METHODS: Three sublines were developed from the sensitive Ehrlich ascites tumour cell line (EHR2) and six sublines from the EHR2/DNR cell line positive for P-glycoprotein (PGP) by treatment with daunorubicin (DNR), a combination of DNR and verapamil (VER), or a combination of DNR and cyclosporin A (CsA).	Daunorubicin	195-207	phosphoglycolate phosphatase	Mus musculus	156-170
12107549-2	2002	METHODS: Three sublines were developed from the sensitive Ehrlich ascites tumour cell line (EHR2) and six sublines from the EHR2/DNR cell line positive for P-glycoprotein (PGP) by treatment with daunorubicin (DNR), a combination of DNR and verapamil (VER), or a combination of DNR and cyclosporin A (CsA).	Daunorubicin	195-207	phosphoglycolate phosphatase	Mus musculus	172-175
12047375-6	2002	Similarly to modulators or ATP depleting agents, all the phosphate analogues increased daunorubicin accumulation in Pgp-expressing cells.	Daunorubicin	87-99	ATP binding cassette subfamily B member 1	Homo sapiens	116-119
11972515-1	2002	In this study, we tested the mechanisms of daunorubicin (DNR)- and the liposomal encapsulated daunorubicin (DaunoXome or DNX)-induced killing in three human leukaemic cell lines, K562, K/Bax and CEM.	Daunorubicin	94-106	BCL2 associated X, apoptosis regulator	Homo sapiens	187-190
12479265-1	2002	Bcl-2 inhibits apoptosis induced by numerous antitumor drugs, including doxorubicin and daunorubicin and is, thus, a major impediment to successful cancer chemotherapy.	Daunorubicin	88-100	B cell leukemia/lymphoma 2	Mus musculus	0-5
11867198-2	2002	Idarubicin (4-demethoxydaunorubicin; Ida), a semisynthetic derivative of daunorubicin (Dnr) is more potent than the parent compound in vitro and in vivo.	Daunorubicin	23-35	alpha-L-iduronidase	Homo sapiens	0-3
11867198-2	2002	Idarubicin (4-demethoxydaunorubicin; Ida), a semisynthetic derivative of daunorubicin (Dnr) is more potent than the parent compound in vitro and in vivo.	Daunorubicin	87-90	alpha-L-iduronidase	Homo sapiens	0-3
11801602-12	2002	Furthermore, doses of D-e-C(6) ceramide that induce the alternative splicing of both caspase 9 and Bcl-x-sensitized A549 cells to daunorubicin.	Daunorubicin	130-142	caspase 9	Homo sapiens	85-94
11801602-12	2002	Furthermore, doses of D-e-C(6) ceramide that induce the alternative splicing of both caspase 9 and Bcl-x-sensitized A549 cells to daunorubicin.	Daunorubicin	130-142	BCL2 like 1	Homo sapiens	99-104
11948114-1	2002	PURPOSE: The putative association between erbB-2 overexpression and favorable response to anthracyline-based therapy in breast cancer is controversial, and the mechanism unclear.	Daunorubicin	90-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	42-48
11989976-0	2002	D4-GDI is cleaved by caspase-3 during daunorubicin-induced apoptosis in HL-60 cells.	Daunorubicin	38-50	caspase 3	Homo sapiens	21-30
11989976-1	2002	Daunorubicin, an anti-cancer drug, is known to induce apoptosis in HL-60 cells in a dose-dependent manner through the activation of caspase-3 (CPP32).	Daunorubicin	0-12	caspase 3	Homo sapiens	132-141
11989976-1	2002	Daunorubicin, an anti-cancer drug, is known to induce apoptosis in HL-60 cells in a dose-dependent manner through the activation of caspase-3 (CPP32).	Daunorubicin	0-12	caspase 3	Homo sapiens	143-148
11849207-7	2002	In conclusion, P-gp overexpression associated with a defect in daunorubicin accumulation is a frequent feature in adult ALL at onset and seems to be related to poorer therapy outcome and, consequently, a shorter disease-free survival.	Daunorubicin	63-75	ATP binding cassette subfamily B member 1	Homo sapiens	15-19
11970764-9	2002	Recently, radiopharmaceuticals including carbon 11-labeled colchicine, verapamil, and daunorubicin have been used in cell line and animal studies for the evaluation of Pgp-mediated transport functions using PET technology.	Daunorubicin	86-98	ATP binding cassette subfamily B member 1	Homo sapiens	168-171
12125964-7	2002	Both, a drug-exporting and a chemoprotective function of P-gp as well as MRP1 could be demonstrated in selected tumor cells by a significant upregulation of cellular 3H-daunomycin accumulation and daunomycin cytotoxicity via administration of transporter antagonists.	Daunorubicin	169-179	ATP binding cassette subfamily B member 1	Homo sapiens	57-61
12125964-7	2002	Both, a drug-exporting and a chemoprotective function of P-gp as well as MRP1 could be demonstrated in selected tumor cells by a significant upregulation of cellular 3H-daunomycin accumulation and daunomycin cytotoxicity via administration of transporter antagonists.	Daunorubicin	169-179	ATP binding cassette subfamily B member 1	Homo sapiens	73-77
11854447-4	2002	In cross-resistance studies, we observed resistance of yeast sky1 Delta cells (i.e., cells from which the SKY1 gene had been disrupted) to cisplatin, carboplatin (but not oxaliplatin), doxorubicin and daunorubicin, and hypersensitivity to cadmium chloride and 5-fluorouracil.	Daunorubicin	201-213	serine/threonine protein kinase SKY1	Saccharomyces cerevisiae S288C	61-65
11854447-4	2002	In cross-resistance studies, we observed resistance of yeast sky1 Delta cells (i.e., cells from which the SKY1 gene had been disrupted) to cisplatin, carboplatin (but not oxaliplatin), doxorubicin and daunorubicin, and hypersensitivity to cadmium chloride and 5-fluorouracil.	Daunorubicin	201-213	serine/threonine protein kinase SKY1	Saccharomyces cerevisiae S288C	106-110
11838671-0	2002	Electrochemical evaluation of the interaction between endocrine disrupter chemicals and estrogen receptor using 17,beta-estradiol labeled with daunomycin.	Daunorubicin	143-153	estrogen receptor 1	Homo sapiens	88-105
11838671-2	2002	To evaluate the binding capacity of EDCs to the estrogen receptor (ER), 17beta-estradiol labeled with daunomycin as an electroactive compound was prepared.	Daunorubicin	102-112	estrogen receptor 1	Homo sapiens	67-69
11809686-5	2002	Our data showed that the expression of MRP1-EGFP results in significantly decreased cellular accumulation of tetramethylrhodamine ethyl ester (TMRE) and daunorubicin, mildly decreased cellular accumulation of mitoxantrone, and decreased nuclear accumulation of doxorubicin.	Daunorubicin	153-165	ATP binding cassette subfamily B member 1	Homo sapiens	39-43
15618650-5	2002	Expression of P-gp was detected by immunocytochemistry, and efflux-directed transport of the P-gp substrate [(3)H]daunomycin was observed.	Daunorubicin	114-124	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	93-97
11774251-3	2002	The anthracyclins daunorubicin and idarubicin increased the expression of activation-associated membrane molecules (GPIIb/IIIa, CD62P, CD63) by normal platelets, daunorubicin then having the strongest effect.	Daunorubicin	18-30	integrin subunit alpha 2b	Homo sapiens	116-121
11774251-3	2002	The anthracyclins daunorubicin and idarubicin increased the expression of activation-associated membrane molecules (GPIIb/IIIa, CD62P, CD63) by normal platelets, daunorubicin then having the strongest effect.	Daunorubicin	18-30	selectin P	Homo sapiens	128-133
11774251-3	2002	The anthracyclins daunorubicin and idarubicin increased the expression of activation-associated membrane molecules (GPIIb/IIIa, CD62P, CD63) by normal platelets, daunorubicin then having the strongest effect.	Daunorubicin	18-30	CD63 molecule	Homo sapiens	135-139
11774251-3	2002	The anthracyclins daunorubicin and idarubicin increased the expression of activation-associated membrane molecules (GPIIb/IIIa, CD62P, CD63) by normal platelets, daunorubicin then having the strongest effect.	Daunorubicin	162-174	integrin subunit alpha 2b	Homo sapiens	116-121
11774251-3	2002	The anthracyclins daunorubicin and idarubicin increased the expression of activation-associated membrane molecules (GPIIb/IIIa, CD62P, CD63) by normal platelets, daunorubicin then having the strongest effect.	Daunorubicin	162-174	CD63 molecule	Homo sapiens	135-139
11734307-3	2002	PK11195 can block p-glycoprotein efflux in AMLs, contributing to increased daunomycin toxicity in efflux-competent AMLs, but can also sensitize AMLs to cytarabine and DNR-sensitize efflux-incompetent AMLs, presumably via mitochondrial pore effects documented in other models.	Daunorubicin	75-85	ATP binding cassette subfamily B member 1	Homo sapiens	18-32
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Daunorubicin	172-184	phosphoglycolate phosphatase	Mus musculus	14-18
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Daunorubicin	172-184	phosphoglycolate phosphatase	Mus musculus	86-90
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Daunorubicin	172-184	phosphoglycolate phosphatase	Mus musculus	86-90
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Daunorubicin	172-184	phosphoglycolate phosphatase	Mus musculus	86-90
11703319-10	2001	Although there was no correlation between BCRP positivity and the effect of mitoxantrone, topotecan or doxorubicin, the median daunorubicin LC(50) value of BCRP(+) cells was fourfold higher than that of BCRP- cells (0.89 micromol/l compared with 0.21 micromol/l, P &lt; 0.05).	Daunorubicin	127-139	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	156-160
11703319-10	2001	Although there was no correlation between BCRP positivity and the effect of mitoxantrone, topotecan or doxorubicin, the median daunorubicin LC(50) value of BCRP(+) cells was fourfold higher than that of BCRP- cells (0.89 micromol/l compared with 0.21 micromol/l, P &lt; 0.05).	Daunorubicin	127-139	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	156-160
11606389-4	2001	In a test system consisting of a NIH-G185 cell line presenting an overexpressed amount of the human transporter Pgp, known Pgp inhibitors, such as cyclosporin A, paclitaxel, verapamil, tamoxifen, and vinblastine, were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin.	Daunorubicin	269-281	ATP binding cassette subfamily B member 1	Homo sapiens	112-115
11709710-3	2001	This study shows that daunorubicin-induced apoptosis and cytotoxicity were reduced in the murine Ba/F3 cells transfected with Kit (Ba/F3-Kit) in the presence of SCF and in Ba/F3 cells transfected with a constitutively active Kit variant (Ba/F3-KitDelta27), compared to either parental Ba/F3 (Ba/F3-wt) or unstimulated Ba/F3-Kit cells.	Daunorubicin	22-34	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	126-129
11709710-3	2001	This study shows that daunorubicin-induced apoptosis and cytotoxicity were reduced in the murine Ba/F3 cells transfected with Kit (Ba/F3-Kit) in the presence of SCF and in Ba/F3 cells transfected with a constitutively active Kit variant (Ba/F3-KitDelta27), compared to either parental Ba/F3 (Ba/F3-wt) or unstimulated Ba/F3-Kit cells.	Daunorubicin	22-34	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	131-140
11709710-3	2001	This study shows that daunorubicin-induced apoptosis and cytotoxicity were reduced in the murine Ba/F3 cells transfected with Kit (Ba/F3-Kit) in the presence of SCF and in Ba/F3 cells transfected with a constitutively active Kit variant (Ba/F3-KitDelta27), compared to either parental Ba/F3 (Ba/F3-wt) or unstimulated Ba/F3-Kit cells.	Daunorubicin	22-34	kit ligand	Mus musculus	161-164
11709710-3	2001	This study shows that daunorubicin-induced apoptosis and cytotoxicity were reduced in the murine Ba/F3 cells transfected with Kit (Ba/F3-Kit) in the presence of SCF and in Ba/F3 cells transfected with a constitutively active Kit variant (Ba/F3-KitDelta27), compared to either parental Ba/F3 (Ba/F3-wt) or unstimulated Ba/F3-Kit cells.	Daunorubicin	22-34	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	137-140
11709710-3	2001	This study shows that daunorubicin-induced apoptosis and cytotoxicity were reduced in the murine Ba/F3 cells transfected with Kit (Ba/F3-Kit) in the presence of SCF and in Ba/F3 cells transfected with a constitutively active Kit variant (Ba/F3-KitDelta27), compared to either parental Ba/F3 (Ba/F3-wt) or unstimulated Ba/F3-Kit cells.	Daunorubicin	22-34	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	137-140
11709710-4	2001	In Ba/F3-wt and in Ba/F3-Kit cells, daunorubicin stimulated within 8-15 min neutral sphingomyelinase and ceramide production but not in SCF-stimulated Ba/F3-Kit or in Ba/F3-KitDelta27 whereas all Ba/F3 cells were equally sensitive to exogenous cell-permeant C6-ceramide.	Daunorubicin	36-48	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	25-28
11709710-4	2001	In Ba/F3-wt and in Ba/F3-Kit cells, daunorubicin stimulated within 8-15 min neutral sphingomyelinase and ceramide production but not in SCF-stimulated Ba/F3-Kit or in Ba/F3-KitDelta27 whereas all Ba/F3 cells were equally sensitive to exogenous cell-permeant C6-ceramide.	Daunorubicin	36-48	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	19-28
11860442-0	2001	FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.	Daunorubicin	97-109	FA complementation group B	Homo sapiens	0-3
11860442-0	2001	FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.	Daunorubicin	97-109	CD14 molecule	Homo sapiens	16-20
11860442-2	2001	We demonstrate that high CD14 expression is highly significantly associated with high cellular Ara-C and Dau resistance in univariate as well as multivariate analyses.	Daunorubicin	105-108	CD14 molecule	Homo sapiens	25-29
11860442-3	2001	FAB subtypes with highest and lowest cellular Ara-C resistance were M4 and M5, respectively (P &lt; 0.01, one-way anova), whereas FAB subtypes with highest and lowest cellular Dau resistance were M4 and M1, respectively (P &lt; 0.01, one-way anova).	Daunorubicin	176-179	FA complementation group B	Homo sapiens	130-133
11860442-8	2001	We conclude that although cases with high blast cell CD14 expression (and FAB-M4 cases) were more resistant to Ara-C as well as Dau in vitro, the clinical and biological significance of this may be debatable because of interactions with major prognostic factors in AML.	Daunorubicin	128-131	CD14 molecule	Homo sapiens	53-57
11860442-8	2001	We conclude that although cases with high blast cell CD14 expression (and FAB-M4 cases) were more resistant to Ara-C as well as Dau in vitro, the clinical and biological significance of this may be debatable because of interactions with major prognostic factors in AML.	Daunorubicin	128-131	FA complementation group B	Homo sapiens	74-77
11585709-4	2001	HGF, at the concentrations which can be detected in the plasma of humans subsequent to myocardial infarction, effectively attenuated death of isolated adult rat cardiac myocytes and cultured HL-1 cardiac muscle cells induced by apoptosis-inducing oxidative stress stimuli such as daunorubicin, serum deprivation, and hydrogen peroxide.	Daunorubicin	280-292	hepatocyte growth factor	Homo sapiens	0-3
11522342-1	2001	The synthesis of two novel daunorubicin-estrogen conjugates with a steroidal and a non-steroidal ligand was undertaken in an attempt to target the cytotoxicity of anthracycline to estrogen-receptor positive cells.	Daunorubicin	27-39	estrogen receptor 1	Homo sapiens	180-197
11585053-4	2001	In this study, we compared the P-gp- and MRP1-mediated efflux of daunorubicin and its enantiomer WP900 in multidrug-resistant cells overexpressing either P-gp (K562/ADR cells) or MRP1 (GLC4/ADR cells).	Daunorubicin	65-77	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
11585053-4	2001	In this study, we compared the P-gp- and MRP1-mediated efflux of daunorubicin and its enantiomer WP900 in multidrug-resistant cells overexpressing either P-gp (K562/ADR cells) or MRP1 (GLC4/ADR cells).	Daunorubicin	65-77	ATP binding cassette subfamily C member 1	Homo sapiens	41-45
11441001-6	2001	Similar results were obtained by increased endogenous ceramide levels in response to nontoxic concentrations of daunorubicin, resulting in the inhibition of telomerase and c-Myc activities.	Daunorubicin	112-124	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	172-177
11672585-0	2001	Daunorubicin inhibits gene expression of cyclooxygenase-2 in vascular smooth muscle cells.	Daunorubicin	0-12	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	41-57
11672585-1	2001	Daunorubicin (0.1-1 microM) concentration-dependently inhibited prostacyclin production induced by interleukin-1beta (IL-1beta, 2.5 ng/ml) in cultured aortic smooth muscle cells isolated from rats.	Daunorubicin	0-12	interleukin 1 beta	Rattus norvegicus	99-116
11672585-1	2001	Daunorubicin (0.1-1 microM) concentration-dependently inhibited prostacyclin production induced by interleukin-1beta (IL-1beta, 2.5 ng/ml) in cultured aortic smooth muscle cells isolated from rats.	Daunorubicin	0-12	interleukin 1 beta	Rattus norvegicus	118-126
11672585-2	2001	IL-1beta stimulation caused activation of nuclear factor-kappaB (NF-kappaB) and expression of cyclooxygenase-2 (COX-2) mRNA and protein, which were inhibited by daunorubicin.	Daunorubicin	161-173	interleukin 1 beta	Rattus norvegicus	0-8
11672585-2	2001	IL-1beta stimulation caused activation of nuclear factor-kappaB (NF-kappaB) and expression of cyclooxygenase-2 (COX-2) mRNA and protein, which were inhibited by daunorubicin.	Daunorubicin	161-173	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	94-110
11672585-2	2001	IL-1beta stimulation caused activation of nuclear factor-kappaB (NF-kappaB) and expression of cyclooxygenase-2 (COX-2) mRNA and protein, which were inhibited by daunorubicin.	Daunorubicin	161-173	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	112-117
11672585-5	2001	Daunorubicin also inhibited nitric oxide (NO) production induced by IL-1beta.	Daunorubicin	0-12	interleukin 1 beta	Rattus norvegicus	68-76
11672585-6	2001	These results suggest that daunorubicin attenuated prostacyclin synthesis through inhibiting expression of COX-2 mRNA, which could be explained by perturbation of NF-kappaB activation.	Daunorubicin	27-39	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	107-112
11457496-2	2001	We found that cultured human astrocytes efficiently released PAI-1, and that both mRNA expression and protein release of PAI-1 were suppressed by pretreatment of the cells with daunorubicin.	Daunorubicin	177-189	serpin family E member 1	Homo sapiens	61-66
11457496-2	2001	We found that cultured human astrocytes efficiently released PAI-1, and that both mRNA expression and protein release of PAI-1 were suppressed by pretreatment of the cells with daunorubicin.	Daunorubicin	177-189	serpin family E member 1	Homo sapiens	121-126
11437380-3	2001	ABCG2 was expressed underglycosylated, and its ATPase activity was stimulated by daunorubicin, doxorubicin, mitoxantrone, prazosin and rhodamine 123, compounds known to be transported by this protein.	Daunorubicin	81-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-5
11437380-3	2001	ABCG2 was expressed underglycosylated, and its ATPase activity was stimulated by daunorubicin, doxorubicin, mitoxantrone, prazosin and rhodamine 123, compounds known to be transported by this protein.	Daunorubicin	81-93	dynein axonemal heavy chain 8	Homo sapiens	47-53
11335714-8	2001	Finally, stable overexpression of human glucosylceramide synthase, which attenuates ceramide levels by converting ceramide to glucosylceramide, prevented the inhibitory effects of C(6)-ceramide and daunorubicin on telomerase.	Daunorubicin	198-210	UDP-glucose ceramide glucosyltransferase	Homo sapiens	40-65
11369136-0	2001	Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators.	Daunorubicin	51-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	26-30
11369136-2	2001	For this reason, we have investigated the effect of combinations of suboptimal concentrations of Pgp blockers on the induction of apoptosis and growth arrest in daunorubicin (D) treated, MDR1 gene transfected cells.	Daunorubicin	161-173	phosphoglycolate phosphatase	Mus musculus	97-100
11430910-3	2001	Of the P-glycoprotein modulators tested, rhodamine123, verapamil and daunomycin concentration-dependently inhibited EMT-mediated uptake of [3H]1-methyl-4-phenylpyridinium ([3H]MPP(+)).	Daunorubicin	69-79	solute carrier family 22 member 3	Homo sapiens	116-119
11331076-6	2001	In addition, deoxycytidine deaminase, responsible for inactivation of dFdC and ara-C, was 9.0-fold lower in H69/DAU cells.	Daunorubicin	112-115	apolipoprotein B mRNA editing enzyme catalytic subunit 3G	Homo sapiens	13-36
11408043-1	2001	The present study examined how the multidrug resistance protein (MRP1), which is an ATP-dependent anionic conjugate transporter, also mediates the transport of reduced glutathione (GSH) and the co-transport of the cationic drug, daunorubicin, with GSH in living GLC4/Adr cells.	Daunorubicin	229-241	ATP binding cassette subfamily C member 1	Homo sapiens	65-69
11408043-6	2001	We investigated the GSH concentration dependence of the MRP1-mediated ATP-dependent transport of daunorubicin under conditions where the transport of daunorubicin became saturated.	Daunorubicin	97-109	ATP binding cassette subfamily C member 1	Homo sapiens	56-60
11408043-6	2001	We investigated the GSH concentration dependence of the MRP1-mediated ATP-dependent transport of daunorubicin under conditions where the transport of daunorubicin became saturated.	Daunorubicin	150-162	ATP binding cassette subfamily C member 1	Homo sapiens	56-60
11408043-8	2001	We were therefore in the situation where GSH acted as an activator: its presence was necessary for the binding and transport of daunorubicin by MRP1.	Daunorubicin	128-140	ATP binding cassette subfamily C member 1	Homo sapiens	144-148
11699226-0	2001	Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.	Daunorubicin	10-22	caspase recruitment domain family member 16	Homo sapiens	103-106
11699226-1	2001	We treated 33 patients with a variant of the standard 3 weekly CHOP regime, replacing doxorubicin with liposomal daunorubicin (DaunoXome, NeXstar Pharmaceuticals) 120 mg/m2 (COP-X).	Daunorubicin	113-125	caspase recruitment domain family member 16	Homo sapiens	174-177
11699226-16	2001	We conclude that the substitution of DaunoXome for doxorubicin in the CHOP regimen to form COP-X provides excellent efficacy against non-Hodgkin"s lymphoma.	Daunorubicin	37-46	DNA damage inducible transcript 3	Homo sapiens	70-74
11699226-16	2001	We conclude that the substitution of DaunoXome for doxorubicin in the CHOP regimen to form COP-X provides excellent efficacy against non-Hodgkin"s lymphoma.	Daunorubicin	37-46	caspase recruitment domain family member 16	Homo sapiens	91-94
11426835-9	2001	We found that daunorubicin induced inhibition of prolidase activity (IC50 = 10 microM), collagen biosynthesis (IC50 = 70 microM) and DNA biosynthesis (IC50= 10 microM) in human skin fibroblasts.	Daunorubicin	14-26	peptidase D	Homo sapiens	49-58
11278608-6	2001	On the other hand, daunorubicin, an NF-kappaB activator, increased the steady-state levels of CFTR mRNA.	Daunorubicin	19-31	nuclear factor kappa B subunit 1	Homo sapiens	36-45
11278608-6	2001	On the other hand, daunorubicin, an NF-kappaB activator, increased the steady-state levels of CFTR mRNA.	Daunorubicin	19-31	CF transmembrane conductance regulator	Homo sapiens	94-98
11482878-4	2001	Resistance to daunorubicin can be explained by amplification of the MDR1 drug transporter gene.	Daunorubicin	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	68-72
11783080-0	2001	[Subcellular distribution of daunorubicin in the P-glycoprotein-mediated multidrug-resistant cell line K562/ADR].	Daunorubicin	29-41	ATP binding cassette subfamily B member 1	Homo sapiens	49-63
11783080-0	2001	[Subcellular distribution of daunorubicin in the P-glycoprotein-mediated multidrug-resistant cell line K562/ADR].	Daunorubicin	29-41	aldo-keto reductase family 1 member B	Homo sapiens	108-111
11783080-1	2001	OBJECTIVE: To examine subcellular distribution of daunorubicin (DNR) in P-glycoprotein-mediated multidrug-resistant cell line K562/ADR and its relation to multidrug resistance.	Daunorubicin	50-62	ATP binding cassette subfamily B member 1	Homo sapiens	72-86
11783080-1	2001	OBJECTIVE: To examine subcellular distribution of daunorubicin (DNR) in P-glycoprotein-mediated multidrug-resistant cell line K562/ADR and its relation to multidrug resistance.	Daunorubicin	50-62	aldo-keto reductase family 1 member B	Homo sapiens	131-134
11783080-1	2001	OBJECTIVE: To examine subcellular distribution of daunorubicin (DNR) in P-glycoprotein-mediated multidrug-resistant cell line K562/ADR and its relation to multidrug resistance.	Daunorubicin	64-67	ATP binding cassette subfamily B member 1	Homo sapiens	72-86
11783080-1	2001	OBJECTIVE: To examine subcellular distribution of daunorubicin (DNR) in P-glycoprotein-mediated multidrug-resistant cell line K562/ADR and its relation to multidrug resistance.	Daunorubicin	64-67	aldo-keto reductase family 1 member B	Homo sapiens	131-134
11311056-5	2001	Daunorubicin and doxorubicin, two widely used antineoplastic agents in tumor therapy, were covalently linked to NPY via two spacers that differ in stability: an acid-sensitive hydrazone bond at the 13-keto position of daunorubicin and a stable amide bond at the 3"-amino position of daunorubicin and doxorubicin.	Daunorubicin	0-12	neuropeptide Y	Homo sapiens	112-115
11311056-5	2001	Daunorubicin and doxorubicin, two widely used antineoplastic agents in tumor therapy, were covalently linked to NPY via two spacers that differ in stability: an acid-sensitive hydrazone bond at the 13-keto position of daunorubicin and a stable amide bond at the 3"-amino position of daunorubicin and doxorubicin.	Daunorubicin	218-230	neuropeptide Y	Homo sapiens	112-115
11311056-5	2001	Daunorubicin and doxorubicin, two widely used antineoplastic agents in tumor therapy, were covalently linked to NPY via two spacers that differ in stability: an acid-sensitive hydrazone bond at the 13-keto position of daunorubicin and a stable amide bond at the 3"-amino position of daunorubicin and doxorubicin.	Daunorubicin	283-295	neuropeptide Y	Homo sapiens	112-115
11311056-10	2001	We found evidence that the active conjugate [C(15)]-NPY-Dauno-HYD releases daunorubicin, which is localized close to the nucleus, whereas the inactive conjugate [C(15)]-NPY-Dauno-MBS is distributed distantly from the nucleus and does not seem to release the drug within the cell.	Daunorubicin	75-87	neuropeptide Y	Homo sapiens	52-55
11336794-0	2001	Daunorubicin attenuates tumor necrosis factor-alpha-induced biosynthesis of plasminogen activator inhibitor-1 in human umbilical vein endothelial cells.	Daunorubicin	0-12	serpin family E member 1	Homo sapiens	76-109
11336794-2	2001	Treatment of human umbilical vein endothelial cells (HUVEC) with daunorubicin markedly decreased the mRNA expression and protein release of plasminogen activator inhibitor-1 (PAI-1).	Daunorubicin	65-77	serpin family E member 1	Homo sapiens	140-173
11336794-2	2001	Treatment of human umbilical vein endothelial cells (HUVEC) with daunorubicin markedly decreased the mRNA expression and protein release of plasminogen activator inhibitor-1 (PAI-1).	Daunorubicin	65-77	serpin family E member 1	Homo sapiens	175-180
11336794-5	2001	The stimulating effect of TNF-alpha on PAI-1 synthesis was attenuated by the pretreatment of HUVEC with daunorubicin.	Daunorubicin	104-116	tumor necrosis factor	Homo sapiens	26-35
11336794-5	2001	The stimulating effect of TNF-alpha on PAI-1 synthesis was attenuated by the pretreatment of HUVEC with daunorubicin.	Daunorubicin	104-116	serpin family E member 1	Homo sapiens	39-44
11336794-7	2001	Fumonisin B(1) treatment restored the daunorubicin-induced decrease in PAI-1 release to approximately 70% of the control, but did not affect the TNF-alpha-induced increase in PAI-1 release.	Daunorubicin	38-50	serpin family E member 1	Homo sapiens	71-76
11336794-8	2001	Thus, these data imply the possibility that the subcellular topology of ceramide production determines its lipid mediator function in the regulation of PAI-1 synthesis in HUVEC, because both TNF-alpha and daunorubicin could increase the ceramide levels.	Daunorubicin	205-217	serpin family E member 1	Homo sapiens	152-157
11106643-2	2001	Activation of p53 in REH cells by treatment with daunorubicin was accompanied by decreased ( approximately 5-fold) levels of hRFC transcripts and methotrexate transport.	Daunorubicin	49-61	tumor protein p53	Homo sapiens	14-17
11106643-2	2001	Activation of p53 in REH cells by treatment with daunorubicin was accompanied by decreased ( approximately 5-fold) levels of hRFC transcripts and methotrexate transport.	Daunorubicin	49-61	solute carrier family 19 member 1	Homo sapiens	125-129
11278000-8	2001	Binding of drugs (4-demethoxy-daunorubicin and 3"-(3-methoxymorpholino)doxorubicin) which accumulate in resistant cells immobilizes MRP1 in a conformational state that is insensitive to ATP binding whereas drugs rejected outside the resistant cells (daunorubicin, doxorubicin) favor a conformational change which may be a required step in the transport process.	Daunorubicin	30-42	ATP binding cassette subfamily C member 1	Homo sapiens	132-136
11396135-4	2001	The fraction bound with high affinity to P-glycoprotein C-terminal cytosolic domain and was as efficient as cyclosporin A to increase intracellular accumulation of daunomycin in K562/R7 leukemic cells.	Daunorubicin	164-174	ATP binding cassette subfamily B member 1	Homo sapiens	41-55
11396174-0	2001	Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.	Daunorubicin	166-178	ATP binding cassette subfamily B member 1	Homo sapiens	180-194
11315194-1	2001	Apoptosis of HL-60 cells induced by actinomycin D, H7, or daunorubicin was shown to involve the activation of caspase-3-like protease, 2 h after the addition of these drugs, based on microassay of enzyme activity by high-performance liquid chromatography.	Daunorubicin	58-70	caspase 3	Homo sapiens	110-119
11315194-7	2001	Inhibition of complex IV by actinomycin D, H7, and daunorubicin were almost fully restored by the addition of cytochrome c.	Daunorubicin	51-63	cytochrome c, somatic	Homo sapiens	110-122
11315194-10	2001	These observations indicate a direct relationship between hydrogen peroxide and the release of cytochrome c during apoptosis caused by actinomycin D, H7, and daunorubicin.	Daunorubicin	158-170	cytochrome c, somatic	Homo sapiens	95-107
11248673-7	2001	The P-gp-mediated efflux of daunorubicin (DNR) and 3"-hydroxy-4-amino (WP608) was determined at different pH values.	Daunorubicin	28-40	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
11248673-7	2001	The P-gp-mediated efflux of daunorubicin (DNR) and 3"-hydroxy-4-amino (WP608) was determined at different pH values.	Daunorubicin	42-45	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
11096091-11	2001	The ability of the anticancer drug and potent genotoxic agent daunorubicin to induce mdr1 independently of AhR.Arnt further supports the proposition that mdr1 is transcriptionally up-regulated by p53 in response to DNA damage.	Daunorubicin	62-74	malic enzyme complex, mitochondrial	Mus musculus	85-89
11096091-11	2001	The ability of the anticancer drug and potent genotoxic agent daunorubicin to induce mdr1 independently of AhR.Arnt further supports the proposition that mdr1 is transcriptionally up-regulated by p53 in response to DNA damage.	Daunorubicin	62-74	aryl-hydrocarbon receptor	Mus musculus	107-110
11096091-11	2001	The ability of the anticancer drug and potent genotoxic agent daunorubicin to induce mdr1 independently of AhR.Arnt further supports the proposition that mdr1 is transcriptionally up-regulated by p53 in response to DNA damage.	Daunorubicin	62-74	aryl hydrocarbon receptor nuclear translocator	Mus musculus	111-115
11096091-11	2001	The ability of the anticancer drug and potent genotoxic agent daunorubicin to induce mdr1 independently of AhR.Arnt further supports the proposition that mdr1 is transcriptionally up-regulated by p53 in response to DNA damage.	Daunorubicin	62-74	malic enzyme complex, mitochondrial	Mus musculus	154-158
11096091-11	2001	The ability of the anticancer drug and potent genotoxic agent daunorubicin to induce mdr1 independently of AhR.Arnt further supports the proposition that mdr1 is transcriptionally up-regulated by p53 in response to DNA damage.	Daunorubicin	62-74	transformation related protein 53, pseudogene	Mus musculus	196-199
11178967-3	2001	The AML-2/DX100 also showed various levels of resistance to daunorubicin and vincristine but was paradoxically sensitive to hydrogen peroxide (5-fold), t-butyl hydroperoxide (3-fold), and paraquat (2-fold) when compared to the drug-sensitive parental AML-2 cells (AML-2/WT).	Daunorubicin	60-72	RUNX family transcription factor 3	Homo sapiens	4-9
11261885-4	2001	Cells that were cultured in hypertonic medium became more resistant to daunorubicin, suggesting that overexpression of AR made the cells more resistant to this drug.	Daunorubicin	71-83	aldo-keto reductase family 1 member B	Homo sapiens	119-121
11212278-8	2001	Accumulation and efflux studies with the P-gp substrates, [3H]daunorubicin and rhodamine 123, demonstrated that XR9576 inhibited P-gp-mediated drug efflux.	Daunorubicin	62-74	phosphoglycolate phosphatase	Mus musculus	41-45
11212278-8	2001	Accumulation and efflux studies with the P-gp substrates, [3H]daunorubicin and rhodamine 123, demonstrated that XR9576 inhibited P-gp-mediated drug efflux.	Daunorubicin	62-74	phosphoglycolate phosphatase	Mus musculus	129-133
11137854-5	2001	Therefore, we compared the effect of daunorubicin and doxorubicin on prolidase activity and collagen biosynthesis in confluent cultured human skin fibroblasts.	Daunorubicin	37-49	peptidase D	Homo sapiens	69-78
11137854-6	2001	We have found that daunorubicin and doxorubicin coordinately induced the inhibition of prolidase activity (IC(50)=0.3 and 10 microM, respectively) and collagen biosynthesis (IC(50)=1 and 15 microM, respectively) in cultured human skin fibroblasts.	Daunorubicin	19-31	peptidase D	Homo sapiens	87-96
11137854-7	2001	The inhibitory effect of daunorubicin or doxorubicin on prolidase activity and collagen biosynthesis was not due to anti-proliferative activity of these drugs as shown by cell viability tetrazoline test.	Daunorubicin	25-37	peptidase D	Homo sapiens	56-65
11137854-15	2001	The higher ability of daunorubicin vs. doxorubicin to chelate manganese and inhibit prolidase activity may explain the potential mechanism for its greater potency to inhibit collagen biosynthesis.	Daunorubicin	22-34	peptidase D	Homo sapiens	84-93
11732624-10	2001	Comparison of transport kinetics for daunorubicin between recombinant vs human erythrocyte RLIP76 revealed higher specific activity of transport for tissue purified RLIP76, indicating that additional factors present in tissue purified RLIP76 can modulate its transport activity.	Daunorubicin	37-49	ralA binding protein 1	Homo sapiens	165-171
11732624-10	2001	Comparison of transport kinetics for daunorubicin between recombinant vs human erythrocyte RLIP76 revealed higher specific activity of transport for tissue purified RLIP76, indicating that additional factors present in tissue purified RLIP76 can modulate its transport activity.	Daunorubicin	37-49	ralA binding protein 1	Homo sapiens	165-171
11993666-4	2001	When SBA-sugar binding occurs, a part of daunomycin of the labeled sugar is taken to the binding sites.	Daunorubicin	41-51	lectin	Glycine max	5-8
11993666-5	2001	As a result, SBA is detected by a change in the peak current of daunomycin, and the SBA-sugar interaction is evaluated.	Daunorubicin	64-74	lectin	Glycine max	13-16
11399635-0	2001	P-Glycoprotein Expression in Acute Myeloid Leukaemia Cells at Diagnosis: Its relationship to Daunorubicin or Idarubicin Induction Therapy and Survival; Malignancy.	Daunorubicin	93-105	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
11399635-1	2001	We investigated the expression of P-glycoprotein (P-gp) in 50 adults with de novo diagnosed acute myeloid leukaemia (AML) and the relationship between presence of P-gp in leukaemic cells and efficacy, as remission induction and survival rate, of two different anthracyclines, daunorubicin (DNR) and idarubicin (IDR).	Daunorubicin	276-288	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
11107162-2	2000	Treatment of cultured human astrocytes with N-acetylsphingosine, a cell-permeable short-chain ceramide analogue or daunorubicin that could increase intracellular ceramide via activation of ceramide synthase or sphingomyelin hydrolysis increased the release of t-PA and conversely decreased the PAI-1 release.	Daunorubicin	115-127	plasminogen activator, tissue type	Homo sapiens	260-264
11107162-2	2000	Treatment of cultured human astrocytes with N-acetylsphingosine, a cell-permeable short-chain ceramide analogue or daunorubicin that could increase intracellular ceramide via activation of ceramide synthase or sphingomyelin hydrolysis increased the release of t-PA and conversely decreased the PAI-1 release.	Daunorubicin	115-127	serpin family E member 1	Homo sapiens	294-299
11107162-5	2000	We also demonstrate that the suppression of PAI-1 release with daunorubicin accelerates the cell death of neuronally differentiated PC12 cells and suggest an antiapoptotic role of PAI-1 in the nervous system.	Daunorubicin	63-75	serpin family E member 1	Rattus norvegicus	44-49
11197207-6	2000	Intracellular daunorubicin/Rhodamine123 content in P-gp+ leukemic blast cells is significantly lower than in P-gp- leukemic blast cells.	Daunorubicin	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	51-55
11197207-6	2000	Intracellular daunorubicin/Rhodamine123 content in P-gp+ leukemic blast cells is significantly lower than in P-gp- leukemic blast cells.	Daunorubicin	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
11082419-0	2000	Roles of nuclear factor-kappaB, p53, and p21/WAF1 in daunomycin-induced cell cycle arrest and apoptosis.	Daunorubicin	53-63	tumor protein p53	Homo sapiens	32-35
11082419-0	2000	Roles of nuclear factor-kappaB, p53, and p21/WAF1 in daunomycin-induced cell cycle arrest and apoptosis.	Daunorubicin	53-63	cyclin dependent kinase inhibitor 1A	Homo sapiens	41-44
11082419-0	2000	Roles of nuclear factor-kappaB, p53, and p21/WAF1 in daunomycin-induced cell cycle arrest and apoptosis.	Daunorubicin	53-63	cyclin dependent kinase inhibitor 1A	Homo sapiens	45-49
11082419-1	2000	Daunomycin is a potent inducer of p53 and NF-kappaB transcription factors.	Daunorubicin	0-10	tumor protein p53	Homo sapiens	34-37
11082419-1	2000	Daunomycin is a potent inducer of p53 and NF-kappaB transcription factors.	Daunorubicin	0-10	nuclear factor kappa B subunit 1	Homo sapiens	42-51
11082419-4	2000	We demonstrated, in human breast and colon carcinoma cells, the binding of NF-kappaB dimers to the kappaB site and the transcriptional activation of the human p21 promoter by daunomycin and by NF-kappaB subunits, thereby confirming the functionality of this kappaB binding site.	Daunorubicin	175-185	nuclear factor kappa B subunit 1	Homo sapiens	75-84
11082419-4	2000	We demonstrated, in human breast and colon carcinoma cells, the binding of NF-kappaB dimers to the kappaB site and the transcriptional activation of the human p21 promoter by daunomycin and by NF-kappaB subunits, thereby confirming the functionality of this kappaB binding site.	Daunorubicin	175-185	cyclin dependent kinase inhibitor 1A	Homo sapiens	159-162
11082419-5	2000	However, using different tumor cell lines where p53 or NF-kappaB was inactive, we showed that p21 activation and cell cycle arrest induced by daunomycin was p53-dependent and NF-kappaB-independent, whereas daunomycin-induced apoptosis was p53- and NF-kappaB-independent.	Daunorubicin	142-152	tumor protein p53	Homo sapiens	48-51
11082419-5	2000	However, using different tumor cell lines where p53 or NF-kappaB was inactive, we showed that p21 activation and cell cycle arrest induced by daunomycin was p53-dependent and NF-kappaB-independent, whereas daunomycin-induced apoptosis was p53- and NF-kappaB-independent.	Daunorubicin	142-152	nuclear factor kappa B subunit 1	Homo sapiens	55-64
11082419-5	2000	However, using different tumor cell lines where p53 or NF-kappaB was inactive, we showed that p21 activation and cell cycle arrest induced by daunomycin was p53-dependent and NF-kappaB-independent, whereas daunomycin-induced apoptosis was p53- and NF-kappaB-independent.	Daunorubicin	142-152	cyclin dependent kinase inhibitor 1A	Homo sapiens	94-97
11082419-5	2000	However, using different tumor cell lines where p53 or NF-kappaB was inactive, we showed that p21 activation and cell cycle arrest induced by daunomycin was p53-dependent and NF-kappaB-independent, whereas daunomycin-induced apoptosis was p53- and NF-kappaB-independent.	Daunorubicin	142-152	tumor protein p53	Homo sapiens	157-160
11082419-5	2000	However, using different tumor cell lines where p53 or NF-kappaB was inactive, we showed that p21 activation and cell cycle arrest induced by daunomycin was p53-dependent and NF-kappaB-independent, whereas daunomycin-induced apoptosis was p53- and NF-kappaB-independent.	Daunorubicin	142-152	nuclear factor kappa B subunit 1	Homo sapiens	175-184
11082419-5	2000	However, using different tumor cell lines where p53 or NF-kappaB was inactive, we showed that p21 activation and cell cycle arrest induced by daunomycin was p53-dependent and NF-kappaB-independent, whereas daunomycin-induced apoptosis was p53- and NF-kappaB-independent.	Daunorubicin	142-152	tumor protein p53	Homo sapiens	157-160
11082419-5	2000	However, using different tumor cell lines where p53 or NF-kappaB was inactive, we showed that p21 activation and cell cycle arrest induced by daunomycin was p53-dependent and NF-kappaB-independent, whereas daunomycin-induced apoptosis was p53- and NF-kappaB-independent.	Daunorubicin	142-152	nuclear factor kappa B subunit 1	Homo sapiens	175-184
11082419-5	2000	However, using different tumor cell lines where p53 or NF-kappaB was inactive, we showed that p21 activation and cell cycle arrest induced by daunomycin was p53-dependent and NF-kappaB-independent, whereas daunomycin-induced apoptosis was p53- and NF-kappaB-independent.	Daunorubicin	206-216	cyclin dependent kinase inhibitor 1A	Homo sapiens	94-97
11082465-0	2000	Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation.	Daunorubicin	125-137	ATP binding cassette subfamily B member 1	Homo sapiens	139-153
11096420-0	2000	Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells.	Daunorubicin	62-74	tumor protein p53	Homo sapiens	103-107
11096420-3	2000	In the TP53-mutated cell lines MeWo and 4451, the survival ratio at 7 Gy measured by colony formation was 2.3-2.8, 8.6-85 and 52-74 for daunorubicin, melphalan and cisplatin, respectively.	Daunorubicin	136-148	tumor protein p53	Homo sapiens	7-11
11082532-2	2000	Treatment of cells with daunorubicin induced chromatin condensation, nuclear fragmentation, internucleosomal DNA degradation, and the proteolytic cleavage of PKC-delta and poly(ADP-ribose) polymerase in A-431 cells.	Daunorubicin	24-36	protein kinase C delta	Homo sapiens	158-199
11082532-3	2000	Daunorubicin, as well as sphingomyelinase (SMase) and the exogenous cell-permeable ceramide analogue C(2)-ceramide, inhibited phospholipase D activity stimulated by phorbol 12-myristate 13-acetate or epidermal growth factor (EGF).	Daunorubicin	0-12	epidermal growth factor	Homo sapiens	200-223
11082532-3	2000	Daunorubicin, as well as sphingomyelinase (SMase) and the exogenous cell-permeable ceramide analogue C(2)-ceramide, inhibited phospholipase D activity stimulated by phorbol 12-myristate 13-acetate or epidermal growth factor (EGF).	Daunorubicin	0-12	epidermal growth factor	Homo sapiens	225-228
11082532-4	2000	Like ceramide, daunorubicin also decreased EGF-induced diacylglycerol generation.	Daunorubicin	15-27	epidermal growth factor	Homo sapiens	43-46
11097180-3	2000	Herein, the Pgp-mediated transport of a marker substrate, daunorubicin (DNR), out of viable cells was examined in the presence of a variety of other known substrates of Pgp.	Daunorubicin	58-70	ATP binding cassette subfamily B member 1	Homo sapiens	12-15
11097180-3	2000	Herein, the Pgp-mediated transport of a marker substrate, daunorubicin (DNR), out of viable cells was examined in the presence of a variety of other known substrates of Pgp.	Daunorubicin	72-75	ATP binding cassette subfamily B member 1	Homo sapiens	12-15
11122104-0	2000	Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.	Daunorubicin	157-169	ATP binding cassette subfamily B member 1	Homo sapiens	183-197
10974159-9	2000	For quantification of P-gp mediated transport with PET in vivo, several agents, such as [(11)C]colchicine, [(11)C]verapamil and [(11)C]daunorubicin have been evaluated.	Daunorubicin	135-147	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
11036110-2	2000	BCRP can render tumor cells resistant to the anticancer drugs topotecan, mitoxantrone, doxorubicin, and daunorubicin.	Daunorubicin	104-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
11004683-9	2000	Short-term exposure (16 hr) to subtoxic daunomycin (DM)-, and bleomycin (BM)-concentrations significantly (up to 4-fold) enhanced LRP expression in 2/4 cell lines tested.	Daunorubicin	40-50	major vault protein	Homo sapiens	130-133
11027568-0	2000	Cholesterol interaction with the daunorubicin binding site of P-glycoprotein.	Daunorubicin	33-45	ATP binding cassette subfamily B member 1	Homo sapiens	62-76
11027568-6	2000	In a NIH-G185 cell line presenting an overexpressed amount of the human transporter P-gp, cholesterol caused dramatic inhibition of daunorubicin transport with an IC(50) of about 8 microM yet had no effect on the parent cell line nor rhodamine 123 transport.	Daunorubicin	132-144	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
10960060-2	2000	In this study, we examined the effect of dexrazoxane (ICRF-187), an iron chelator which prevents anthracycline cardiotoxicity, on RyR2 gene expression in rats treated chronically with daunorubicin.	Daunorubicin	184-196	ryanodine receptor 2	Rattus norvegicus	130-134
10960060-6	2000	Dexrazoxane pre-treatment (50 mg kg(-1); 1 h prior to each daunorubicin injection) prevented the decrease in RyR2/GAPDH mRNA ratio and histopathologic lesions in daunorubicin-treated rats.	Daunorubicin	162-174	ryanodine receptor 2	Rattus norvegicus	109-113
10942898-0	2000	Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.	Daunorubicin	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
10942898-1	2000	BACKGROUND: S9788 and PSC833 were developped as P-glycoprotein (Pgp) blockers and found to act additionally on daunorubicin subcellular distribution, involving different putative targets.	Daunorubicin	111-123	ATP binding cassette subfamily B member 1	Homo sapiens	48-62
10942898-1	2000	BACKGROUND: S9788 and PSC833 were developped as P-glycoprotein (Pgp) blockers and found to act additionally on daunorubicin subcellular distribution, involving different putative targets.	Daunorubicin	111-123	ATP binding cassette subfamily B member 1	Homo sapiens	64-67
10978781-1	2000	We examined the subcellular distribution of daunorubicin (DNR) in resistant K562 cell line which overexpress the P-glycoprotein by confocal laser scanning microscopy.	Daunorubicin	44-56	ATP binding cassette subfamily B member 1	Homo sapiens	113-127
10978781-8	2000	Our studies demonstrate that daunorubicin may be sequestered in mitochondrial compartment in the resistant cells and P-glycoprotein plays an important role on mediating DNR transport.	Daunorubicin	29-41	ATP binding cassette subfamily B member 1	Homo sapiens	117-131
10969785-3	2000	Here we show that CD34+/CD38- leukemia precursors have reduced in vitro sensitivity to daunorubicin, a major drug used in leukemia treatment, in comparison with the CD34+/CD38+ counterpart, and increased expression of multidrug resistance genes (mrp/lrp).	Daunorubicin	87-99	CD34 molecule	Homo sapiens	18-22
10969785-3	2000	Here we show that CD34+/CD38- leukemia precursors have reduced in vitro sensitivity to daunorubicin, a major drug used in leukemia treatment, in comparison with the CD34+/CD38+ counterpart, and increased expression of multidrug resistance genes (mrp/lrp).	Daunorubicin	87-99	CD38 molecule	Homo sapiens	24-28
10969785-3	2000	Here we show that CD34+/CD38- leukemia precursors have reduced in vitro sensitivity to daunorubicin, a major drug used in leukemia treatment, in comparison with the CD34+/CD38+ counterpart, and increased expression of multidrug resistance genes (mrp/lrp).	Daunorubicin	87-99	ATP binding cassette subfamily C member 1	Homo sapiens	246-249
10969785-3	2000	Here we show that CD34+/CD38- leukemia precursors have reduced in vitro sensitivity to daunorubicin, a major drug used in leukemia treatment, in comparison with the CD34+/CD38+ counterpart, and increased expression of multidrug resistance genes (mrp/lrp).	Daunorubicin	87-99	LDL receptor related protein 1	Homo sapiens	250-253
10996485-2	2000	Amongst anthracycline antibiotics, we have found daunorubicin and epirubicin able to acutely stimulate prolactin (PRL) secretion both in vivo, in the rat, and in vitro, from rat anterior pituitary cell cultures.	Daunorubicin	49-61	prolactin	Rattus norvegicus	103-112
10996485-2	2000	Amongst anthracycline antibiotics, we have found daunorubicin and epirubicin able to acutely stimulate prolactin (PRL) secretion both in vivo, in the rat, and in vitro, from rat anterior pituitary cell cultures.	Daunorubicin	49-61	prolactin	Rattus norvegicus	114-117
10910943-3	2000	Using 2 myeloid cell lines, HL60 and NB4, evidence is presented that prior incubation with the CD44-specific monoclonal antibody (mAb) A3D8, reported to induce differentiation of AML blasts, significantly decreases apoptosis induced by 3 drugs used in AML chemotherapy: daunorubicin (DNR), mitoxantrone, and etoposide.	Daunorubicin	270-282	CD44 molecule (Indian blood group)	Homo sapiens	95-99
10910943-3	2000	Using 2 myeloid cell lines, HL60 and NB4, evidence is presented that prior incubation with the CD44-specific monoclonal antibody (mAb) A3D8, reported to induce differentiation of AML blasts, significantly decreases apoptosis induced by 3 drugs used in AML chemotherapy: daunorubicin (DNR), mitoxantrone, and etoposide.	Daunorubicin	284-287	CD44 molecule (Indian blood group)	Homo sapiens	95-99
10917553-5	2000	Furthermore, V-104 partially inhibits daunorubicin transport by MRP1 but not vinblastine transport by MRP2.	Daunorubicin	38-50	ATP binding cassette subfamily C member 1	Canis lupus familiaris	64-68
10917554-4	2000	In these cells MRP1 transports daunorubicin, and MRP2 vinblastine; both transporters export reduced glutathione (GSH) into the medium.	Daunorubicin	31-43	ATP binding cassette subfamily C member 1	Canis lupus familiaris	15-19
10869171-8	2000	Cell-type-specific effects of cholesterol content on function of human Pgp were detected by use of daunomycin, another substrate for Pgp, although efficacy of inhibitors remained independent of cholesterol.	Daunorubicin	99-109	ATP binding cassette subfamily B member 1	Homo sapiens	71-74
10869171-8	2000	Cell-type-specific effects of cholesterol content on function of human Pgp were detected by use of daunomycin, another substrate for Pgp, although efficacy of inhibitors remained independent of cholesterol.	Daunorubicin	99-109	ATP binding cassette subfamily B member 1	Homo sapiens	133-136
10869171-9	2000	Conversely, both function and inhibition of hamster Pgp as measured with Tc-Sestamibi and daunomycin were in part dependent on normal cell content of cholesterol.	Daunorubicin	90-100	ATP binding cassette subfamily B member 1	Homo sapiens	52-55
10891476-2	2000	Transfection and enforced expression of BCRP in drug-sensitive cells confer resistance to mitoxantrone, doxorubicin, daunorubicin, and topotecan.	Daunorubicin	117-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	40-44
10806112-7	2000	Reduced levels of mitoxantrone, daunorubicin, bisantrene, topotecan, rhodamine 123 and prazosin were observed in the two sublines with high MXR expression.	Daunorubicin	32-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	140-143
10865967-1	2000	The expression of the drug transport protein, P-glycoprotein (Pgp/MDR1) has been found to be of prognostic significance for the achievement of complete remission (CR) or the duration of survival after daunorubicin (DNR)-containing induction therapy in acute myeloid leukemia (AML).	Daunorubicin	201-213	ATP binding cassette subfamily B member 1	Homo sapiens	46-60
10865967-1	2000	The expression of the drug transport protein, P-glycoprotein (Pgp/MDR1) has been found to be of prognostic significance for the achievement of complete remission (CR) or the duration of survival after daunorubicin (DNR)-containing induction therapy in acute myeloid leukemia (AML).	Daunorubicin	201-213	phosphoglycolate phosphatase	Homo sapiens	62-65
10865967-1	2000	The expression of the drug transport protein, P-glycoprotein (Pgp/MDR1) has been found to be of prognostic significance for the achievement of complete remission (CR) or the duration of survival after daunorubicin (DNR)-containing induction therapy in acute myeloid leukemia (AML).	Daunorubicin	201-213	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
11876999-0	2000	[Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR].	Daunorubicin	37-49	ATP binding cassette subfamily B member 1	Homo sapiens	61-75
11876999-0	2000	[Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR].	Daunorubicin	37-49	aldo-keto reductase family 1 member B	Homo sapiens	121-124
10772630-3	2000	Using daunorubicin as a fluorescent marker and vanadate as a positive control compound, a functional flow cytometry method for assessing the ability of a drug to inhibit Pgp-mediated drug efflux from CR1R12 multidrug-resistant cells has been evaluated.	Daunorubicin	6-18	ATP binding cassette subfamily B member 1	Homo sapiens	170-173
10772630-5	2000	Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin.	Daunorubicin	176-188	ATP binding cassette subfamily B member 1	Homo sapiens	6-9
10772630-5	2000	Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin.	Daunorubicin	176-188	ATP binding cassette subfamily B member 1	Homo sapiens	153-156
10965990-0	2000	The mechanism of daunorubicin-induced inhibition of prolidase activity in human skin fibroblasts and its implication to impaired collagen biosynthesis.	Daunorubicin	17-29	peptidase D	Homo sapiens	52-61
10965990-6	2000	We have found that daunorubicin (DNR) induced coordinately inhibition of prolidase activity (IC50 = 0.3 microM) and collagen biosynthesis (IC50 = 1 microM) in cultured human skin fibroblasts.	Daunorubicin	19-31	peptidase D	Homo sapiens	73-82
10965990-8	2000	Since prolidase is metaloprotease, requiring manganese for catalytic activity and anthracyclines are known as a chelators of divalent cations we considered that the chelating ability of anthracyclines may be an underlying mechanism for daunorubicin-induced inhibition of prolidase activity.	Daunorubicin	236-248	peptidase D	Homo sapiens	6-15
10965990-8	2000	Since prolidase is metaloprotease, requiring manganese for catalytic activity and anthracyclines are known as a chelators of divalent cations we considered that the chelating ability of anthracyclines may be an underlying mechanism for daunorubicin-induced inhibition of prolidase activity.	Daunorubicin	236-248	peptidase D	Homo sapiens	271-280
10784624-0	2000	P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.	Daunorubicin	91-103	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
10784624-0	2000	P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.	Daunorubicin	91-103	ATP binding cassette subfamily B member 1	Homo sapiens	129-143
10784627-4	2000	MDR1 expression was evaluated by reverse transcriptase polymerase chain reaction, flow cytometry, and the ability of CSA at 2.5 micromol/L to increase intracellular accumulation of (3)H-daunomycin in blasts from bone marrow specimens.	Daunorubicin	186-196	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
10784627-4	2000	MDR1 expression was evaluated by reverse transcriptase polymerase chain reaction, flow cytometry, and the ability of CSA at 2.5 micromol/L to increase intracellular accumulation of (3)H-daunomycin in blasts from bone marrow specimens.	Daunorubicin	186-196	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	117-120
10766178-10	2000	Activation of caspase-3 after daunorubicin or doxorubicin treatment of either nonactivated or activated lymphocytes was demonstrated by the cleavage of poly(ADP-ribose) polymerase, which was, as apoptosis, inhibited by the peptide benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone.	Daunorubicin	30-42	caspase 3	Homo sapiens	14-23
10766178-10	2000	Activation of caspase-3 after daunorubicin or doxorubicin treatment of either nonactivated or activated lymphocytes was demonstrated by the cleavage of poly(ADP-ribose) polymerase, which was, as apoptosis, inhibited by the peptide benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone.	Daunorubicin	30-42	poly(ADP-ribose) polymerase 1	Homo sapiens	152-179
10778983-3	2000	Plasma samples from patients were analyzed in an in vitro assay to monitor the effect on the cellular retention of tritium-labeled daunorubicin in MDR1-transfected P388 cells.	Daunorubicin	131-143	ATP binding cassette subfamily B member 1	Homo sapiens	147-151
10783828-10	2000	The Pgp-/MRP+ cells responded to PSC 833 and 280-446 by increased accumulation of daunorubicin (p = 0.0022 and p = 0.0005, respectively) and sensitization to the drug (p = 0.0009 and p = 0.0007, respectively).	Daunorubicin	82-94	ATP binding cassette subfamily B member 1	Homo sapiens	4-7
10783828-10	2000	The Pgp-/MRP+ cells responded to PSC 833 and 280-446 by increased accumulation of daunorubicin (p = 0.0022 and p = 0.0005, respectively) and sensitization to the drug (p = 0.0009 and p = 0.0007, respectively).	Daunorubicin	82-94	ATP binding cassette subfamily C member 1	Homo sapiens	9-12
10727524-10	2000	Phe(335) also plays a role in the coupling of verapamil binding and modulation of daunorubicin intracellular accumulation in wild-type P-gp.	Daunorubicin	82-94	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
10729360-8	2000	We now examined the effect of PAK-104P on Pgp-and MRP1-mediated efflux of three anthracyclines, daunorubicin, pirarubicin, hydroxydoxorubicin and of calcein acetoxymethyl ester and calcein.	Daunorubicin	96-108	ATP binding cassette subfamily C member 1	Homo sapiens	50-54
10729360-11	2000	PAK-104P also non-competitively inhibits the MRP(1)-mediated efflux of daunorubicin, pirarubicin, hydroxyrubicin, calcein acetoxymethyl ester and calcein.	Daunorubicin	71-83	ATP binding cassette subfamily C member 1	Homo sapiens	45-50
10708754-7	2000	In contrast, a GSH conjugate of daunorubicin (WP811) does induce the ATPase activity of MRP1.	Daunorubicin	32-44	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
10685076-9	2000	After long-term exposure to daunorubicin and acquisition of drug resistance, expression of P-gp was accompanied by a decrease in the number of Fas sites at the cell surface with a correlated desensitization to Fas-induced apoptosis.	Daunorubicin	28-40	phosphoglycolate phosphatase	Homo sapiens	91-95
10724034-4	2000	Transfer of either mutant or wild-type MDR1 to K562 erythroleukemia cells or primary murine bone marrow resulted in reduced accumulation of daunomycin and vinblastine because of increased drug efflux.trans-(E)-Flupentixol at concentrations up to 10 microM failed to reverse drug efflux mediated by the product of the mutant MDR1 while wild-type P-glycoprotein was inhibited.	Daunorubicin	140-150	ATP binding cassette subfamily B member 1	Homo sapiens	39-43
10774745-4	2000	They were also slightly more resistant than the parental cell (AML-2/WT) to etoposide, camptothecin and daunorubicin.	Daunorubicin	104-116	RUNX family transcription factor 3	Homo sapiens	63-68
10679746-4	2000	We compared the two different techniques, DiOC(6)(3) uptake and Annexin V-propidium iodide co-labeling in the quantification of cytarabine, vincristine and daunorubicin induced apoptosis on three leukemia cell lines (HL-60, CEM, U937), and bone marrow blasts from 26 children with acute myeloid leukemia, 14 with T cell acute lymphoblastic leukemia.	Daunorubicin	156-168	annexin A5	Homo sapiens	64-73
10708946-0	2000	Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.	Daunorubicin	69-81	ATP binding cassette subfamily C member 3	Homo sapiens	117-156
10708946-4	2000	In our study, we examined the effects of buthionine sulphoximine (BSO), an inhibitor of GSH biosynthesis, on the nuclear accumulation of daunorubicin (DNR), in etoposide (VP16) and doxorubicin (ADR) resistant MCF7 cell lines, overexpressing respectively MRP1 (MCF7/VP) and Pgp (MCF7/ADR).	Daunorubicin	137-149	host cell factor C1	Homo sapiens	171-175
10681718-16	2000	Some, but not all, of these differences in daunorubicin accumulation and efflux as well as in the effect of cyclo-sporin A can be explained by a heterogenous expression of the mdr1-gene.	Daunorubicin	43-55	ATP binding cassette subfamily B member 1	Homo sapiens	176-180
10961687-0	2000	The ability of new formamidine sugar-modified derivatives of daunorubicin to stimulate free radical formation in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase and xanthine oxidase.	Daunorubicin	61-73	cytochrome p450 oxidoreductase	Homo sapiens	158-189
10961687-1	2000	Some sterically hindered N-substituted derivatives of daunorubicin are known to be poor substrates for NADH dehydrogenase, NADPH cytochrome P450 reductase and xanthine oxidase.	Daunorubicin	54-66	cytochrome p450 oxidoreductase	Homo sapiens	123-154
11279304-3	2000	We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.	Daunorubicin	221-233	natriuretic peptide B	Homo sapiens	85-88
10651723-0	2000	P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.	Daunorubicin	117-129	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
10651723-0	2000	P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.	Daunorubicin	117-129	ATP binding cassette subfamily C member 3	Homo sapiens	19-58
10651723-1	2000	The in vitro intracellular daunorubicin accumulation (IDA) of blast cells from 69 patients with newly diagnosed acute myeloid leukaemia (AML) was correlated with the expression and functional activity of the multidrug resistance (MDR) proteins, P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP) and lung-resistance protein (LRP).	Daunorubicin	27-39	ATP binding cassette subfamily B member 1	Homo sapiens	245-259
10651723-1	2000	The in vitro intracellular daunorubicin accumulation (IDA) of blast cells from 69 patients with newly diagnosed acute myeloid leukaemia (AML) was correlated with the expression and functional activity of the multidrug resistance (MDR) proteins, P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP) and lung-resistance protein (LRP).	Daunorubicin	27-39	ATP binding cassette subfamily B member 1	Homo sapiens	261-264
10651723-1	2000	The in vitro intracellular daunorubicin accumulation (IDA) of blast cells from 69 patients with newly diagnosed acute myeloid leukaemia (AML) was correlated with the expression and functional activity of the multidrug resistance (MDR) proteins, P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP) and lung-resistance protein (LRP).	Daunorubicin	27-39	ATP binding cassette subfamily C member 3	Homo sapiens	267-306
10651723-1	2000	The in vitro intracellular daunorubicin accumulation (IDA) of blast cells from 69 patients with newly diagnosed acute myeloid leukaemia (AML) was correlated with the expression and functional activity of the multidrug resistance (MDR) proteins, P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP) and lung-resistance protein (LRP).	Daunorubicin	27-39	ATP binding cassette subfamily C member 3	Homo sapiens	308-311
10651723-1	2000	The in vitro intracellular daunorubicin accumulation (IDA) of blast cells from 69 patients with newly diagnosed acute myeloid leukaemia (AML) was correlated with the expression and functional activity of the multidrug resistance (MDR) proteins, P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP) and lung-resistance protein (LRP).	Daunorubicin	27-39	major vault protein	Homo sapiens	317-340
10651723-1	2000	The in vitro intracellular daunorubicin accumulation (IDA) of blast cells from 69 patients with newly diagnosed acute myeloid leukaemia (AML) was correlated with the expression and functional activity of the multidrug resistance (MDR) proteins, P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP) and lung-resistance protein (LRP).	Daunorubicin	27-39	major vault protein	Homo sapiens	342-345
10611712-0	2000	Bcl-2, Bax, and c-Fos expression correlates to RPE cell apoptosis induced by UV-light and daunorubicin.	Daunorubicin	90-102	BCL2 apoptosis regulator	Homo sapiens	0-5
10611712-0	2000	Bcl-2, Bax, and c-Fos expression correlates to RPE cell apoptosis induced by UV-light and daunorubicin.	Daunorubicin	90-102	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	16-21
27420927-0	2000	P-Glycoprotein Expression in Acute Myeloid Leukaemia Cells at Diagnosis: Its relationship to Daunorubicin or Idarubicin Induction Therapy and Survival.	Daunorubicin	93-105	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
27420927-1	2000	We investigated the expression of P-glycoprotein (P-gp) in 50 adults with de novo diagnosed acute myeloid leukaemia (AML) and the relationship between presence of P-gp in leukaemic cells and efficacy, as remission induction and survival rate, of two different anthracyclines, daunorubicin (DNR) and idarubicin (IDR).	Daunorubicin	276-288	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
10773966-7	2000	Flow cytometry was used to evaluate P-glycoprotein activity in peripheral blood mononuclear cells isolated by gradient centrifugation and incubated with the P-glycoprotein substrate daunorubicin.	Daunorubicin	182-194	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
10773966-7	2000	Flow cytometry was used to evaluate P-glycoprotein activity in peripheral blood mononuclear cells isolated by gradient centrifugation and incubated with the P-glycoprotein substrate daunorubicin.	Daunorubicin	182-194	ATP binding cassette subfamily B member 1	Homo sapiens	157-171
10773967-7	2000	Peripheral blood mononuclear cells isolated by gradient centrifugation were incubated in the presence of daunorubicin (a fluorescent drug extruded by P-glycoprotein) at 37 degrees C or 4 degrees C for 30 min.	Daunorubicin	105-117	ATP binding cassette subfamily B member 1	Homo sapiens	150-164
10617675-8	2000	Further comparison revealed that although MDR1 easily impaired uptake of vincristine, daunomycin, paclitaxel, and digoxin, SPGP had no effect on uptake of these drugs.	Daunorubicin	86-96	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	42-46
10601617-2	2000	The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin.	Daunorubicin	188-200	ATP binding cassette subfamily B member 1	Homo sapiens	40-54
10601617-2	2000	The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin.	Daunorubicin	188-200	ATP binding cassette subfamily B member 1	Homo sapiens	56-60
10602713-1	1999	New prodrugs of daunorubicin and doxorubicin designed for selective activation by the serine protease plasmin are described.	Daunorubicin	16-28	plasminogen	Homo sapiens	102-109
10746169-1	1999	The reversal effect of itraconazole on P-glycoprotein (P-gp)-mediated resistance of vinblastine, daunorubicin and doxorubicin was analyzed from a cellular pharmacokinetic point of view, namely by [3H]azidopine photoaffinity labeling, intracellular accumulation and transcellular transport experiments.	Daunorubicin	97-109	phosphoglycolate phosphatase	Homo sapiens	55-59
10746169-4	1999	[3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp.	Daunorubicin	82-94	phosphoglycolate phosphatase	Homo sapiens	145-149
10746169-4	1999	[3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp.	Daunorubicin	82-94	phosphoglycolate phosphatase	Homo sapiens	215-219
10586216-0	1999	Liposome encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP related multidrug resistance.	Daunorubicin	22-34	phosphoglycolate phosphatase	Homo sapiens	94-97
10565860-4	1999	TER199 reversed the accumulation deficit of daunorubicin in MRP1-transfected NIH3T3 fibroblasts and maintained intracellular levels for &gt;2 h after daunorubicin removal.	Daunorubicin	44-56	ATP binding cassette subfamily C member 1	Homo sapiens	60-64
10585232-8	1999	Addition of the Pgp inhibitor SDZ PSC 833 showed a modulation of the idarubicin (IDA) and daunorubicin (DNR) transport, which was larger during transport from the basolateral to the apical side than in the reverse direction.	Daunorubicin	90-102	PGP	Canis lupus familiaris	16-19
10665657-7	1999	The inhibition of [14C]docetaxel transport by the MDR modulators, as well as daunorubicin and vinblastine, was also found in LLC-PK1 cells, which endogenously express P-gp at lower levels, and concentrations showing similar levels of inhibition were lower than those in the case of LLC-GA5-COL150 cells.	Daunorubicin	77-89	ATP binding cassette subfamily B member 1	Homo sapiens	167-171
10630360-6	1999	There was a strong inverse correlation between P-gp levels and cellular drug accumulation (rho = -0.83, p = 0.04) and cytotoxicity (rho = -0.95, p = 0.01) of daunorubicin.	Daunorubicin	158-170	phosphoglycolate phosphatase	Homo sapiens	47-51
10630360-7	1999	Also the cytotoxicity of DaunoXome and doxorubicin was related to P-gp levels (rho = -0.96, p = 0.01 and rho = -0.90, p = 0.07, respectively).	Daunorubicin	25-34	phosphoglycolate phosphatase	Homo sapiens	66-70
10697518-3	1999	K562/VP-H2 cells were also resistant to doxorubicin, daunorubicin and mitoxantrone, but showed little or no resistance to vincristine, aclarubicin, idarubicin, idarubicinol, cytosine arabinoside, cis-platinum or camptothecin.	Daunorubicin	53-65	transmembrane protein 199	Homo sapiens	5-10
10510309-4	1999	Compounds such as carvedilol, rolitetracycline and daunomycin, which are shown to inhibit Abeta fibril formation, also prevent the formation of species of peptide that demonstrate biological activity in a human neuroblastoma cell line.	Daunorubicin	51-61	amyloid beta precursor protein	Homo sapiens	90-95
10527882-6	1999	GFP-NPM(N) dissociates from nucleoli after treatments with daunomycin, actinomycin D, camptothecin, and toyocamycin.	Daunorubicin	59-69	nucleophosmin 1	Homo sapiens	4-7
10499507-9	1999	By comparison, transforming growth factor alpha, a factor previously found to attenuate apoptosis and apoptosis-inducing agents (e.g. paclitaxel, C8-ceramide, daunorubicin, UV irradiation) failed to phosphorylate Bcl-X(LONG).	Daunorubicin	159-171	transforming growth factor alpha	Gallus gallus	15-47
10573208-8	1999	After 24 h, TT2 induces as much DNA cleavage as camptothecin and DAU, two anti-cancer drugs producing DNA strand breaks and known to respectively inhibit DNA topoisomerase I and II activities.	Daunorubicin	65-68	topoisomerase (DNA) I	Mus musculus	154-173
10496352-5	1999	The accumulation of daunorubicin in GLC4/ADR cells is increased by flavopiridol and by other non-glycosylated (iso)flavonoids that interact with MRP1 ATPase activity.	Daunorubicin	20-32	aldo-keto reductase family 1 member B	Homo sapiens	41-44
10496352-5	1999	The accumulation of daunorubicin in GLC4/ADR cells is increased by flavopiridol and by other non-glycosylated (iso)flavonoids that interact with MRP1 ATPase activity.	Daunorubicin	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
10496352-5	1999	The accumulation of daunorubicin in GLC4/ADR cells is increased by flavopiridol and by other non-glycosylated (iso)flavonoids that interact with MRP1 ATPase activity.	Daunorubicin	20-32	dynein axonemal heavy chain 8	Homo sapiens	150-156
10561359-1	1999	PURPOSE: The Cancer and Leukemia Group B conducted parallel phase I trials of cytarabine, daunorubicin, and etoposide (ADE) with or without PSC-833 (P), a modulator of p-glycoprotein-mediated multidrug resistance.	Daunorubicin	90-102	ATP binding cassette subfamily B member 1	Homo sapiens	168-182
10482990-5	1999	The data demonstrate that daunorubicin DNA intercalation is affected by both Pgp and MRP1 whereas idarubicin DNA intercalation is affected only by MRP1.	Daunorubicin	26-38	ATP binding cassette subfamily B member 1	Homo sapiens	77-80
10482990-5	1999	The data demonstrate that daunorubicin DNA intercalation is affected by both Pgp and MRP1 whereas idarubicin DNA intercalation is affected only by MRP1.	Daunorubicin	26-38	ATP binding cassette subfamily C member 1	Homo sapiens	85-89
10419897-0	1999	Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia.	Daunorubicin	80-92	ATP binding cassette subfamily C member 1	Homo sapiens	25-29
10419897-0	1999	Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia.	Daunorubicin	80-92	phosphoglycolate phosphatase	Homo sapiens	34-37
10448891-5	1999	Protein expression of cyclooxygenase-2 induced by interleukin-1beta was inhibited by daunorubicin at 0.1-1 microM, but was not affected by other antitumor agents.	Daunorubicin	85-97	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	22-38
10448891-5	1999	Protein expression of cyclooxygenase-2 induced by interleukin-1beta was inhibited by daunorubicin at 0.1-1 microM, but was not affected by other antitumor agents.	Daunorubicin	85-97	interleukin 1 beta	Rattus norvegicus	50-67
10448891-6	1999	These results suggest that daunorubicin inhibits induction of cyclooxygenase-2 and subsequent prostacyclin production in rat aortic smooth muscle cells.	Daunorubicin	27-39	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	62-78
10652618-0	1999	Multidrug resistance-associated protein (MRP) mediated transport of daunomycin and leukotriene C4 (LTC4) in isolated plasma membrane vesicles.	Daunorubicin	68-78	ATP binding cassette subfamily C member 3	Homo sapiens	0-39
10652618-0	1999	Multidrug resistance-associated protein (MRP) mediated transport of daunomycin and leukotriene C4 (LTC4) in isolated plasma membrane vesicles.	Daunorubicin	68-78	ATP binding cassette subfamily C member 3	Homo sapiens	41-44
10444168-0	1999	Liposome-encapsulated daunorubicin for PGP-related multidrug resistance.	Daunorubicin	22-34	phosphoglycolate phosphatase	Homo sapiens	39-42
10444168-1	1999	The possibility that Daunoxome (DNX), a combination of daunorubicin (DNR) with a liposomal targeting system, escapes PGP was tested.	Daunorubicin	21-30	phosphoglycolate phosphatase	Homo sapiens	117-120
10444168-1	1999	The possibility that Daunoxome (DNX), a combination of daunorubicin (DNR) with a liposomal targeting system, escapes PGP was tested.	Daunorubicin	32-35	phosphoglycolate phosphatase	Homo sapiens	117-120
10444168-6	1999	In 15 cases with a low PGP expression intracellular DNR accumulation was faster and higher with free DNR than with DNX.	Daunorubicin	115-118	phosphoglycolate phosphatase	Homo sapiens	23-26
10384122-0	1999	Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.	Daunorubicin	93-103	interleukin 10	Mus musculus	13-19
10384122-0	1999	Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.	Daunorubicin	93-103	transforming growth factor, beta 1	Mus musculus	24-32
10400421-0	1999	Caspase-3-like activity is necessary but not sufficient for daunorubicin-induced apoptosis in Jurkat human lymphoblastic leukemia cells.	Daunorubicin	60-72	caspase 3	Homo sapiens	0-9
10400421-3	1999	By utilizing synthetic fluorochrome-linked substrates of the caspases, we observed that a caspase-3-like enzyme had dramatically increased activity (3340 130% with respect to basal levels) in response to daunorubicin treatment.	Daunorubicin	204-216	caspase 3	Homo sapiens	90-99
10361105-11	1999	In 1 patient with AML, an increase in Pgp levels was observed in vivo at 4 and 16 hours after the administration of standard chemotherapy with DAU/AraC.	Daunorubicin	143-146	ATP binding cassette subfamily B member 1	Homo sapiens	38-41
10386580-0	1999	The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines.	Daunorubicin	58-70	AKT serine/threonine kinase 1	Homo sapiens	30-33
10386580-3	1999	Daunorubicin activates Akt, a downstream phosphoinositide 3-kinase effector.	Daunorubicin	0-12	AKT serine/threonine kinase 1	Homo sapiens	23-26
10354400-1	1999	A series of dihydrobenzopyrans and tetrahydroquinolines was synthesized and pharmacologically tested for their ability to inhibit P-glycoprotein mediated daunomycin efflux in multidrug resistant CCRF-CEM vcr1000 cells.	Daunorubicin	154-164	ATP binding cassette subfamily B member 1	Homo sapiens	130-144
10230770-0	1999	A study of correlation between NPM-translocation and apoptosis in cells induced by daunomycin.	Daunorubicin	83-93	nucleophosmin 1	Homo sapiens	31-34
10230770-13	1999	Taken together, these results indicate that NPM-translocation correlates with apoptosis induced by daunomycin.	Daunorubicin	99-109	nucleophosmin 1	Homo sapiens	44-47
10339502-5	1999	Since the advent of more intensive CALGB therapy which incorporated cyclophosphamide and the early use of L-asparaginase into the backbone of daunorubicin, vincristine and prednisone, together with central nervous system prophylaxis for adult ALL, no significant differences in response rates, remission duration, or survival have been seen in those patients coexpressing myeloid antigens.	Daunorubicin	142-154	asparaginase and isoaspartyl peptidase 1	Homo sapiens	106-120
10427537-1	1999	Colchicine, corticosteroids, daunomycin, fluorouracil, heparin and retinoids have been used in man and show an effect in different stages of the development of PVR.	Daunorubicin	29-39	PVR cell adhesion molecule	Homo sapiens	160-163
10216102-3	1999	Because apoptosis induced by anticancer drugs has been proposed to involve CD95/CD95 ligand interaction, we investigated the mechanism of caspase activation by daunorubicin, doxorubicin, etoposide, and mitomycin C.	Daunorubicin	160-172	caspase 8	Homo sapiens	138-145
10342576-0	1999	Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.	Daunorubicin	93-105	ATP binding cassette subfamily B member 1	Homo sapiens	171-175
10342576-1	1999	Ways of restoring an altered drug sensitivity in P-170 glycoprotein (MDR1) positive leukemias are being actively sought for, mostly using MDRI negative regulators together with the MDR1-sensitive anthracycline-type drugs daunorubicin and mitoxantrone.	Daunorubicin	221-233	ATP binding cassette subfamily B member 1	Homo sapiens	69-73
10342576-1	1999	Ways of restoring an altered drug sensitivity in P-170 glycoprotein (MDR1) positive leukemias are being actively sought for, mostly using MDRI negative regulators together with the MDR1-sensitive anthracycline-type drugs daunorubicin and mitoxantrone.	Daunorubicin	221-233	ATP binding cassette subfamily B member 1	Homo sapiens	181-185
10342576-8	1999	Altogether, study results in MDR1+ cells incubated with CsA 1500 ng/ml plus idarubicin+idarubicinol 100+20 ng/ml, that are peak levels achievable in vivo with an idarubicin dose &gt; or = 12 mg/m2 plus cyclosporin A 16 mg/kg/d, were in the range of those obtained with standard-dose daunorubicin in MDR1- cells (p=n.s.).	Daunorubicin	283-295	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
10086980-0	1999	Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo.	Daunorubicin	37-49	apolipoprotein E	Mus musculus	63-79
10086980-0	1999	Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo.	Daunorubicin	37-49	low density lipoprotein receptor	Mus musculus	129-161
10086980-4	1999	In this study, we incorporated a lipophilic derivative of daunorubicin (LAD) into the apoE liposomes.	Daunorubicin	58-70	apolipoprotein E	Mus musculus	86-90
10098741-9	1999	Similarly, HL-60/Vinc cells underwent apoptosis at 50-100 microM daunorubicin and mitotic cell death at 10 microM.	Daunorubicin	65-77	nuclear paraspeckle assembly transcript 1	Homo sapiens	17-21
10079321-8	1999	Several agents, including [11C]colchicine, [11C]verapamil and [11C]daunorubicin, have been evaluated for the quantification of Pgp-mediated transport with PET in vivo.	Daunorubicin	67-79	ATP binding cassette subfamily B member 1	Homo sapiens	127-130
10079321-9	1999	The results suggest that radiolabelled colchicine, verapamil and daunorubicin are feasible substrates with which to image Pgp function in tumours.	Daunorubicin	65-77	ATP binding cassette subfamily B member 1	Homo sapiens	122-125
10215105-0	1999	IGF-I in experimental daunorubicin-induced cardiomyopathy in rabbits.	Daunorubicin	22-34	insulin-like growth factor I	Oryctolagus cuniculus	0-5
10215105-2	1999	The occurrence of IGF-I was investigated in rabbits with experimentally daunorubicin-induced cardiomyopathy.	Daunorubicin	72-84	insulin-like growth factor I	Oryctolagus cuniculus	18-23
10215105-5	1999	A significant increase in the IGF-I was found in the left heart ventricle in daunorubicin cardiomyopathy (152.9 +/- 10.0 ng/g vs 95.1 +/- 4.2 ng/g in the control group).	Daunorubicin	77-89	insulin-like growth factor I	Oryctolagus cuniculus	30-35
10215105-9	1999	Furthermore, in skeletal muscle, the levels of IGF-I in the daunorubicin group (839.0 +/- 142.1 ng/g) were significantly higher in comparison with the control group (482.5 +/- 83.1 ng/g).	Daunorubicin	60-72	insulin-like growth factor I	Oryctolagus cuniculus	47-52
10215105-11	1999	The level of IGF-I in the left ventricle in the daunorubicin group (but not in the control group) was significantly higher than that in the liver.	Daunorubicin	48-60	insulin-like growth factor I	Oryctolagus cuniculus	13-18
10215105-14	1999	The increase in IGF-I concentrations in the left heart ventricle after the administration of daunorubicin may thus reflect possible autocrine/paracrine role of IGF-I in cardiomyopathy.	Daunorubicin	93-105	insulin-like growth factor I	Oryctolagus cuniculus	16-21
10215105-14	1999	The increase in IGF-I concentrations in the left heart ventricle after the administration of daunorubicin may thus reflect possible autocrine/paracrine role of IGF-I in cardiomyopathy.	Daunorubicin	93-105	insulin-like growth factor I	Oryctolagus cuniculus	160-165
10188979-6	1999	In the presence of reduced glutathione (GSH), there was an ATP-dependent uptake of vincristine and daunorubicin, but not of APDA, into GLC4/Adr and S1(MRP) membrane vesicles which could be inhibited by the MRP1-inhibitor MK571.	Daunorubicin	99-111	ATP binding cassette subfamily C member 1	Homo sapiens	151-154
10188979-6	1999	In the presence of reduced glutathione (GSH), there was an ATP-dependent uptake of vincristine and daunorubicin, but not of APDA, into GLC4/Adr and S1(MRP) membrane vesicles which could be inhibited by the MRP1-inhibitor MK571.	Daunorubicin	99-111	ATP binding cassette subfamily C member 1	Homo sapiens	206-210
10188979-7	1999	ATP- and GSH-dependent transport of daunorubicin and vincristine into GLC4/Adr membrane vesicles was inhibited by the MRP1-specific monoclonal antibody QCRL-3.	Daunorubicin	36-48	ATP binding cassette subfamily C member 1	Homo sapiens	118-122
10188979-8	1999	MRP1-mediated daunorubicin transport rates were dependent on the concentration of GSH and were maximal at concentrations &gt; or = 10 mM.	Daunorubicin	14-26	ATP binding cassette subfamily C member 1	Homo sapiens	0-4
10188979-11	1999	In conclusion, these results demonstrate that MRP1 transports vincristine and daunorubicin in an ATP- and GSH-dependent manner.	Daunorubicin	78-90	ATP binding cassette subfamily C member 1	Homo sapiens	46-50
10025900-0	1999	Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?	Daunorubicin	87-99	ATP binding cassette subfamily B member 1	Homo sapiens	3-17
10025900-0	1999	Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?	Daunorubicin	87-99	major vault protein	Homo sapiens	43-46
10025900-0	1999	Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?	Daunorubicin	87-99	major vault protein	Homo sapiens	47-50
10500777-3	1999	We describe an investigation into the expression, using MRK16 and UIC2, and function of P-gp using daunorubicin with and without modulators by flow cytometric analysis on previously frozen blast cells from 27 patients with primary or secondary AML.	Daunorubicin	99-111	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
9933132-1	1999	Expression of P-glycoprotein (Pgp), the drug efflux pump which mediates multidrug resistance (MDR), has been widely reported in chronic lymphocytic leukaemia (CLL) and improved accumulation of daunorubicin has been reported using the MDR reversing agent cyclosporin A (CSA).	Daunorubicin	193-205	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
9933132-1	1999	Expression of P-glycoprotein (Pgp), the drug efflux pump which mediates multidrug resistance (MDR), has been widely reported in chronic lymphocytic leukaemia (CLL) and improved accumulation of daunorubicin has been reported using the MDR reversing agent cyclosporin A (CSA).	Daunorubicin	193-205	ATP binding cassette subfamily B member 1	Homo sapiens	30-33
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Daunorubicin	227-239	ATP binding cassette subfamily B member 1	Homo sapiens	55-69
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Daunorubicin	227-239	ATP binding cassette subfamily B member 1	Homo sapiens	71-75
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Daunorubicin	227-239	ATP binding cassette subfamily B member 1	Homo sapiens	162-166
11498841-0	1999	[Study on the sensitization of acute myeloid leukemia cell to daunorubicin by recombinant human interleukin-3].	Daunorubicin	62-74	interleukin 3	Homo sapiens	96-109
11498841-1	1999	OBJECTIVE: To evaluate the effect of recombinant human interleukin-3(rhIL-3) on the sensitization of acute myeloid leukemia(AML) cells to daunorubicin(DNR).	Daunorubicin	138-150	interleukin 3	Homo sapiens	55-68
9861027-4	1998	Enforced expression of the full-length BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicin, reduces daunorubicin accumulation and retention, and causes an ATP-dependent enhancement of the efflux of rhodamine 123 in the cloned transfected cells.	Daunorubicin	131-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	39-43
9861027-4	1998	Enforced expression of the full-length BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicin, reduces daunorubicin accumulation and retention, and causes an ATP-dependent enhancement of the efflux of rhodamine 123 in the cloned transfected cells.	Daunorubicin	153-165	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	39-43
9862571-0	1998	Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes.	Daunorubicin	67-79	low density lipoprotein receptor	Mus musculus	0-32
9862571-0	1998	Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes.	Daunorubicin	67-79	apolipoprotein E	Mus musculus	120-136
9822694-11	1998	Like wild-type MRP1, the MRP1 protein without the TMD0 region was routed to the lateral plasma membrane and transported dinitrophenyl glutathione and daunorubicin.	Daunorubicin	150-162	ATP binding cassette subfamily C member 1	Canis lupus familiaris	15-19
9822694-11	1998	Like wild-type MRP1, the MRP1 protein without the TMD0 region was routed to the lateral plasma membrane and transported dinitrophenyl glutathione and daunorubicin.	Daunorubicin	150-162	ATP binding cassette subfamily C member 1	Canis lupus familiaris	25-29